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ABSTRACT 
 
The neutrophil is believed to be central to the development of COPD.  Whilst critical in 
the clearance of bacteria, neutrophils also have the capacity to cause extensive tissue 
damage, as the substances contained within their cytoplasmic granules are able to 
degrade all components of the extra-cellular matrix.  To enter lung tissue, neutrophils 
must migrate accurately from the circulation to areas of inflammation.  There have been 
few studies examining neutrophil migration in COPD, and due to contradictory results, it 
is unclear which migratory stimuli are important.  It is also unclear whether neutrophils 
from patients with COPD vary in their migratory behaviour, either to age-matched 
controls (as the majority of studies have not stringently age-matched) or patients with 
similar lung disease.  It is also unclear whether neutrophil migration is compatible with 
emerging theories of advanced ageing as a component of the development of COPD. 
 
Sputum and plasma samples were collected on eleven occasions during one month from 
patients with COPD. There was significant variability in all inflammatory indices but 
variability could be reduced by using a rolling mean of individual patient data points.   
Significant correlations were demonstrated both between the inflammatory biomarkers 
themselves and between inflammatory biomarkers and markers of disease. Some 
relationships were not apparent when results from a single sample were used and the 
reliability of inter-relationships improved as more data points were used for each patient. 
IL-8 correlated the most strongly with other inflammatory mediators, neutrophil counts and 
clinical indices of disease, suggesting that it is an important migratory signal in COPD. 
 
To assess the affect of ageing on neutrophil migration, neutrophils were isolated from 
healthy young and older subjects.  Although the speed of migration was intact, neutrophils 
from older subjects migrated with less velocity, less directional persistence and less 
d 
accuracy in the presence of IL-8 and GROα.  Differences in migration could not be 
accounted for by cell surface receptor expression or shedding, but an inhibitor of CXCR2 
receptor function gave young neutrophils and old migratory phenotype, suggesting altered 
downstream signalling. 
 
Neutrophils from patients with COPD did not display changes compatible with increased 
ageing, but instead migrated with increased speed and reduced accuracy compared with age-
matched controls or patients with a similar lung disease, in the presence of IL-8, GROα and 
sputum.  Structurally, COPD neutrophils formed less pseudopodia when migrating, and had 
reduced surface expression of CXCR1 and CXCR2.   These changes were not seen in 
healthy controls, healthy smokers, or patients with a similar lung disease (who were 
matched for age, gender, lung physiology, smoking status and medications), suggesting that 
smoking, lung disease, inflammation or its treatment were not the cause of the altered 
behaviour.  Studies of the migratory function of CXCR1 and CXCR2 suggested that both 
were important in neutrophil migration, but that CXCR2 was the predominant receptor 
when migrating in gradients of biological samples.  Inhibition of CXCR1 and CXCR2 could 
not give healthy neutrophils a COPD phenotype, suggesting that a reduction in receptor 
expression was not the only factor potentially altering migratory dynamics.  Treating COPD 
cells with a PI3 Kinase inhibitor differentially altered their migratory behaviour, reducing 
the speed, but increasing the accuracy, so that cells now resembled those from healthy 
individuals.  This suggests strongly that the mechanism of altered migration lies within this 
migratory pathway and potentially provides a new therapeutic target for patients with 
COPD.   
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1 INTRODUCTION 
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1.1 THE NORMAL BRONCHIAL TREE 
1.1.1 Anatomy 
The airways of the respiratory tract are classified as either conductive or respiratory, 
based upon their participation in gaseous exchange.  The largest conducting airway is 
the trachea; this divides into the main bronchi, sub-segmental bronchi and then 
bronchioles.  The final, purely conductive airways are the terminal bronchioles, beyond 
which gas exchange occurs.   
 
There are approximately three generations of respiratory bronchioles following the 
terminal bronchioles. The respiratory bronchioles are transitional, as they conduct gas 
and participate in gaseous exchange.  After the respiratory bronchioles are two to nine 
generations of alveolar ducts, which terminate in the alveolar sacs. 
 
The conducting airway walls contain epithelial, lymphoid, muscular, vascular and 
nervous elements which are placed in a connective tissue supportive frame which is 
arranged as follows:  firstly there is a lining mucosa of surface epithelium, basement 
membrane and supporting elastic lamina propria.  Secondly, there is the submucosa in 
which lie the glands, muscle and cartilage; and finally, there is the adventitial coat. 
 
The alveoli are lined with squamous epithelium that is in continuity with the columnar 
epithelium of the conducting airways.  The alveolar epithelium consists of two principle 
cell types (type I and type II pneumocytes).  These cells are separated from the 
connective tissue and capillaries of the interstitium by a basement membrane.  Type I 
cells provide a continuous but thin covering of the alveolus and prevent fluid loss while 
facilitating rapid gas exchange.  Type II cells are twice as numerous as Type I, but 
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because of their cuboidal shape and size, they cover only 7% of the alveolar surface 
(Crapo, Barry et al. 1982).  Type II cells have an important role in surfactant production 
and also retain some plasticity, as they can differentiate to replace damaged type I cells 
(Evans, Cabral et al. 1975).  
 
1.1.2 Blood Supply 
The trachea is supplied with systemic blood through branches of the inferior thyroid 
and bronchial arteries, which anastomose with each other.  The bronchial and 
bronchiole walls receive systemic blood through the bronchial arteries, which are 
derived from the descending aorta and the intercostal and internal mammary arteries 
(Deffebach, Charan et al. 1987).  There is a rich vascular network supplying the airway 
wall (Laitinen, Laitinen et al. 1987) which is able to participate in gas exchange, via 
broncho-pulmonary anastomoses. The network also helps to control heat exchange and 
contributes transudate to airway secretions. 
 
Each airway is accompanied by a branch of the pulmonary artery that divides with the 
airways, forming a capillary meshwork in the alveolar wall, which is in close contact 
with the alveolar space.  The capillaries converge at the periphery of the acinus to form 
pulmonary veins.  Blood leaves the lungs via the hilar and bronchial veins from the 
bronchi; via the pulmonary veins deep in the lung; and via the thyroid veins from the 
trachea (Jeffrey 1995). 
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1.1.3 Immune function 
As well as gas exchange, the airways also warm and humidify inhaled air, and have 
important host defence functions against potentially harmful inhaled particles and 
micro-organisms.  The primary host defence system is outlined below. 
1.1.3.1 Airway epithelium 
The epithelial cells of the conducting airways provide an important mechanical barrier 
to inhaled particles and micro-organisms.  The epithelium is primarily composed of 
pseudostratified, ciliated and columnar cells, although many other cell types are 
present, including goblet cells, serous cells, clara cells, endocrine, basal and brush cells, 
as well as a variety of transitional forms (Jeffrey and Reid 1975; Breeze and Wheeldon 
1977; Jeffrey 1983).  Most airway pathogens will not adhere to bronchial epithelium 
unless it has been damaged (Bredt, Feldner et al. 1982; Tuomanen and Hendley 1983). 
Where cells are damaged bacteria are able to adhere (Plotkowski, Beck et al. 1989; 
Feldman, Read et al. 1992) via lectin like substances, exopolysaccharide secretion and 
the expression of hair like fimbrae (Wilson and Rayner 1997). 
1.1.3.2 Airways secretions 
Airways secretions form an important component of the primary host defence system.  
In the trachea, there are approximately 4000 submucosal glands which produce mucus 
(Tos 1970), antibacterial proteins (including lysozyme (Bowes and Corrin 1977) and 
lactoferrin (Bowes, Clark et al. 1981)), the secretory component necessary for 
immunoglobulin (Ig) A transport (Brandtzaeg 1974), and the antiproteinase, secretory 
leukoprotease inhibitor (SLPI) (Kramps, Franken et al. 1981).  Submucosal glands are 
composed of a central acinus consisting of serous cells, and a tubule lined with mucous 
cells.  Plasma cells (responsible for the production of IgA) are also found in the 
submucosal glands (Soutar 1976). 
 
5 
The serous and mucous cells of the bronchial glands secrete the majority of the 
bronchial secretions, although goblet cells, and both the serous and clara cells of the 
airway epithelium make important contributions.  Secretions are further diluted by 
alveoli surfactant and plasma fluid transudate (Puchelle, Girod de Bentzmann et al. 
1995).    
 
Bronchial mucus comprises of a continuous watery sol layer which overlays the 
bronchial epithelium and in which the cilia beat; and a more viscous gel layer, which 
lies on the tips of the cilia.  The sol layer is 5 - 10µm deep, and is derived from the clara 
cells in the airway epithelium at the bronchiolar level with some contribution from fluid 
transudation.   The major control mechanism of the water content of the sol phase of 
airway secretions relates to the movement of sodium and chloride ions, and the balance 
between the water content of the interstitium and the lumen.  The sol layer enables the 
cilia to propel the gel layer over its surface, and is fundamental to mucociliary 
clearance.  The mucus gel layer is derived from several sources including goblet and 
serous cells in the airway epithelium, clara cells at the bronchiolar level (Widdicombe 
and Pack 1982) and the submucosal glands (Shimura and Takishima 1994).  The sol 
phase contains soluble bronchial proteins and serum proteins, whilst the gel phase 
contains the mucinous glycoproteins, other serum proteins and also proteins bound to 
mucins (Kim 1997).  The mucins are high molecular mass mucoglycoproteins (King 
and Rubin 1994), and confer viscoelastic properties on the gel phase which enable the 
mucociliary escalator to function even in areas where ciliated epithelium is interrupted.  
A number of different mucin proteins have been identified, and the quantitative 
expression of individual mucins appears to alter with disease, especially in the presence 
of inflammation, altering the nature of the gel phase and potentially its ability to clear 
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pathogens and particles from the lung.   Phospholipids appear to be important in 
weakening adhesion of the mucus to the epithelium, aiding mucociliary clearance 
(Rubin, Ramirez et al. 1992). 
  
Bronchial mucus has many functions.  It reduces evaporative loss from the respiratory 
tract, provides a protective barrier over the bronchial epithelium and removes trapped 
inhaled particles via ciliary action.  The mucus also provides a medium for 
immunoglobulins and other protective proteins. 
 
1.1.3.3 Mucociliary clearance 
In healthy individuals, airway secretions are moved up to the mouth by ciliary action in 
the mucociliary escalator.  Ciliated cells are found primarily in the tracheo-bronchial 
epithelium, although they are also present in the bronchioles (Shimura and Takishima 
1994; Widdicombe and Widdicombe 1995).  There are approximately 200 – 300 cilia 
per cell; each is 4 – 6 µm long and 0.1 – 0.2 µm in diameter.  The cilia beat 1000 times 
per minute, and in health the action of the cilia is co-ordinated, both within a single cell 
and between adjacent cells (Sanderson and Sleigh 1981).  The ciliary beat cycle has two 
components.  The first is movement towards the larynx; this is the effective stroke, and 
is followed by a recovery stroke in the opposite direction where the cilia bend and 
disengage from the mucus (Sleigh, Blake et al. 1988).  Microvili project between the 
cilia and are believed to regulate the depth of the periciliary fluid level. 
 
The clearance of mucus depends on ciliary action (Puchelle, Zahm et al. 1980), cough, 
mucus volume, and the viscoelasticity and adhesiveness of the mucus to the airway 
epithelium.  Mucus transportation has two phases, a fast phase related to ciliary 
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clearance and cough, which is completed after a few hours in healthy individuals, and a 
slower phase which represents alveolar clearance and occurs over weeks or months 
(Pavia 1984; Hasania and Pavia 1989). 
 
Mucocilary clearance is impaired in a variety of conditions including bronchitis and 
bronchiectasis.  There are many reasons for the impairment, including inhibition of 
ciliary activity by proteinases such as neutrophil elastase (NE) (Smallman, Hill et al. 
1984), the presence of bacterial products (Wilson, Pitt et al. 1987) and epithelial 
damage.  In chronic lung disease the excess and accumulated secretions are 
expectorated in the form of sputum, which is a mixture of bronchial secretions, cells, 
cellular debris, cleared organisms and saliva. 
1.1.3.4 Secretory proteins 
There are many proteins in airway secretions including albumin, lysozyme, lactoferrin, 
immunoglobulins, antioxidants and antiproteinases such as alpha-1-antitrypsin (α1AT), 
alpha-1-chymotrypsin and SLPI (Stockley 1997).  Lactoferrin and lysozyme are 
involved in host defence (Ellison and Giehl 1991), other molecules such as catalase and 
glutathione have anti-oxidant and anti-inflammatory properties (Cantin, Fells et al. 
1990).  The roles of anti-proteinases will be discussed in section 1.3.  
 
Immunoglobulin A (IgA) is also an important component of airway secretions, 
predominantly in the upper respiratory tract (Morgan, Hussein et al. 1980).  In contrast, 
the other immunoglobulins contribute little to bronchial mucus.  In the lung, most of 
IgA is dimeric, with 70% being of the IgA1 subclass and 30% being of the IgA2 
subclass (Burnett 1986).  This local IgA is thought to be secreted by submucosal 
plasma cells and is released as a dimer joined by a 15kDa protein linker called the “J” 
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chain.  The dimer binds to the polymeric IgA receptor on the basal surface of epithelial 
cells, is internalised and transported to the apical surface where the receptor is cleaved 
leaving a small IgA bound fragment (the secretory component).   
 
The dimeric form of IgA is believed to reduce bacteria and viral adherence to epithelial 
cells (Jefferis 1997).  The secretory component of IgA enhances macrophage 
phagocytosis (Richards and Gauldie 1985) and (working with IgG) facilitates cell 
mediated cytotoxicity (Shen and Fanger 1981).   IgA also appears to stabilise bronchial 
mucus by forming cross-links with the mucopolysaccharides. 
 
1.1.3.5  Immune cells and the lung 
Monocytes in the systemic circulation are continuously recruited to the lung tissues 
where they differentiate into pulmonary macrophages and dendritic cells (Poulter 
1997). These cells are further classified by their location, and include pleural, 
interstitial, alveolar and airway macrophages, and dendritic cells (found solely within 
the bronchial epithelium).     Inhaled bacteria are able to reach the alveolar (as is any 
particulate matter less than 3 µm in diameter), where they are recognised and 
phagocytosed by macrophages.   The process of phagocytosis begins with the bacteria 
adhering to the surface of the macrophage by receptors that recognise bacterial 
mannose sugars or the C3b complement receptors (once C3 has been activated by 
binding to the organism).  Following phagocytosis, the phagosome fuses with a 
lysosome, exposing the bacterium to anaerobic acid hydrolases and products of the 
respiratory burst, resulting in its death.  Macrophages also release free oxygen radicals, 
proteinases and acid hydrolases, which may contribute to extracellular bacterial killing 
(Poulter 1997). 
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It appears that bacterial loads of less than 105 organisms can be eradicated by 
macrophages and other components of the innate host defence.  However, greater 
bacterial loads require neutrophil recruitment and the involvement of the secondary 
acquired immune response (Onofrio, Toews et al. 1983).   Macrophages and dendritic 
cells facilitate this in a variety of ways.  They are able to migrate to the bronchial lymph 
nodes, particularly to the T cell paracortical areas (Thepen, Claassen et al. 1993) where 
the antigen they carry is available for primary stimulation of the T cell clones.  T cell 
derived cytokines then amplify the effector function of macrophages by enhancing their 
phagocytic and anti-microbial capacity (Skerrett and Martin 1994).   Interactions 
between neutrophils and macrophages are described in section 1.5.6.4. 
 
Macrophages interact with different bacteria using similar mechanisms, but their ability 
to clear and kill varies with each pathogen. In the main, gram positive bacteria are 
readily killed after phagocytosis, whereas gram negative bacteria are often resistant to 
macrophage killing.  Mycobacteria, Listeria and Legionella are readily ingested but are 
able to withstand the respiratory burst and pathogen clearance can only be achieved by 
removal of the affected macrophages (Horwitz and Silvrstein 1981).   Macrophages 
laden with phagocytosed bacteria are removed from the lungs by transport up the 
bronchial tree until they are swallowed with airway secretions. 
 
Healthy epithelium also contains migratory lymphocytes and mast cells.  Lymphocytes 
remove allergenic particles from the airways and occur singly or in aggregated 
lymphoid follicles (known collectively as bronchus associated lymphoid tissue) 
(McDermott, Befus et al. 1982).  The T cell surface markers found in bronchial 
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epithelium include the universal lymphocyte marker CD3, as well as the more specific 
CD4+ (helper) and CD8+ (cytotoxic) cells.  In the epithelium CD8+ cells are 
predominant, while in the lamina propria this is reversed and there is an preponderance 
of CD4+ cells (Azzawi, Bradley et al. 1990).  B lymphocytes make up only a small 
proportion of cells seen in the lung.  
 
1.2 THE NEUTROPHIL 
The neutrophil is the most abundant circulating leukocyte.  The average peripheral 
blood neutrophil count is 2.5 – 7.5 x 106 /ml and when inactivated, its’ circulating half 
life is only 6 – 8 hours, which means that the bone marrow is required to produce and 
release more than 5 – 10 x 1010 neutrophils daily, with the capacity to increase 
production further if needed. 
1.2.1 Differentiation, maturation and apoptosis 
Neutrophils have a characteristic multi-lobed nucleus and abundant storage granules in 
their cytoplasm.  The mature neutrophil has three chemically distinct granule types, 
which appear at different stages of maturation (see table 1.1).   
 
The neutrophil differentiates and matures within bone marrow, developing from a 
bipotential progenitor cell, the granulocyte-macrophage colony forming unit.  In the 
first developmental stage, the cell divides and differentiates from myeloblasts to 
promyelocytes.  During this stage the azurophilic or primary granules are produced.  
These granules contain myeloperoxidase (MPO), antibacterial proteins (such as 
defensins, lysozyme and azurocidin) and three serine proteinases, neutrophil elastase  
(NE), cathepsin G (CG) and proteinase 3 (PR3). 
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Table 1.1: Enzymes and other constituents of human neutrophil granules 
 
Granules Constituents 
Azurophil Specific Small storage 
Antimicrobial 
Myeloperoxidase 
Lysozyme 
Definsins 
Bacterial permeability-
increasing protein (BPI) 
Lysozyme 
Lactoferrin 
  
Neutral 
proteinases 
Elastase 
Cathepsin G 
Proteinase 3 
Collagenase 
Complement 
activator 
Gelatinases 
Plasminogen 
activator 
 
Acid Hydrolases 
Cathepsin D 
ß-D-Glucuronidase 
α-Mannosidase 
Phospholipase A2 
Phospholipase A2  
 
Cathepsin B and  D 
ß-D-Glucuronidase 
α-Mannosidase 
Cytoplasmic  
membrane 
receptors   
CR3, CR4 
fMLP receptors 
Laminin receptors 
  
Others 
Chondroitin-4-sulphate Cytochrome b558 
Monocyte 
chemotactic factor 
Histaminase 
Vitamin B12 
binding protein 
Cytochrome b558 
 
The enzymes and other constituents of human neutrophil granules.  
fMLP = N-formylmethionyl-leucyl-phenylalanine  
 
 
The serine proteinases are produced as pre-proenzymes, with gene expression stopping 
at the metamyelocyte stage (Fouret, du Bois et al. 1989) and are activated by a 
lysosomal cysteine proteinase, dipeptidyl peptidase (Adkison, Raptis et al. 2002).  The 
specific or secondary granules are formed as the cell enters the myelocytic stage.  These 
granules contain lysozyme, lactoferrin, collagenase and various membrane receptors.  
The small storage (or tertiary) granules are formed last, at the metamyelocyte stage, and 
contain Gelatinases (matrix metalloproteinases) and Cathepsin B and D.  At maturation 
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(which takes approximately 2 weeks) each neutrophil contains a full complement of 
proteins which provide the mechanisms of cell migration, opsonophagocytosis and a 
formidable arsenal against pathogens.  However, the neutrophil proteinases (especially 
NE) also have the capacity to be intensely destructive, degrading structural lung 
proteins (including elastin, collagen and gelatine) and appear to be involved in the post-
translational processing of enzymes, cytokines and receptors (Stockley 2002).  Fully 
mature neutrophils leave the bone marrow in a non-activated state and have a half life 
of 4 – 10 hours before marginating and entering tissue pools (Burnett 1997).   Once in 
tissue, neutrophils are usually removed by apoptosis leading to their recognition and 
phagocytosis by macrophages in the main and by other neutrophils when the 
macrophage clearance system is overwhelmed (Rydell-Tormanen, Uller et al. 2006).  
This mechanism prevents cell necrosis and the release of the remaining cellular content 
of proteinase and other mediators. 
 
Apoptosis is regulated cell death that allows the elimination of unwanted or damaged 
cells.  Currently, three caspase dependent apoptosis pathways have been described.  The 
first pathway is triggered in response to extracellular signals (the receptor mediated 
extrinsic pathway), mediated by the binding of tumour necrosis factor related proteins 
(such as Fas ligand) to death receptors on the cell surface. This results in the formation 
of the death inducing signalling complex (DISC), that activates a series of Caspases, 
leading to DNA fragmentation by DNAse (Muzio, Chinnaiyan et al. 1996; Hirata, 
Takahashi et al. 1998; Muzio, Stockwell et al. 1998; Scaffidi, Fulda et al. 1998; Tang 
and Kidd 1998).  A second pathway, the mitochondrial intrinsic pathway, responds to 
stress signals by the release of cytochrome C from mitochondria. Cytochrome C, 
apoptotic protease activating factor-1 (Apaf-1) and caspase-9 activate caspase-3, leading 
to apoptosis (Liu, Kim et al. 1996; Zou, Henzel et al. 1997; Slee, Harte et al. 1999).  
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Finally, in the endoplasmic reticulum pathway, caspase-12 is activated in response to 
stress signals such as hypoxia (Rao, Hermel et al. 2001; Szegezdi, Fitzgerald et al. 
2003), leading to apoptosis. 
    
Clearance following apoptosis physiologically has no inflammatory sequelae.  
However, if phagocytosis fails, apoptotic cells undergo secondary necrosis with cell 
rupture, which is inflammatory in nature and increases both the pro-inflammatory 
proteins and proteinase burden in the lung (Rydell-Tormanen, Uller et al. 2006).  Figure 
1.1 describes the appearance of neutrophils during induced lung inflammation, showing 
both activated and apoptotic cells, apoptotic cells undergoing secondary necrosis and 
neutrophils containing phagosomes with neutrophilic cell remnants. 
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Figure 1.1.  Neutrophils during an LPS induced lung inflammation 
Legend. 
Electron micrographs displaying neutrophils during an LPS-induced lung 
inflammation. Highly activated neutrophils are shown (N) (characterized by  
phagosomes and/or cytoplasmatic protrusions), lying amongst apoptotic neutrophils 
(black arrow) and cell debris (black arrowhead) (Figure A). Secondary necrosis 
(characterized by membrane rupture of cells with an otherwise apoptotic morphology) of 
neutrophils is shown in figure B.  Neutrophils containing large phagosomes (asterisks) 
enclosing neutrophilic cell remnants such as apoptotic nuclei and neutrophil granulae are 
shown in images C-E. 
 
Used with kind permission from Rydell-Tormanen et al, Respir research 2006; 7: 143 
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1.2.2 Neutrophil migration 
 
Neutrophils are present at both the bronchial and alveolar level in COPD, and therefore 
it is likely that neutrophil migration occurs from both the bronchial and pulmonary 
circulation.  Most of our understanding of neutrophil migration has been derived from 
in vitro studies using systemic vessels in the mesentery and dermis.  Studies using 
samples of lung tissue suggests that while migration in the bronchial circulation occurs 
in a similar fashion to migration in other tissues, migration in the pulmonary capillaries 
may depend on distinct mechanisms.   
 
1.2.2.1 Neutrophil migration in the bronchial circulation 
Initiation of migration  
In the bronchial circulation, neutrophils migrate from vessel to tissue in a step-like 
process, dictated by the sequential activation of adhesive proteins and their ligands on 
neutrophils and endothelial cells.   
 
Migration begins with the capture of neutrophils from flowing blood, causing the cell to 
roll along the endothelial surface. Tethering and rolling of the neutrophil along the 
vessel wall is a normal feature of circulating neutrophils and is due to reversible binding 
of transmembrane glycoprotein adhesive molecules called “selectins”, which are found 
both on neutrophils and endothelial cells (Wagner and Roth 2000).   
 
Leukocyte Selectin (L-Selectin) is constitutively expressed on projecting microvilli on 
the surface of neutrophils and binds an endothelial ligand that is believed to be a 
sialomucin oligosaccharide (potentially a fucosylated variant of CD34).  L-Selectin 
induced neutrophil capture can be transient in non-inflamed tissue (“stick and release”), 
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however, during both transient and prolonged rolling interactions, L-Selectin, once 
bound, is shed from neutrophils (Walchek, Kahn et al. 1996).  Both L-Selectin binding 
and shedding is enhanced in the presence of inflammatory products such as Tumour 
Necrosis factor alpha (TNFα), Interleukin 8 ( IL-8), the bacterial peptide Formyl-
methionyl-leucyl-phenylalanine (fMLP) and Lipopolysaccharide (LPS) (Drost and 
MacNee 2002).  Once bound and cleaved, L-Selectin molecules cannot be replaced and 
low expression has been associated with neutrophilic apoptosis (Matsuba, Van Eeden et 
al. 1997).    
 
In the presence of inflammation, at least two further endothelial bound selectins are 
expressed, Platelet Selectin (P-Selectin) and Endothelial Selectin (E-Selectin).  P-
Selectin is stored intracellularly in Weibal-Palade bodies in endothelial cells (Malik and 
Lo 1996) and can be mobilised rapidly in response to various inflammatory mediators 
including oxygen free radicals, components of the complement cascade and many 
cytokines (Spertini, Luscinskas et al. 1991).  Its neutrophilic counterligand is P-Selectin 
glycoprotein ligand-1 (PSGL1) which is uniformly expressed on the surface of 
neutrophils. P-Selectin–PSGL1 interactions occur after L-Selectin-ligand interactions, 
and have greater longevity. In the presence of other adhesion molecules, P-
Selectin/PSGL1 binding slows neutrophil rolling velocities and eventually causes cell 
tethering to the endothelium but in the absence of other adhesive events, binding is also 
transient (Alon, Chen et al. 1997).   
 
E Selectin is not stored, and peak expression is seen 4 – 6 hours after endothelial exposure 
to inflammatory mediators (Klein, Bittenger et al. 1995). It binds to E-Selectin ligand 1 
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(Steegmaier, Levinovitz et al. 1995) and it is thought to maintain neutrophil tethering after 
P-selectin has been down regulated.  
 
Firm Adhesion 
The next step in neutrophil migration is the transition from reversible rolling to firm 
adhesion with the endothelium. This is achieved by the sequential activation of  
neutrophil receptors called Integrins  (Crockett-Torabi and Fantone 1995; Williams and 
Solomkin 1999).  
 
The Integrins are heterodimeric transmembrane glycoproteins that comprise an alpha 
and beta subunit, which together form an extra cellular binding site.  Integrins are found 
on many haematopoietic cells, with differing alpha and beta subunits. The two most 
important integrins on neutrophils share a beta2 subunit (CD18), and are called 
Macrophage antigen 1 (MAC1; CD11b/CD18) and Lymphocyte-associated function 
antigen 1 (LFA-1; CD11a/CD18).  A third CD18 integrin, p150,95 can also promote 
neutrophil migration, but MAC1 appears to be the most important integrin in models of 
neutrophil migration (Diamond, Staunton et al. 1990; Rainger, Buckley et al. 1997). 
 
MAC1 is stored in secretory granules (Borregaad and Cowland 1997) and is rapidly 
mobilised to the cell surface after exposure to inflammatory stimuli (including fMLP, 
TNF-α and LPS).  Inflammatory stimuli also promote transcription and translation of 
the MAC1 gene via a G-protein, Rho (Laudanna, Campbell et al. 1996), further 
increasing its surface expression (Spertini, Luscinskas et al. 1991).  Some MAC1 is 
expressed constitutively on the neutrophil, but these proteins are incapable of binding 
ligands unless activated by intra or extracellular signals, where conformational changes 
occur exposing a requisite binding epitope (Michishita, Videm et al. 2003).  
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MAC1 has a high affinity for Intercellular adhesion molecule 1 (ICAM1), an 
immunoglobulin-like protein that is expressed in low numbers on the endothelial cell 
surface, but is rapidly induced in inflammation (Hashimoto, Shingu et al. 1994).   
Vascular cell adhesion molecule-1 (VCAM-1) is also an immunoglobulin-like molecule 
expressed by endothelial cells which it binds selectively to α4ß1-integrin, called Very 
Late Antigen-4 (VLA-4) on neutrophils (Davenpeck, Steeber et al. 1988). 
MAC1/ICAM1 interactions cause enhanced expression of both ICAM1 and VCAM1 on 
endothelial cells, suggesting that both may be important in inflammatory driven 
neutrophil migration (Clayton, Evans et al. 1998).  
 
Migration 
The final step of neutrophil recruitment from the bronchial circulation to the lungs is 
transendothelial migration.  This was believed to occur preferentially at tricellular 
junctions (Burns, Walker et al. 1997), requiring the activation of Platelet endothelial cell 
adhesion molecule (PECAM1) (Newman 1997) which is distributed evenly around the 
neutrophil and at intercellular junctions of endothelial cells.  PECAM1 is thought to act 
as a homing beacon that directs migration towards cellular junctions and blocking 
PECAM1 on either neutrophils or endothelial cells using antibodies does not prevent 
adhesion but does prevent migration through the basement membrane both in vitro and 
in vivo (Muller 1995).   A recent study has suggested an alternative route for 
transmigrating neutrophils, with 70% crossing the endothelial barrier by an active 
process of engulfment by endothelial cells that is dependent on the small GTPase RhoG 
(van Buul, Allingham et al. 2007).   The role and implications of this second process 
have yet to be pursued. 
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Once through the endothelial cell layer, leukocytes bind to matrix components such as 
collagen and laminin via ß1 integrins, with VLA-6 and 9 being perhaps the most 
important in allowing neutrophils to move through venule basement membrane and lung 
tissue (Shang and Issekutz 1997; Shang, Yednock et al. 1999; Yadav, Larbi et al. 2002).  
Endothelial/neutrophil PECAM1 interactions lead to increased neutrophil surface 
expression of VLA-6 (α6ß1) and VLA-6 facilitates passage thorough the basement 
membrane and beyond. To support this, neutrophils from PECAM1 knock out mice do 
not have the associated rise in VLA-6 which is seen in the wild type (Thompson, Noble 
et al. 2001). Migration is accompanied by release of neutrophil proteinases especially 
neutrophil elastase (Wright and Gallin 1979), which may facilitate passage by matrix 
degradation, exposing laminin for VLA-6 binding.  Selectin and Integrin interactions 
are summarised in figure 1.2. 
 
Direction of migration and neutrophil movement 
Neutrophils migrating within the lung encounter multiple chemoattractants signals in 
complex spatial and temporal patterns as endothelial, epithelial cells and immune cells 
respond to infection or injury.  Individual chemoattractants can vary in their ability to 
affect neutrophils and in vitro models have demonstrated that neutrophils can migrate 
up and down chemical gradients, responding to one signal, migrating to its 
concentration peak and then migrating up a novel, more distant chemoattractant 
gradient, from endothelium to tissue. 
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Figure 1.2: Schematic summary of Neutrophil and Endothelial Cell Adhesion 
Molecules and their ligands in neutrophil transendothelial migration. 
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Early but short   Interaction between      Firm adhesion  PECAM-1 
lived binding       P-Selectin and PSGL-1         occurs through  interactions 
between L-Selectin  and E-Selectin and ESL-1      integrins and  allow homing to 
and ligand  slows neutrophil rolling      ICAM-1  intracellular 
    and causes transient      interactions  junctions and 
tethering    diapedis via b1  
    integrins 
Modified from (Wagner and Roth 2000) 
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Neutrophils can ignore a high concentration source (due to receptor saturation, 
desensitization and /or receptor sequestration) and preferentially respond to novel 
chemoattractants (Foxman, Campbell et al. 1997).  Under agarose studies have 
suggested that neutrophils are able to migrate in the direction of the vector sum of two 
or more differing signals (Foxman, Kundel et al. 1999).  If two sources of the same 
agonist are used, migration towards the second attractant is poor (Foxman, Campbell et 
al. 1997), so two distinct agonists are required for precise targeting.  These findings may 
account for the observation that activated cells characteristically secrete multiple 
induced chemoattractants concurrently.  Cells can regain their prior sensitivity, but this 
process takes time, requiring recycling of receptors.  For example neutrophils 
preincubated with low chemotactic levels of Leukotriene B4 (LTB4) showed a 
significant reduction in chemotaxis to LTB4 which improved after 10 minutes (Foxman, 
Campbell et al. 1997).   
 
Neutrophil movement itself is achieved by the formation of locally protruding actin-rich 
pseudopods while retracting other regions of the cell body (Devreotes and Janetopoulos 
1988).   In order to achieve this, directed neutrophil chemotaxis begins with cell 
polarisation.  Following stimulation, neutrophils acquire polarity through a self-
organising process involving positive “frontness” and negative “backness” feedback 
loops.  “Backness” is enhanced by inhibiting the formation of a leading edge and with 
the development of a uropod.  This is achieved by actin-myosin II meshworks, regulated 
by Rho-A and PTEN.   The leading edge is composed of F-actin rich lamellipodia, and 
highly polarized distributions of lipids that are up-regulated during cell alignment 
(including PIP3, Cdc42, PAK1 and Akt). In keeping with the role of the leading and 
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trailing edge of the neutrophil, receptors for chemoattractants and integrins are 
redistributed to pseudpods (Gomez-Mouton, Lacelle et al. 2001) and those for adhesion 
(such as PSGL-1 and ICAM-3) are redistributed to the uropod  (Fais and Malorni 2003).  
 
The cell-signaling pathway involved in neutrophil chemotaxis has been described.  
Chemoattractants bind to their specific cell surface receptors and activate Gi proteins, 
which are heterotrimeric G proteins (subunits α,β and γ).  Ligand bound receptors 
promote exchange of GDP with GTP on the α subunits, and GTP-bound Gα dissociates 
from the βγ subunits.  The Gβγ subunit up-regulates PLC, PI3Kγ, ion channels, G-
protein coupled receptor kinases and PAK1.  The Gα subunit also couples with 
chemoattractants, leading to activation of RhoA. 
 
PI3K is required for PIP3 production, and PIP3  is required to orient the cell’s leading 
edge in accordance with the chemoattractant cue by localizing the formation of F actin-
rich lamellipodia using PAK/PIXα activation of Cdc42. (a member of the Rho family of 
small GTPases), and this confers cell motility (Wu 2005). The persistent presence of 
PIP3 at a particular site on the plasma membrane causes cells to acquire an elongated 
shape in which one F-actin enriched psuedopod becomes the leading edge of the 
migrating cell, whereas retraction of pseudopods at the rear and sides of the cell is 
mediated by cortical myosin II (Charest and Firtel 2007). 
 
Although there may be many proximal signal pathways by which polarisation is 
regulated, the key event appears to be activation of the RhoGTPases, Rho and Rac via 
integrins (Huttunlocher 2005).  The α4ß1 integrin forms a complex with paxillin and 
GIT1 which inhibits Rac activation at the sides and rear of the cell, but this inhibitory 
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complex is impeded at the leading edge of the cell by phosphorylation of the α4 integrin 
cytoplasmic tail, which allows Rac activation (Nishiya, Kiosses et al. 2005). At the front 
of the cell Rac activation leads to the f-actin polymerisation while at the rear of the cell 
Rho activation leads to assembly of myosin, with both GTPases working in a co-
operative manner to establish and stabilise cell polarity (Ohta, Hartwig et al. 2006). 
 
PTEN is a negative regulator of this pathway, dephosphorylating PIP3. PTEN is 
localized at the posterior of cells (localization is dependent upon PIXα) and may also be 
involved in cell directionality.  While  PIP3 and Cdc42 localise F actin formation, they 
are not required for F actin formation (which is Rac dependent).  Rac activation appears 
to depend on P-Rex-1 (Wu 2005).  Figure 1.3 summarises the pathways believed to be 
of importance. 
 
The neutrophil appears to “steer” by sustaining pseudopods that are aligned with the 
chemoattractant gradient. Pseudopods are made in spatially restricted sites by splitting 
of the leading edge of the cell, and the generation of these protrusions appears to be 
random in both their direction and timing.  In a study where cells were exposed to a pro-
migratory stimulus which was then relocated once an accurate trajectory was 
established, pseudopod generation occurred randomly, but pseudopods that extended 
towards the stimulus were more likely to be retained, while those which extended in 
inaccurate directions were retracted (see figure 1.4).  Therefore it appears that 
neutrophils migrate up chemoattractant gradients by choosing the best aligned of 
competing randomly generated pseudopods (Andrew and Insall 2007).                       .   
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Figure 1.3.  Outline of the chemoattractant signalling pathways and neutrophil cell 
polarisation involved in neutrophil chemotaxis 
Legend 
A. The signalling pathway involved in neutrophil chemotaxis 
B. The proteins involved in the polarisation and mechanics of cell movement. 
Figure reproduced from (Wu 2005) with kind permission.  See text for full explanation. 
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Figure 1.4. Neutrophil migration by pseudopod generation towards a pro-
migratory stimulus 
Legend. 
A representation of pseudopods generated over the time course. A. When cells were 
quiescent, pseudopod generation was noted across the breadth of the leading edge of the 
cell in a random fashion.  B. The direction of the chemoattractant gradient is shown by 
the large red arrow.  Pseudopods generated towards the stimulus were more likely to be 
retained while pseudopods that extended in inaccurate directions were more likely to be 
retracted (the sustained pseudopods over the time course is shown schematically).  C. A 
polarised (elongated) neutrophil migrating towards Interleukin 8 in a Zigmond chamber. 
It appears that neutrophils migrate up chemoattractant gradients by choosing the best 
aligned of competing randomly generated pseudopods.  
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Transmigration though extra cellular matrix 
 
Neutrophil proteinases are released during migration through extra cellular matrix 
(Wright and Gallin 1979) but it has been difficult to ascertain whether proteinases are 
necessary for neutrophil migration.  Chemotaxis through artificial substrates in response 
to fMLP can be inhibited by 50% using α1AT (Stockley, Shaw et al. 1990) and CG 
antibodies; synthetic inhibitors of CG and α1ACT also reduce neutrophil migration 
(Lomas, Stone et al. 1996).  Furthermore, fMLP-stimulated migration across an artificial 
basement membrane is also reduced by inhibitors of both NE and Matrix 
metalloproteinase 9 (MMP-9) (Declaux, Delacourt et al. 1996).  However, in vitro studies 
of endothelial monolayers and basement membrane matrices  have shown consistently 
that proteinase inhibitors are ineffective at stopping neutrophil migration (Allport, Ding et 
al. 1997; Mackeral, Cottell et al. 1999) although degradation of basement membrane 
components is reduced (Steadman, St John et al. 1997).  In animal studies, neutrophils 
from mice whose genes for NE and CG had been “knocked out” showed normal 
migration both in vitro and in vivo when exposed to LPS although pathogen clearance was 
impaired (Tkalcevic, Novelli et al. 2000) and mice deficient in Gelatinase B had normal 
neutrophilic migration into the lungs (Betsuyaku, Shipley et al. 1999).  However, animal 
studies of cigarette smoke inhalation suggest that neutrophil influx into the lung is 
reduced in the presence of proteinase inhibitors (Delacourt, Herigault et al. 2002; Wright, 
Farmer et al. 2002). 
 
The mechanisms remain unresolved, but the conflicting results may well reflect the study 
model used, including the density of the ECM studied and in particular the presence or 
absence of cross linked collagen (compare, for example (Chun, Sabeh et al. 2004) and 
(Sabeh, Ota et al. 2004)).  The majority of recent studies have used tumour cells, but there 
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is evidence to suggest that migrating cells can change their behaviour depending on the 
matrix and stimuli they are exposed to.  For example, in a non-cross linked collagen 3D 
matrix, cells migrate along fibres, but can squeeze between fibres in the presence of anti-
proteinases, therefore migration is not inhibited but redirected.  On the other hand in a 
dense cross linked collagen 3D matrix, cells require proteinases to migrate and migration 
is inhibited in the presence of anti-proteinases.  Cell derived matrices are cross linked but 
have gaps and migrating cells appear to preferentially seek out these gaps to migrate 
through.  In this scenario proteinases may or may not be required, depending on the size 
of the gap (Even-Ram and Yamada 2005).  If neutrophil migration in vivo is partially 
proteinase-dependent, migration may not require degradation of “loose” in vitro extra 
cellular matrix by proteinases to allow cell passage, but instead the generation/activation 
of inflammatory chemokines and cytokines or modulation of adhesion molecules 
(enhancing expression, increasing their activation or exposing binding sites (Yadav, Larbi 
et al. 2002)) by proteinases, and this may be more easily decreased or prevented by 
inhibitors, explaining the apparent experimental contradictions. 
 
1.2.2.2 Neutrophil migration in the pulmonary circulation 
 
The majority of neutrophils appear to enter the lung from the pulmonary capillary 
network rather than the post capillary venules (Doerschuk, Allard et al. 1989; Downey, 
Worthen et al. 1993). Neutrophil emigration into lung from the pulmonary circulation is 
less well understood than from the bronchial circulation, however there seem to be 
important differences in mechanism, probably due to the size of capillary networks.  
Forty to sixty percent of  pulmonary capillary segments are narrower than a spherical 
neutrophil, which on average is 7 to 8 µm in diameter (Hogg 1987; Doerschuk, Beyers 
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et al. 1993), so neutrophil rolling is unlikely because of size constraints.  Neutrophils 
entering the pulmonary capillary network have to undergo a shape change, from a sphere 
to an oblong, to allow passage through these narrow vessels.  This slows their transit 
time, and indeed, radio labelled neutrophils from patients with stable COPD have been 
shown to have a slower transit time in the pulmonary circulation compared with red 
blood cells (Selby, Drost et al. 1994).  When activated, neutrophils become less 
deformable due to actin polymerization, and this slows their progression through the 
capillary network further (Erzurum, Downey et al. 1992).  In such circumstances there is 
no need for transient adhesion via the selectins to initiate neutrophil rolling along the 
endothelium, as the leukocytes are already in close contact with the endothelium, and 
indeed there is evidence to suggest that some migration can occur without conventional 
adhesion molecules (Doerschuk 1992; Morland, Morland et al. 2000). 
 
In the bronchial circulation, adhesion and migration appears to be primarily dependent 
upon ICAM1 interactions, however, in the pulmonary circulation both CD18 dependent 
and independent adhesion pathways have been described and the path utilised appears to 
be stimulus specific.  For example, in animal models, bacteria such as streptococcus 
pneumoniae and Staphylococcus aureus and hydrochloric acid  have induced CD18 
independent neutrophil migration, while human studies have demonstrated CD18 
independent migration towards host-derived chemoattractants such as Leukotriene B4 
(LTB4), IL8  and sputum  (Mackeral, Russell et al. 2000; Morland, Morland et al. 2000).  
In contrast, Interleukin 1 (IL-1), phorbol myristate acetate and gram negative bacterial 
stimuli including LPS elicit migration via pathways predominantly mediated by CD18 
(Doerschuk, Winn et al. 1990; Hellewell, Young et al. 1994; Qin, Quinlan et al. 1996; 
Ramamoorthy, Saski et al. 1997).   CD18 dependent migration may not only be stimulus 
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driven but also inflammatory mediator driven. Rabbits produce both IL8 and TNF-α 
during a bacterial pneumonia but CXCL8 and TNF-α production during a gram negative 
pneumonia are 2 and 10 fold greater respectively than seen during a gram positive 
pneumonia (Shoburg, Quinlan et al. 1994). It may be that the varying concentrations of 
these pro-inflammatory stimuli elicit a CD18 dependent response, perhaps by inducing 
nuclear factor-κβ (Doerschuk, Winn et al. 1990) rather than the bacterial insult itself.  
Animal models have suggested that selectins are required where CD18 dependent 
migration occurs, but not for CD18 independent migration. For example, L-Selectin 
knock out mice had significantly less neutrophil recruitment into the lungs in response to 
LPS (a CD18 dependent stimulus) while recruitment in response to Streptococcus 
pneumoniae (a CD18 independent stimulus) was unaffected (Doyle, Bhagwan et al. 
1997).   
 
1.2.2.3 Phagocytosis and bacterial killing 
The role of the neutrophil is to kill and remove micro-organisms.  The neutrophil 
achieves this by a process of phagocytosis, the respiratory burst and the release of 
cytotoxic peptides and proteins. 
  
Phagocytosis 
Ingestion of bacteria precedes intracellular killing.  Immunoglobulins bind to bacterial 
surface antigens (a process of opsonisation), enhancing phagocytosis and causing the 
activation of the complement system. The neutrophil then binds both the 
immunoglobulin (via the FcγR receptor) and complement factor C3 (via the 
Complement receptor type 3 receptor, CD11b/CD18, Mac-1) (Burnett 1997).  Ingested 
bacteria are encapsulated within the phagolysosome, where they are killed and 
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degraded.  Bacterial killing is achieved via the respiratory burst and the action of 
cytotoxic proteins while bacterial degradation is achieved via the release of granule 
proteases.  
 
Respiratory burst 
The respiratory burst describes the release of oxidative molecules that originated from 
the membrane-bound NADPH oxidase system.  Superoxide production starts with the 
reduction of oxygen by NADPH to form the superoxide radical, O2-. The radicals can 
react spontaneously with water to form molecular oxygen and hydrogen peroxide, or 
the reaction can be catalysed by superoxide dismutase.  MPO (stored in azurophil 
granules) catalyses the reduction of hydrogen peroxide to water or to hyperchlorous 
acid when chloride is present.  These powerful products are released into the 
phagolysosome, where they destroy ingested bacteria.  These products are also capable 
of damaging adjacent cells when released outside of the neutrophil (Weiss, Young et al. 
1981), a process that is limited by the relevant antioxidants in healthy individuals 
(MacNee 2000). The importance of the respiratory burst as a means to destroy bacteria 
is amply illustrated in chronic granulomatous disease, where phagocytic cells are 
unable to generate the products of the respiratory burst, leading to recurrent bacterial 
infections.       
 
Cytotoxic peptides and proteins 
The neutrophil also contains cytotoxic proteins, most of which are stored in the 
azurophil granules.  These proteins include human neutrophil peptides 1 – 4 
(collectively known as “the defensins”). They account for 50% of the total protein 
31 
content of azurophil granules and are highly toxic to fungi, enveloped viruses and 
bacteria (Burnett 1997). 
   
The three most important neutrophil serine proteinases are elastase, cathepsin G and 
proteinase 3.  The serine proteinases are located within the primary granules, whereas 
metalloproteinases are located within the specific granules.   The serine proteinases will 
be discussed in section 1.5.6. 
 
1.3 ANTI-PROTEINASES 
1.3.1 α1-antitrypsin 
α1-antitrypsin (α1AT) is the major plasma inhibitor of neutrophil elastase and probably 
the most important antiproteinase in the distal airways and alveoli (Stockley 1997).  It 
is a 54 kDa glycoprotein that is secreted by hepatocytes, with little secretion occurring 
in the lung (Stockley, Mistry et al. 1979).  Inflammation leads to an acute rise in the 
plasma concentration of α1AT with a corresponding increase in passive diffusion into 
the lung. α1AT inactivates free neutrophil elastase, cathepsin G and proteinase 3 in the 
airways (Lee and Downey 2001).  Its importance becomes obvious in patients with a 
severe hereditary deficiency associated with a low serum concentration of α1AT, in 
whom uncontrolled elastase activity leads to the early onset of emhysema (see section 
1.7). 
1.3.2 Secretory leukoprotease inhibitor 
Secretory leukoprotease inhibitor (SLPI) is the main inhibitor of elastase in the 
proximal airways.  It is of low molecular mass (12 kDa) and is produced locally by lung 
epithelial cells and is present in serous glands and clara cells (Mooren, Kramps et al. 
1983; De Water, Willems et al. 1986; Maruyama, Hay et al. 1994).  SLPI can also be 
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produced by type II pneumocytes (Sallenave J.M., Shulman et al. 1994), is secreted 
from the basolateral surface of submucosal glands and has been detected in the lung 
interstitium (Willems, Otto-Verberne et al. 1986; Dupuit, Jacquot et al. 1993) 
suggesting a more widespread role throughout the lung.  As well reversibly inhibiting 
NE and CG (Sallenave J.M. 2000), SLPI  has anti-viral, anti-bacterial and anti-fungal 
properties (Tomee, Koeter et al. 1998).  Its regulation in the lung is mainly unknown, 
although elastase can reduce its release from epithelial cells (Sallenave J.M., Shulman 
et al. 1994). 
 
1.3.3 Other anti-proteinases that inhibit neutrophil proteinases. 
α1-antichymotrypsin (A1ACT) is produced by hepatocytes and present in serum and 
rapidly inactivates CG (Stockley 1997).  A1ACT is present in the lung due to passive 
diffusion, active transport and some local production (Stockley 1983).  
 
Other proteinase inhibitors that have been identified in the lung include elafin, α2-
macroglobulin A2M) and  monocyte/neutrophil elastase inhibitor (MNEI). Table 1.2 
provides a summary of the anti-proteinases which inhibit neutrophil proteinases 
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Table 1.2. The inhibitors of neutrophil proteinases 
 
Inhibitor Source Target proteinase Inhibition 
Alpha 1 anti trypsin Produced in the liver Found in serum NE, CG, PR3 Irreversible 
Alpha 1 antichymotrypsin Liver and macrophages CG Reversible 
Alpha 2 macroglobulin 
Liver and macrophages 
NE, CG, PR3,  
MMP 8, MMP 9 Irreversible 
Secretory leucoproteinase 
inhibitor Mucosa NE, CG Reversible 
Elafin Mucosa NE, PR3 Reversible 
Monocyte-neutrophil 
elastase inhibitor Neutrophils / monocytes NE, CG, PR3 Irreversible 
Tissue Inhibitors of 
metalloproteinases 
Many cell types including  
epithelial cells, fibroblasts,  
neutrophils and monocytes 
Gelatinases (MMP 8 
and MMP-9) Irreversible 
 
 
1.4 Ageing and neutrophil function 
 
Developments in medicine, public health and socioeconomics, has led to an increase in 
our average lifespan.  Statistics from the World Health Organisation website shows that 
10% of the world’s population is made up of individuals aged 60 years or older, and this 
figure is expected to rise to 22% in 2050 (Dorshkind, Montecino- Rodriguez et al. 
2009).  
 
It is well established that the efficiency of the immune system declines with increasing 
age.  This phenomenon has been termed “immunesenescence” and is most obviously 
demonstrated by the increased risk of infection-associated morbidity and mortality 
experienced by the elderly (Fein 1999; Bonomo 2002; Gavazzi and Krause 2002).    
Bacterial dysentery is three times more common in older adults, and there is a 50% 
higher mortality from gram negative bacterial sepsis in the elderly (Martin, Mannino et 
al. 2006). Furthermore, deaths from gastrointestinal infections, pneumonia and influenza 
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are largely confined to patients above the age of 65 (Liang and Mackowiak 2007).  In 
addition, older adults are at increased risk of post-surgical complications such as lower 
respiratory tract infections and show a delayed resolution of inflammation, which is 
associated with an increased risk of tissue damage and the onset of physical frailty 
(Butcher, Killampalli et al. 2003).  
 
The high incidence of bacterial infections in older adults is highly suggestive of a sub-
optimal neutrophil response, as these cells are fundamental in clearing bacteria, and 
recent studies have described functional differences in neutrophil behaviour in older 
adults.    
 
With advancing age, neutrophil priming and activation is reduced in response to a 
number of ligands including fMLP, GM-CSF, G-CSF and LPS (Fortin 2008). These 
receptors have distinct signalling pathways and their modulation during aging suggests a 
common underlying mechanism. Ex vivo animal studies have suggested that neutrophils 
from older populations demonstrate increased membrane fluidity that seems to be 
related to a reduced cholesterol content within the cell (Alvarez 2001). This was 
associated with a decrease in superoxide generation in response to fMLP but not to the 
phorbol ester, phorbol myristic acid (PMA).  fMLP acts via a specific receptor, while 
PMA activates downstream signalling events via direct activation of protein kinase C 
(PKC), suggesting  a proximal signalling defect, potentially within the lipid raft.   
 
Lipid rafts are regions of reduced fluidity within the phospholipid bilayer and are 
enriched for cholesterol and phospholipids with long saturated fatty acid side chains.  
They are important for the regulation of cell signalling because they provide a means to 
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segregate receptors and their proximal signalling components within the membrane, 
with receptor activity modulated by the inclusion or exclusion of signalling elements in 
the lipid raft-associated signalsome (Simons 2000).     Alterations in cell fluidity would 
interfere with lipid raft formation and thus could impact on a wide range of cellular 
signalling pathways, including those involved with migration, phagocytosis, and 
apoptosis. Currently, there are no published studies assessing membrane fluidity in 
human neutrophils, however, there is indirect evidence of alterations in lipid raft 
function with increasing age.   The negative regulator of GM-CSF receptor signalling 
(SHP-1) is excluded from lipid rafts within one minute of stimulation of neutrophils 
from young donors with GM-CSF, but remains associated with lipid rafts in neutrophils 
from old donors (Fortin, Larbi et al. 2006).  Furthermore, agonist receptors such as 
TREM-1 and TLR4 show reduced recruitment to lipid rafts in neutrophils from old 
donors, compromising their signalling function (Fulop, Larbi et al. 2004; Fortin, Larbi et 
al. 2007).   
 
Comparisons of neutrophils from healthy young and older subjects have demonstrated 
that bactericidal (superoxide generation and degranulation) and phagocytic function are 
dramatically reduced in circulating cells isolated from older subjects (Lipschitz, Udupa 
et al. 1984; Fulop, Komaromi et al. 1986; Wenisch, Patruta et al. 2000; Butcher, Chahal 
et al. 2001).  This may have major implications for their role in infection in the elderly. 
 
Superoxide generation in response to the bacterial peptide fMLP and to gram negative 
bacteria appear to be maintained in older subjects (Corberand, Ngyen et al. 1981; 
Esparza, Sanchez et al. 1996; Butcher, Chahal et al. 2001). However, superoxide 
generation in response to gram positive stimuli (such as Staphlococcus aureus) appear to 
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be significantly reduced (Wenisch, Patruta et al. 2000) and it is known that older adults 
have a reduced ability to resolve infections caused by Gram positive organisms 
(Whitelaw, Rayner et al. 1992).  Furthermore, the mechanisms underpinning these 
alterations to function have been partially characterised.  A reduction in cell surface 
expression of CD16 may account for reduced phagocytic function (Butcher, Chahal et 
al. 2001), and alterations in intra-cellular signalling through the Jak-STAT and SHP-1 
pathways due to  changes in membrane fluidity may contribute to reduced superoxide 
generation, particularly in response to GM-CSF (Fortin, Larbi et al. 2006; Fortin, Larbi 
et al. 2007; Tortorella, Simone et al. 2007). 
 
In contrast, the effects of ageing upon neutrophil migration is poorly understood.  Some 
studies have shown no effects on migration in aging adults, with unaltered neutrophil 
adherence to endothelium (MacGregor and Shalit 1990; Esparza, Sanchez et al. 1996) 
and comparable expression of adhesion molecules in older subjects (Rao, Currie et al. 
1992) (Esparza, Sanchez et al. 1996).   In other reports, peripheral neutrophils from 
aging donors have demonstrated reduced movement towards chemotactic signals (Niwa, 
Kasama et al. 1989; Wenisch, Patruta et al. 2000; Fulop, Larbi et al. 2004).  
Interestingly, one study reported intact chemokinesis, but reduced chemotaxis in 
neutrophils from older subjects (Wenisch, Patruta et al. 2000).  However, studies 
performed to date have not been able to characterise individual neutrophil migration in 
detail and so it still remains unclear of ageing impacts upon neutrophil chemotaxis. 
 
Ageing in association with chronic obstructive pulmonary disease is discussed in section 
1.6. 
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1.5 Chronic Obstructive Pulmonary Disease 
1.5.1 Definition and classification of disease severity 
Chronic obstructive pulmonary disease (COPD) is characterised by airflow obstruction 
with related symptoms including cough, shortness of breath, expectoration and wheeze.  
The widely accepted Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
has classified COPD as “a disease state characterised by airflow limitation that is not 
fully reversible.  The airflow limitation is usually both progressive and associated with 
an abnormal inflammatory response of the lungs to noxious particles or gases” 
(Pauwels, Buist et al. 2001). The GOLD definition for airflow limitation is a forced 
expiratory volume in 1 second (FEV1 / forced vital capacity (FVC) ratio of < 70% and 
disease severity is classified into four stages: stage 1 (FEV1 > 80% predicted); stage 2 
(FEV1 > 50 to < 80% predicted); stage 3 (FEV1 > 30 to < 50% predicted); stage 4 
(FEV1 < 30 or < 50% predicted in the presence of chronic respiratory failure) (Global 
Initiative for chronic obstructive lung disease. 2007). 
 
COPD also includes chronic bronchitis, small airways disease (bronchiolitis) and 
emphysema, and these conditions can co-exist in varying proportions between affected 
individuals (Saetta, Turato et al. 2001).  Chronic bronchitis is defined clinically as the 
presence of chronic productive cough for 3 months in each of 2 successive years 
(Medical Research Council. 1965).  Emphysema is defined pathologically as the 
destruction of alveolar walls and the permanent enlargement of the airspaces distal to 
the terminal bronchioles.  
 
1.5.2 Prevalence and impact 
Chronic Obstructive Pulmonary Disease (COPD) is one of the foremost causes of 
chronic morbidity and mortality worldwide.  Globally, it affected 44 million people in 
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1990 (Lomas 2002) and recent estimates have suggested that currently COPD affects 
approximately 210 million people (World Health Organization 2007) with the 
prevalence continuing to rise.  In 2007, COPD accounted for 5% of all deaths (World 
Health Organization 2007) but the WHO predicts an increase in COPD related deaths of 
more than 30% in the next 10 years, emphasising the continued impact this disease will 
have internationally (Mannino and Holguin 2006).  
 
1.5.3 Pathogenesis 
Cigarette smoking remains the most important risk factor for the development of COPD 
(Doll, Peto et al. 1994) although only approximately 20% of smokers develop clinically 
significant disease (Tashkin, Clark et al. 1984).  This suggests that a combination of 
genetic and environmental factors interact to cause COPD, and there has been much 
research aiming to identify candidate genes that may confer genetic susceptibility.  To 
date, however, only deficiency alleles on the α1AT gene have been robustly identified 
as predisposing to disease (Sanford and Silverman 2002). 
 
Pathologically, COPD is characterised by widespread inflammation of the peripheral and 
central airways with destruction of the lung parenchyma.  Oedema, fibrosis, smooth 
muscle hypertrophy and loss of elastic recoil lead to bronchial wall thickening, which 
cause airflow obstruction (Saetta, Turato et al. 2001). 
 
COPD, while primarily a lung disease, is associated with increased co-morbidity 
including cardiovascular disease, and systemic pathology such as muscle wasting and 
dysfunction. It has been hypothesised that persistent low-grade inflammation may drive 
the co-morbidity and the systemic effects noted with this disease (Sin, Anthonisen et al. 
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2006).  The systemic manifestations of COPD are important, as they are not only 
associated with increased morbidity, but are also predictive of disease outcome, 
especially Body Mass Index (BMI) which forms part of the BODE index (Body Mass, 
airflow obstruction, dyspnoea and exercise capacity) (Celli, Cote et al. 2004). 
 
There is controversy concerning whether increased and sustained pulmonary 
inflammation causes increased systemic inflammation.  However C-reactive protein 
(CRP) (a generic marker of systemic inflammation) is raised in patients with COPD 
compared to healthy controls (Pinto-Plata, Mullerova et al. 2004) irrespective of cigarette 
smoke exposure and ischaemic heart disease (an independent cause of a raised CRP).  It 
is unclear whether these systemic changes are incidental or driven by pulmonary 
inflammation. 
 
1.5.3.1 Neutrophilic presence in the lung 
There is a substantial body of evidence to support the hypothesis that the neutrophil is 
the primary effector cell in Chronic Obstructive Pulmonary Disease (COPD) and that 
neutrophil proteinases, especially NE are responsible for the main pathological features 
seen.  
 
Studies have shown that patients with COPD have increased numbers of neutrophils in 
proximal airway secretions (Stansecu, Sanna et al. 1996; Rutgers, Timens et al. 2000) 
and broncheoalveolar lavage fluid (BALF) (Martin, Raghu et al. 1985) compared with 
asymptomatic smokers, and that the percentage of neutrophils in BALF is higher in 
patients with the greatest degree of  airflow obstruction (Thompson, Daughton et al. 
1989; Lacoste, Bousquet et al. 1993).  Furthermore, in a recent study of bronchial 
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biopsies, small airways intra-epithelial neutrophil counts were greater in patients with 
COPD compared with both smoking and non-smoking controls, and correlated with 
airway obstruction (Pilette, Colinet et al. 2007). Increased neutrophil counts have been 
found in the bronchial walls and in BALF samples from patients during exacerbations of 
COPD (Balbi, Bason et al. 1997; Tsoumakidou, Tzanakis et al. 2005), with increased 
neutrophil sequestration in the pulmonary microcirculation and such episodes relate to 
subsequent progression of airflow obstruction (Selby, Drost et al. 1991).   Resolution of 
the neutrophillic inflammation occurs approximately 5 days after appropriate treatment 
of the exacerbation, which coincides with clinical recovery (Gompertz, O'Brien et al. 
2001).  In addition, a recent study by Donaldson et al (Donaldson, Seemungal et al. 
2005) reported that patients with higher numbers of neutrophils in their sputum had a 
faster decline in FEV1 compared with those with lower neutrophil counts, losing 
approximately 1% more than predicted each year.  Parr et al (Parr, White et al. 2006) 
demonstrated that baseline markers of neutrophilic inflammation relate to subsequent 
decline of lung function and CT quantification of emphysema over the subsequent four 
years.  Gas transfer (the most direct physiological measure of emphysema) has been 
shown to be inversely proportional to levels of neutrophil associated markers, such as 
MPO and human neutrophil lipocalin in patients with COPD (Ekberg-Jansson, 
Andersson et al. 2001).  Both clinical and sub-clinical emphysema (noted on HRCT) are 
associated with an increase in NE and other neutrophil proteins in BALF (Betsuyaku, 
Nishimura et al. 1999; Yoshioka, Betsuyaku et al. 2005) and in established emphysema, 
severity is proportional to NE immuno-reactivity in tissue (Ge, Zhu et al. 1990) and 
enzyme activity in BALF (Fujita, Nelson et al. 1990).    Finally, both neutrophil counts 
and NE concentration appear to decline with smoking cessation (Rennard, Daughton et 
al. 1990) which is consistent with the benefits of this intervention. 
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The increased numbers of neutrophils seen in the lungs of patients with COPD may 
accumulate because of an increased influx from peripheral blood or because of 
prolonged neutrophil survival.  Exposure to cigarette smoke appears to stimulate 
neutrophil differentiation and maturation, causing a peripheral leucocytosis (Corre, 
Lellouch et al. 1971; Van Eeden and Hogg 2000) which has been found to correlate with 
the severity of airflow obstruction (Yeung and Buncio 1984).  This suggests that a 
peripheral neutrophilia facilitates an increased neutrophil transmigration into the lung.   
Platz and colleagues (Pletz, Ioanas et al. 2004) described a reduction of peripheral 
neutrophil apoptosis (based on Annexin V-PE binding and nuclear morphology) during 
exacerbations of COPD compared with healthy controls, which returned to control levels 
upon resolution of symptoms.  This increased cell longevity would facilitate increased 
neutrophil accumulation into the lung during exacerbations, again predisposing to 
enhanced lung damage.  Once in the lungs, it has been suggested that reduced neutrophil 
apoptosis may account for the high numbers seen in the lung and the increased 
inflammation described in COPD, although recent studies present conflicting results 
(Uller, Persson et al. 2006).  Rytila et al (Rytila, Plataki et al. 2006) found no differences 
in the proportion of apoptotic neutrophils in induced sputum, or in the in vitro anti-
apoptotic activity detected in the sputum fluid phase in patients with COPD, healthy 
smokers or healthy controls despite patients with COPD having a significantly higher 
percentages of neutrophils in the samples.  The authors suggested that the increased 
neutrophilic presence in COPD was more likely due to an increased influx rather than a 
reduction in apoptosis.   
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1.5.4 Pro-migratory stimuli 
Neutrophils migrate into the lung in response to soluble mediators.  Pro-migratory 
stimuli can be classified as non-chemotactic cytokines, chemotactic cytokines 
(chemokines) or chemoattractants. 
1.5.4.1 Non-chemotactic Cytokines 
Tumour Necrosis Factor alpha (TNF-α) is thought to be one of the most important pro-
adhesive cytokines in COPD.  It is produced by activated monocytes and macrophages 
(but also epithelium, endothelium and probably smooth muscle cells) and has been 
implicated in the pathogenesis of  COPD (Churg A., Dai et al. 2002; Sakao, Tatsumi et 
al. 2002).  Increased levels of TNFα have been measured in serum, sputum 
(Hacievliyagil, Gunen et al. 2006) and in bronchoalveolar lavage samples from patients 
with COPD, demonstrating a dose dependent relationship with cigarette exposure 
(Kuschner, D'Alessandro et al. 1996), with further increases during exacerbations 
(Aaron, Angel et al. 2001).  TNFα has also been associated with the systemic 
manifestations of COPD, including a low BMI (Di Francia, Barbier et al. 1994) 
(perhaps via leptin); (Calikoglu, Sahin et al. 2004) and abnormal resting energy 
expenditure (Nguyen, Bedu et al. 1999). TNFα over-expression (due to genetic 
polymorphism) has been linked to early COPD development and rapid progression 
(Brogger, Steen et al. 2006).    In support of this, mouse models with an inducible TNFα 
gene construct have shown that over-expression of TNFα is associated with the 
development of emphysema associated with a general increase in lung inflammation 
(Vuillemenot, Rodriguez et al. 2004) probably by inducing  MMP production (Wright, 
Tai et al. 2007). TNFα receptor knock out mice demonstrate reduced smoking or 
elastase induced emphysema in comparison with the wild type (Lucey, Keane et al. 
2002; Churg A., Wang et al. 2004) suggesting a central role for this cytokine. 
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IL-1ß is also produced by macrophages ( although neutrophils and epithelial cells can 
also produce the cytokine)  and increased levels have been found in sputum of patients 
with stable COPD, which increase further during exacerbations (Chung 2001). IL-1ß 
production is enhanced by cells cultured from smokers with COPD following cigarette 
smoke exposure compared with controls (Rusznak, Mills et al. 2000) and there is some 
evidence that over-expression of IL-1ß (caused by polymorphisms such as the -511 SNP 
with a cytosine/thymine transition) may increase susceptibility to COPD (Asada, 
Yamaya et al. 2005). Furthermore, animal studies using inducible IL-1ß systems have 
described a neutrophilic infiltrate, distal airspace enlargement, increased thickness of 
the conducting airways and enhanced mucin production when IL-1ß was over-expressed 
(Lappalainen, Whitsett et al. 2005). 
 
TNFα and IL-1ß are not directly chemotactic, but they act by increasing expression of 
integrins on the neutrophil surface and increasing endothelial expression of selectins 
and I-CAM1, aiding capture and firm adhesion of neutrophils to the vascular 
endothelium (Burke-Gaffney and Hellewell 1996; Scholz, Devaux et al. 1996).  They 
also increases production of directly chemotactic mediators from endothelial cells to 
enhance the migration process (Smart and Casale 1994). 
1.5.4.2 Chemoattractants 
Neutrophils possess at least five different receptors for chemotactic stimuli, including 
unique receptors for leukotriene B4 (LTB4), complement protein C5a, bacterial peptides 
including Formyl-methionyl-leucyl-phenylalanine (fMLP) and platelet activating factor 
(PAF).   
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Leukotriene B4 
LTB4 is mainly produced by monocytes, alveolar macrophages and activated 
neutrophils and its production is up-regulated by a number of inflammatory mediators 
including C5a, IL-1ß, TNF-α, granulocyte-macrophage colony stimulating factor (GM-
CSF), PAF, NE and even LTB4 itself (Crooks and Stockley 1998; Borgeat, Krump et al. 
2003).  LTB4 enhances neutrophil aggregation and chemotaxis via two neutrophil 
surface receptors.   A low affinity receptor induces degranulation and increases 
oxidative metabolism whereas a high affinity receptor induces aggregation, 
chemokinesis and adhesion via the integrin Mac-1 (Tonnesen, Anderson et al. 1989).  
LTB4 may also activate endothelial cell monolayers in vitro, enhancing neutrophil 
emigration (Nohgawa, Sasada et al. 1997). LTB4 concentrations are elevated in sputum 
(Hill, Bayley et al. 2000) and exhaled breath condensate (Montuschi, Kharitonov et al. 
2003) from patients with COPD.  Concentrations correlate with the degree of airway 
neutrophilia (Bhowmik, Seemungal et al. 2000) and increase further during bacterial 
exacerbations (Gompertz, O'Brien et al. 2001), returning to baseline once bacteria have 
been successfully eradicated (White, Gompertz et al. 2003).  In addition, LTB4 
concentrations also correlate with the subsequent decline in gas transfer implicating 
neutrophilic infiltration in the pathophysiology of emphysema (Parr, White et al. 2006).    
 
In vitro chemotaxis studies, using functional antibodies against IL-8 and an LTB4 
receptor antagonist, have demonstrated that over 60% of the chemotactic activity of 
sputum can be accounted for by contributions from both IL-8, and  LTB4 (Woolhouse, 
Bayley et al. 2002; Beeh, Kornmann et al. 2003).  
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LTB4 is degraded by oxidation in myeloid cells and hepatocytes rendering it 
biologically inactive (Feinmark, Lindgren et al. 1981).  There is also a negative 
feedback loop where LTB4 stimulates the production of degradative enzymes, limiting 
its own duration of activity (Crooks and Stockley 1998).  
 
Complement protein C5a 
Cleavage of complement protein C5 yields C5a, a component of the membrane attack 
complex, and C5a, a powerful chemoattractant.  Circulating C5a is produced during the 
activation of the classical complement cascade in blood and can bind to circulating 
neutrophils (Kohl and Bitter-Suermann 1983).  Tissue macrophages and epithelial cells 
produce proteins of the alternative complement pathway (Strunk, Eidlen et al. 1988) 
(including C5), and so C5a is able to promote neutrophil migration by the formation of 
a concentration gradient. C5a has been shown to enhance adhesion molecule expression 
(especially ICAM-1) in airway epithelial cells and interestingly, this effect was 
exaggerated in the presence of cigarette smoke (Floreani, Wyatt et al. 2003). There 
have been few in vivo studies monitoring C5a levels in COPD, and to date, levels have 
not appeared elevated in COPD patients (McLeod, Mack et al. 1985).     
 
Formyl-methionyl-leucyl-phenylalanine 
Formylated bacterial peptides are produced following the cleavage of the NH2 –terminal 
portions of common bacterial proteins during synthesis; there are no similar formylated 
peptides in mammalian cells, which makes these proteins highly specific targets for 
neutrophil activation and degranulation.  The fMLP receptor consists of seven 
transmembrane-spanning loops and they are expressed on neutrophils and monocytes 
both when quiescent and activated, however, the presence of fMLP (or other agents) 
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causes the mobilisation of secretory vesicles, leading to a five fold increase in surface 
receptor expression (Borregaard and Cowland 1997).  The presence of fMLP has 
multiple affects on neutrophils, including degranulation, oxidative burst, cytoskeletal 
changes, and chemotaxis (Wagner and Roth 2000). 
 
The numbers of fMLP receptors are elevated in both healthy smokers and subjects with 
COPD who smoked, but not non-smoking patients with COPD (Matheson, Rynell et al. 
2003) suggesting that fMLP may play a role in the recruitment of neutrophils leading to 
the development of disease and its progression whilst smoking and especially during 
bacterial exacerbations (where bacterial formyl peptides may be most important). 
 
Platelet activating factor  
PAF is produced by endothelial cells, platelets, neutrophils and macrophages.  It is pro-
inflammatory and enhances neutrophil adhesion to the endothelial surface, promoting 
migration (Mathiak, Szewczyk et al. 1997).  Its’ role or relevance in the pathogenesis of 
COPD is unknown. 
 
1.5.4.3 Chemokines 
Chemokines are a group of small proteins (approximately 40 in number) with similar 
cysteinyl-containing structures.  They are classified by the sequence of the two most 
NH2 –proximal cysteines; in the CXC chemokines, the cysteines are separated by an 
amino acid whereas in the CC chemokines, the cysteines are adjacent to one another.  In 
general, CC chemokines are more strongly chemotactic for monocytes and CXC 
chemokines are more strongly chemotactic for neutrophils.  CXC chemokines include 
interleukin 8 (IL-8); Growth related oncogene (GRO) alpha, beta and gamma; epithelial 
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cell derived neutrophil activating peptide (ENA)-78 and neutrophil activated peptide 
(NAP)-2.  Interleukin 8 is the most well studied and is believed to be one of the most 
important chemoattractants in COPD. 
 
Interleukin-8 
IL-8 is a 16kDa protein that is primarily produced by leukocytes (monocytes, T cells, 
neutrophils and natural killer cells) and airway epithelial cells.  Production is not 
constitutive but is induced by pro-inflammatory cytokines such as IL-1ß and TNFα 
(Matsushima, Morishita et al. 1988), bacteria and bacterial products (DiMango, Zar et 
al. 1995; Khair, Davies et al. 1996), viruses such as adenovirus and rhinovirus (Alcorn, 
Booth et al. 2001) and oxidants from cigarette smoke (Deforge, Preston et al. 1993).  
Once secreted, IL-8 binds to CXC Receptors on leukocytes resulting in activation of 
protein kinase B and GTPases, which lead to enhanced neutrophil adherence to 
endothelial cells (by increasing expression of ß2-integrins) and directed cell migration.  
IL-8 also activates Ras and mitogen activated protein kinases and extracellular signal-
related kinases in neutrophils, causing degranulation.   
 
In COPD, sputum IL8 correlates with levels of neutrophil activation markers such as 
myeloperoxidase (MPO) and neutrophil elastase (NE) (Hill, Bayley et al. 1999) and 
relates to airflow obstruction (Yamamoto, Yoneda et al. 1997), oxygen saturation, 
cigarette exposure (Hacievliyagil, Gunen et al. 2006) and progression of emphysema 
quantified by CT scan (Parr, White et al. 2006).  It has been suggested that oxidative 
stress (caused by cigarette smoke and bacterial and viral infections) induces IL-8 
production in both airway epithelial and endothelial cells, leading to neutrophil 
adhesion, chemotaxis and degranulation.   
48 
Growth Related Oncogene Alpha 
 
GROα is detectable in bronchial secretions (Traves, Culpitt et al. 2002) and both GROα 
and ENA-78 have been measured in BAL fluid (Morrison, Strieter et al. 1998). One 
study has suggested that chemotaxis towards GROα and NAP2 is increased in COPD 
compared with healthy controls and smokers (Traves, Smith et al. 2004), but their 
contribution to the pathogenesis of COPD is unknown.   
 
Neutrophils possess two chemokines receptors, CXCR1 and CXCR2.  IL-8 can bind 
both with high affinity, but the other chemokines exert affects primarily through 
CXCR2, and have only a low affinity for CXCR1 (Wagner and Roth 2000). 
 
The individual importance of each pro-inflammatory or pro-migratory protein in COPD 
has yet to be unravelled, certainly many of these proteins appear to have similar actions 
and a degree of overlap or redundancy is likely to exist in the inflammatory cascade.  
However, there is increasing interest in identifying the key inflammatory mediators in 
COPD as potential targets for therapeutic interventions.   To date, trials which have 
aimed to block a specific mediator have not proved helpful (de Boer 2005).  
 
1.5.5 Neutrophil migration in COPD 
Given the increased presence of neutrophils in the lungs of patients with COPD, it has 
been hypothesised that neutrophils in COPD reflect an enhanced chemotactic response.  
However, there is conflicting evidence for both overall neutrophil migration and for an 
up-regulation of adhesion molecules in COPD.  Burnett and colleagues demonstrated a 
clear increase in chemotaxis and extracellular proteolysis compared with matched 
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controls (Burnett, Chamba et al. 1987), whereas Yoshikawa et al found the reverse, and 
described a reduction in overall chemotaxis in COPD (Yoshikawa, Dent et al. 2007). 
 
Noguera et al (Noguera, Batle et al. 2001) measured MAC-1, LFA-1 and L-Selectin 
expression on neutrophils from controls and patients with COPD, prior and post 
stimulation with TNF-α.  Neutrophils from patients with COPD had enhanced expression 
of these adhesion molecules compared with controls, and differences were even more 
pronounced following stimulation with chemoattractants.  Woolhouse et al (Woolhouse, 
Bayley et al. 2005) demonstrated up-regulation of CD11b (a component of MAC1) on 
neutrophils from smokers with COPD compared with controls.  Furthermore Di Stefano 
et al demonstrated increased expression of E-selectin and ICAM-1 on basal epithelial 
cells in the bronchial mucosa of chronic bronchitis with airflow obstruction (Di Stefano, 
Maestrelli et al. 1994). However, Gonzalez (160) found no differences between levels of 
adhesion molecules in smokers with and without airflow obstruction and Noguera et al 
found decreased levels of soluble ICAM-1 in patients with COPD compared with healthy 
controls (Noguera, Busquets et al. 1998).  
 
Despite the conflicting results, neutrophil function does appear to be different in COPD, 
with enhanced reactive oxygen species production (Noguera, Batle et al. 2001), 
enhanced phagocytosis and potentially enhanced migration (Burnett, Chamba et al. 
1987) with increased adhesion to endothelial cells under flow conditions (Woolhouse, 
Bayley et al. 2005).   The differences may be accounted for by genetic polymorphisms 
and be apparent during maturation in bone marrow.  Alternatively neutrophils could be 
“primed” following their release into the circulation, perhaps by inflammatory 
cytokines, so that they are more responsive, with an increased ability to respond and 
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degranulate compared with those of healthy individuals.  This priming may also occur 
during transmigration and studies have confirmed differences between neutrophils prior 
to and following migration even in healthy controls with increased expression of 
proteinases on the cell surface, increased adhesion molecule expression and 
enhancement of the respiratory burst (Dangerfield, Larbi et al. 2002; Yadav, Larbi et al. 
2002). However, these processes have not been studied in COPD. It remains unclear 
whether current observations reflect a predisposing factor for COPD or a consequence of 
the disease.    
 
The contradictory findings in migration and adhesion molecule expression may be 
explained by differences in patient groups and variations in methodologies, however, it 
is difficult to formulate a robust theory of the pathogenesis of COPD without these 
issues being resolved. 
 
1.5.6 Proteinases in COPD 
Table 1.3 provides an overview of neutrophil serine proteinases. 
Table 1.3: An overview of neutrophil serine proteinases 
  
  Neutrophil elastase Cathepsin G Proteinase 3 
Size 218 amino acids 235 amino acids 222 amino acids 
Mass 
(kDa) 39 28.5 29 
Substrate 
specificity 
Val- Xaa >  
Ala - Xaa 
Aromatic acids in P1 
position 
Same as NE, accepts basic  
amino acids in P1 position 
Elastolytic 
activity   20% potency of NE 40% potency of NE 
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1.5.6.1 Neutrophil Elastase 
A significant physiological role of NE is bacterial killing.  This is achieved when 
opsonised bacteria are ingested in phagasomes that fuse with lysosymes containing 
proteinases and oxidants.  NE is also intensely destructive and this is believed to be the 
primary cause of lung damage seen in both emphysema and chronic bronchitis.  NE was 
the first serine proteinase to be shown to produce emphysema in animal models. Intra-
tracheal instillation of purified NE induced emphysema in dogs and hamsters (Janoff, 
Sloan et al. 1977; Senior, Tegner et al. 1977) and intra-tracheal instillation of other 
elastases have given similar results in various animal models -  Papain (pineapple 
elastase) in rats (Gross, Pfizer et al. 1964), neutrophil lysates in dogs (Marco, Mass et al. 
1971) and porcine pancreatic elastase in rats and hamsters (Blackwood, Hosannah et al. 
1973; Snider, Hayes et al. 1974).  In fact the development of emphysema seems specific 
to elastase activity with emphysema severity relating proportionally to the elastolytic 
potency of the elastase used (Blackwood, Hosannah et al. 1973; Snider, Hayes et al. 1974) 
and in these models emphysema can be prevented by specific elastase inhibitors 
(Rudolphus, Kramps et al. 1994; Lucey, Stone et al. 1998). 
 
NE acts upon a wide range of proteins and can degrade elastin, fibronectin and collagen 
(Beith 1986; Kafienah, Buttle et al. 1998), and also decrease the function of 
immunoglobins and activate components of the complement cascade (Niederman, Merrill 
et al. 1986; Vogt 2000).  NE may also effect wound healing, by its actions on 
transforming growth factor β and the epithelins (Ashcroft, Lei et al. 2000).  During 
activation, azurophil granule proteinases (including NE) are expressed on the neutrophil 
membrane (Owen, Campbell et al. 1995; Owen, Campbell et al. 1997) and in vitro, over 
95% remains associated with the cell by a charge dependent mechanism, while less than 
5% is released into the liquid mileu or directly onto tissue, causing damage by close 
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contact between cells and matrix (Owen, Campbell et al. 1997; Campbell, Campbell et al. 
2000).  Recent elegant studies have shown that NE polarises towards the leading edge of 
the neutrophil as it migrates.  Some is then left behind as the cell moves on where it may 
cause collateral connective tissue damage (Cepinskas, Sandig et al. 1999).  
 
Free NE activity has been detected in secretions of patients with COPD (Hill, Bayley et 
al. 1999) and this is felt to be fundamental in the development of the condition in vivo.  
Free NE may accumulate from degranulating neutrophils, or (in contrast with apoptotic 
cells) may be freely released during cell necrosis (Fadok, Bratton et al. 2001).  Also the 
process of phagocytosis may cause the release of significant quantities of proteinases into 
the media (“sloppy eating”), especially during “frustrated phagocytosis”, when cells 
attempt to ingest large particles (Ohlsson, Linder et al. 1996).  Free NE can also be 
released from activated macrophages, which scavenge the proteinase from apoptotic 
neutrophils via endocytosis and subsequently release it during the first 24 hours of their 
own inflammatory response (Weitz, Huang et al. 1987).   This is important, as although 
cell-associated proteinases have partial resistance to native inhibitors such as α1AT 
(Owen, Campbell et al. 1997), free NE is more readily inactivated by both serum and 
tissue-based inhibitors (Weitz, Huang et al. 1987) if sufficient quantities are present, 
which means that in health, free NE should be completely inactivated at a short distance 
from the activated cell.  
 
Indeed, it has been shown that the concentration of free NE released from neutrophils 
falls exponentially away from the cell (Liou and Campbell 1996).  In healthy subjects, the 
serum concentration of α1-AT, which inhibits NE on a one to one molar basis, is 30µMol.  
This is at least two orders of magnitude lower than NE concentrations in the neutrophil 
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granule. Therefore following degranulation NE cannot be completely inhibited until it has 
diffused far enough to reduce its concentration to 30µMol.  This phenomenon is called 
quantum proteolysis (Liou and Campbell 1996) and was clearly demonstrated in a series 
of experiments using serum from patients with normal or deficient α1AT where an area of 
obligate enzyme activity existed even in the presence of serum from healthy subjects, but 
was far greater using serum from patients with α1 antitrypsin deficiency (Campbell, 
Campbell et al. 1999).  Membrane bound NE is less susceptible to anti-proteinases 
(Owen, Campbell et al. 1997) and the combination of increased free and membrane bound 
NE present in COPD may be sufficient to overcome local inhibitors, causing the tissue 
destruction which is characteristic of the disease.  
 
NE interacts with matrix proteins and cells, and this affects not only its own activity, but 
also the efficacy of its inhibitors and other proteinases.  For example, although free NE is 
irreversibly inhibited by α1AT, elastin bound NE is poorly inhibited by α1AT, while the 
inhibitory effect of SLPI is unaffected (Morrison, Kramps et al. 1987; Rice and Weiss 
1990).  Adhesion to goblet cells appears to alter the neutrophil membrane, enhancing the 
release of membrane bound NE into the inter-cellular space (Takeyama, Agusti et al. 
1998) potentially causing mucus secretion.  Furthermore, animal models have 
demonstrated that NE can induce secretory cell metaplasia which is prevented by NE 
specific inhibitors (Lanone, Zheng et al. 2002).  It has been suggested that mucous gland 
epidermal growth factor receptor interacts with NE as part of a signalling cascade to 
mediate this effect (Shim, Dabbagh et al. 2001).  In human studies, there is a clear 
relationship between the amount of mucus production and the concentration of active 
neutrophil elastase in the lung secretions.   
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NE can damage the respiratory epithelium in vitro, reduce ciliary beating (Smallman, Hill et 
al. 1984; Amitani, Wilson et al. 1991) and trigger a state of oxidative stress in cells 
(Aoshiba, Yasuda et al. 2001) all of which are abrogated by NE inhibitors.  NE can also 
induce apoptosis of epithelial cells  (Nakajoh, Fukushima et al. 2002) and detachment of 
bronchial epithelial cells from the extra cellular matrix (Rickard and Rennard 1989) and 
both PR3 and NE induce detachment and apoptosis of endothelial cells (Ballieux, Hiemstra 
et al. 1994) which has also been implicated in the pathogenesis of COPD (Tuder, Zhen et al. 
2003).   
 
NE stimulates the release of LTB4 by macrophages (Hubbard, Fells et al. 1991) and may 
cause release of IL8 from bronchial epithelial cells which enhances neutrophil migration into 
the lung.  This inflammatory response is greater in patients with α1-AT deficiency, who have 
higher levels of  both LTB4 and elastase. The increased inflammatory burden amplifies 
neutrophil recruitment, increasing the potential for tissue destruction compared with patients 
with normal anti-proteinase function, which explains in part the more severe and rapidly 
progressive disease of α1 – AT deficiency patients (Hill, Bayley et al. 2000).   
 
The most important risk factor for COPD is cigarette smoke exposure and the 
relationships between smoke inhalation and NE have been studied in depth.  In animal 
models NE knock out mice are partially protected (45%) against the development of 
emphysema (Shapiro 2000), however, these models are limited, as CG and PR3 persist, 
and CG has also been shown to cause secretory cell metaplasia (Lucey, Stone et al. 1985) 
whereas PR3 causes both emphysema and secretory cell metaplasia (Kao, Wehner et al. 
1988).  Furthermore, animal models have suggested that both synthetic (Lucey, Stone et 
al. 1989) and natural NE inhibitors (Lucey, Stone et al. 1990; Stone, Lucey et al. 1990; 
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Rudolphus, Kramps et al. 1994) can limit emphysema development when delivered 
simultaneously with the elastase insult.   Most animal models suggest that neutrophil 
influx is greatest during the early stages of lung damage with macrophage influx, and 
their metalloproteinases accumulating at a later stage (Ofulue, Ko et al. 1998; Zay, Loo et 
al. 1999).  However, even when given in established disease, NE inhibitors still limit 
inflammation and connective tissue breakdown (Wright, Farmer et al. 2002) suggesting 
that this enzyme plays a key role throughout disease development and progression. 
 
COPD is characterised by periods of stability of symptoms punctuated with exacerbations 
(which are intermittent worsening of symptoms and (most probably) of the inflammatory 
load (Sapey and Stockley 2006)).  NE activity relates to sputum purulence, which is due to 
MPO and can be graded visually (Gompertz, O'Brien et al. 2001).  During bacterial 
exacerbations of COPD, sputum purulence, neutrophil influx, NE activity and tissue 
degradation products increase (Dowson, Guest et al. 2001; Gompertz, O'Brien et al. 2001; 
Donaldson, Seemungal et al. 2002) and therefore it is likely that proteinase induced tissue 
damage also increases.  More frequent exacerbations are associated with a faster decline in 
lung function as well as increased morbidity and mortality and it may be that the increases 
in NE load and activity during these periods causes progressive lung damage which is 
reflected in markers of disease severity (Dowson, Guest et al. 2001).  Table 1.4 summarises 
the actions of NE in COPD.                           .
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Table 1.4.  The actions of neutrophil elastase in COPD 
 
Intra-cellular : engulfed  
organisms in phagosome 
Bacterial Killing Extra cellular: Targeting and cleaving 
bacterial  virulence factors in released 
granule proteins 
Degradation 
ECM components 
Cystatin C 
TIMPs 
T Lymphocyte surface antigen 
Activation MMP-2, MMP-3, MMP-9,  Cathepsin B 
Modification of inflammatory  
mediators 
Enhances epithelial secretion of CXCL8 
Enhances macrophage secretion of LTB4 
Inhibits cellular reponse to TNFRII 
prolonging half life of TNF 
Increases SLPI expression but reduces 
secretion of SLPI 
Increases elafin expression  
Increases alpha1-AT expression by 
monocytes and alveolar macrophages   
Cell migration 
NE/alpha 1 antitrypsin complexes  
are chemotactic for neutrophils 
Modification of ICAM1 expression 
enhancing adhesion 
Cell apoptosis Increases epithelial and endothelial  cell apoptosis 
Cell function 
Disruption and detachment of epithelial cells 
Reduces ciliary beating of columnar 
epithelium    
Enhances oxidative stress    
Increases mucin MUC5AC protein content  
Increases bacterial adherence and 
colonisation 
 
Legend 
References included in text.    
 
 
57 
1.5.6.2 Matrix metalloproteinases 
Both neutrophils and macrophages produce large amounts of Metalloproteinases (MMPs) 
and their inhibitors, the tissue inhibitors of metalloproteinases (TIMPs).  The MMPs are 
proteolytic enzymes that are secreted as proenzymes (activated by other MMPs and NE) 
and remain bound to cell membranes.  MMPs not only degrade matrix proteins, but also 
inactivate anti-proteinases such as α1-AT and α1-ACT, activate enzymes involved in the 
clotting cascade and interact with cytokines and adhesion molecules, so their potential 
role in the pathogenesis of COPD is complex and wide ranging.      
 
Over 24 mammalian MMPs have been described, and although they are primarily 
grouped according to the proteins they degrade (collagenases, gelatinases etc.), most can 
degrade all extra cellular substrates.  MMPs are inhibited by α2-macroglobulin and by 
the four TIMPs described to date (Baker, Edwards et al. 2002).  The main MMPs 
secreted by neutrophils are MMP-9 (Gelatinase B), which degrades collagen, elastin and 
gelatine; and MMP-8 (Neutrophil collagenase) which degrades collagen types I-III.  
 
MMP-9 is increased in lung tissue, BALF and plasma taken from patients with COPD 
(Segura-Valdez, Pardo et al. 2000), levels are negatively correlated with airflow 
obstruction and relate to the number of sputum neutrophils (Vignola, Bonanno et al. 
1998; Beeh, Kornmann et al. 2003).  MMP-9 not only acts as a proteinase, but also 
modifies cellular functions by regulating cytokines and matrix bound growth factors and 
therefore may have a role in lung remodelling after the inflammatory insult resolves (Li, 
Cui et al. 2002; Atkinson and Senior 2003).  MMP-9 deficient mice exposed to intra-
tracheal LPS showed no differences in histological tissue damage, neutrophil migration 
or infiltration than the wild type mouse, suggesting a limited role for this MMP in the 
pathogenesis of COPD (Betsuyaku, Shipley et al. 1999).  In a further study MMP-9 
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knock out mice displayed greater neutrophil influx than the wild type, perhaps because 
MMP-9 can degrade neutrophil chemoattractants (Lanone, Zheng et al. 2002).  However 
smoke exposed guinea pigs displayed a reduction in the severity of emphysema and 
MMP-9 activity in BALF after introduction of a broad spectrum MMP inhibitor, 
although this may also have reflected inhibition of other metalloproteinases (Selman, 
Cisneros-Lira et al. 2003).  Genetic polymorphisms of MMP-9 have been identified that 
cause enhanced protein expression, and in a Japanese study, polymorphism -1562C/T  
was associated with an increased risk of smoking induced emphysema (Minematsu, 
Nakamura et al. 2001)  although this has yet to be replicated in other populations 
(Wallace and Sandford 2002). 
 
MMP-8 has been less studied in COPD compared with MMP-9, however one study 
described both raised concentrations and increased activity of MMP-8 in the induced 
sputum of patients with COPD compared with smokers without evidence of COPD.  
Furthermore both the levels and activity of MMP-8 correlated inversely with FEV1 and 
positively with sputum neutrophil counts (Vernooy, Lindeman et al. 2004).  There are 
currently no relevant animal studies to elucidate the importance of MMP-8 in COPD.    
 
1.5.6.3 Macrophages 
Macrophage numbers are elevated in the lungs of patients with COPD, where they 
accumulate in the alveoli, bronchioli and small airways (Saetta, Turato et al. 2001).   
There is also a correlation between alveolar wall macrophage numbers and the degree of 
small airways obstruction in COPD (Jeffery 1998). Macrophage metalloproteinases 
potentially contribute to the  breakdown of connective tissue in COPD, with increased 
elasteolytic activity seen in smoke exposed cells (Russell, Thorley et al. 2002).  “Knock 
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out” mouse models have demonstrated a role for macrophage metalloproteinases as well 
as neutrophil elastase in the development of tobacco smoke induced emphysema, 
although the relationship between these models to human disease remains unknown.    
Interactions between neutrophils and macrophages are described in section 1.5.6.4 and 
summarised in figure 1.5.   
 
1.5.6.4 Interactions between Neutrophil Elastase and Matrix metalloproteinases 
It is likely that the serine proteinases and MMPs act synergistically in lung disease.  NE 
degrades TIMPs (Itoh and Nagase 1995) facilitating MMP activity, and can activate 
several MMPs converting pro-enzymes, including MMP-9, to the active form (Ferry, 
Lonchampt et al. 1997).  Conversely MMP-12 inactivates α1-AT thereby enhancing NE 
activity (Desrochers, Jeffrey et al. 1991).  The majority of animal “knock out” models of 
emphysema support a multi-faceted pathogenic process in the disease, as inhibition of 
serine, cysteine or matrix metalloproteinases all show partial protection from the 
development of emphysema (Lanone, Zheng et al. 2002; Wright, Farmer et al. 2002).  
The noticeable exception is MMP-12 and there have been several conflicting animal 
studies comparing MMP-12 activity, macrophage and neutrophil influx and emphysema.  
MMP-12 knock-out mice (Line 129  mice) exposed to cigarette smoke did not develop 
emphysema and lung inflammation was reduced, although macrophage recruitment to the 
lungs was normal (Hautamaki, Kobayashi et al. 1997). In a study of Sprague-Dawley 
rats, neutrophil numbers increased in the first month following smoke exposure, but 
breakdown of connective tissue and the development of emphysema occurred later and 
related to a subsequent increase in macrophages (Ofulue, Ko et al. 1998). However, in a 
further studies, cigarette exposed mice showed an acute influx of neutrophils with 
evidence of both elastin and collagen degradation in a dose dependent manner.  This was 
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reduced by neutrophil depletion or the administration of the serine proteinase inhibitor 
α1-AT (Zay, Loo et al. 1999).  Other animal models have also found an early rise in 
neutrophil number and activity, and a corresponding rise in matrix breakdown products 
after exposure to cigarette smoke (Wright, Farmer et al. 2002).  
 
In order to understand the relationship between macrophages and neutrophils in COPD, 
MMP-12 knock out mice were studied further.  Cigarette smoke exposed MMP-12 knock 
out mice did not display the early neutrophilic infiltrate or the release of desmosine and 
hydroxyproline (matrix breakdown products) that is characteristic of wild type mice, 
although low levels of macrophage infiltration did occur.   When the MMP-12 knock-out 
mice underwent intra-tracheal instillation of normal macrophages, a neutrophil influx 
was seen and the use of an MMP inhibitor also prevented a neutrophilic infiltrate and 
subsequent matrix breakdown (Churg A., Dai et al. 2002).  Following these observations, 
studies demonstrated that cigarette smoke induced production of TNF-α from alveolar 
macrophages in wild type mice, but not in MMP-12 knock out mice while levels of TNF-
α mRNA were the same in both groups.  It was surmised that MMP-12 processes TNF-α 
after secretion and it is likely, therefore, that MMP-12 is needed to activate TNF-α which 
in turn initiates neutrophil recruitment, leading to degranulation and tissue damage 
(Churg, Wang et al. 2003)..   
 
When interpreting results from in vitro work and animal models, it is crucial to consider 
that there may be important variations in the pathogenesis of COPD between cell types 
and differing species, and indeed, conflicting results are common.  However it seems 
likely that neutrophil infiltration is an early event and that both neutrophil numbers and 
elastinolytic activity relate well to lung damage in the early stages of disease.  
61 
Macrophages seem central to neutrophil recruitment, probably via activation of TNF-α 
by metalloproteinases, and may be needed to sustain the inflammatory process and hence 
development of emphysema.    
 
Figure 1.5. The pro-inflammatory properties of MMP-12 and macrophage / 
neutrophil interactions. 
 
Legend. 
1.  Cigarette smoke causes the release of chemotactic peptides which recruit 
macrophages and neutrophils to airways.   
2.  Activated macrophages secrete MMP-12 which activates epithelial cells and causes 
degradation of extracellular matrix components.   
3.  MMP-12 facilitates the release of active TNFα which activates epithelial cells 
further.   
4.  Activated epithelial cells release chemotactic cytokines and increase the expression 
of pro-adhesive proteins such as E-Selectin.   
5.  Neutrophils migrate to areas of activated epithelium and release free NE during 
frustrated phagocytosis or sloppy eating.  NE promotes epithelial cell apoptosis and 
increases expression of pro-inflammatory mediators such as LTB4 and CXCL8. 
6.  NE proteolytically converts  proMMP-12 to active MMP-12 and proteolytically 
inactivates TIMP, both of which enhance MMP-12 activity.   
7.  MMP-12 proteolytic inactivation of α1AT causes the further release of pro-migratory 
proteins and allows increased NE activity. 
8. Macrophages scavenge free NE which is then reused to further degrade extracellular 
matrix components 
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1.5.7 Other Inflammatory Cells 
1.5.7.1 Lymphocytes 
There are increased numbers of T lymphocytes (predominantly CD8+) in the lungs of 
smokers with COPD (Saetta, Di Stefano et al. 1998) (O'Shaughnessy, Ansari et al. 
1997), although the role of the lymphocyte in the pathogenesis of COPD has yet to be 
established.     Supporting published data is limited, nethertheless, one theory suggests 
that smoking induced lung injury leads to structural alterations to self antigens leading 
to the activation and proliferation by auto-reactive T cells.  T cells could then damage 
the lungs further by promoting cellular inflammation, as well as cellular necrosis and 
apoptosis, leading to airway remodelling (Cosio, Majo et al. 2002).    
 
1.5.7.2 Eosinophils 
The absolute numbers of eosinophils found in the lung are much lower than other cell 
types, but levels appear to be raised  in bronchial lavage fluid, biopsies and alveolar 
tissue taken from some patients with COPD (Lacoste, Bousquet et al. 1993; Pesci, Balbi 
et al. 1998; Retamales, Elliot et al. 2001).  Eosinophils are classically associated with 
asthma, and it appears that eosinophils are a feature of a clinically distinct subset of 
patients with COPD with a more “asthmatic” phenotype, as corticosteroid related 
reversibility of airflow obstruction correlates with eosinophilic cationic protein 
(Chanez, Vignola et al. 1997). 
 
1.5.8 Oxidative Stress 
There is evidence of oxidative stress in smoking related lung disease.  Cigarette smoke 
contains approximately 1015 oxidant molecules per puff (Church and Pryor 1985), and 
oxygen free radicals and hydrogen peroxide are released from activated neutrophils and 
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macrophages (Ludwig and Hoidal 1982; Schaberg, Haller et al. 1992).  In health, free 
reactive species are scavenged by anti-oxidants and anti-oxidant enzymes as part of the 
oxidant/antioxidant balance (MacNee 2000), however, smokers have increased lipid 
peroxidation and reduced plasma antioxidant capacity, indicating an increased oxidative 
burden (Rahman, Morrison et al. 1996).   
 
An increase in oxidative burden appears to be capable of causing emphysema in mouse 
models. Antioxidant transcription factor nuclear erythroid-related factor 2 (which 
among other genes regulates the expression of glutathione peroxidase 2 (Singh, 
Rangasamy et al. 2006)) knock out mice are susceptible to cigarette smoke exposure. 
These mice developed airspace enlargement as well as more pronounced inflammation 
and apoptosis of alveolar septal epithelial and endothelial cells (Rangasamy, Cho et al. 
2004).  Furthermore, oxidant/antioxidant imbalance is able to cause emphysematous 
change, even in the absence of cigarette smoke.   Zhang et al. (Zhang, Shan et al. 2006) 
followed TLR4-knockout mice (Tlr4–/– mice) into middle age and found that the 
animals spontaneously developed emphysema due to increased Nox3 (a novel NADPH 
oxidase) gene expression and subsequent elastin degradation. Interestingly, the elastin 
breakdown was caused by oxidants, since NADPH oxidoreductase inhibition prevented 
the elastin breakdown. Also of interest, the Tlr4–/– mice did not show infiltration of the 
lung parenchyma with inflammatory cells, and the authors speculate that the source of 
oxidants and of proteolytic activity may be the alveolar septal endothelial cells. 
 
The presence of oxidative stress could contribute to the pathogenesis of COPD by a 
number of other mechanisms.  Firstly, by the oxidative inactivation of anti-proteinases 
(Johnson and Travis 1979); by the increased sequestration of neutrophils in the 
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pulmonary microvasculature (Drost, Selby et al. 1992); and by increase gene expression 
of pro-inflammatory mediators (Antonicelli, Parmentier et al. 2002).  
 
1.5.9 Bacteria and Viruses 
A proportion of patients with COPD have airways that are colonised with bacteria, even 
when clinically stable.  Colonisation is associated with increased sputum concentrations 
of inflammatory mediators including IL-8, LTB4 and NE (Hill, Campbell et al. 2000).  
Lower airway bacterial colonisation in the stable state appears to increase the frequency 
and alter the character of COPD exacerbations (Patel, Seemungal et al. 2002). 
Exacerbation frequency relates to subsequent decline in lung function (Donaldson, 
Seemungal et al. 2002) and health status (Seemungal, Donaldson et al. 1998); 
suggesting that colonisation may be important in disease progression. 
 
Viruses have also been implicated in the pathogenesis of COPD.  Alveolar epithelial 
expression of adenovirus E1A protein has been associated with emphysema, and in 
particular inflammatory cell tissue destruction (Retamales, Elliot et al. 2001), 
potentially by amplification of lung inflammation (for example, increased transcription 
of  IL-8 (Gilmour, Rahman et al. 2001)).  Furthermore, cell culture studies suggest that 
20% of COPD exacerbations may be virally related (PCR studies place this figure closer 
to 40%), which again may be associated with lung damage by many mechanisms 
including enhanced neutrophil recruitment, increased release of reactive oxygen species, 
and increased expression of pro-inflammatory mediators (Sapey and Stockley 2006). 
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1.6 The relationship between COPD and ageing 
 
There has been recent speculation that many chronic disease states, including COPD, 
may represent a form of advanced ageing.  Certainly, there is a higher prevalence of 
COPD in ageing subjects, even when cigarette smoke exposure is accounted for 
(Fukuchi, Nishimura et al. 2004; Buist, McBurnie et al. 2007).   Greater burden of 
COPD in the elderly may be attributable to two hypotheses.  The first is that age-
associated structural and functional changes within the body per se may cause an 
increase in patho-genetic susceptibility to COPD, potentially even causing COPD.  The 
second hypothesis suggests that the repeated insults endured by an organ so intimately 
associated with the environment over a prolonged life may cumulatively make lung 
disease more apparent or progress faster, but that ageing itself does not contribute to the 
development of the disease.   The ability of the immune system to respond to pathogens 
appears diminished in the elderly, and it is known that the elderly experience more 
pulmonary infections than the young.  Perhaps these repeated insults alongside with 
damage caused by smoking make COPD more apparent in the elderly.  
 
All organs see a decline in function with advancing age, and natural ageing (as opposed 
to a pathological decline in function) must satisfy four principles.  It is intrinsic, 
universal, progressive and unfortunately detrimental to function (Strehler, Mark et al. 
1959).    Pulmonary physiology changes with normal ageing, characterised by a 
significant reduction in the elastic recoil of the lung, a loss of power of the muscles of 
respiration and increased chest wall rigidity (Turner, Mead et al. 1968; Knudson, Clark 
et al. 1977).  These physiological changes lead to a reduction in the FEV1 /FVC ratio and 
a greater measured residual volume, changes that are also seen in COPD which could 
lead to an over-diagnosis of COPD in healthy elderly subjects.   However, histologically, 
the changes seen with advancing age are distinguishable from COPD.  With advancing 
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age, there is alveolar enlargement without the alveolar wall destruction and distal duct 
ectasia seen in emphysema (Verbeken, Cauberghs et al. 1992).  These changes have 
been termed “Ageing Lung”.  
 
Senescence accelerated mouse models (including senescent prone and senescent 
resistant mice strains) have been used to study age dependent changes in the lung. 
Firstly, these studies confirmed that normal ageing was associated with alveolar 
enlargement, but not emphysema.  In these models, it seems clear that ageing per se 
does not cause COPD.   Secondly, when both age-prone and age-resistant strains were 
exposed to cigarette smoke, accelerated ageing was associated with more emphysema 
for matched smoke exposure compared with age-resistant strains.  Advancing age made 
the mice more sensitive to extrinsic insults (Fukuchi 2009), but these studies could not 
determine whether this was due to changes in the lung alone, or age related changes in 
other body systems.    
 
In pulmonary emphysema, there is believed to be an imbalance between increased 
alveolar cell apoptosis and increased alveolar cell proliferation, which favours alveolar 
wall destruction (Calabrese, Giacometti et al. 2005; Imai, Mercer et al. 2005).  In vitro 
and in vivo studies suggest that cigarette smoke induces cellular senescence, increasing 
the expression of markers of senescence such as β-galactosidase (Tsuji, Aoshiba et al. 
2004).  Human studies have found increased levels of the senescent markers p16 INK4a  
and p21 CIPI/WAFI/Sdil (antagonists of cyclin dependent kinase, which is required for cell 
cycle turnover) in type II alveolar cells in patients with emphysema compared with age 
matched controls (Tsuji, Aoshiba et al. 2006).  Cellular senescence is associated with a 
decrease in cellular proliferation (Aoshiba. K. and Nagai 2009).  If senescence causes an 
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imbalance in cellular degradation and proliferation, this could explain some of the 
changes seen in ageing lung.  Furthermore, if the combination of natural ageing and 
smoke exposure increases cellular senescence, the usual compensatory rise in cellular 
proliferation that one would expect following alveolar cell damage would be diminished, 
leading to a greater degree of lung damage than one would normally expect.   
 
Ageing is pro-inflammatory, and is believed to be the result of prolonged exposure to 
damaging insults with a high antigenic burden (Franceschi, Bonafe et al. 2000).    In 
addition, studies of senescent cells suggest that they produce more inflammatory 
mediators both when quiescent and stimulated, including TNFα, IL-1β and IL-8 
(Shelton, Chang et al. 1999; Mariotti, Bernardini et al. 2006).   Senescent human type II 
alveolar cells express more phosphorylated IκB and TNFα and there is a positive 
relationship between the degree of p16INK4a  positive cell senescence and the severity of 
inflammation in patients with emphysema (Aoshiba. K. and Nagai 2009). 
 
In view of all these data, we proposed that the pathogenesis of COPD may be an 
interplay between genetic susceptibility, environmental exposure and age.     Potentially, 
smoking and ageing (in susceptible individuals) leads to alveolar and airway cell 
senescence, casing arrested tissue repair.  Cellular senescence leads to chronic 
inflammation with increased inflammatory cell recruitment, and associated tissue 
damage.  This may be heightened in COPD due to aberrant inflammatory cell responses, 
in particular, neutrophilic responses, enhancing inflammatory tissue damage.   
Furthermore, the deterioration of immune function with age might increase 
susceptibility to infection (and COPD exacerbations), with further inflammation and 
tissue damage. 
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Finally, studies of neutrophil migration in COPD have not always applied rigorous age 
matching when comparing patients with controls (for example, (Strassburg, Droemann 
et al. 2004; Yoshikawa, Dent et al. 2007)).  Without an appreciation of the affects of age 
on neutrophil migration, it is difficult to interpret these studies as one cannot 
differentiate whether reported differences are due to disease, age or both.  
1.7 Alpha 1-Antitrypsin Deficiency 
Alpha-1 antitrypsin deficiency (A1ATD) is a hereditary condition, where the 
inheritance of two deficiency alleles on the α1AT gene (located on chromosomal 
segment 14q 32.1 (Darlington, Astrin et al. 1982)) result in a severe deficiency of 
A1AT.  There are more than 100 phenotypes of the A1AT protein, many of which are 
caused by a single amino acid substitution.  The variants are described alphabetically 
and have differing electrophoretic properties that are detectable by isoelectric focusing 
(Hoffman and van der Brock 1977).  The most common phenotype is “M”, of which 
there are at least four subtypes, although none are thought to lead to ill health.  The “Z” 
variant is the most common of the deficiency phenotypes, with an estimated gene 
frequency in Europe of 2 - 24 per 1000 (Hutchinson 1998).   The homozygous form of 
the “Z” phenotype has an estimated prevalence of 0.02 – 0.06% in Europe (Hutchinson 
1998) and this variant results in very low serum concentrates of α1AT (typically less 
than 11 µM).  The mutation affects the tertiary structure of α1AT, resulting in the 
formation of chains or polymers.  These polymers become entangled in the 
endoplasmic reticulum of hepatocytes, effectively preventing secretion (Lomas, Evans 
et al. 1992). 
 
Severe deficiency of A1AT is associated with early onset panacinar emphysema, which 
can occur in non-smokers (Piitulainen, Tornling et al. 1997), although morbidity and 
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mortality are increased in patients who smoke (Larsson 1978). A1ATD is also 
associated with cirrhosis of the liver, hepatocellular carcinoma and the vasculitides 
(Eriksson, Carlson et al. 1986; Fortin, Fraser et al. 1991). 
 
The pulmonary disease is believed to develop due to an imbalance in the levels of 
neutrophil elastase present in the lung, compared with the low concentration of A1AT.  
This imbalance leads to an inability to neutralise elastase during neutrophil migration 
and degranulation, resulting in a wider area of tissue destruction.  The presence of 
elastase enhances the release of other pro-inflammatory mediators (for example; 
elastase stimulates the secretion of LTB4 from macrophages), which further enhances 
neutrophil migration, with further release of neutrophil elastase that is poorly 
inactivated due to the deficiency of A1AT, leading to a perpetual amplification of 
inflammation (Hubbard, Fells et al. 1991).  This cycle of inflammation is supported by 
studies demonstrating increased numbers of neutrophils and increased concentrations of 
inflammatory mediators in samples taken from patients with A1ATD compared to 
patients with COPD without the genetic deficiency in A1AT (Morrison, Kramps et al. 
1987; Hill, Bayley et al. 2000). 
 
There are few studies of neutrophil migration in A1ATD, but those carried out to date 
suggest that neutrophil migration towards sputum in A1ATD may be enhanced, but this 
is likely to be due to increased concentrations of pro-inflammatory mediators (in 
particular LTB4 and IL8) (Woolhouse, Bayley et al. 2002) rather than aberrant 
neutrophil behaviour.  However, there have been no detailed studies of the mechanics 
of neutrophil migration in this disease, and further studies are awaited.    Furthermore, 
patients with A1ATD form a sound control group when studying neutrophil migration 
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in COPD, as these patients can be matched for the presence of lung disease, pulmonary 
inflammation, smoking exposure and treatments, all of which may alter immune cell 
function in disease.  
 
1.8 Summary 
 
COPD is an important and complex, chronic disease.  The neutrophil, and its proteolytic 
enzymes, have been shown to cause all of the pathological features of COPD, and 
neutrophil numbers (and their associated products) relate to disease severity and disease 
progression.  However, it remains unclear if these cells are primarily and directly 
responsible for the development of COPD, or whether other cell types and disease 
processes are also involved.  The inefficacy of inflammatory mediator inhibitors (such 
as anti-TNFα) suggest that the disease is not caused by a single mediator, but little is 
known of the day to day concentrations of these mediators, making it difficult to predict 
the outcome of therapeutic interventions.  Although a wealth of data supports the 
neutrophil as being the most likely effector cell in COPD, little is understood of its 
migratory behaviour in the disease, which may explain the preponderance of cells in the 
lungs.  These may well prove to be important issues in identifying points of intervention 
in order to treat the disease.   
 
It is known that ageing affects neutrophil function and that advancing age is associated 
with COPD.  While some studies have examined the effects of senescence on lung 
tissue in relation to COPD, none have focused on the neutrophil.    Given the likely 
importance of this cell in the pathogenesis of COPD, it is of importance to understand 
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how ageing effects the neutrophil, and how any functional differences compare with 
those noted in COPD.  
 
Patients with A1ATD have a similar spectrum of disease as usual COPD and have 
similar patterns of lung inflammation (although this can be heightened).  Current 
treatments for A1ATD-related symptoms are identical to those used in usual COPD, 
and they have a similar burden of bacterial colonisation.  In light of this, it was felt that 
these patients were an ideal secondary control group for cellular studies of usual COPD, 
as this would help determine if any differences noted were specific to COPD or 
common to lung disease, pulmonary and systemic inflammation and their treatments. 
 
1.9 Structure of this thesis 
 
The studies presented in this thesis were performed to examine some of the aspects of 
neutrophil recruitment and migration in healthy aging and COPD.  In particular, we 
wished to answer three questions. 
 
 1.  What are the key inflammatory mediators that are involved in neutrophil 
recruitment in COPD and are likely to be important in neutrophil migration, and how 
variable is their expression in pulmonary secretions? 
 
In order to study this, Chapter 3 examines the expression pro-inflammatory mediators 
in  pulmonary secretions from patients with COPD, and explores relationships between 
mediators and neutrophils and markers of disease severity, to ascertain which mediators 
were of likely importance  in studies of neutrophil migration.  
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2. Does ageing affect neutrophil migration towards the chemoattractants that are 
believed to be physiologically important in COPD?  
 
In order to study this Chapter 4 examines, in vitro, neutrophil migration towards IL-8 
and GROα using both the well established under agarose assay and a newly validated 
assay using a Modified Dunn Chamber.  Surface expression of receptors is semi-
quantified and migratory antagonists are used in order to identify potential mechanisms. 
The work presents evidence of aberrant neutrophil migration in the healthy elderly and 
proposes that directed neutrophil movement (chemotaxis) is selectively diminished with 
increasing age, with no alterations in random cellular movement  (chemokinesis).   This 
work highlights the importance of age matching in studies of neutrophil function. 
 
3. Are there functional and structural differences in migratory neutrophils isolated 
from patients with COPD compared with age matched healthy controls and disease 
matched patients with A1ATD? 
 
In order to study this, Chapters 5 and 6 include work that examines quantitative 
differences in neutrophil migratory pathways and neutrophil structure during migration 
towards IL-8 and GROα.  Chapter 7 and 8 examine potential mechanisms for the 
differences seen, including receptor expression and function, and down stream 
signalling in the migratory pathway.  The work presents evidence of  aberrant 
neutrophil migration in patients with COPD and proposes that this  is distinct from that 
seen in healthy ageing.  Namely, there is an increase in neutrophil chemokinesis in 
usual COPD, coupled with a reduction in chemotaxis.  These differences appear unique 
to this group, and cannot be explained by age, cigarette smoke exposure (past or 
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present), lung inflammation nor its treatments. Furthermore, these differences can be 
corrected using antagonists of the migratory pathway.  
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2 METHODS 
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2.1 Ethical Approval 
All studies reported in this thesis were approved by the South Birmingham Health 
Authority ethics committee and all subjects provided written informed consent. 
2.2 Patients 
The characteristics of the individual patient groups are described in the relevant section 
of the thesis.  COPD was defined clinically using accepted definitions (GOLD criteria 
(Pauwels, Buist et al. 2001), patients with α1ATD were homozygotes for the Z variant.  
Patients with chronic bronchitis were defined by daily sputum production for at least 3 
months of 2 consecutive years (Medical Research Council. 1965).  
2.3 Pulmonary Function Testing 
Pulmonary function tests were performed according to national guidelines (British 
Thoracic Society and the Association of Respiratory Technicians and Physiologists, 
1994).  All pulmonary function tests were performed by trained Respiratory 
Physiologists at the Lung Investigation Unit, University Hospital Birmingham NHS 
Foundation Trust.   
2.4 Sputum and Blood Sample Collection 
Spontaneously expectorated sputum samples were collected from waking for four hours, 
into a sterile container.  Patients undertook mouth washing procedures to minimise 
saliva contamination.  Blood samples were taken peripherally using the vacutainer® 
system of blood collection (Becton Dickson Ltd, Oxford, UK) 
2.5 Sputum Processing 
Sputum samples were processed within 2 hours of collection completion. 
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2.5.1 Sputum Colour 
Each sputum sample was allocated a number referenced to a standard colour chart 
(Stockley, Bayley et al. 2001) according to its macroscopic appearance.  Values of 1 -2 
(colourless to white) were classified as mucoid and values of 3-5 (yellow to green) were 
classified as mucopurulent to purulent. 
2.5.2 Quantitative bacterial culture   
Where appropriate an aliquot of sputum (with a minimum weight of 1g) was removed 
from the sputum sample prior to any processing, and the presence and number of viable 
organisms was determined (as described previously (Pye, Stockley et al. 1995).  Results 
are expressed in terms of the colony forming units per ml of sputum (cfu/ml). 
2.5.3 Sputum sol phase collection 
The major aliquot of sputum (with a minimum weight of 1g) was ultracentrifuged at 
50,000g for 90 minutes at 4ºC and the supernatant stored at -70ºC until required. 
2.5.4 Cytospin preparation 
A final aliquot of sputum was taken and used for cytospin preparation using a modified 
protocol from that previously described (Pavord, Pizzichini et al. 1997).  In brief, freshly 
prepared dithiothreitol (DTT, Sputolysin; Calbiochem corp, CA, USA) was added to the 
sputum at a ratio of 4:1 (volume/weight).  The mixture was briefly vortexed and then 
rocked for 15 minutes at room temperature.  A further 4 volumes of 0.9% sodium 
chloride (NaCl) was added to the aliquot which was then rocked for 5 minutes.  The 
sample was filtered (using a 48µm nylon gauze) and the filtrate was centrifuged at 400g 
for 10 minutes at 4°C.  The resultant cell pellet was resuspended in 1ml phosphate 
buffered saline (PBS, Gibco Invitrogen Corp, Paisley, UK).  Total cell counts and 
viability assessments were performed following the addition of 20µl trypan blue (Sigma 
Chemicals Ltd, Poole, UK) to an equal volume of the suspension.  Ten microlitres of the 
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mixture was pipetted onto a haemocytometer for cell counting using  low power light 
microscopy and cells that excluded trypan blue were classified as viable.  Total cell 
count per ml of sputum was calculated using the following formula: 
 
Total cell count = total number of non-squamous cells x trypan blue dilution factor x 
104. 
 
The cell suspension was diluted to give a concentration of 200,000 cells/ml and 100µl 
aliquots were added to pre-prepared cytospin blocks.  The  blocks were centrifuged at 
450rpm for 3 minutes in a Shandon cytospin centrifuge (Thermo Shandon Inc, PA, 
USA) resulting in a thin film of approximately 20,000 cells per slide.  Two slides were 
stained using Diff Quick® (Gamidor Ltd, Oxford, UK) and 300 cells were counted to 
produce a differential cell count.  The cell sample was considered adequate if the slides 
contained greater than 50% neutrophils and less than 10% squamous cells. 
2.5.5 Peripheral blood processing 
Blood samples were processed with 30 minutes of collection. 
2.5.6 Plasma sample 
A plasma sample was obtained by centrifuging the blood at 3000rpm for 10 minutes at 
4°C and stored at -70ºC until analysed. 
2.5.7 Isolation of Neutrophils  
 
Neutrophils were purified from peripheral blood by discontinuous percoll density 
gradients, using the method of Jepsen and Skottun (1982). 
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An isotonic stock solution of percoll (Sigma-Aldrich Company Ltd., Poole, UK), was 
prepared in a ratio of 9:1 (v/v) with 1.5 M sterile saline solution (NaCl). The stock 
percoll was further diluted with sterile physiological saline (0.15 M NaCl) to 78% 
(density 1.096 g/ml) and 54% (1.075 g/ml). The discontinuous gradients were prepared 
by careful underlaying of 2 ml 54% percoll with 3 ml 78% percoll in 10 sterile 15 ml 
test tubes. 
 
Peripheral venous blood samples were collected into lithium heparin Vacutainer® tubes 
(Becton Dickinson Vacutainer Systems, Franklin Lakes, USA), and then diluted with an 
equal volume of sterile saline (0.15 M NaCl) and 7 ml was layered onto the gradients. 
The tubes were then centrifuged at 200 g for 25 minutes in a Heraeus Christ Bactifuge at 
20°C. After centrifuging distinct bands were present with mononuclear cells at the 
interface of the plasma and the 54% percoll. The band at the interface of the 54% and 
78% Percoll contained neutrophils and the basal pellet consisted of erythrocytes. The 
neutrophil layer (extending into the 78% percoll) was removed using a sterile pastette 
and placed in a sterile universal tube. The cells were then washed twice with sterile 0.15 
M NaCl, centrifuging at 1500 g. The cells were counted using a haemocytometer with 
improved Neubaur markings and then resuspended in Roswell Park Memorial Institute 
1640 medium (RPMI, Sigma Chemicals Ltd, Poole, UK) at the correct concentration for 
the assays. 
 
Lithium heparin blood tubes were utilised for blood collection.  Each tube contained 90 
Unit Standard Potency (USP) lithium heparin per 6mL blood.  This is the equivalent of 
15 USP of heparin per ml blood, where 1 USP = 1 Umg-1/ml, with the heparin having 
been sprayed on to the internal walls of the tube.  Tubes were medical grade and sterile 
(information from manufacturer).  All methods of isolating neutrophils are associated 
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with a risk of activation with the potential for alteration in receptor expression and 
function.   
 
The majority of studies investigating the affects of heparin have treated endothelial cells 
with heparin, and then observed neutrophil adhesion.  There is clear evidence that 
unfractionated heparin and fractionated low molecular weight heparins (at 
concentrations of   20 – 1000U ml-1  (with 1 U = 125 – 180 Umg-1/ml)) have been shown 
to reduce neutrophil adhesion to Human Umbilical Vein Endothelial Cells (HUVEC), 
without significantly altering expression of ICAM-1 or E-Selectin (Lever, Hoult et al, 
2000: Xie et al, 1997: Silvestro et al,1994).  Neutrophils are also capable of binding to 
heparin (as described by Diamond, et al (1995), potentially through integrins receptors.   
However the majority of these studies have used concentrations of heparin that are much 
higher than those seen in standard blood tubes. 
 
A recent study attempted to address this by comparing techniques for neutrophil 
isolation (including the use of heparin, EDTA and citrate) and found that heparin and 
citrate  increased PMA-induced calcium signalling and respiratory burst more than 
EDTA (Freitas, Portp et al, 2008), however, once again, higher concentrations of 
heparin were used than are present in standard lithium heparin tubes. 
 
Despite the lack of data regarding the affect of low dose heparin on neutrophil function, 
it is likely that even 90 USP of heparin may alter neutrophil responses.  However, this 
body of work aimed to identify differential effects of neutrophils isolated from young 
and old healthy subjects, and patients with COPD, and it was reasoned that as long as 
neutrophil isolation was standardized, the results would be comparable. 
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2.6 Biochemical Assays 
2.6.1 Growth Related Oncogene 
Growth related oncogene alpha (GROα) was measured by ELISA using a commercially 
available kit (R&D Systems Ltd, Abingdon, UK).  Two hundred microlitres of standard 
or sample (diluted by diluent RD5K) were added to each well.  The wells were covered 
with an adhesive strip and incubated at room temperature for one and a half hours.  
Wash buffer was prepared by diluting 20ml of wash buffer concentrate (R&D Systems) 
with 480ml of distilled water and each well was washed three times.   Two hundred 
microlitres of GROα conjugate were then added to each well and the plate was 
incubated for a further one hour at 2 - 8º C after which each well was washed a further 
three times with wash buffer.  Two hundred microlitres of substrate solution (equal 
volumes of colour reagents A and B) were then added to each well and the plate 
incubated for 15 minutes at room temperature, protected from the light.  The reaction 
was stopped using 50µl of stop solution and the absorbance read at 450nm, with 540 nm 
correction, using a Dynatech MR 5000 microplate reader (Dynatech Corporation, 
Burlington, VT, USA).  The GROα concentration was calculated by interpolation from 
the standard curve. 
 
For this, and subsequent assays, single samples from separate sputum sol phase pools 
collected from patients with chronic bronchitis were assayed on 4 to 6 occasions to 
obtain the intra-assay co-efficient of variation.  A known quantity of pure mediator was 
then added to the sample and it was re-assayed.  The result of this “spiked” sample was 
obtained  by interpolation from the standard curve and compared to the expected value 
to obtain the proportion recovered.  The lower limit of detection, intra-assay co-efficient 
of variation and recovery of pure GROα from samples spiked with a known 
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concentration are shown in Table 2.1.  The standard curve for GROα is shown in Figure 
2.1. 
Table 2.1. The lower limit of detection, intra-assay coefficient of variation (CV) and 
spike recovery for the GROα assay. 
 
 
Lower limit of detection Intra-assay CV (%) Spike recovery (%) 
10 pg/ml 3.75 88.9 
 
 
Figure 2.1 Standard curve for GROα  
 
2.6.2 Interleukin-1β  
Interleukin -1β (IL-1β) was measured in sputum sol phase by ELISA using a 
commercially available kit (R&D Systems Ltd, Abingdon, UK). Two hundred 
microlitres of standard or sample (dissolved in calibrator diluent RD5) were added to 
each well.  The wells were covered in an adhesive strip and allowed to incubate for 2 
hours at room temperature.  Five hundred ml of wash buffer were produced by 
dissolving 20ml of wash buffer concentrate with 480ml distilled water.  Each well was 
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then washed 3 times with wash buffer.  Two hundred microlitres of IL-1β conjugate 
were then added to each well and the plate was incubated for a further 1 hour at room 
temperature and then each well was washed 3 times with wash buffer. Two hundred 
microlitres of substrate solution (equal volumes of colour reagents A and B) were then 
added to each well and the plate incubated for 20 minutes at room temperature, 
protected from the light.  The reaction was stopped using  50µl of stop solution and the 
absorbance read at 450nm with a 540nm correction, using a Dynatech MR 5000 
microplate reader.  The IL-1β concentration in the sample was calculated by 
interpolation from the standard curve. 
 
The lower limit of detection, intra-assay coefficient of variation and recovery of pure IL-
1β from samples spiked with a known amount are shown in Table 2.2.  The standard 
curve is shown in Figure 2.2. 
 
Table 2.2. The lower limit of detection, intra-assay coefficient of variation (CV) and 
spike recovery for the IL-1β assay. 
 
Lower limit of detection Intra-assay CV (%) Spike recovery (%) 
0.207 pM 3.9 95.5 
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Figure 2.2. Standard curve for IL-1β  in sputum sol 
 
2.6.3 High sensitivity Interleukin-1β  
Interleukin -1β (IL-1β) was measured in plasma by ELISA using a commercially 
available high sensitivity kit (R&D Systems Ltd, Abingdon, UK).  One hundred 
microlitres of diluent RD1-82 were added to each well followed by 150µl of standard or 
sample (diluted by diluent RD6-44).  The wells were covered in an adhesive strip and 
allowed to incubate for 3 hours at room temperature on a horizontal orbital microplate 
shaker set at 500 rpm.  One litre of wash buffer was produced by dissolving 100ml of 
wash buffer concentrate with 900ml distilled water and each well was washed 6 times 
with wash buffer (200µl per well).  Two hundred microlitres of IL-1β HS conjugate 
were added to each well and the plate was incubated for a further 2 hours at room 
temperature on the shaker.  Each well was then washed a further 6 times with wash 
buffer.  Fifty microlitres of substrate solution were then added to each well and the plate 
was incubated for one hour at room temperature on the shaker.  Fifty µl of amplifier 
solution were then added to each well and allowed to incubate for 30 minutes at room 
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temperature on the shaker.  The reaction was stopped using 50µl of stop solution and the 
absorbance read at 490nm, with a 650nm correction, using a Dynatech MR 5000 
microplate reader.  The IL-1β concentration in the samples was calculated by 
interpolation from the standard curve. 
 
The lower limit of detection, intra-assay coefficient of variation and recovery of pure IL-
1β from samples spiked with a known amount are shown in Table 3.3.  The standard 
curve is shown in Figure 2.3. 
 
Table 2.3. The lower limit of detection, intra-assay coefficient of variation (CV) and 
spike recovery for the IL-1β assay. 
 
Lower limit of detection Intra-assay CV (%) Spike recovery (%) 
0.057 pg/ml 7.9 87.9 
   
 
 
Figure 2.3. Standard curve for High sensitivity IL-1β  in plasma 
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2.6.4 Interleukin-8 
Interleukin -8 (IL-8) was measured in sputum sol by ELISA using a commercially 
available kit (R&D Systems Ltd, Abingdon, UK).  One hundred microlitres of diluent 
RD1-8 were added to each well followed immediately by 50µl of standard or sample 
(dissolved in calibrator diluent RD5-P) and 100µl of IL-8 conjugate.  The wells were 
covered by an adhesive strip and allowed to incubate for 2.5 hours at room temperature.  
Wash buffer (500ml) was produced by dissolving 20ml of wash buffer concentrate with 
480ml of distilled water and each well was washed 6 times (200µl per well per wash). 
Two hundred microlitres of substrate solution (equal volumes of colour reagent A and 
B) were then added to each well and the plate was incubated for 30 minutes at room 
temperature. The reaction was stopped using 50µl of stop solution and the absorbance 
read at 450nm, with a 540nm correction, using a Dynatech MR 5000 microplate reader.  
The IL-8 concentration in the samples was calculated by interpolation from the standard 
curve. 
 
The lower limit of detection, intra-assay coefficient of variation and recovery of pure IL-
8 from samples spiked with a known amount are shown in Table 2.4.  The standard 
curve is shown in Figure 2.4.  Plasma IL-8 concentrations were measured by 
AstraZeneca using a kit this company have developed and validated.  Results are 
included with their permission. 
 
Table 2.4. The lower limit of detection, intra-assay coefficient of variation (CV) and 
spike recovery for the IL-8 assay. 
 
Lower limit of detection Intra-assay CV (%) Spike recovery (%) 
0.0125 nM 6.18 98.9 
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Figure 2.4. The standard curve for IL-8 in sputum sol 
 
2.6.5 Leukotriene-B4 
Leukotriene-B4 (LTB4) was measured by ELISA using a commercially available kit 
(Amersham International plc, Buckinghamshire, UK).  One hundred microlitres of assay 
buffer were added to the non-specific binding wells, followed immediately by 50 µl of 
standard or sample (dissolved in assay buffer).  Fifty microlitres of LTB4 antiserum 
were then added to all wells  except the non-specific binding wells and the plate was 
covered with an adhesive strip.  The plate was incubated for two hours at room 
temperature whilst shaking at 150 rpm on a rotary shaker (Fisher Scientific, 
Loughborough, UK).  Fifty microlitres of LTB4 peroxidase conjugate were then added 
to each well and the plate covered with an adhesive strip.  The plate was then incubated 
for a further 1 hour at room temperature whilst shaking at 150 rpm on the rotary shaker.  
Twenty millilitres of wash buffer concentrate were dissolved in 480 ml of distilled water 
to produce 500 ml of wash buffer.  Each well was then washed 4 times with wash buffer 
and 150µl of enzyme substrate were then added to each well and the plate was covered 
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with an adhesive strip before a final incubation period of 30 minutes at room 
temperature, whilst shaking at 150 rpm on a rotary shaker.  The reaction was stopped 
using 100 µl of 1M sulphuric acid and the absorbance read at 450 nm using a Dynatech 
MR 5000 microplate reader.  The LTB4 concentrate in the samples was calculated by 
interpolation from the standard curve. 
 
The lower limit of detection, intra-assay coefficient of variation and recovery of pure 
LTB4 from samples spiked with a known amount are shown in Table 2.5.  The standard 
curve is shown in Figure 2.5. 
 
Table 2.5. The lower limit of detection, intra-assay coefficient of variation (CV) and 
spike recovery for the LTB4 assay. 
 
Lower limit of detection Intra-assay CV (%) Spike recovery (%) 
137 pM 9.67 105.7 
 
 
Figure 2.5. The standard curve for LTB4  
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2.6.6 Tumour Necrosis Factor Alpha 
Tumour necrosis factor alpha (TNFα) was measured by ELISA in sputum sol phase and 
plasma, using a commercially available high sensitivity kit (R&D Systems Ltd, 
Abingdon, UK).   Fifty microlitres of assay diluent RD1F were added to each well 
followed immediately by 200 µl of standard or sample (dissolved in calibrator diluent  
RD6 – 13).  The wells were covered in an adhesive strip and the plate was incubated for 
3 hours at room temperature.  Wash buffer concentrate (100ml) was added to 900 ml of 
distilled water to make 1 litre of wash buffer and each well was washed 6 times (200µl 
per well per wash).  Two hundred millilitres of TNFα HS conjugate were added to each 
well and the plate incubated for a further 2 hours at room temperature.  Each well was 
then washed a further 6 times with wash buffer and 50µl of substrate solution 
(lyophilised substrate mixed with 6 ml of substrate solution) were added to each well.  
The plate was then covered with an adhesive strip and incubated for one hour, after 
which 50µl of amplifier solution (lyophilised amplifier dissolved in 6 ml of amplifier 
substrate) were added to each.  The plate was again covered in an adhesive strip and 
incubated for a further 30 minutes at room temperature.  The reaction was then stopped 
using 50 µl of stop solution and the absorbance read at 490 nm with a 650 nm 
correction, using a Dynatech MR 5000 microplate reader.  The TNFα concentration in 
the samples were calculated by interpolation from the standard curve.   
 
The lower limit of detection, intra-assay coefficient of variation and the recovery of pure 
TNFα from samples spiked with a known amount are shown in Table 2.6 for sputum 
and 2.7 for plasma.  The standard curve for sputum is shown in Figure 2.6 and for 
plasma is shown in Figure 2.7. 
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Table 2.6. The lower limit of detection, intra-assay coefficient of variation (CV) and 
spike recovery for the TNFα assay in sputum sol phase. 
 
Lower limit of detection Intra-assay CV (%) Spike recovery (%) 
0.052pM 6.12 111.1 
 
 
Figure 2.6. Standard curve for TNFα  in sputum sol phase 
 
Table 2.7. The lower limit of detection, intra-assay coefficient of variation (CV) and 
spike recovery for the TNFα assay in plasma. 
 
Lower limit of detection Intra-assay CV (%) Spike recovery (%) 
0.052pM 3.92 100.15 
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Figure 2.7. The standard curve for TNFα in plasma 
2.6.7 Myeloperoxidase 
Sputum myeloperoxidase measurements were used as a marker of neutrophil influx and 
activation.  MPO activity was measured by chromogenic substrate assay relative to a 
preparation of lysed neutrophils of known concentration.  Ten microlitres of standard or 
sample were added to the wells in a microtitre plate, followed by 150µl of 1 mg/ml 
(w/v) O-dianisidine dihydrochloride (Sigma chemicals Ltd., Poole, UK), 0.01% (v/v) 
30% H202 in 50nM K3HPO4 and 0.5% w/v hexadecyl trimethyl ammonium bromide (pH 
6) (Sigma Chemicals Ltd.,Poole, UK).  The plate was then incubated for 15 minutes at 
25°C and the absorbance measured at 450nm using a Dynatech MR 5000 microplate 
reader. The MPO concentration in the samples was calculated by interpolation from the 
standard curve and expressed as mg/l. 
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The lower limit of detection, intra-assay coefficient of variation and the recovery of pure 
MPO from samples spiked with a known amount are shown in Table 2.8.  The standard 
curve for sputum is shown in Figure 2.8. 
 
Table 2.8. The lower limit of detection, intra-assay coefficient of variation (CV) and 
spike recovery for the MPO assay in sputum sol phase. 
 
Lower limit of detection Intra-assay CV (%) Spike recovery (%) 
2.93 mg/l 4.59 94.89 
 
 
Figure 2.8. The standard curve for MPO  
   
2.7 Chemotaxis Assays 
Neutrophil chemotaxis was assessed using two methods.  The first employed 
modifications of the agarose chemotaxis assays of Cutler (1974), Nelson et al. (1975) 
and John and Sieber (1976) and the second employed a modified Dunn Chamber and 
time lapse photography (Andrew and Insall 2007). 
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2.7.1 Agarose Gel Chemotaxis Assay 
Agarose chemotaxis plates were prepared as follows: agarose (0.5g, Sigma Aldrich, 
Poole, UK) were boiled at 100oC in 25ml distilled water and allowed to cool to 56oC.  
RPMI (Sigma Aldrich) (0.82g) and 0.25g gelatin (Sigma Aldrich) were dissolved in 
25ml distilled water at 56oC in a water bath and the two solutions were mixed and kept 
at 56oC until required.  The mixture (6ml) was pipetted into a 50 x 15mm tissue culture 
dish (Griener UK, Gloucester, UK).  The plates were left to set at room temperature for 
20 minutes and placed at 4oC for 10 minutes.  Wells were cut into the agarose gel with a 
3.2mm diameter punch using the template illustrated in figure 2.9 
RPMI control
Neutrophils (5 x 10^7 per ml)
Chemotactic agent
 
 
 
Figure 2.9.  Template for under agarose chemotaxis assay 
 
Freshly harvested neutrophils were resuspended at 5 x 107 cells/ml in RPMI. Ten µl of 
RPMI were placed into each of the inner wells, 10 µl of cells were placed into each of 
the centre wells and 10 µl of chemoattractant (10-7 FMLP in RPMI) into each of the 
outer wells. Blank wells had RPMI in the inner and outer wells. The plates were 
incubated at 37°C (5% CO2) for 2 hours and then flooded with methanol for overnight 
fixation of the cells. The gel was carefully removed and the plates washed under slow 
running tap water. The plates were then stained with Diff Quick® and left to dry. For 
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each well the chemotactic and chemokinetic responses were read using an eye-piece 
graticule. The overall response to the chemoattractant (chemotactic differential) was 
calculated by subtracting the chemokinetic from the chemotactic response (see Figure 
2.10). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.10.  Calculation of the chemotactic differential (chemotactic response A – 
chemokinetic response B) 
 
2.7.2 Modified Dunn Chamber Chemotaxis Assay 
2.7.2.1 Video microscopy 
All DIC and phase time-lapse recordings were made using wither a Zeiss Axiovert 100 
or S100 inverted microscope fitted with a Mono-10bit or a FAST Mono-12bit QICAM 
digital camera respectively. Images were captured using Improvision OpenLab 
software, at 30 second intervals for 20 minutes. 
 
2.7.2.2 Modified Dunn Chamber Assay 
The chemotaxis assay was performed using a modified Dunn Chamber (Weber 
Scientific International Ltd, Teddington) with an adaptation of methods described 
 
Outer well  
(chemoattractant) 
Middle well  
(neutrophils) 
Inner well  
(RPMI) 
Chemotactic response A 
 
 
Chemotactic differential = A – B 
 
 Chemokinetic response B 
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previously (Zicha, Dunn et al. 1991; Andrew and Insall 2007).  Dunn chamber 
coverslips (Weber Scientific International Ltd, Teddington) were prepared by acid 
etching and baking before being coated with 7.5% culture-tested bovine serum albumin 
(Sigma-Aldrich, UK).  Neutrophils (suspended at 5 x 106 /ml) were allowed to adhere to 
this surface for 20 minutes at room temperature.  The coverslip was then inverted on to 
the modified Dunn chamber, with the channel pre-filled with buffer (RPMI 1640 
medium (Flow Laboratories, Rickmansworth, UK) containing 0.15% bovine serum 
albumin (Sigma-Aldrich, UK)).  The buffer was replaced with either the same control 
buffer or containing IL-8 (Sigma-Aldrich, UK). The gradient was allowed to develop for 
10 minutes at room temperature before filming.  Analysis was performed on 10 
randomly assigned cells from each experiment.  Figure 2.11 is a diagrammatic 
representation of the modified Dunn chamber.  Figure 2.12 is a diagrammatic 
representationof the assay. 
 
Figure 2.11. Diagrammatic representation of the modified Dunn Chamber 
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Figure 2.12.  Diagrammatic representation of the Modified Dunn Chamber 
migration assay 
 
2.7.2.3 Image analysis 
 
Analysis of cell tracks 
 
The java software ImageJ (Wayne Rasband, NIH, Bethesda) was used to outline whole 
cells in time lapse images using plugs-in developed previously (Andrew and Insall 
2007). The 10 cells analysed were chosen at random and all analyses were carried out 
blinded (unaware of which patient group or treatment the cells belonged to).  Each 
chosen cell was digitally tagged and the migratory pathways were used to analyse 
specific migratory parameters.  See figure 2.13a and 2.13b. 
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Figure 2.13a.  Digital tagging of initial cell position 
Legend.  Each randomly chosen cell was digitally tagged using Image J software at the 
start of the assay (as shown by a coloured dot).  
 
 
 
Figure 2.13b.  Neutrophil migration pathways identified using digital tagging. 
Legend.  Each cell was followed during migration using the digital tags.  The migratory 
pathway is shown as a coloured line.  Each point on the line has digital co-ordinates to 
allow quantification of migratory parameters. 
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Analysis of pseudopods 
The java software ImageJ (Wayne Rasband, NIH, Bethsada) was used to outline 
individual pseudopods of time lapse images using plug-ins developed by Natasha 
Andrew (Biosciences, University of Birmingham).  Pseudopods were defined as being 
granule free regions of the cell that had some protrusive activity.  New pseudopods were 
defined as “daughter” or “new lateral” pseudopods.  Daughter pseudopods were 
identified after having split from the parent pseudopod (noted when a granular region 
divided a granule free area into two regions), sharing pixels with their parents in the 
previous frame.  Any new pseudopod that did not have a parent defined by this criterion 
was defined as a new lateral pseudopod.  
 
Analysis of migrational parameters 
Differences in chemotaxis were assessed using the mean data of the 10 cells per 
experiment.  Chemotaxis was assessed using 4 parameters.  The first was cell speed of 
movement (measured from the distance travelled between two frames in µm/minute).  
The second was cell velocity (speed in a consistent direction towards the 
chemoattractant source measured in µm/minute).  The third was directional persistence 
(a measure of the continuity of cell orientation over time, calculated by the cosine of the 
angle between directions in consecutive frames, expressed as 0 to 1). Cells that tend to 
move in a straight line, or cells that execute slow changes in direction, have a high 
persistence value; whereas cells that move randomly and rapidly change direction do 
not. The fourth parameter was chemotactic index, a measure of the accuracy of the cell’s 
directional orientation, calculated by the cosine of the angle between the cell’s direction 
and the orientation of the chemoattractant gradient, expressed as a score between -1 and 
1.   
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2.8 Fluorescent antibody cell sorting 
2.8.1 Immunofluorescent labelling of CXCR1 and CXCR2 receptors on 
isolated neutrophils 
 
Neutrophils, isolated from peripheral blood as described in section 2.5.7, were 
resuspended at 5 x 106 /ml in EBM with 0.1% Bovine Serum Albumin.  The 
appropriated wells of a 96 well plate were coated with Foetal Calf Serum and 100µl of 
cell solution were added to each well. The plate containing the cells was spun in a  pre-
cooled centrifuge for 3 min, at 1200 rpm at 4°C and the plate was then washed once with 
PBS.   
 
Immunofluorescent staining was performed by adding 100ml Fluorescein Isothiocyanate 
Isomer (FITC) conjugated monoclonal antibodies (mAb) directed against CXCR1 or 
CXCR2 receptors, (both IgG2a, R&D Systems).  Controls were incubated using isotype 
matched irrelevant antibodies directed against human IgG2a  (supplied by R&D 
Systems, UK). 
 
The neutrophils were incubated with the CXCR1 or 2 receptor monoclonal antibody for 
30 minutes at 4°C, protected from the light.  Following this, the cells were spun in the 
precooled centrifuge for 3 min, at 1200 rpm at 4°C and again washed once with PBS. 
The neutrophils were then resuspended in 300ml of PBS and 2% bovine serum albumin, 
ready for analysis. 
 
2.8.2 Flow cytometry 
 
Flow cytometry was performed using a Coulter Epics XL machine (Coulter Corp., FL, 
USA).  Cells (100,000 per sample) were analysed by flowing them through a laser at an 
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excitation wave length of 488nm and the fluorescence emission from each cell was 
measured at 530nm.  Different cell populations were identified from their patterns of 
forward and 90° light scattering.  These signals were used for gating so that the 
fluorescence signals from the neutrophils alone were analysed.  The intensity of 
fluorescence for neutrophils labelled with specific antibody was determined relative to 
the intensity of fluorescence for cells labelled with the non-specific antibody. 
 
2.9 Statistical analysis 
Statistical analyses were performed using the SPSS statistical program (version 16.0 
Chicago, USA).  Data were tested for normality using the Shapiro-Wilk test and the 
appropriate paired or unpaired statistical test used to compare groups.  Relatonships 
between variables were examined using the Pearson rank correlation test and a  p value 
< 0.05 was considered to be statistically significant.  
 
Power calculations for sample size were performed using the formula  
!
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1   
for a cross over design. Here, D was the smallest difference to be detected  (for 
example, a 50% decrease in mediator concentration or cell count) and s represented the 
standard deviation of the observations.  C = 7.85 to provide an 80% power of detecting 
a reduction in mean mediator concentration or cell counts at the 5% level of significance 
(Snedecor and Cochran 1989). 
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3 The quantification and variability of neutrophils and 
inflammatory mediators associated with neutrophil migration 
in COPD 
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3.1 Brief introduction 
 
It is generally accepted that COPD is an inflammatory condition, and that the neutrophils 
is a key effector cell. Neutrophils migrate into the lung following chemoattractant 
gradients formed by the secretion of pro-inflammatory mediators and these mediators 
and their corresponding receptors have been highlighted as potential targets for specific 
anti-inflammatory therapeutic intervention (de Boer 2005).  
 
The mediators which have attracted most attention for study are IL-8, LTB4, IL-1, TNFα 
and GROα, with MPO as a marker of neutophilic inflammation. However the daily 
variability is unknown, and their inter-relationships have not been clearly documented.   
 
The studies described in this chapter were performed to assess the relationship between 
neutrophils and mediators that have been implicated in the pathogenesis of COPD, 
especially those thought to drive neutrophilic inflammation, in order to determine those that 
may be of primary importance in COPD assessment and intervention.    
 
Before this could be achieved, it was necessary to clarify the variability of neutrophils and 
related inflammatory mediators and cells in spontaneous sputum and plasma in stable 
COPD that is seen with daily sampling.   The current studies propose that multiple sampling 
significantly reduces this variability and that these data can be used for calculations to 
power clinical trials accurately with a primary end-point of a specified reduction in mediator 
concentration or inflammatory cell number.  
 
Plasma mediator measurements were limited to those mediators that appeared of interest 
following analysis of the data gathered from sputum.  
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3.2 Experiments 
3.2.1 Study subjects 
 
Patients aged 50 – 78 years with a diagnosis of GOLD stage III COPD (Pauwels, Buist et al. 
2001) were recruited.  Patients were daily sputum producers with a history of chronic 
bronchitis as defined by the MRC criteria (Medical Research Council. 1965) and were 
current or ex-smokers. All patients were confirmed to have obstructive airways disease at 
screening by spirometric measurements and had stable symptoms of COPD for at least eight 
weeks prior to recruitment with no changes in medications during this time.  Alternative and 
concomitant lung disease was excluded clinically and by high resolution computed 
tomography. 
3.2.2 Study Design 
 
Patients were seen on 11 occasions over four weeks (daily for 5 days, then twice weekly for 
three weeks).  On each visit, patients underwent review, symptoms were noted and samples 
of spontaneous sputum and blood were collected. Spirometry was assessed weekly to 
confirm disease stability. 
 
Patients were asked to complete daily diary cards, described previously (Woolhouse, Hill et 
al. 2001), throughout the study.  Symptoms (including dyspnoea, sputum volume and 
colour) were recorded using an ordinal scale that allowed differentiation between normal for 
the patient and better or worse than usual to ensure that there were no changes suggestive of 
an exacerbation.  
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3.2.3 Sample collection & processing 
 
Spontaneous sputum samples were collected as described in section 2.4. Sputum collection 
and analysis occurred at the same time on each visit.  The samples were divided into 2 
aliquots: the first was used to prepare a sol phase sample to determine mediator 
concentrations.  The second was treated with dithiothreitol to assess total cell numbers and 
cytospins prepared for total and differential cell counts of squamous cells, neutrophils, 
eosinophils, macrophages and lymphocytes (Mikami, Llewellyn-Jones et al. 1998) and  
cytospins were prepared for total and differential cell counts. Where relevant patients were 
asked to abstain from smoking from waking until sputum collection was complete.  Blood 
samples were collected in order to obtain a plasma sample to measure mediator 
concentrations. 
 
3.2.4 Measurement of mediators 
 
Mediators were measured using Enzyme Amplified Sensitivity Immunoassay (R&D 
Systems, Abingdon, UK) and are expressed in molar concentrations.  All assays were 
validated to determine their working range and the variability of mediator measurements 
both within and between assay plates using methods described previously (Woolhouse, 
Bayley D.L. et al. 2002).  
 
In order to reduce intra-patient variability in biomarkers, the effects of employing a rolling 
mean was assessed.  A three-day rolling mean was determined for each mediator and cell 
count in each patient by averaging the results from visits one, two and three (“ rolling mean 
3a”), then from visits two, three and four (“rolling mean 3b”) etc., until the final visit was 
incorporated into a rolling mean (“rolling mean 3i”).  A five-day rolling mean was also 
determined for each biomarker in each patient by averaging the results from visits one to 
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five (“rolling mean 5a”), then from visits two to six (“rolling mean 5b”), etc., until the final 
visit (“rolling mean 5g”).   In order to overcome bias induced by the previous two days of a 
subsequent mean, comparisons were also made using random groups of 3 or 5 samples. 
3.2.5 Statistical Analysis 
 
Data analysis was performed using SPSS 12.0 for Windows (SPSS, Chicago, IL, USA). 
Normally distributed data are expressed as mean and standard deviations, categorical data as 
percentages and non-normally distributed data as median and inter-quartile range (IQR).  
Non-normally distributed continuous variables (such as mediator concentrations and cell 
counts) were log transformed to achieve normality and allow calculation of co-efficient of 
variation (CV).  The correlations between logged mediator concentrations and cell counts 
were evaluated by Pearson’s correlation coefficient (PCC).  Sample size calculations were 
performed as described previously. 
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3.3 Results 
3.3.1 Subject characteristics 
 
14 patients were enrolled and their baseline characteristics are summarized in Table 3.1.  
The medications each patient was taking during the study are listed in Table 3.2.  
Exacerbations, defined clinically (Anthonisen, Manfreda et al. 1987) were excluded on each 
visit by review of daily dairy cards, clinical examination, confirmation of unchanged 
therapy (Rodriguez-Roisin 2000) and weekly spirometry.  None of the patients experienced 
an exacerbation during the study period and there were no significant changes in diary 
scores or lung function between visits. 
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Table 3.1.  Intra-patient variability: Baseline characteristics of the study patients 
 
 
Age, yr       65.5 ± 8.5 
Male, %       6 (43) 
Diagnosis, yr       6.4 ± 5.4 
FEV¹, L       0.89 ± 0.3 
FEV¹, % of predicted      40 ± 8.3 
FVC, L       2.28 ± 0.61 
FEV¹/FVC       42 ± 11 
Increase in FEV1 following 400µg inhaled salbutamol,  
mL      132 ± 77 
% predicted     5 ± 3.3 
BMI, kg/m²       23.8 ± 4.5 
Current smokers, (%)      6 (43) 
Pack year history      45 ± 20.7 
Receiving inhaled steroids at enrolment, (%)   11 (79) 
 
Legend. 
Results are presented as average + standard deviation or percentage (shown in parentheses).  
The length of time from a formal diagnosis of COPD is shown.  
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Table 3.2: The list of medications taken by each patient during the study period. 
Patient Medications Patient Medications 
1 Salbutamol 100mcg inh bd 8 Salbutamol 100mcg inh qds 
  Tiotropium 18mcg inh od   Iprtropium 20mcg inh bd 
  Beclometasone dipropionate 200mcg inh bd   Theophylline modified release 175mg po bd 
  Aspirin 75mg po od   Seretide (250mcg/50mcg) inh bd 
     Gliclazide 80mg po od 
2 Salmeterol 50mcg inh bd     
  Salbutamol 100mcg inh prn 9 Salbutamol 100mcg inh prn 
  Budesonide 200mcg inh bd     
  Ipratropium 40mcg inh bd     
  Theophylline modified release 250mg po bd     
       
3 Salmeterol 100mcg inh bd 10 Salmeterol 50mcg inh bd 
  Salbutamol 100mcg inh bd   Salbutamol 100mcg inh prn 
  Ipratropium 40mcg inh bd   Fluticasone propionate 200mcg inh bd 
  Fluticasone propionate 100mcg inh bd     
  Ranitidine 300mg po od     
       
4 Seretide (250mcg/ 50mcg) inh bd 11 Salbutamol 100mcg inh qds 
  Salbutamol 100mcg inh prn   Ipratropium 20mcg inh bd 
     Fluticasone propionate 250mcg inh bd 
       
5 Salmeterol 50mcg inh bd 12 Salmeterol 50mcg inh bd 
  Salbutamol 100mcg inh prn   Salbutamol 100mcg inh prn 
  Ipratropium 20mcg inh bd   Fluticasone propionate 250mcg inh bd 
  Beclometasone dipropionate 20mcg inh bd     
  Paracetamol 1g po QDS     
       
6 Salmeterol 50mcg inh bd 13 Combivent inh (100mcg/20mcg) inh qds 
  Salbutamol 100mcg inh prn   Beclometasone dipropionate 200mcg inh bd 
  Ipratropium 20mcg inh qds     
       
7 Ipratropium 20mcg inh bd     
  Fluticasone propionate 250mcg inh bd 14 Formoterol fumarate 4.5mcg inh bd 
  Lansoprazole 15mg po od   Tiotropium 18mcg inh od 
  Warfarin 3mg po od (variable dose)     
  Furosemide 20mg po od     
 
Legend. 
Medications taken during the study period.  Medications did not change for 8 weeks prior to 
the study or during the study period. 
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3.3.2 Assay Variability and sputum characterisation 
 
In all cases, the mediator intra and inter-assay variability was less than 10%  The median 
percentage of squamous cells in the sputum samples was 0.6% (IQR = 0 – 7.9%) and the 
median percentage of viable cells (assessed by trypan blue exclusion) was 83% (IQR = 63 – 
92%) which is comparable to that seen with induced sputum  (Bhowmik, Seemungal et al. 
1998). 
 
3.3.3 Intra-patient variability in sputum cell and mediator concentrations  
 
There was considerable variability in the concentrations of neutrophils, mediators and other 
cells within individual patients over the study period.   Figure 3.1 demonstrates the 
variability seen for one patient and Table 3.3 describes the intra-patient variability for all 
mediators, and sputum neutrophil and macrophage counts for each patient.   
 
The variability in sputum inflammatory markers seen within patients was wide, irrespective 
of the inflammatory mediator or cell type measured.  The median intra-patient co-efficient 
of variation for each mediator (calculated from each patient’s co-efficient of variation) is 
shown in Table 3.4. This variability was not related to any changes in individual symptoms 
as recorded in the patients’ diary card scores, clinical features, sputum microbiology or lung 
function (all of which remained stable). 
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Figure 3.1a: Changes in raw data over one month for Patient 1 for the sputum sol 
mediators IL-1beta, TNF alpha and IL-8 
Each data point represents the measured concentration of one mediator for a single patient 
on a single visit (in units as per figure legend).  IL-1ß concentrations are given on the right 
hand axis, TNFα and IL-8 concentrations are given on the left hand axis.   
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Figure 3.1b: Changes in raw data over one month for Patient 1 for the sputum sol 
phase mediators MPO, LTB4, GRO alpha and absolute neutrophil counts  
Each data point represents the measured concentration of one mediator for a single patient 
on a single visit (in units as per figure legend).  MPO concentrations are given on the right 
hand axis, LTB4, GROα concentrations and absolute neutrophil counts (106/ml) are given 
on the left hand axis.  
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Table 3.3.   The within patient variability in pulmonary inflammatory mediators and 
cells seen in stable patients with COPD over one month 
 
Patient 
IL-1ß  
(pM) 
TNFα  
(pM) 
CXCL8  
(nM) 
MPO  
(mg/ml) 
LTB4 
(nM) 
GROα 
(nM) 
PMN 
(106/ml) 
Macrophage 
(106/ml) 
1 
Median 
IQR 
CV 
606 
399 - 1104 
11 
72.2 
66 - 141 
11.3 
14.27 
10.9-16.1 
15.9 
7.2 
5.34-9.5 
32.9 
91.2 
35-120 
16.9 
29.1 
24-33 
16 
4.8 
1.8-13.4 
77.3 
0.09 
0.06 – 0.17 
31.8 
2 
Median 
IQR 
CV 
19.1 
9.3 - 26.6 
19.6 
0.4 
0.19 - 0.69 
87 
4.8 
3.85-6.68 
25.4 
1.8 
1.24-1.8 
162.5 
1.4 
0.85-1.96 
194 
14.7 
12-20.4 
9.6 
1.3 
0.4-1.95 
471 
0.18 
0.14 – 0.34 
37.1 
3 
Median 
IQR 
CV 
5.8 
3.4 - 6.6 
30.3 
0.3 
0.2-0.6 
45.3 
1.4 
1.2-1.5 
85 
1.7 
1.4-1.9 
61.2 
5.9 
5-6.5 
22.2 
18.1 
16.6-19.7 
12.3 
0.9 
0.7-1.4 
804 
0.12 
0.07 – 0.13 
44 
4 
Median 
IQR 
CV 
501 
417 - 865 
8.3 
52.2 
48.5 - 68.8 
6.6 
24.4 
19.8-27.5 
20.7 
2.41 
1.6-4.5 
84.3 
28 
20.5-42 
13.5 
16.8 
14.7-18.7 
9.5 
5.35 
2.5-7.4 
44.9 
0.2 
0.13 – 0.42 
51.7 
5 
Median 
IQR 
CV 
697 
375 - 775 
10 
74.6 
33.2-105 
31 
26 
18.4-43 
13.9 
4.13 
2-7.2 
74.3 
10.23 
7.4-23.4 
25.1 
3.16 
1.5-3.8 
96.8 
6.25 
5.2-25.9 
44.8 
0.4 
0.26 – 0.81 
81.7 
6 
Median 
IQR 
CV 
120.2 
65.9 - 343 
21.2 
4.32 
0.4-42 
159 
5.37 
2.5-6.9 
44.3 
4.27 
3.4-6.4 
35.4 
11.17 
2.2-17.6 
47.9 
12.3 
10.2-16.5 
18.5 
3.4 
2.2-5.9 
38.7 
0.27 
0.16 – 0.3 
30.4 
7 
Median 
IQR 
CV 
606 
504-1128 
12 
253 
212-301 
5.6 
40.1 
27.7-61.4 
12.5 
5.79 
3.4-13.8 
59.2 
49.04 
21.7-75.7 
21.9 
12.3 
10.6-21.2 
16.4 
18.1 
12.7-24.9 
17.3 
0.46 
0.31 – 0.73 
98.3 
8 
Median 
IQR 
CV 
5.1 
3.1-5.9 
39.8 
0.1 
0.03-0.14 
29.8 
0.33 
0.24-0.41 
29 
1.15 
1.04-1.43 
224 
0.95 
0.6-1.5 
1299 
4.87 
3.5-6.4 
189 
0.4 
0.3-0.8 
92.5 
0.03 
0.03 – 0.06 
31.3 
9 
Median 
IQR 
CV 
9.26 
3.5-43.4 
55.5 
0.25 
0.02-1.1 
113 
1.04 
0.5-2.6 
633 
1.93 
1.1-2.6 
70.5 
0.49 
0.32-0.7 
159.4 
8.12 
4.7-9.8 
20.6 
0.4 
0.2-1.6 
236.5 
0.33 
0.17 – 0.65 
86.7 
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Table 3.3.  (continued). The within patient variability in pulmonary inflammatory 
mediators and cells seen in stable patients with severe COPD over one month 
 
Patient 
IL-1ß  
(pM) 
TNFα  
(pM) 
CXCL8  
(nM) 
MPO  
(mg/ml) 
LTB4 
(nM) 
GROα 
(nM) 
PMN 
(106/ml) 
Macrophage
s 
(106/ml) 
10 
Median 
IQR 
CV 
156.9 
88 - 417 
19 
5.25 
3 -10.4 
37.4 
2.11 
1.7-3 
49.2 
2.03 
1.9-2.4 
22.7 
10.81 
7.1-15.1 
27.9 
5.04 
3.9-5.3 
11.6 
2.15 
0.95-12.6 
181 
0.7 
0.31 – 2.07 
152.4 
11 
Median 
IQR 
CV 
10.6 
7.5 - 11.8 
11.4 
0.06 
0.04-0.2 
29.2 
0.11 
0.06-0.14 
24.3 
1.38 
1.2-2.6 
85.7 
6.74 
3.8-11.7 
32 
0.3 
0.1-0.4 
54.1 
1.65 
1.1-2.2 
92.4 
0.35 
0.09 – 0.68 
104.7 
12 
Median 
IQR 
CV 
31 
18 - 41.9 
16.3 
4.89 
2.7-10 
87 
3.7 
2.8-4.3 
32.7 
0.88 
0.6-1.1 
186.7 
3.07 
2.3-7.6 
111.2 
24 
21.4-28.4 
4.4 
5.1 
4.1-6.7 
20 
3.31 
2.3 – 3.9 
44.5 
13 
Median 
IQR 
CV 
13.8 
6.7-30.8 
31.2 
0.19 
0.1-0.3 
29.3 
2.05 
1.3-3.7 
73.8 
1.28 
1 - 1.4 
107.9 
1.77 
0.9-1.8 
111.8 
16.8 
7.8-21.8 
4.4 
1.8 
0.8-5.3 
178 
1.92 
0.28 – 2.56 
1100 
14 
Median 
IQR 
CV 
3.12 
2 - 4.9 
46.9 
0.16 
0.1-0.2 
13.4 
2.03 
1.4-2.6 
60.1 
0.78 
0.3-0.9 
129.5 
0.49 
0.2-1.6 
180 
19.7 
18.4-22 
5.5 
2.65 
2.2-5.2 
50.1 
1.12 
1 – 1.53 
159.7 
 
 
Legend 
The median biomarker concentration (with corresponding inter-quartile range) is given 
for each patient.  The co-efficient of variation (CV) for each patient was determined 
from log transformed data and is expressed as a percentage. 
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Table 3.4:  The median intra-patient co-efficient of variation (CV) in sputum  
 
Mediator      CV (%)  IQR 
 
IL-1ß (pM)      19.4           (11 – 33) 
TNFα (pM)      30.3           (13 – 88) 
LTB4 (nM)      39.9           (22 – 165) 
IL-8 (nM)      30.8           (19 – 63) 
GROα (nM)      16.2           (10 – 29) 
Absolute neutrophil count (106/ml)   77.3           (42 – 180) 
Absolute macrophage count (106/ml)   74.2           (41 -  102)  
MPO (mg/ml)      79.3           (53 – 138) 
 
 
Legend 
The median intra-patient CV is derived from each individual patient’s CV. Each 
patient’s mediator-specific CV was calculated using the average data from eleven 
sequential visits. 
 
 
3.3.4 Intra-patient variability in plasma cells and mediator concentrations 
  
Plasma concentrations of IL-8, LTB4, GROα and MPO were below the lower limit of 
detection for the assays available when writing this thesis, (12.5pM for IL-8, 130pM for 
LTB4, 10pM for GROα and 2.93mg/ml for MPO). Given the inability to accurately quantify 
these mediators, they were excluded from further analysis.  Plasma concentrations of TNFα 
and IL-1β could be accurately assessed for all patients, as could cell counts of neutrophil and 
monocytes, and so these were included in the analysis of variability.  
 
There was less variability in the plasma concentrations of neutrophils, monocytes and 
mediators within individual patients over the study period.   Figure 3.2 demonstrates the 
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variability seen for the same patient  as shown in figure 3.1 and Table 3.5 describes the 
intra-patient variability for TNFα, IL-1β, and peripheral blood neutrophil and macrophage 
counts for each patient.  
  
 
Figure 3.2: Changes in raw data over one month for Patient 1 for the plasma 
mediators IL-1beta, TNF alpha and absolute neutrophil and monocyte counts. 
Each data point represents the measured concentration of one mediator for a single patient 
on a single visit. IL-1ß and TNFα concentrations are given in pM (log), neutrophil and 
monocyte counts are 106/ml. 
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Table 3.5.  The within patient variability in measurable plasma inflammatory mediators 
and cells seen in stable patients with severe COPD over one month 
 
Patient 
IL-1ß  
(pM) 
TNFα  
(pM) 
Neutrophils 
(106/ml) 
Monocytes 
(106/ml) 
1 
Median 
IQR 
CV 
0.05 
0.04 – 0.07 
10 
0.12 
0.12 – 0.13 
9 
4.7 
3.9-5.2 
21 
0.7 
0.7 – 0.8 
11 
2 
Median 
IQR 
CV 
0.05 
0.04 – 0.05 
11 
0.1 
0.1 - 0.12 
10 
4.5 
4.3-4.8 
10 
0.6 
0.5 – 0.6 
13 
3 
Median 
IQR 
CV 
0.06 
0.05 – 0.06 
17 
0.11 
0.1-0.2 
12 
6.5 
6.3-6.9 
6 
0.8 
0.8 – 0.9 
10 
4 
Median 
IQR 
CV 
0.05 
0.04 – 0.08 
22 
0.08 
0.08 – 0.09 
10 
7.1 
6.7 – 7.2 
11 
0.92 
0.9 – 0.97 
13 
5 
Median 
IQR 
CV 
0.06 
0.05 – 0.07 
22 
0.7 
0.7 – 0.8 
13 
4.9 
4.4 – 5.3 
18 
0.7 
0.7 – 0.8 
13 
6 
Median 
IQR 
CV 
0.03 
0.02 – 0.04 
20 
0.07 
0.05 – 0.08 
31 
5.8 
4.5 – 7.4 
33 
0.8 
0.8 – 0.9 
12 
7 
Median 
IQR 
CV 
0.02 
0.02 – 0.03 
15 
0.07 
0.06 – 0.07 
11 
5.2 
5.0 – 5.3 
8 
0.7 
0.6 – 0.7 
17 
8 
Median 
IQR 
CV 
0.03 
0.02  0.03 
10 
0.6 
0.5 – 0.65 
14 
4.8 
4.4 – 4.9 
8 
0.6 
0.5 – 0.65 
14 
9 
Median 
IQR 
CV 
0.02 
0.01 – 0.02 
30 
0.06 
0.04 – 0.07 
20 
4.8 
4.8 – 5.1 
6 
0.5 
0.5 – 0.6 
18 
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Table 3.5.  (continued). The within patient variability in plasma 
inflammatory mediators and cells seen in stable patients with severe 
COPD over one month 
 
Patient 
IL-1ß  
(pM) 
TNFα  
(pM) 
Neutrophils 
(106/ml) 
Macrophages 
(106/ml) 
10 
Median 
IQR 
CV 
0.06 
0.05 – 0.07 
12 
0.09 
0.08 – 0.09 
8 
6.2 
5.2 – 6.6 
13 
1 
0.8 – 1.1 
44 
11 
Median 
IQR 
CV 
0.05 
0.04 – 0.05 
6.9 
0.04 
0.04 - 0.05 
9.8 
3.1 
2.9 – 3.2 
10 
0.4 
0.3 – 0.4 
5 
12 
Median 
IQR 
CV 
0.05 
0.02 – 0.05 
32 
0.04 
0.04 – 0.05 
15 
6.5 
6.1 – 7.0 
9 
0.5 
0.5 – 0.6 
17 
13 
Median 
IQR 
CV 
0.06 
0.05 – 0.07 
14 
0.05 
0.04 – 0.05 
30 
4.8 
4.3 – 5.7 
16 
0.65 
0.6 – 0.7 
8.4 
14 
Median 
IQR 
CV 
0.03 
0.03 – 0.04 
6 
0.05 
0.04 – 0.05 
10 
3 
2.7 – 3.4 
19 
0.4 
0.3 – 0.4 
20 
 
 
Legend 
The median biomarker concentration (with corresponding inter-quartile 
range) is given for each patient.  The co-efficient of variation (CV) for 
each patient was determined from log transformed data and is expressed 
as a percentage. 
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In comparison with sputum, there was little intra-patient variability in plasma inflammatory 
markers and cells (the values were similar to the inherent variability seen within each assay, 
which is approximately 10%).  The median intra-patient co-efficient of variation for each 
mediator (calculated from each patient’s co-efficient of variation) is shown in Table 3.6. 
This variability did not relate to any changes in individual symptoms as recorded in the 
patients’ diary card scores, clinical features, sputum microbiology or lung function (all of 
which remained stable). 
 
Table 3.6:  The median intra-patient co-efficient of variation (CV) in blood. 
Mediator/ Cell     CV     IQR     . 
IL-1β (pM)     14%   10 - 19 
TNFα      10%   8 - 15  
Neutrophils (106/ml)    10%   8 - 17 
Monocytes  (106/ml)    13%   11 - 17 
 
Given the stability of blood inflammation in this group of patients, further analysis to reduce 
intra-patient variability was limited to measurements taken from sputum. 
3.3.5 Reducing intra-patient variability in sputum samples 
 
It was proposed that multiple sampling would significantly reduce intra-patient variability, 
and so a rolling mean technique was adopted to test this hypothesis. Table 3.7 compares the 
effects of a rolling mean on intra-patient variability for all patients and all sputum mediators 
(expressed as CVs). When comparing a single mediator within patients, a significant 
reduction in variability of the raw data (as determined by the CV) was obtained using a 
three-day rolling mean in all biomarkers except for sputum neutrophil counts.  A further 
reduction in variability was seen using a five-day rolling mean in all biomarkers, including 
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sputum neutrophil counts.   Figures 3.3a – 3.3c compare graphically the variability in 
mediator concentrations and the effect of rolling means for one representative patient.   
 
Figure 3.3a: Rolling means.  Changes in raw data over one month for a representative 
patient (here, Patient 5) for the sputum sol phase mediators IL-1beta, TNFα and IL-8 
IL-1ß concentrations are given on the right hand axis, TNFα and IL-8 concentrations are 
given on the left hand axis.   Data points represent the measured concentration of one 
mediator for a single patient on a single visit (in units as per figure legend).   
 
 
Figure 3.3b:  Changes in mediators over one month for Patient 5 using a three day 
rolling mean 
IL-1ß concentrations are given on the right hand axis, TNFα and IL-8 concentrations are 
given on the left hand axis.  Data points represent the mean measured concentration of one 
mediator for three consecutive days for a single patient. A three-day rolling mean was 
determined for each mediator and cell count in this patient by averaging the results from 
visits one, two and three  (rolling mean “3a” on x axis), then from visits two, three and four 
(rolling mean “3b”) etc., until the final 3 visits were incorporated into a rolling mean (“3i”).  
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Figure 3.3c:  Changes in mediators over one month for a Patient 5 using a five day 
rolling mean  
Data points represent the mean measured concentration of one mediator for five consecutive 
days for a single patient.  A five-day rolling mean was determined for each biomarker in 
this patient by averaging the results from visits one to five (rolling mean “5a” on x axis), 
then from visits two to six (rolling mean “5b”), etc., until the final visit (“rolling mean 5g). 
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Table 3.7. Comparison of the median intra-patient coefficient of variation for each mediator 
using daily data, a three-day rolling mean and a five-day rolling mean 
 
Legend 
The median coefficient of variation has been derived from the marker specific CV from each 
patient.  Differences in CVs were assessed using the Friedman’s matched samples test and the 
Wilcoxon’s matched pairs signed rank test.  * = significant reduction in mean CV from raw data 
(p < 0.05).  ‡ = significant reduction in mean CV from 3 day rolling mean (p < 0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
IL-1ß 
(pM) 
TNFα 
(pM) 
IL-8  
(nM) 
MPO  
(mg/l) 
LTB4  
(nM) 
GROα  
(pM) 
Sputum  
neutrophils 
(106/ml) 
Sputum 
macrophages 
(106/ml) 
Raw 
data 
Median 
CV  (%) 
(IQR) 
19.4 
 
(11 - 33) 
30.3 
 
(13 - 88) 
30.8 
 
(19 - 63) 
79.3 
 
(53 - 138) 
39.9 
 
(22 – 165) 
16.2 
 
(10 - 29) 
77.3 
 
(42 - 180) 
 
74.2 
 
(41 – 102) 
3 day 
rolling 
mean 
Median 
CV  (%) 
(IQR) 
    11.2 * 
 
  (6 - 17) 
20.6 * 
 
(8 - 50) 
17.3 * 
 
(12.6) 
44.5 * 
 
(20 - 60) 
22.5 * 
 
(10 - 96) 
7.6 * 
 
(4 – 11) 
46.7 
 
(13 - 218) 
 
33.9 * 
 
(26 – 59) 
 
5 day 
rolling 
mean 
 
 Median 
CV  (%) 
(IQR) 
 
 
6.9 * ‡ 
 
(4 - 9) 
 
12.2 * ‡ 
 
(2 - 37) 
 
9.5 * ‡ 
 
(4 - 20) 
 
22 * ‡ 
 
(13 - 39) 
 
13.8 * ‡ 
 
(4 - 53) 
 
 
4.1* ‡ 
 
(2.6 – 6.8) 
 
     13.4 * ‡ 
 
     (8 - 124) 
 
 
          
 
         20 * 
 
(13 – 32) 
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3.3.6 Inter-patient variability and the effects of a rolling mean. 
 
There was marked variability in inflammatory biomarkers between patients with COPD 
using data from a single day.  Using a three-day or five-day rolling mean for each patient 
did not alter the inter-patient variability suggesting that it relates to individual differences in 
the degree of airway inflammation. When all mediators were considered together, the 
median variability between patients using daily data (expressed as the CV) was 101% (IQR 
90 – 123%) and the median variability between patients using the first five day rolling mean 
was only slightly reduced to 91% (IQR 73 – 115%) (see Table 3.8). 
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Table 3.8:  Comparison of the inter-patient coefficient of variation for each mediator 
using  
 
 
 
Legend 
The median biomarker concentration (and IQR) is calculated from all measurements for 
all patients.  In order to calculate the inter-patient CVs, the mean logged concentrations 
were calculated for each biomarker in each patient (either using daily data or data from 
the first 5 day rolling mean).   
 
 
 
 
  
IL-1ß  
(pM) 
TNFα  
(pM) 
IL-8  
(nM) 
MPO  
(mg/ml) 
LTB4  
(nM) 
 
GROα  
(nM) 
Sputum 
macrophag
es 
(106/ml) 
Sputum 
neutrophils  
(106/ml) 
Median 
CV 
(IQR) 
Median 43.3 2.07 3.6 1.8 6.1 12.3 0.29 2.65   
IQR 
 
7.5 – 
413 
 
0.2 – 
55 
 
1.4 - 14.4 
 
1.1 - 3.5 
 
1.5 - 18.6 
 
5 - 19.5 
 
(0.13 – 
0.75) 
 
1 - 6.4 
   
CV 
calculated  
from raw 
data 
53.5 407.8 145.4 102 99.8 60.9 100 115.4 101% (90-123) 
CV 
calculated  
using a 5-
day 
rolling 
mean 
52.15 234.6 131 92.15 78.2 58.5 110 89.4 91% (73 – 115) 
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3.3.7 Determining the sample size required to power interventional studies. 
 
Using a cross-over design, the number of patients needed to confirm a 50% reduction in 
sputum neutrophil counts with 80% power and at the 5% significance level using a single 
data point per patient would be 72.  However, if a three-day average is used, the number 
needed to confirm the same reduction would be 23 and 20 using a five-day average.  For a 
parallel design, the number needed to confirm a 50% reduction in sputum neutrophil counts 
using a single data point would be 140 (70 per group), which would be reduced to 106 and 
103 using a three or five-day average respectively.  
 
Table 3.9 summarises the average number of patients required (with SEM) to detect similar 
changes in other mediators when a single sputum sample is collected or when the average of 
three or five consecutive samples is used for power calculations.  
 
Using the same formula for a cross-over design, the number of patients needed to confirm a 
50% reduction in plasma TNFα with 80% power and at the 5% significance level using a 
single data point per patient would be  6.    To see the same reduction in IL-1β with the same 
power and at the same significance, one would need to include 4 patients. In comparison with 
sputum samples, fewer subjects would be required for studies with adequate power, due to the 
reduction in variability.   However, it must be recalled that both IL-1β and TNFα are at the 
lower limits of detection for both of the assays that were used in this thesis, and so a further 
reduction is likely to be unquantifiable if measured using the same techniques..                         
.
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Table 3.9: A comparison of the numbers needed in a cross-over study design when one day’s 
data, the mean of three days’ data or the mean of five days’ data are used for calculations 
 
 
 
  
 
 
Legend. 
Numbers required to provide an 80% chance of detecting a 50% decrease in mediators or cells 
at the 5% level of significance. For 1 day’s data, power calculations were performed for each 
mediator on each visit, and the mean of this is presented (with the standard error of the mean 
(SEM)).  For three days’ data; power calculations were performed on the first three days (visit 
1 to 3), then the next three days (visit 2 to 4) until visit 9 – 11.  These were used to calculate 
the mean number of patients required.       
For five days’ data; power calculations were performed on the first five days (visit 1 to 5), 
then the second five days (visit 2 to 6) until visit 7 to 11.  These were used to calculate the 
mean number of patients required. 
 
 
 
   IL-1ß  TNF α IL-8 MPO LTB4 GRO α 
Absolute 
macrophage 
counts 
Absolute  
neutrophil 
 counts 
1 days data 
Mean number 
 of patients 
10 330 61 62 41 20 
 
52 72 
  SEM 0.76 74.72 7.14 15.90 4.79 4.95 11.2 11.11 
3 days data 
Mean number 
 of patients 
2 23 7 16 7 5 
 
12 23 
  SEM 0.73 9.08 1.93 4.01 2.13 1.94 1.7 6.69 
5 days data 
Mean number 
 of patients 
2 15 5 13 7 5 
 
6 
 
20 
  SEM 0.07 3.12 0.30 1.49 0.45 1.34 0.6 2.25 
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3.3.8 The relationship between sol phase inflammatory mediators and 
sputum cell counts 
 
All biomarkers measured showed inter-relationships with each other of varying 
significance.  Of the chemoattractants studied, IL-8 (followed by LTB4) was most closely 
associated with neutrophils and other inflammatory mediators, with the most significant 
correlations.  None of the mediators correlated with sputum macrophage counts.  The 
weakest and often non-significant correlations were obtained using a single days sample.  
The strength of correlations between mediators and neutrophils (and the significance of 
these correlations) increased as more data points were used for each patient, see table 3.10.  
Table 3.11. shows the relationships between cytokines.  With the exception of GROα, good 
correlations were seen however many days data were used. However, in general, there was 
an increase in the correlation coefficient using the mean of three days’ data as opposed to 
one day’s data (mean difference in Pearson’s correlation coefficient between one day’s data 
and the mean of three days data = 0.11, CI = 0.04 – 0.18, p = 0.003), however there was no 
further increase in the strength of the correlation using the mean of more data points. The 
exception to this was GROα, which showed no correlation with neutrophils or any other 
mediator measured in sputum, apart from CXCL8. 
 
 
 Figure 3.4a – 3.4c demonstrates the correlations seen between the absolute sputum 
neutrophil count and IL-8, TNFα and  IL-1β respectively, using the average value for all 
eleven samples for each patient. 
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Table 3.10: Correlations between cells and mediators  
 
 
 
 
Legend 
Data describes the relationships between mediators and cell counts when one days data is 
used (here, the first day), or the mean of the first 3, 5 or all 11 days’ data.  Relationships are 
expressed as  Pearsons Correlation Co-efficient (PCC) and p value. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mediator  
or cell line 
Data used 
for  
correlations  
PCC (p) 
Sputum  
neutrophils IL-8 LTB4 TNFα MPO IL-1ß GROα 
Sputum  
neutrophils 
1 day 
 
3 days 
 
5 days 
 
11 days 
  0.6 (0.02) 
 
0.8 (<0.001) 
 
0.66 (0.005) 
 
0.7 (0.004) 
0.5 (ns) 
 
0.61 (0.01) 
 
0.65 (0.01) 
 
0.7 (0.008) 
0.46 (0.09) 
 
0.84 (<0.001) 
 
0.71 (0.003) 
 
0.81 (<0.001) 
0.18 (0.53) 
 
0.2 (0.5) 
 
0.2 (0.5) 
 
0.13  (0.64) 
0.60 (0.02) 
 
0.77 (0.001) 
 
0.77 (0.001) 
 
0.83 (<0.001) 
0.13 (0.7) 
 
0.16 (0.6) 
 
0.3 (0.36) 
 
0.25 (0.4) 
Sputum  
macrophages 
1 day 
 
3 days 
 
5 days 
 
11 days 
0.38 (0.17) 
 
0.45 (0.1) 
 
0.29 (0.3) 
 
0.4 (0.12) 
0.1 (0.7) 
 
0.22 (0.44) 
 
0.11 (0.7) 
 
0.19 (0.51) 
0.006 (0.9) 
0.05 (0.89) 
-0.15 (0.6) 
-0.19 (0.5) 
0.08 (0.8) 
 
0.09 (0.73) 
 
0.05 (0.8) 
 
0.09 (0.8) 
-0.35 (0.22) 
 
-0.37 (0.2) 
 
-0.14 (0.6) 
 
-0.39 (0.16) 
-0.08 (0.8) 
 
0.09 (0.73) 
 
0.07 (0.8) 
 
0.03 (0.9) 
0.08 (0.8) 
 
0.22 (0.44) 
 
0.16 (0.6) 
 
0 (0.9) 
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Table 3.11: Correlations between mediators  
Mediator  
or cell line 
Data used 
for  
correlations  
PCC (p) 
CXCL8 LTB4 IL-1ß TNFα MPO GROα 
CXCL8 
1 day 
 
3 days 
 
5 days 
 
11 days 
  0.52 (0.06) 
 
0.66 (0.01) 
 
0.60 (0.02) 
 
0.64 (0.02) 
0.85 (<0.001) 
 
0.84 (<0.001) 
 
0.85 (<0.001) 
 
0.82 (<0.001) 
0.84 (<0.001) 
 
0.83 (<0.001) 
 
0.8 (<0.001) 
 
0.83 (<0.001) 
0.41 (0.07) 
 
0.5 (0.07) 
 
0.51 (0.04) 
 
0.53 (0.04) 
0.22 (0.5) 
 
0.23 (0.5) 
 
0.6 (0.03) 
 
0.56 (0.02) 
LTB4 
1 day 
 
3 days 
 
5 days 
 
11 days 
   0.52 (0.06) 
 
0.66 (0.01) 
 
0.60 (0.02) 
 
0.64 (0.02) 
  0.78 (0.002) 
 
0.84 (<0.001) 
 
0.8 (<0.001) 
 
0.8 (<0.001) 
0.87 (<0.001) 
 
0.84 (<0.001) 
 
0.87 (<0.001) 
 
0.82 (<0.001) 
0.51 (0.04) 
 
0.6 (0.012) 
 
0.62 (0.011) 
 
0.6 (0.02) 
0.12 (0.7) 
 
0.16 (0.6) 
 
0.01 (0.99) 
 
0.03 (0.9) 
IL-1ß 
1 day 
 
3 days 
 
5 days 
 
11 days 
0.85 (<0.001) 
 
0.84 (<0.001) 
 
0.85 (<0.001) 
 
0.82 (<0.001) 
0.78 (0.002) 
 
0.84 (<0.001) 
 
0.8 (<0.001) 
 
0.8 (<0.001) 
  0.84 (<0.001) 
 
0.96 (<0.001) 
 
0.87 (<0.001) 
 
0.88 (<0.001) 
0.34 (0.2) 
 
0.4 (0.1) 
 
0.4 (0.1) 
 
0.51 (0.06) 
0.1 (0.8) 
 
0.06 (0.9) 
 
0.15 (0.6) 
 
0.13 (0.6) 
 
Legend 
Data describes the relationships between mediators and cell counts when one days data is used 
(here, the first day), or the mean of the first 3, 5 or all 11 day’s data.  Relationships are expressed 
as Pearson’s Correlation Co-efficient (PCC) and p value. 
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Figure 3.4a 
 
 
Figure 3.4b 
 
Figure 3.4: The relationship between sputum neutrophil counts and sputum IL-8 (a), 
and TNFα (b).  
In all figures the data has been log transformed. Each point represents the mean of eleven 
sequential samples for each patient. The correlation is described using Pearson’s correlation 
coefficient (r) together with the significance of the relationships (p). 
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Figure 3.4: The relationship between sputum neutrophil counts and sputum IL-1ß.  
In all figures the data has been log transformed. Each point represents the mean of eleven 
sequential samples for each patient. The correlation is described using Pearson’s correlation 
coefficient (r) together with the significance of the relationships (p). 
 
 
3.3.9 The relationship between sol phase inflammatory mediators, cell 
counts and disease 
 
Correlations were seen between neutrophil counts, inflammatory mediators and markers of 
disease.  IL-8 correlated with airflow obstruction (FEV1/FVC ratio, r = -0.4, p = 0.04), but 
no other chemoattractant correlated with markers of airways disease.   Neutrophil counts 
correlated both with smoking history  (pack years, r = 0.61, p = 0.008) and negatively with 
FEV1 (r = -0.6, p = 0.01).   
 
Once again, the strength of the correlation (and the significance value) increased as more 
data points were used for each patient.  Using the first days data for each patient, only 
IL-1β correlated with BMI (r = -0.5, p = 0.03).  Using the mean of the first three days for 
each patient, significant correlations were seen between BMI and IL-1β (r =   -0.5, p = 
0.02) and TNFα (r = -0.48, p = 0.03).  However, using the average of eleven data points 
per person, significant correlations were present between BMI and IL-1β  (r = -0.41, p = 
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0.05), TNFα (r = -0.4, p = 0.05) and LTB4 (r = -0.51, p = 0.03); smoking history with 
sputum neutrophils (see above) and sputum macrophages (r = 0.46,p = 0.05); FEV1 with 
sputum neutrophils (see above) and TNFα (r = -0.45, p = 0.04) and  FEV1/FVC ratio 
with IL-1β (r = -0.5, p = 0.03) and IL8 (see above). 
  
3.4  Discussion 
 
There is marked variability in inflammatory mediators and cells, both between patients and 
within each patient over the course of a four week period in well characterised patients with 
GOLD stage III COPD and chronic bronchitis.  Given the heterogenous nature of COPD, it 
is perhaps unsurprising that inflammatory cells and mediators vary between individuals and 
indeed this finding is in agreement with a wealth of previously published data (Rutgers, 
Timens et al. 2000; Biernacki, Kharitonov et al. 2003) . 
 
The variability of the raw data within individuals was also marked, even in samples taken 
on consecutive days; and the fluctuations did not relate to changes in symptom scores, 
clinical findings or changes in FEV1 (all of which remained stable).  It is likely that the 
variability reflects changes in sampling methodology, contamination with oropharyngeal 
secretions or sputum humidification over the study period rather than individual patients 
showing wide fluctuations in the daily inflammatory load of the lungs without this 
impacting on daily symptoms.  It may also be that only when changes in lung inflammatory 
load are sustained at a higher magnitude over consecutive days that it relates to changes in 
clinical status.  A similar relationship has been demonstrated in patients with prednisone-
dependent asthma where clinical indices deteriorate much later than the inflammatory 
changes in sputum (Pizzichini, Pizzichini et al. 1999).  The studies confirm that serial 
sampling can be used to dramatically reduce within patient variability, and this reduction 
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decreases the number of subjects who would need to be recruited to adequately power 
putative studies where a reduction in neutrophil counts (or other sputum mediator 
concentrations) was the primary outcome.   
 
The current study demonstrated clear inter-relationships between neutrophils and the 
majority of measured inflammatory mediators and some important clinical parameters of 
disease activity. Previous studies have reported indirect evidence that some biomarkers may 
be involved in the pathogenesis of COPD, including the presence of higher concentrations 
of mediators in disease compared with matched controls and the increases seen during 
exacerbations (Hill, Campbell et al. 2000; Saetta, Turato et al. 2001; Traves, Culpitt et al. 
2002).  This study is the first to describe the relationships seen between several biomarkers 
and the strength of these correlations in lung secretions.  
 
Many cells and mediators have been found to be raised in COPD, but it is unlikely that all 
will be central to the pathogenesis of the disease.  FEV1 is the most consistent single 
predictor of survival and quality of life in COPD (Wise 2006). The relationships described 
between absolute sputum neutrophil counts and FEV1, airflow obstruction and smoking 
history is highly suggestive that neutrophils are of importance in the pathogenesis of airflow 
obstruction.   
 
Three neutrophil chemoattractants were studied, IL-8, LTB4 and GROα.  In the current 
study, sputum IL-8 concentrations correlated with all other mediators and airflow 
obstruction in stable COPD; while previous work has found associations between IL-8 and 
various disease parameters (Yamamoto, Yoneda et al. 1997; Hacievliyagil, Gunen et al. 
2006; Parr, White et al. 2006), making it a clear candidate for modification of neutrophil 
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dependent pathophysiological parameters.  IL-8 binds to both CXCR1 and CXCR2 on 
neutrophils with equal affinity.  The inflammatory effects of GROα are mediated mainly via 
CXCR2 receptors, and although this chemokine did not relate to other mediators or markers 
of disease, it maybe of importance in planned studies of CXCR2 antagonists. LTB4 did not 
correlate with lung physiology, but did correlate inversely with BMI, perhaps suggesting a 
more systemic reflection of this mediator. 
 
IL-1β and TNFα also correlated with neutrophils, the chemoattractants and some clinical 
parameters of disease (in particular, BMI).  It is recognized that weight loss and low body 
weight are common in COPD, and that low body weight is associated with increased 
mortality independent of lung function (Wilson, Rogers et al. 1989; Gray-Donaldson, 
Gibbons et al. 1996).  Further studies have suggested that loss of muscle mass is the most 
important component of weight loss in COPD, and it is this which affects patients 
functionally (Mador 2002). Previous studies have linked a low BMI to systemic 
inflammation (Eid, Ionescu et al. 2001), however, in the current study, IL-1β and TNFα in 
particular correlated negatively with BMI, supporting the hypothesis that an increase in lung 
inflammation is associated with a lower body weight.  
 
This study used spontaneous sputum to assess pulmonary inflammation.  Sampling 
techniques vary between studies of inflammation in COPD, however, the intra and inter-
patient variability of measured mediators is unknown for most methodologies.  Spontaneous 
sputum collection is non-invasive and has no inflammatory sequelae to limit sequential 
sampling.  Furthermore, spontaneous sputum samples are the only medium where an 
artificial dilution factor is absent.   However, there is still an inherent physiological dilution 
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present in all lung secretions, which will have an impact upon the ability to obtain accurate 
serial measurements.  
 
Sputum is a mixture of lower airways and oropharyngeal secretions. Lower airway 
secretions are affected by exudation of plasma-derived proteins into the airway lumen (van 
Zuijlen, van de Graaf et al. 2001) which occurs both when the epithelial mucosa is damaged 
(Persson, Erjefait et al. 1998) and intact both structurally and functionally (Erjefalt and 
Sundler 1996) and presents a dilutional factor inherent in all sampling methodologies.   
 
Oropharyngeal contamination can be reduced by patient education and supported by 
measuring the percentage of squamous cells in the sample, which should typically be less 
than 10%.  In our study, squamous cells accounted for less than 1% of cells seen in the 
samples, which suggests that oropharyngeal contamination was low.  Although we took the 
precaution of the patients rinsing their mouths prior to expectoration the rinse itself or any 
remaining oropharyngeal secretions could still dilute the sputum samples.  Indeed this could 
explain some of the intra-patient variability seen day to day and similar effects could 
influence the between patient variability.   
 
If mediator and cell values were overwhelmingly influenced by dilution, it would be 
predicted that mediator concentrations between patients would correlate well, as dilute 
samples would have low measured concentrations of mediators and concentrated samples 
would have high measured concentrations of mediators, even if all patients were in the same 
inflammatory state and mediator secretion was identical.   The data for GROα however 
suggests that this is not the case. In our study GROα failed to correlate with any other 
mediator except CXCL8. This suggests firstly that the remaining correlations reflect 
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different inflammatory states per patient, and secondly that GROα does not reflect 
inflammatory differences between patients nor the neutrophil content of airway secretions. 
Thus the data suggests that GROα may be less important in the development or progression 
of COPD than other mediators. It is possible that GROα has a different spectrum of activity 
than previously suspected (Traves, Culpitt et al. 2002), or that GROα is maximally 
expressed in COPD patients with chronic bronchitis irrespective of the subsequent degree of 
inflammation.  However, the fact that GROα does not correlate with other biomarkers 
provides sound evidence that the relationships seen between other mediators are not purely 
dilutional in nature.  Furthermore the correlations with systemic markers of disease (BMI, 
and FEV1) and the use of repeated sampling (when any variable dilutional factors would be 
minimised) also makes this explanation unlikely. 
 
By studying spontaneous sputum, we limited our recruitment to patients with chronic 
bronchitis.  Although there remains some controversy as to the importance of sputum 
production in COPD, a body of evidence is emerging that suggests that chronic bronchitis 
may be a predictor of mortality and morbidity independent of FEV1.  Previous work has 
concluded that the inflammatory burden is higher in patients with chronic bronchitis 
compared with matched patients without (Gompertz, Hill et al. 2006).  Furthermore, chronic 
mucus hyper-secretion is consistently associated with both an excess FEV1 decline, an 
increased risk of subsequent hospitalization (Vestbo, Prescott et al. 1996) and death from 
respiratory infections (Prescott, Lange et al. 1995). Given the importance of this symptom 
in COPD and its relationship to inflammation, it is important to understand the relationships 
between inflammatory mediators in this group of patients.  Studying spontaneous sputum 
samples prevents comparison with healthy controls, which is a limitation of the current 
study.  However, it has been established that the mediators and cells measured in the current 
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study are raised in COPD compared with healthy controls even in studies using induced 
sputum (Gompertz, Bayley D et al. 2001; Franciosi, Page et al. 2006).   
 
The wide inter-patient variability is determined from a relatively small cohort of patients. It 
is possible that others may have inflammation vastly outside the range documented here, 
which could affect the power calculations for a parallel study.  However the single day data 
is consistent with stable state results in previous larger studies of over 100 patients with a 
wide range of FEV1 (Gompertz and Stockley 2002) (Hill, Campbell et al. 2000; Gompertz, 
O'Brien et al. 2001; Gompertz, Hill et al. 2006) suggesting that the current data is 
representative.  Of importance, the inter-patient variability was not significantly affected 
even by the use of the average of 11 collections per patient, suggesting that it represents true 
inter-patient variability.   
 
It is difficult to comment on the likely bioavailability of any of the mediator measured in 
this thesis. The relationships seen with other biomarkers and with disease markers could be 
indicative of their overall activity, suggesting a central role in the pathogenesis of COPD.  
Alternatively, the relationships could be a confounding association, and other, as yet 
unidentified  mediators may drive both the disease and the expression of the two cytokines.   
Certainly, further studies are warranted in order to try and determine the likelihood of 
activity in the stable state, but would be beyond the scope of this body of work.  
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Interestingly, the present study has found some similarity in results to the recently published 
ECLIPSE study (Singh, Edwards, et al, 2010).  In this study, annual induced sputum 
samples and a blood sample were collected in 166 patients with COPD for two years.  Here, 
the percentage of neutrophils in sputum correlated positively with disease severity (as 
characterised by GOLD) and negatively (albeit weakly) with FEV1.    There was no 
association with absolute neutrophil count and FEV1, or association between the percentage 
neutrophil count and systemic inflammatory mediators.  Sputum mediators were not 
studied.   The systemic mediators measured in plasma in the ECLIPSE dataset differed from 
those measured in the present study. However, given the low concentration of plasma 
mediators, their bio-availability and short half-life it is perhaps unsurprising that plasma 
concentrations did not correlate with neutrophil percentages.  It is disappointing that sputum 
mediators were not studied, as this may have reflected the inflammatory burden of disease 
better.   
 
The ECLIPSE authors suggest that a lack of correlation between sputum numbers and FEV1 
may be due to the wide inter-patient variability in neutrophil numbers in sputum, even in 
patients with similar disease burdens. The current study is consistent with this hypothesis, 
as, in spontaneous sputum, the inter-patient CV of neutrophil counts was 115%. However, 
the ECLIPSE study does not comment on intra-patient variability, which would also affect 
results. In contrast with inter-patient variability, intra-patient variability can be reduced by 
serial sampling, increasing likelihood of identifying significant clinical associations.  As 
stated, it is likely that serial sampling reduces variability by reducing the effects of variable 
sample dilution.  Unlike spontaneous sputum, induced sputum has an artificial dilution 
factor (that of the inhaled hypertonic saline), which may impact upon sputum dilution and 
the variability of sputum cell counts and mediator concentrations, however, due to 
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inflammatory nature of the technique of sputum induction, it cannot be repeated on a daily 
basis. The ECLIPSE study suggests that over 125 patients would be needed to sufficiently 
power a study to identify a 50% reduction in induced sputum neutrophils. This is 
significantly greater than the numbers needed to identify the same differences using a single 
sample of spontaneous sputum, and over 5 fold higher than needed if serial sampling is 
employed. The ECLIPSE data may have failed to find an association between absolute 
neutrophil counts and FEV1 either because no association truely exists, or because it was 
insufficiently powered to identify this relationship using a single induced sputum sample 
per patient.    Neutrophil percentages in sputum are not as variable, both in terms of inter 
and intra-patient variability, and this reduction in variability will enhance the identification 
of associations, and may account for the association between percentage of neutrophils and 
FEV1 in the ECLIPSE dataset.  Finally, differences in sampling methodologies may account 
for differences seen between the current work and the ECLIPSE data, but there are currently 
insufficient studies comparing the two sampling techniques to allow for further comment. 
 
In conclusion, this study documents the variability in neutrophil and mediator 
concentrations both between and within patients with stable severe COPD. Of importance, 
intra-patient variability is reduced significantly by averaging sequential biomarker 
measurement, which minimizes this variation irrespective of alterations in the inflammation 
signal. In addition, averaging sequential samples enabled relationships between mediators to 
be identified with more confidence providing at least 3 samples were obtained. This 
protocol would therefore be ideal for studying inflammatory change in COPD and can be 
used to power short term proof of concept studies. 
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The study demonstrates that positive correlations exist between neutrophil counts and 
inflammatory mediators, and inverse correlations exist between neutrophils, some mediators 
and clinical markers of disease severity.   Out of the three chemoattractants studied, IL-8  
appears to be more clinically relevant, correlating strongly with other mediators and lung 
function.  Further studies of neutrophil migration focused upon this chemokines and its’ 
receptors are indicated.  The strong correlations seen with TNFα and IL-1β have been 
pursued separately.       
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4 Neutrophil migration in the healthy elderly 
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4.1 Brief introduction 
 
The increased morbidity and mortality from bacterial infections in older adults is highly 
suggestive of a sub-optimal neutrophil response and in support of this, there is clear 
evidence of a reduction in bactericidal (superoxide generation and degranulation) and 
phagocytic function in circulating cells isolated from older subjects (Lipschitz, Udupa et 
al. 1984; Fulop, Komaromi et al. 1986; Wenisch, Patruta et al. 2000; Butcher, Chahal et 
al. 2001). 
 
In contrast, the affects of ageing upon neutrophil migration is poorly understood with 
studies showing contrasting results, including no differences (MacGregor and Shalit 
1990; Esparza, Sanchez et al. 1996), and reduced movement towards chemotactic 
signals (Niwa, Kasama et al. 1989; Wenisch, Patruta et al. 2000; Fulop, Larbi et al. 
2004).  Reassessing this issue is of importance because studies of neutrophilic 
inflammation in COPD involves patients middle aged and above. 
 
Previous studies used under agarose and Boyden chamber assays, and while these 
techniques can provide information about overall migratory patterns, they are not 
designed to study the migratory parameters of individual cells, such as speed or accuracy 
of movement and they cannot characterise any  differences in migration.  
 
Previous studies of neutrophil migration in COPD have not included closely age-
matched controls; for example (Yoshikawa, Dent et al. 2007).  Without a sound 
understanding of the impact of healthy ageing on neutrophil migration, it is difficult to 
be sure if differences reported reflect true disease-based processes or differences that are 
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seen generally with increasing age.   Furthermore, to explore if chronic diseases such as 
COPD are driven by pathological or heightened ageing,  it is important to identify and 
quantify any neutrophil behavioural differences that are age dependent . 
 
The studies described in this chapter were performed to examine, firstly, overall 
migratory patterns of circulating neutrophils using the Under Agarose assay.  This 
would provide a point of comparison with previous work.  Secondly, a newer 
migrational assay was validated in order to provide quantitative detail of individual cell 
behaviour. Finally, a CXCR2 inhibitor was used and surface expression of CXCR1 and 
CXCR2 were measured to explore potential mechanisms or features that influence 
results.  
 
Given the relevance of IL-8 in COPD (as proposed in Chapter 3) this was used as the 
main chemoattractant for studies included in this chapter.  GROα was also included to 
determine if any differences seen were CXCR1 or CXCR2 dependent. 
 
4.2 Experiments 
 
4.2.1 Study subject 
 
Healthy older subjects consisted of volunteers over the age of 65, who had never smoked, 
had no evidence of chronic disease, normal spirometry and were medication free.   
Healthy younger controls (who were under 35), had the same entry criteria and were 
gender matched to the older subjects.   All studies were approved by the local Research 
and Ethics Committee and all subjects gave their informed written consent. 
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4.2.2 Isolation of blood neutrophils 
 
Neutrophils were isolated from the whole blood as described previously (methods 2.5.7) 
(Mikami, Llewellyn-Jones et al. 1998).  The neutrophils (>95% pure, > 97% viable, by 
exclusion of trypan blue) were resuspended in buffer (RPMI 1640 medium (Flow 
Laboratories, Rickmansworth, UK) containing 0.15% bovine serum albumin (Sigma-
Aldrich, UK) at a concentration of 2 million cells/ml. 
 
4.2.3 Neutrophil Chemotaxis 
4.2.3.1 Under Agarose Assay 
 
Neutrophil chemotaxis was firstly assessed using the under-agarose assay, as described 
previously  (methods section 2.7.1) (Nelson, Quie et al. 1975).  Following dose response 
experiments, peripheral neutrophils isolated from old (n=6) or young (n=6) subjects 
migrated towards 100nM IL-8 and both a negative control (Assay buffer: RPMI 1640 
(Flow Laboratories, UK) containing 0.15% bovine serum albumin (Sigma-Aldrich)) and 
positive control (fMLP 100nM, Sigma-Aldrich).  Migration is expressed in mm, with 
differentiation between chemotaxis and chemokinesis. Each experimental condition was 
repeated three times per subject and averaged to form an intra-subject mean.  Each intra-
subject mean was also averaged as an overall mean for both subject groups (Healthy 
older subjects or healthy young controls). 
 
4.2.3.2 Modified Dunn Chamber 
 
Neutrophil chemotaxis was then measured using a modification of the Dunn chamber.  
Full methodological details are included in the methods (section 2.7.2). Chemotaxis was 
assessed as described in general methods (section 2.7.2.3). 
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Following appropriate dose responses, neutrophils migrated in gradients of a negative 
control (Assay buffer, see above), IL-8 (RnDSystems) (10nM) and GROα 
(RnDSystems) 100nM. Neutrophil migration was then assessed towards IL-8 (10nM), 
following neutrophillic incubation with 5nM of a CXCR2 antagonist (kindly provided 
by AstraZeneca) (5nM) for 45 minutes at room temperature.  The CXCR2 antagonist 
provided by AstraZeneca was an unknown compound, with no documentation of its 
structure, specificity or potency.  
 
4.2.4 Flow Cytometry 
 
CXCR1 and 2 receptor expression on isolated neutrophils was measured as described in 
section 2.8 of the general methods.  All measurements were carried out in triplicate, and 
a median result used for each subject.  Anti-CXCR1 (IgG2A stock concentration 50 
µg/ml) diluted to 2ng/ml in 2% BSA PBS, Anit-CXCR2 (IgG2A stock concentration 50 
µg/ml) diluted to 3ng/ml in 2% BSA PBS and an isotype matched irrelevant FITC 
labelled IgG2A  (stock concentration 200 µg/ml), diluted to 2ng/ml in 2% BSA PBS, was 
used as a control. Both were incubated on ice for 20 minutes and the resuspended cells 
were analysed following FACS within twenty minutes of preparation. Samples from 
young and older subjects were read at the same time point to allow comparison of 
receptors.    
 
CXCR1 and 2 receptor expression over time was assessed by measuring the receptors at 
3 time points (time 0, +1 hour and + 2 hours).  Samples were incubated on ice between 
readings.   The affects of cell stimulation on CXCR1 and CXCR2 expression were 
investigated by measuring CXCR2 receptors following neutrophil incubation with three 
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concentrations of IL-8 (1, 10 and 100nM) and a negative control (RPMI 1640).  
Neutrophils were incubated with IL-8 for ten minutes prior to preparation for cell 
sorting. The dose range  for IL-8 was chosen as this represented a physiological spread 
of concentrations that the neutrophil would encounter on migrating towards the sputum 
and were chosen following appropriate validatory experiments (see section 4.3.5). 
  
4.2.5 Statistical analysis 
 
Migrational differences seen using the Under Agrose assay were compared using the 
mean chemotactic response, chemokinetic response and chemotactic differential (see 
figure 2.10) of experiments completed in triplicate for each individual.  Migrational 
differences seen using the Modified Dunn Chamber were compared using the mean 
data of 10 cells per experiment, per subject.  Differences in chemotaxis criteria were 
compared using an Independent t test. Differences in CXCR2 surface expression were 
compared using a Mann Whitney U test. A p value of less than 0.05 was considered to 
be statistically significant.   
 
Under agarose studies were exploratory, and sample size calculations were not 
performed.  For the Modified Dunn chamber, sample size calculations were based 
upon a two group parallel comparison, to provide an 80% power of detecting a 25% 
difference in mean speed at the 5% level of significance.   For CXCR2 expression, 
sample size calculations were based upon a two group parallel comparison, to provide 
an 80% power of detecting a 25% difference in expression at the 5% level of 
significance (both as described in section 2.9). 
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4.3 Results 
4.3.1 Under agarose assay: Validation 
 
The neutrophil chemotactic response was maximal towards IL-8 at a concentration of 
100nM.  See figure 4.1.                                                   . 
 
Figure 4.1.  The chemotactic response of neutrophils towards increasing 
concentrations of IL-8 
The results shown are the mean (and SEM) values of six experiments.  Negative control 
is buffer (RMPI (Sigma-Aldrich).  Positive control is fMLP (Sigma-Aldrich) 10 -7 M. 
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4.3.2 Under agarose assay:  Results 
4.3.2.1 Baseline characteristics 
Demographic data for the old and young healthy controls are shown in Table 4.1. 
Table 4.1. Ageing studies Under agarose:  Demographic data for healthy old and 
young controls 
 
Healthy older 
subjects 
Young Controls 
 
N 6 6 
Age (years) 71 (66 - 84) 27 (21 – 33) * 
Male 4 (66%) 3 (50%) 
Smoking status All never All never 
Pack years 0 0  
FEV1 (percent predicted) 94 (7.9) 113 (4.6)  
FEV1/FVC (%) 82 (5.3) 85 (3.9)  
BMI 23 (2.7) 21 (3.2) 
 
Legend 
Normally distributed data is presented as mean (with range or SEM).  Categorical data is 
presented with percentages given in parentheses. * = significantly different from healthy 
older subjects (p < 0.05). 
 
 
4.3.2.2 Neutrophil migration towards IL-8 
 
Table 4.2 describes the mean chemotaxis, mean chemokinesis and mean chemotactic 
differential for each group.  The chemotactic differential for circulating neutrophils from 
older subjects was reduced in gradients of both IL-8 and fMLP (p = 0.001 for both).   
This was due to a reduction in chemotaxis towards both inflammatory mediators (p = 
0.04 and 0.001 respectively), without any difference in chemokinesis.  See figure 4.2. 
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Table 4.2.  The mean chemotaxis, chemokinesis and chemotactic differential for 
each subject group. 
 
Healthy older 
subjects 
Healthy young 
controls 
Negative control   
Chemotaxis 0.39 (0.02) 0.41 (0.02) 
Chemokinesis 0.41 (0.02) 0.38 (0.02) 
Chemotactic differential -0.02 (0.02) 0.02 (0.02) 
   
IL-8   
Chemotaxis 0.71 (0.03)    0.85 (0.03) * 
Chemokinesis 0.44 (0.01) 0.41 (0.01)  
Chemotactic differential        0.26 (0.03)     0.43 (0.03) * 
   
Positive Control 
Chemotaxis 0.79 (0.02)   1.06 (0.03)* 
Chemokinesis 0.44 (0.03) 0.43 (0.02) 
Chemotactic differential        0.39 (0.03)    0.59 (0.06)* 
   
Legend. 
Results are overall means for each group (migration in mm).  * = significantly different 
from healthy older subjects.   
 
 
 
Figure 4.2a.  Under agarose chemotaxis in the healthy elderly:  The chemotactic 
differential response of circulating neutrophils from older and younger subjects 
(legend after figure 4c). 
 *               * 
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Figure 4.2b. The chemotactic response of circulating neutrophils from older and 
younger subjects (legend after figure 4c). 
                                . 
                           
Figure 4.2c.  The chemokinetic response of circulating neutrophils from older and 
younger subjects. 
Legend for figures 4.2a, b and c 
The results show the overall mean migratory parameter (and SEM) for both groups. 
RPMI 1640 (Sigma-Aldrich) is the negative control, and the positive control is fMLP  
10 -7M (Sigma-Aldrich).  See Methods 2.7.1 for an explanation of terms.  * = significant 
difference from healthy older subjects (p<0.05).   
       *               * 
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These data confirm that healthy ageing is associated with differences in neutrophil 
migration, including a reduction in chemotactic differential.  This was caused by a 
reduction in chemotaxis with preserved chemokinesis.  
 
4.3.3 Modified Dunn Assay : Validation 
 
A Modified Dunn chamber was used to characterise individual cell behaviour and study 
separate components of migration, including speed, velocity, changes in directional 
orientation (persistence) and overall migratory accuracy (chemotactic index).  This assay 
needed to be modified prior to use with neutrophils (see below for validation). 
4.3.3.1 Coverslip preparation 
 
For optimal migration, neutrophils needed to adhere to the coverslip, but overcome static 
forces to enable chemotaxis.  In order to ascertain the optimal conditions for neutrophil 
adhesion to the coverslip, migration was tested using uncoated coverslips, or those 
coated in 0.1% fibronectin from human plasma (Sigma-Aldrich, UK) or albumin (1%, 
7.5%, 15%, 30%) (Sigma-Aldrich, UK). Optimal adherence was assessed by 
determination of the percentage of adhered neutrophils and the percentage of adhered 
cells that were able to migrate towards IL-8 and was achieved using 7.5% bovine serum 
albumin for coating of the coverslips (Sigma-Aldrich) (see figure 4.3). 
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Figure 4.3.  Assessing optimal neutrophil adherence to coverslip 
Legend. 
The figure demonstrates the effect of uncoated or coated coverslips on neutrophil 
adherence and subsequent migration to IL-8.  Adhered neutrophils = adhered 
neutrophils/total neutrophil count per field x 100.  Migrating cells = migrating 
neutrophils / adhered neutrophils per field x 100.   The results shown are the mean (and 
SEM) of 6 experiments. 
 
4.3.3.2 Assay buffer 
 
The intra-patient percentage of neutrophils migrating towards IL-8 was found to differ 
over time using HBSS (1.3mM CaCl2, 5.0mM KCL, 0.3mM KH2PO4, 138mM NaCl, 
0.3mM Na2HPO4, 0.8mM MgSO4, 10mM HEPES-Na, pH7.6) (the original buffer for 
the assay).   It was theorised that this may be due to a lack of glucose in the buffer. To 
determine the optimal buffer for migration, neutrophils were suspended in either HBSS  
or RPMI 1640 medium (Flow Laboratories, Ricksmansworth, UK).  RPMI 1640 
(Sigma-Aldrich) was used in all experiments following time response experiments, 
where neutrophils were incubated with either buffer for varying times from purification 
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before being placed on the coverslips (see figure 4.4 and 4.5).   These time response 
experiments also proved that neutrophils were able to be stored in RPMI for up to 4 
hours without it effecting adherence (figure 4.4) migratory function (figure 4.5). 
 
Figure 4.4.  The affects of differing buffers on neutrophil adherence over time 
(legend following figure 4.5). 
 
 
Figure 4.5. The affects of differing buffers on cell migration over time. 
Legend for figure 4.4 and 4.5. 
The graphs demonstrate the effect of HBSS or RPMI buffer on neutrophil adherence and 
migration to IL-8 over time. Adherent cells = adherent cells/ total number of cells per 
field x 100.  Migrating cells = migrating neutrophils / adhered neutrophils per field x 
100.   The results shown are the mean (and SEM) of 3 experiments. 
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4.3.3.3 Dose response experiments 
 
Dose response experiments for increasing concentrations of IL-8 and GROα were 
performed to establish the concentrations where neutrophil chemotaxis was maximal.   
The neutrophil chemotactic response was maximal towards IL-8 at a concentration of 
10nM, therefore this concentrations was used for subsequent experiments (see figure 
4.6). The neutrophil chemotactic response was maximal towards GROα at a 
concentration 100nM and so this concentration was used for subsequent experiments 
(see figure 4.7). 
 
Figure 4.6. The chemotactic index of neutrophils towards increasing concentrations 
of IL-8 in the modified Dunn chamber (legend after figure 4.7). 
 
153 
 
 
Figure 4.7. The chemotactic index of neutrophils towards increasing concentrations 
of GROα in the modified Dunn chamber. 
Legend for figure 4.6 and 4.7  
The results shown are the mean chemotactic index (and SEM) values of four 
experiments related to chemoattractant concentration.  For an explanation of terms see 
section 2.7.2.3. 
 
 
Dose response experiments were also performed on neutrophils pre-incubated with 
increasing concentrations of the CXCR2 antagonist to establish a dose where 
chemotaxis inhibition was maximal without impairing adherence or random 
chemokinesis (see figure 4.8 and 4.9).  Concentrations of  5nM were found to be 
optimum and were used for all subsequent experiments for this partial inhibition of 
migration.   
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Figure 4.8.  The affect of increasing concentrations of CXCR2 antagonist on 
neutrophil adherence to the coverslip and migration 
Legend.  The graph demonstrates the effect of increasing concentrations of a CXCR2 
antagonist on neutrophil adherence and subsequent migration to IL-8 10nM.  Adhered 
neutrophils = adhered neutrophils/total neutrophil count per field x 100.  Migrating cells 
= moving neutrophils / adhered neutrophils per field x 100.   The results shown are the 
mean (and SEM) of 4 experiments. 
 
 
 
Figure 4.9. The chemotactic response of neutrophils towards 10nM IL-8 following 
incubation with increasing concentrations of the CXCR2 antagonist. 
Legend.  The results shown are the mean chemotactic index (and SEM) values of four 
experiments.  For an explanation of terms see section 2.7.2.3. 
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4.3.3.4 Power calculations 
 
Power calculations were performed to determine the numbers needed to confirm a 50 – 
25% reduction in migrating neutrophil speed with 80% power and at the 5% significance 
level, using the mean of data from 10 cells per subject.  Table 4.3 summarises the mean 
speed of neutrophil migration, the variation in inter-patient migratory speeds and the 
number of subjects required in each group.  Based on these data, 20 participants were 
recruited to each subject group, to provide a clear opportunity to see any differences in 
migration of this magnitude. 
 
Table 4.3.  The numbers needed in a parallel design study to detect varying 
difference in neutrophil migratory speed between groups 
 
Mean speed (µm/minute) 3.36 
SEM 0.28 
Co-efficient of variation 20% 
  
Number of subjects needed in each group to detect:  
50% difference in speed 4 
40% difference in speed 5 
35% difference in speed 6 
30% difference in speed 8 
25% difference in speed 11 
 
4.3.4 Modified Dunn Chamber: Results 
4.3.4.1 Baseline characteristics 
Demographic data for the healthy elderly and young controls is shown in Table 4.4.  The 
results shown are for FEV1 expressed as a percentage of the value predicted for the 
subject’s age, gender and height (British Thoracic Society 1994) and the ratio of FEV1to 
forced vital capacity (FEV1/FVC).    
4.3.4.2 Neutrophil migration towards IL-8 
 
Figure 4.10 and 4.11 provide examples of the cell tracks that were recorded for a 
representative subject in each group.
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Table 4.4:  Demographic data for elderly and young healthy subjects 
  Younger subjects Older subjects 
N 20 20 
Age (range) 28 (21 – 34) 76 (66 - 89) 
Male (%) 10 (50%) 10 (50%) 
Smoking history (pack years) 0 0 
FEV1 percent predicted 113 (93 - 131) 117 (101 - 144) 
FVC percent predicted 121 (108 - 132) 130 (109 - 145) 
 
Legend 
Age and lung function parameters are presented as the mean (with the range in 
parentheses).  Gender is the number of males in each group, together with the percentage 
in parentheses.   
 
 
 
Figure 4.10 Neutrophil migratory tracks from a representative subject aged > 65. 
Legend: The images show the final neutrophil positions within the Dunn chemotaxis 
chamber following 20 minutes of time-lapse recording.  The blue arrow at the top of 
each picture represents the direction of the source of the chemotactic signal (IL-8 at a 
concentration of 10nM for all figures).  The tracks (shown in red) indicate the path of 
migration for each cell analysed:  each track begins where the cell was positioned at the 
start of recording and ends where the cell was positioned at the end of recording.  
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Figure 4.11. Neutrophil migratory tracks from a representative subject aged < 35 
Legend: The images show the final neutrophil positions within the Dunn chemotaxis 
chamber following 20 minutes of time-lapse recording.  The blue arrow at the top of 
each picture represents the direction of the source of the chemotactic signal (IL-8 at a 
concentration of 10nM for all figures).  The tracks (shown in red) indicate the path of 
migration for each cell analysed:  each track begins where the cell was positioned at the 
start of recording and ends where the cell was positioned at the end of recording.  
 
The migratory tracks from neutrophils from older subjects appeared to migrate along a 
more convoluted pathways than those isolated from young subjects.  
 
Speed 
Peripheral neutrophils from both young and elderly subjects demonstrated increased 
speed of migration in the presence of IL-8 compared with the negative control (mean 
difference between speed of migration in RPMI or IL-8: elderly 0.7 µm/minute, 95% 
confidence intervals 0.48 – 0.92 p = 0.0001; young 1.2µm/minute, 95% confidence 
intervals 0.9 – 1.4, p = 0.0001).   However, elderly neutrophils displayed increased 
random migration (increased speed) in the presence of the negative control (mean 
difference 0.47 µm/minute, 95% confidence intervals 0.24 – 0.7, p = 0.0001) but this 
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was not the case in the presence of IL-8, where the speed of migration was the same.  
See figure 4.12. 
 
Figure 4.12: The mean speed of migrating neutrophils from elderly and younger 
subjects in shallow gradients of IL-8. 
Legend: Measurements were taken from 10 cells from each individual. The average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups. * = p < 0.05.  Neutrophils from older subjects moved with 
significantly greater speed in the presence of RPMI than the younger controls (mean 
difference 0.47 µm per minute,  p = 0.0001) but not in the presence of IL-8, where there 
was no difference. 
 
Velocity 
Peripheral neutrophils from both young and elderly subjects demonstrated increased 
velocity of migration in the presence of IL-8 compared with the negative control (mean 
difference between velocity of migration in RPMI or IL-8: elderly 0.52 µm/minute, 95% 
confidence intervals 0.29 – 0.71, p = 0.001; young 1.28 µm/minute, 95% confidence 
intervals 0.6 – 1.5 p < 0.0001).   However, elderly neutrophils migrated with less 
velocity towards IL-8 (mean difference 0.73 µm/minute, 95% confidence intervals 0.48 
– 0.98, p < 0.0001).  See figure 4.13. 
        * 
159 
 
 
Figure 4.13. The mean velocity of migrating neutrophils from elderly and younger 
subjects in the presence of IL-8 
Measurements were taken from 10 cells from each individual. The average results for 
each subject were calculated, and an overall average was used for comparisons between 
groups. * = p < 0.05.  Neutrophils from older subjects moved with significantly less 
velocity in the presence of IL-8 than those from the younger controls (mean difference 
0.73 µm per minute,  p < 0.0001). 
 
Directional Persistence 
Peripheral neutrophils from both young and elderly subjects demonstrated less changes 
of cellular direction when migrating towards IL-8 compared with the negative control 
(mean difference between persistence of migration in RPMI or IL-8: elderly mean 
difference 0.09, 95% confidence intervals 0.04 – 0.15, p = 0.001; young, mean 
difference 0.31, 95% confidence intervals 0.24 – 0.38, p < 0.001). However, elderly 
neutrophils migrated with less directional persistence towards IL-8 (mean difference 
0.14, 95% confidence intervals 0.12 – 0.25,  p=0.0001).  See figure 4.14. 
 * 
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Figure 4.14. The mean persistence of migrating neutrophils from elderly and 
younger subjects in gradients of IL-8. 
Measurements were taken from 10 cells from each individual. The average results for 
each subject were calculated, and an overall average was used for comparisons between 
groups. * = p < 0.05. Neutrophils from older subjects moved with significantly less 
directional persistence in the presence of IL-8 than the younger controls (mean 
difference 0.14, p = 0.0001). 
 
Chemotactic accuracy 
Peripheral neutrophils from both young and elderly subjects demonstrated more 
chemotactic accuracy when migrating towards IL-8 compared with the negative control 
(mean difference between accuracy of migration towards the source of RPMI or IL-8: 
elderly 0.17, 95% confidence intervals 0.1 – 0.2, p = 0.001; young 0.4, 95% confidence 
intervals 0.34 – 0.47, p < 0.0001).  However, elderly neutrophils migrated with less 
accuracy towards IL-8 (mean difference 0.23, 95% confidence intervals 0.16 – 0.29, p < 
0.0001).  See figure 4.15. 
 * 
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Figure 4.15: The mean chemotactic accuracy of migrating neutrophils from elderly 
and younger subjects in gradients of IL-8 
Measurements were taken from 10 cells from each individual. The average results for 
each subject were calculated, and an overall average was used for comparisons between 
groups. * = p < 0.05. Neutrophils from older subjects moved with significantly less 
accuracy in the presence of IL-8 than the younger controls (mean difference 0.23,  p < 
0.0001). 
 
In summary, neutrophils from the elderly moved randomly with the same speed 
(chemokinesis) as those taken from younger subjects in the presence of IL-8, but with 
significantly less velocity (chemotaxis).  Also, the neutrophils from older subjects 
changed direction more than cells from younger subjects, and hence displayed less 
chemotactic accuracy.   
 
4.3.4.3 Neutrophil migration towards GROα  
 
IL-8 acts upon CXCR1 and CXCR2 with equal efficacy. Further migratory studies were 
performed in the presence of GROα (which acts preferentially via CXCR2) to explore if 
mechanisms were CXCR2 or CXCR1 dependent.  Here, neutrophils from older subjects 
 * 
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migrated with similar speed (see figure 4.16) but with decreased velocity (mean 
difference 0.25 µm/min, confidence intervals 0.001 – 0.41, p = 0.04, see figure 4.17), 
decreased persistence (mean difference 0.17, confidence intervals 0.003 – 0.34, p =0.04, 
see figure 4.18), and decreased chemotactic accuracy (mean difference 0.16, confidence 
intervals 0.02 – 0.3, p =0.03, see figure 4.19) than neutrophils isolated from younger 
subjects.  
  
Figure 4.16: The mean speed of migrating neutrophils from elderly and younger 
subjects in shallow gradients of GROα. 
Legend: Measurements were taken from 10 cells from each individual. The average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups. Standard error bars are displayed.  
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Figure 4.17: The mean velocity of migrating neutrophils from elderly and younger 
subjects in shallow gradients of GROα. 
Legend: Measurements were taken from 10 cells from each individual. The average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups. Standard error bars are displayed. * = p < 0.05.  
 
Figure 4.18: The mean persistence of migrating neutrophils from elderly and 
younger subjects in shallow gradients of GROα. 
Legend: Measurements were taken from 10 cells from each individual. The average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups. Standard error bars are displayed. * = p < 0.05.  
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Figure 4.19: The mean chemotactic index of migrating neutrophils from elderly 
and younger subjects in shallow gradients of GROα . 
Legend: Measurements were taken from 10 cells from each individual. The average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups. Standard error bars are displayed. * = p < 0.05.  
 
 
Given the similar migratory patterns seen in neutrophils from elderly individuals to both 
IL8 and GROα, the CXCR2 receptor  was initially focused upon for the initial 
exploration of  the underlying mechanism. 
 
4.3.4.4 Neutrophil migration towards IL-8 following incubation with a CXCR2 
antagonist 
 
A CXCR2 receptor antagonist (a small molecule antagonist kindly provided by 
AstraZeneca, UK) was used to test the hypothesis that the aberrant migration seen in 
elderly subjects may reflect alterations in CXCR2 receptor expression or function.  5nM 
of the CXCR2 antagonist was incubated with isolated neutrophils, and migration studies 
were repeated towards Il-8 (10nM). 
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Some differential effects were seen following pre-incubation with a CXCR2 antagonist 
in elderly and young subjects.  There was a trend towards the CXCR2 antagonist 
reducing the speed of migration in both groups (young cells: from 3.6 + 0.1 µm/min to 
2.8 + 0.1 µm/min, p=0.05.  Older cells: from3.4 + 0.1µm/min to 2.7 + 0.1µm/min, 
p=0.06) (see figure 4.20).   
 
Figure 4.20: The mean speed of migrating neutrophils from elderly and younger 
subjects in shallow gradients of  IL-8 following incubation with CXCR2 antagonist. 
Legend: Measurements were taken from 10 cells from each individual. The average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups. Standard error bars are displayed.  
 
However, incubation with the CXCR2 antagonist did decrease the velocity of migration 
towards IL-8 in both groups (Young subject: from 1.1 + 0.1µm/min to 0.4 + 0.1µm/min, 
p< 0.0001. Elderly subjects: from 0.5 + 0.1 to 0.1 + 0.1µm/min, p = 0.001). See figure 
4.21.  
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Figure 4.21: The mean velocity of migrating neutrophils from elderly and younger 
subjects in shallow gradients of  IL-8 following incubation with 5nM CXCR2 
antagonist. 
Legend: Measurements were taken from 10 cells from each individual. The average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups. Standard error bars are displayed. * = p = 0.001 or less.  
 
 
The CXCR2 antagonist reduced persistence in young (from 0.32 + 0.01 to 0.19 + 0.02,  
p = 0.001) but not elderly subjects (from 0.28 + 0.02 to 0.25 + 0.02), see figure 4.22. 
Furthermore, the antagonist reduced chemotactic accuracy in both groups (young: from 
0.3 + 0.03 to 0.06 + 0.02, p<0.0001.  Elderly: from 0.1 + 0.03 to 0.002 + 0.02, p = 
0.0001;), see figure 4.23.  
 
                                     
*        * 
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Figure 
4.22: The mean persistence of migrating neutrophils from elderly and younger 
subjects in shallow gradients of  IL-8 following incubation with 5nM CXCR2 
antagonist. 
Legend: Measurements were taken from 10 cells from each individual. The average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups. Standard error bars are displayed. * = p < 0.001.  
 
 
 
Figure 4.23: The mean chemotactic index of migrating neutrophils from elderly 
and younger subjects in shallow gradients of  IL-8 following incubation with 5nM 
CXCR2 antagonist. 
Legend: Measurements were taken from 10 cells from each individual. The average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups. Standard error bars are displayed. * = p = 0.0001 or less.  
 
     * 
     *      * 
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Expressed as a percentage (where naive neutrophil migration towards IL-8 is 100%), 
pre-incubation with a CXCR2 antagonist reduced speed (chemokinesis) by a small 
amount in both old and young neutrophils (20 + 8% for both groups), however, 
migrational velocity (chemotaxis) was reduced by 74 + 7% in neutrophils from elderly 
subjects, p=0.001 and by 65 + 9% in neutrophils from younger subjects, p < 0.0001. 
Incubation with the CXCR2 inhibitor reduced directional persistence by 12 + 4% in the 
elderly (which was not significant), but by 40 + 9% in the young, p=0.001.  
Furthermore, the CXCR2 antagonist reduced chemotactic accuracy by 98 + 2% in the 
elderly, p = 0.0001 and 75 + 4% in the young, p=0.0001.  See figure 4.24   
 
 
Figure 4.24.The affect on migration following pre-incubation with a CXCR2 
antagonist. 
Legend.  Data is presented as the percentage of the migratory parameter following 
incubation with the CXCR2 antagonist, compared to migration of naive cells (naïve cells 
are expressed as 100% of migratory parameter, migration following incubation with the 
CXCR2 antagonist is expressed as the percentage of remaining migration).  * = p =0.001 
or less (see preceding text)). 
 
 
  *  * 
 * 
 *  * 
169 
Pre-treating neutrophils from young subjects with the CXCR2 antagonist appeared to 
adjust migration so that it resembled migratory pathways from older subjects, giving 
credence to the hypothesis that migratory flaws may be in part due to CXCR2 
expression or function.   To explore this further, CXCR1 and CXCR2 surface expression 
was measured on circulating neutrophils.  
 
4.3.5 CXCR1 and 2 receptor surface expression: validation 
 
Dose response experiments determined that antiCXCR1 2ng/ml and antiCXCR2 3ng/ml 
were the most appropriate to measure surface expression of CXCR1 and CXCR2 (see 
figure 4.25 and 4.26).  
 
Figure 4.25.  CXCR1 surface expression using differing concentrations of 
antiCXCR1. 
Legend:  Data is the median  fluorescence intensity for six young subjects in anti-human 
CXCR1 (IL-8 RB)-Fluorescein supplied as 50 µg antibody in 1 mL PBS containing 
0.1% sodium azide.  The anti-CXCR1 was serially diluted using PBS 2% BSA.  Error 
bars represent interquartile range.  
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Figure 4.26.  CXCR2 surface expression using differing concentrations of 
antiCXCR2. 
Legend: Data is the median  fluorescence intensity for six young subjects in anti-human 
CXCR2 (IL-8 RB)-Fluorescein supplied as 50 µg antibody in 1 mL PBS containing 
0.1% sodium azide.  The anti-CXCR2 was serially diluted using PBS 2% BSA.  Error 
bars represent interquartile range. 
 
Time course experiments determined that neutrophil  CXCR1 and CXCR2 expression in 
both young and old subjects (n = 6 for both) was greatest immediately following 
neutrophil isolation (0 Hour).  For these experiments, neutrophils were prepared as 
documented in the methods, but were kept at room temperature (21oC) for the duration 
of the time course, with the appropriate antibody being added 30 minutes before the 
measured time point.   Neutrophil surface expression of both receptors was seen to 
decrease in both subject groups in a time dependent manner. In light of these results, 
expression was measured at the same time in young and old subjects, as soon as the 
neutrophils were isolated, and not longer than 20 minutes from preparation.  See figure 
4.27 and 4.28. 
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Figure 4.27.  Time course for CXCR1 surface expression. 
Legend: Data is the median  fluorescence intensity for six young subjects in anti-human 
CXCR1 (IL-8 RB)-Fluorescein 2ng/µl over 3 time points. Error bars represent 
interquartile range. 
 
 
 
Figure 4.28.  Time course for CXCR2 surface expression. 
Legend:  Data is the median  fluorescence intensity for six young subjects in anti-human 
CXCR2 (IL-8 RB)-Fluorescein 3ng/µl over 3 time points. Error bars represent 
interquartile range. 
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4.3.5.1 Power calculations 
 
Power calculations were performed to determine the numbers needed to confirm a 50 – 
10% difference in CXCR1 and CXCR2 surface expression with 80% power and at the 
5% significance level.  Table 4.5 summarises the median fluorescence intensity, the 
variation in inter-patient expression and the number of subjects required in each group.  
20 participants were recruited to each subject group, to provide an 80% chance of 
detecting a 20% difference in CXCR1 and a 25% difference in CXCR2. 
Table 4.5. The numbers needed in a parallel design study to detect varying 
difference in CXCR1 and CXCR2 surface expression 
 
 CXCR1 CXCR2 
Median expression 82 46 
Inter-quartile Range 64 - 100 35 – 53 
Co-efficient of variation 22% 28% 
   
Numbers needed in each group  to detect   
   
50% difference 4 6 
30% difference 10 14 
25% difference 14 21 
20% difference 21 32 
10% difference 80 126 
 
4.3.5.2 Quiescent CXCR1 and CXCR2 expression 
 
There were no differences in surface receptor expression of CXCR1 (young; median 
fluorescence intensity 82, inter-quartile range 61 – 104: old; median fluorescence 
intensity 76, inter-quartile range 60 – 98) or CXCR2 (young; median fluorescence 
intensity 28, inter-quartile range 17- 48:  old; median fluorescence intensity 39, inter-
quartile range 29 – 53),on quiescent neutrophils isolated from either groups.   See figure 
4.29 and 4.30. 
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Figure 4.29.  Median CXCR1 surface expression. 
Legend:  Data is the median  fluorescence intensity for each of 20 young subjects and 
20 older subjects in anti-human CXCR1 (IL-8 RB)-Fluorescein 2ng/µl. The horizontal 
line is the group median value. 
 
 
 
Figure 4.30.  Median CXCR2 surface expression. 
Legend:  Data is the median  fluorescence intensity for each of 20 young subjects and 
20 older subjects in anti-human CXCR2 (IL-8 RB)-Fluorescein 3ng/µl.  The horizontal 
line is the group median value. 
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4.3.5.3 Surface expression of CXCR1 and CXCR2 over time 
 
Graphs of surface receptor expression over three time points for CXCR1 and CXCR2 
are shown previously (graph 4.27 and 4.28).  There was a reduction in surface 
expression of CXCR1 in both young and older groups over time (Young Vs Older, 
median results (IQR): time point zero,  96  (74 – 118) Vs. 79 (50 – 108); 1 hour , 74 (45 
– 103) Vs 54 (20 – 88); 2 hours, 27 (4 – 50) Vs 36 (15 – 57).  However, there was no 
differential decline in surface expression of CXCR1 between young and older subjects 
over the time course. 
 
There was a reduction in surface expression of CXCR2 in both young and older groups 
over time (Young Vs Older, median results (IQR): time point zero, 26 (5 - 45) Vs. 23 (4 
- 42); 1 hour , 18 (2 - 32) Vs 14  (3 - 26); 2 hours, 6 (1 - 11) Vs 5 (2 – 8).  However, 
there was no differential decline in surface expression of CXCR2 between young and 
older subjects over the time course. 
 
This suggested that in the quiescent state, neutrophils from young and older subjects 
reduced surface expression to a similar degree. 
 
4.3.5.4 Surface expression of CXCR1 and CXCR2 following stimulation with IL-8 
 
Surface expression of CXCR1 following neutrophil stimulation with three 
concentrations of IL-8 are shown in figure 4.31.  Surface expression of CXCR2 
following neutrophil stimulation with three concentrations of IL-8 are shown in figure 
4.32. 
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Figure 4.31.  Median CXCR1 surface expression following stimulation with IL-8. 
Legend:  Data is the median  fluorescence intensity for 20 young subjects and 20 older 
subjects in anti-human CXCR1 Fluorescein 2ng/µl stimulated with the stated doses of 
IL-8.  Error bars represent the inter quartile range.  There were no differences in 
expression between groups.  
 
Figure 4.32.  Median CXCR2 surface expression following stimulation with IL-8. 
Legend:  Data is the median  fluorescence intensity for 20 young subjects and 20 older 
subjects in anti-human CXCR2 Fluorescein 3ng/µl stimulated with the stated doses of 
IL-8. Error bars represent the inter quartile range.  There was no difference in expression 
between groups. 
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Although stimulation with IL-8 led to a decline in CXCR1 surface expression in a dose 
dependent manner, there was no difference in CXCR1 expression between neutrophils 
isolated from young and older subjects (Young Vs older median MFI (IQR); Negative 
control, 94 (72 – 116) Vs 83 (59 – 107); 1nM IL-8, 32 (14 – 50) Vs 26 (11 – 41); 10nM 
IL-8, 19 (10 – 28) Vs 21 (11 – 31); 100nM, 15 (7 – 23) Vs 10 (3 – 17).  Furthermore, 
there was no difference in CXCR2 expression between neutrophils isolated from young 
and older subjects (Young Vs older median MFI (IQR); Negative control, 21 (5 - 36) Vs 
22 (3 - 39); 1nM IL-8, 4 (1 - 16) Vs 7 (1 - 9); 10nM IL-8, 1 (0 .1- 4) Vs 5 (1 - 7); 
100nM, 0.7 (0.1 - 4) Vs 1 (0.1 – 5).  These data suggest that there is no differential 
expression of CXCR1 or CXCR2 following stimulation with IL-8, when semi-quantified 
using MFI. 
4.4 Discussion  
 
These data describe significant differences in the migratory behaviour of neutrophils 
from healthy older subjects compared with gender matched healthy younger controls.  
This was firstly demonstrated using the simple under agarose technique and 
subsequently studied in more detail using the Dunn chamber.  Neutrophils from the 
older subjects moved randomly with a similar speed (chemokinesis), but were less 
chemotactic, exhibiting a lower migratory velocity and a lower chemotactic index than 
younger controls.  Neutrophils did not vector towards IL-8 or GROα as well as 
neutrophils from young controls, making them less accurate in their migratory pathways. 
Neutrophils from older subjects also changed their directional orientation more, 
resulting in lower levels of persistence. The cells made fine alterations in directional 
orientation while moving towards the source of IL-8 and GROα, whereas neutrophils 
from younger subjects migrated with more directional purpose.  
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In summary, clear differences were observed in the migratory dynamics of neutrophils 
from older subjects. Although speed of movement (chemokinesis) was preserved, the 
cells demonstrated a decrease in chemotactic accuracy (denoted by the decrease in 
velocity, decrease in persistence and decrease in chemotactic index). The cells appeared 
unable to respond optimally to chemotactic signals which should have changed their 
direction.  This observation has been suggested previously in a study where 
chemokinesis and chemotaxis were assessed separately using the under agarose assay 
(Wenisch, Patruta et al. 2000) and confirmed in studies reported here.  
 
This is a crucial distinction as longitudinal and cross-sectional studies (Niwa, Kasama et 
al. 1989; Egger, Aigner et al. 2004) have suggested that reduced neutrophil chemotaxis, 
rather than chemokinesis, is associated with higher mortality in elderly subjects.   As 
previously described, bacterial infections are associated with increased mortality and an 
increased burden of morbidity in elderly people (Liang and Mackowiak 2007).  It is 
clear that neutrophil phagocytic function and in some situations, superoxide production 
is reduced with increasing age (Wenisch, Patruta et al. 2000; Butcher, Chahal et al. 
2001).  If chemotaxis is significantly impaired, (as was clearly demonstrated in the 
current study) the combination of aberrant neutrophil function is likely to impact on 
bacterial clearance in disease. 
 
Ageing is also associated with a decline in organ function.  For example, there is a clear 
reduction in lung function with increasing age, which has been associated with a higher 
circulating inflammatory load in a dose dependent manner (Fogarty, Jones et al. 2007; 
Jiang, Burke et al. 2008).  It could be hypothesised that the decline in organ function 
may be due, in part, to low-grade neutrophilic inflammation.   During activation, a high 
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proportion of neutrophil proteinases are expressed on the neutrophil membrane (Owen, 
Campbell et al. 1995; Owen, Campbell et al. 1997; Campbell, Campbell et al. 2000), 
polarising towards the leading edge of the neutrophil as it migrates (Cepinskas, Sandig 
et al. 1999). A proportion of the proteinase is left behind as the cell moves on (Clayton, 
Evans et al. 1998; Cepinskas, Sandig et al. 1999) and it has been clearly demonstrated 
that an area of obligate enzyme activity always exists following the secretion of free NE 
until concentrations have decreased by diffusion to match the concentration of 
surrounding proteinase inhibitors (Liou and Campbell 1996; Campbell, Campbell et al. 
1999).    
 
Inaccurate chemotaxis would lead to neutrophils from elderly subjects spreading further 
during migration compared to those from younger controls.  If migratory routes taken by 
elderly neutrophils are more circuitous than normal (as shown here), the potential for 
collateral damage would be increased, as more membrane bound NE would be released 
during the prolonged journey to the inflammatory source.  The net result would be an  
increase in the distribution of obligate enzyme activity, with an associated increase in 
collateral tissue damage.  Furthermore, the presence of this extra NE, and any resultant 
tissue and cell damage, could increase the secretion of other pro-inflammatory mediators 
(such as LTB4 and IL-8 (Hubbard, Fells et al. 1991)), amplifying the migration of 
inflammatory cells into the surrounding tissue (including more neutrophils and 
macrophages) with their resultant pro-inflammatory interactions (Itoh and Nagase 1995; 
Ferry, Lonchamp et al. 1997).  This would establish a low grade, self perpetuating cycle 
of damaging inflammation which may (in part) account for the age dependent 
development of structural lung damage (Verbeken, Cauberghs et al. 1992). 
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We hypothesised that intact chemokinesis with aberrant chemotaxis was suggestive of a 
fault with the process of determining cellular orientation within a chemical gradient 
because of an inability to compare pro-inflammatory receptor occupancy distributed 
spatially around the cell body (Jin and Hereld 2006; Levine and Rappel 2006).  
Theoretically, this would reduce the accuracy of pseudopod selection and therefore 
directed motility. Such a fault could conceivably be caused by hypersensitivity or 
insensitivity to spatial signals, driven by an alteration in receptor numbers or activity. 
Since similar migratory patterns were seen in the presence of IL-8 and GROα, it was 
hypothesised that the aberrant migration may be dependent upon CXCR2 receptor 
expression or function.   
 
CXCR2 is a member of a superfamily of G protein-coupled receptors (GPCRs) that 
transduce signals to the interior of the cell through heterotrimeric guanine nucleotide-
binding proteins (G proteins). These receptors share a common putative structural 
topology composed of seven-transmembrane domains separated by three extracellular 
and three intracellular loops. Upon agonist binding, CXCR2 activates G protein-
mediated phosphoinositide hydrolysis to generate diacylglycerol and inositol 1,4,5-
trisphosphate, thereby activating protein kinase C and mobilizing Ca2+ to initiate a 
variety of cellular response. Receptor activation is followed by receptor phosphorylation 
on multiple serine residues and subsequent desensitization of the receptor to further 
stimulations. The receptors then either undergo dephosphorylation and recycle back to 
the cell surface, becoming resensitized or are degraded and down-regulated (Yang, 
Wang et al. 1999). 
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To assess CXCR2 function, neutrophils were incubated with a selective CXCR2 
antagonist, which is a small molecule antagonist that binds to the intracellular receptor 
domain, preventing downstream signalling.  The overall affects of the antagonist were a 
significant decrease in velocity of migration (chemotaxis) but not speed (chemokinesis).  
This is highly suggestive of a role for CXCR2 receptors in sensory awareness of pro-
inflammatory mediators during migration rather than movement itself.  Migratory 
persistence and accuracy were also significantly decreased following incubation with a 
CXCR2 antagonist, which again suggests that CXCR2 receptors are involved in the 
perception of pro-inflammatory gradients rather than the mechanics of cellular 
movement per se.  Overall, the addition of a CXCR2 antagonist to neutrophils from 
younger subjects resulted in them adopting the migratory dynamics of cells from older 
subjects, with reduced velocity, persistence and accuracy with a maintained speed, 
reinforcing the hypothesis that CXCR2 expression or function may be altered on older 
cells.   
   
CXCR1 and CXCR2 receptor surface expression was semi-quantified on neutrophils 
isolated from young and older subjects using FACS analysis, and found to be 
comparable.  At this time, there are no other published data regarding CXCR1 or 
CXCR2 receptor expression on neutrophils in healthy ageing subjects from which to 
make comparisons.  The current study had sufficient power to detect a 25% difference in 
expression between groups, which was felt to be the smallest difference likely to be 
clinically relevant, so it is unlikely that the differences seen in migration are due to 
receptor expression alone.  Furthermore, there were no differences in surface expression 
of either receptor over time, or when stimulated with IL-8, again suggesting no obvious 
fault with cell surface receptor shedding or internalisation.  However, given the complex 
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nature of CXCR1 and CXCR2 endocytosis and recycling, it is overly simplistic to 
assume that there are no differences in receptor function.   It is also possible that deficits 
in migration are caused by differences in the migratory pathway downstream to the 
CXCR receptors and this could be assessed by measuring other components of the 
migratory pathway in these two groups.   Identifying potential mechanisms that underpin 
aberrant migration is being pursued separately.  Nevertheless, the inaccurate migration 
of neutrophils from elderly subjects may be of importance in the defence against 
infection, with poor bacterial capture leading to the increased incidence of clinically 
severe infections in the elderly.  Further studies are  warranted to investigate this further. 
 
In conclusion, clear differences were in seen in the migratory dynamics of neutrophils 
from older healthy subjects, with reduced chemotaxis but preserved chemokinesis 
moving towards IL-8 and GROα.  Neutrophils from younger subjects displayed  similar 
migratory patterns following incubation with a CXCR2 antagonist,  leading to the 
hypothesis that CXCR2 receptor expression or function is aberrant in cells from elderly 
subjects, and indeed, a CXCR2 antagonist heightened the migratory flaws, consistent 
with this hypothesis.  There was no difference in CXCR1 or CXCR2 surface expression, 
suggesting that the problem may relate to intracellular processing of the receptor, or its 
signalling pathway. The aberrant migration could theoretically delay bacterial clearance 
and increase by-stander tissue damage during migration.   
 
These data confirm that migrational studies of neutrophils in COPD need to ensure that 
control subjects are age matched.  Furthermore, using these data, it will be possible to 
assess whether the patterns of neutrophil migration in COPD are in keeping with 
theories that the pathophysiology is related to advanced ageing. 
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5 Aberrant neutrophil migration in COPD 
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5.1  Brief introduction 
 
It is widely accepted that airway inflammation is central to the development and 
progression of COPD, leading to destruction of lung parenchyma, goblet cell hypertrophy 
and tissue remodelling.  There is a wealth of data supporting the hypothesis that the 
neutrophil is of fundamental importance in the pathophysiology of the disease, including 
an increased cellular presence in the lung (Martin, Raghu et al. 1985; Selby, Drost et al. 
1991; Stansecu, Sanna et al. 1996; Rutgers, Timens et al. 2000) and correlations with 
clinical markers of disease severity and progression (Thompson, Daughton et al. 1989; Ge, 
Zhu et al. 1990; Lacoste, Bousquet et al. 1993; Betsuyaku, Nishimura et al. 1999; 
Yoshioka, Betsuyaku et al. 2005; Parr, White et al. 2006; Pilette, Colinet et al. 2007). 
Furthermore, Neutrophil elastase (NE) has been shown to cause all of the pathological 
features of COPD (Blackwood, Hosannah et al. 1973; Snider, Hayes et al. 1974; 
Smallman, Hill et al. 1984; Rickard and Rennard 1989; Amitani, Wilson et al. 1991; 
Ballieux, Hiemstra et al. 1994; Nakajoh, Fukushima et al. 2002).  However, it remains 
unclear whether the increased number of neutrophils present in the lung is an effect of the 
disease (due to increased inflammatory signal) or central to the pathophysiology as a result 
of increased or aberrant migration. 
 
Observations of neutrophil migration in COPD to date have employed modifications of the 
under agarose assay, the Boyden Chamber assay (in which cells migrate through a filter in 
a transwell dish) or migration under flow, and results have been contradictory.   For 
example, Burnett et al (Burnett, Chamba et al. 1987) described increased neutrophil 
migration in patients with COPD compared to patients with bronchiectasis and healthy 
controls.  In a more recent study by Yoshikawa et al (Yoshikawa, Dent et al. 2007), the 
number of neutrophils that had successfully migrated towards IL-8 was reduced in patients 
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with stage II - IV COPD compared with healthy controls and healthy smokers, although 
interestingly, neutrophils from patients with early (stage 1) COPD demonstrated more 
migration than all other groups.    
 
These contradictory results could be explained by the assays used or the diverse group of 
patients included. The characteristics of the migration platform in the Boyden chamber 
assay can cause variations in migration (for example pore size and associated chemotactic 
gradient formation), differences in cell activation has a profound affect, and the assay only 
assesses overall migratory patterns and not individual cell behaviour. Studies have also not 
always included rigorously age matched controls, which, as demonstrated in the previous 
chapter, can have a profound effect on neutrophil migration.  These studies were, 
therefore, unable to address the fundamental question of whether and how cells from 
COPD patients differ from healthy controls.   
 
The studies described in this chapter were performed to firstly examine overall migratory 
patterns in COPD under agarose, to provide a point of comparison with previous work.  
Secondly, (using the modified Dunn Chamber) to provide quantitative detail of individual 
neutrophil migration, assessing the effects of smoking, and the role of lung inflammation 
and its treatment on chemotaxis and chemokinesis, testing the hypothesis that neutrophil 
migration in COPD would be compatible with a state of advanced ageing.  
 
It is known that COPD is associated with heightened pulmonary and systemic 
inflammation and thus any differences seen in neutrophil migration between healthy 
controls and COPD patients could be a non specific response to inflammation, lung 
disease itself or both.  For these reasons we carefully selected the control groups and 
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specifically included patients with A1ATD as these patients can be selected with the same 
degree of functional impairment, cigarette exposure and similar pulmonary inflammation 
and therapy to usual COPD (all of which may influence results).  Thus, if neutrophil 
migration in A1ATD resembles health more than COPD, it could be surmised that any 
differences in migratory patterns was not due to the presence of pulmonary and systemic 
inflammation or lung disease alone. 
 
IL-8 was chosen as the main chemoattractant in these studies as this chemokine has been 
shown to have intimate relationships with both neutrophil numbers in lung secretions and 
COPD disease burden (Sapey, Bayley et al. 2008), as proposed previously.   GROα was 
also used to help to differentiate whether affects were driven by signalling via CXCR1 or 
CXCR2.  
 
5.2 Experiments 
 
5.2.1 Study subjects 
 
COPD patients had moderate to severe disease defined by GOLD criteria (Pauwels, Buist 
et al. 2001).  They were ex-smokers, aged between 50 and 70.  All patients were clinically 
stable for at least eight weeks prior to recruitment with no changes in medication.  
Alternative and concomitant disease was excluded clinically, physiologically and 
radiologically.   
 
Controls consisted of age and gender matched healthy volunteers and patients with 
A1ATD.  Patients with A1ATD (PiZ) were chosen as they have a similar phenotype of 
lung disease and a similar inflammatory signal in the lung but with a known genetic cause 
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of disease.  The A1ATD patients were ex-smokers and matched for the severity of airflow 
obstruction, age, gender and medications.  Healthy volunteers were divided into two 
groups.  The first had never smoked, had no evidence of chronic disease (including lung 
disease)  and were medication free.  The second group of healthy controls were current 
smokers who had no evidence of lung disease (or other co-morbidities) and were also 
medication free, the so called “healthy smokers”. These two control groups were chosen as 
comparisons with healthy controls would allow an understanding of differences from 
normal, including the effects of smoking and comparisons with patients with A1ATD 
would differentiate the effects of pulmonary inflammation and lung disease per se. 
 
5.2.2 Isolation of blood neutrophils 
 
Neutrophils were isolated from the whole blood as described previously (methods 2.5.7) 
The neutrophils (>95% pure, > 97% viable, by exclusion of trypan blue) were resuspended 
in buffer (RPMI 1640 medium (Flow Laboratories, Rickmansworth, UK) containing 
0.15% bovine serum albumin (Sigma-Aldrich, UK). 
5.2.3 Neutrophil Chemotaxis 
5.2.3.1 Under agarose assay 
 
Neutrophil chemotaxis was firstly assessed using the under-agarose assay, (methods 
section 2.7.1).  Following dose response experiments, peripheral neutrophils isolated 
from patients with COPD, healthy non smoking controls and patients with A1ATD (n=6 
for all groups) migrated towards 100nM IL-8 and both a negative control (Assay buffer: 
RPMI 1640 (Flow Laboratories, UK) containing 0.15% bovine serum albumin (Sigma-
Aldrich)) and a positive control (fMLP 100nM (Sigma Aldrich).  Migration is expressed 
in mm, with differentiation between chemotaxis and chemokinesis.  Each experimental 
condition was repeated three times per subject to provide the mean result for the 
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individual.  Each subject mean result was used to form an overall mean for the subject 
group (Healthy control, PiM COPD or PiZ COPD). 
 
5.2.3.2 Modified Dunn Chamber 
 
Neutrophil chemotaxis was then measured using a modification of the Dunn chamber.  
Full methodological details are included in the methods (section 2.7.2). Each subject’s 
neutrophils were studied with a negative control (assay buffer, see above) and with IL-8 
10nM and GROα 100nM (concentrations were chosen following appropriate dose 
response experiments, see 4.3.3.3).   Migratory dynamics were firstly compared between 
healthy non-smokers and “healthy smokers” (n=6 for each group).  Finally, neutrophil 
migration was assessed for patients with COPD, healthy controls and patients with 
A1ATD (n=12 for each group).   
 
5.2.4 Statistical analysis 
 
Migrational differences seen using the Under Agrose assay were compared using the 
mean chemotactic response, chemokinetic response and chemotactic differential (see 
figure 2.10) of experiments completed in triplicate for each individual.  Migrational 
differences seen using the Modified Dunn Chamber were compared using the mean 
data for 10 random cells per experiment, per subject.  Differences in chemotaxis 
criteria were compared using an Independent t test. A p value of less than 0.05 was 
considered to be statistically significant.   
 
Under agarose studies were exploratory, and formal sample size calculations were not 
performed.  For the Modified Dunn chamber, sample size calculations were based 
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upon a two group parallel comparison, to provide an 80% power of detecting a 35% 
change in mean speed at the 5% level of significance between healthy smokers and 
non smokers and a 25% change in mean speed at the 5% level of significance between 
patients with COPD, healthy controls and patients with A1ATD (both as described in 
section 2.9). 
 
5.3 Results 
5.3.1 Under Agarose and Modifed Dunn Assays: validation 
 
For both assays, dose response experiments were performed with increasing 
concentrations of IL-8 (R&D Systems) to establish the concentration at which neutrophil 
chemotaxis was maximal  (see 4.3.1 and 4.3.3). 
 
5.3.2 Under Agarose assay: Results 
5.3.2.1 Baseline characteristics 
 
Demographic data for the COPD patients, healthy controls and patients with A1ATD are 
shown in Table 5.1. 
 
 
 
 
 
 
 
 
189 
Table 5.1. COPD neutrophil migration.  Demographic data for COPD patients and 
control groups 
 COPD Healthy Controls A1ATD 
N 6 6 6 
Age (years) 65 (57 - 75) 59 (55 - 66) 53 (45 - 67) 
Male 4 (66%) 3 (50%) 3 (50%) 
Smoking status All ex All never All ex 
Pack years 33 (5.8) 0 * 13.2 (3) 
FEV1 (percent predicted) 45 (2.9) 107 (3.4) * 47 (13) 
FEV1/FVC (%) 56 (6.1) 80 (1.49) * 63 (11) 
Inhaled steroids 6 (100%) 0 (0%) 6 (100%) 
Theophyllines 1 (16.5%) 0 0 
Sputum colonization  1 (16.5%) 0 0 
BMI 22 (1.6) 25 (1.22) 24 (1.7) 
Legend 
Normally distributed data is presented as mean (with range or SEM).  Categorical data is 
presented with percentages given in parentheses. * = significantly different from PiM 
COPD patients (p < 0.05). The 1 COPD patient where bacteria were isolated was 
colonised with Moraxella. Catarrhalis 6 x 10 6 . Including or excluding this patient  had 
no effect on overall results and hence data from this subject was included in the analysis.  
 
5.3.2.2 Neutrophil migration towards IL-8 
 
Table 5.2 summarises the mean chemotaxis, mean chemokinesis and mean chemotactic 
differential for each group.  The chemotactic differential for circulating neutrophils from 
patients with COPD was similar to both control groups migrating towards IL-8 and 
100nM fMLP (used as a positive control). There was an increase in chemokinesis in 
gradients of both inflammatory mediators in COPD patients compared to healthy 
controls (p < 0.0001 for both IL-8 and fMLP) and compared to patients with A1ATD 
(IL-8, p = 0.005; fMLP p<0.0001).   There was also a corresponding increase in 
chemotaxis towards both IL-8 and fMLP compared to healthy controls (IL-8, p = 0.002; 
fMLP, p= 0.001) and A1ATD patients (p = 0.01 and p<0.001 respectively).  See figure 
5.1 – 5.3. 
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Table 5.2.  The mean chemotaxis, chemokinesis and chemotactic differential for 
each subject group. 
 COPD 
Healthy 
controls A1ATD 
Negative control (Assay buffer)    
Chemotaxis     0.5 (0.02) 0.44 (0.03) 0.44 (0.02) 
Chemokinesis     0.47 (0.03) 0.42 (0.02) 0.42 (0.02) 
Chemotactic differential     0.03 (0.03) 0.02 (0.02) 0.02 (0.02) 
    
Positive control (fMLP)    
Chemotaxis    1.24 (0.05) *$    1.1  (0.1)     1.00 (0.09)   
Chemokinesis   0.73 (0.02) *$ 0.52 (0.03)  0.47 (0.02)   
Chemotactic differential    0.51 (0.06)    0.58 (0.08) 0.53 (0.09)   
    
IL-8    
Chemotaxis   1.14 (0.05) *$ 0.84 (0.04) 0.89 (0.05) 
Chemokinesis    0.67 (0.02) *$      0.41(0.03)  0.48 (0.03)  
Chemotactic differential    0.47 (0.04)    0.43 (0.04)       0.41 (0.03)    
 
Legend. 
Results are overall means for each group (migration in mm). Standard errors are given in 
parentheses.   * = significantly different from Healthy control.  $ = significantly 
difference from patients with A1ATD.   
 
 
Figure 5.1.  The chemokinetic response of  COPD neutrophils 
 *$                                         *$ 
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Figure 5.2.  The chemotactic response of neutrophils 
Figure 5.3.  The chemotactic differential of circulating neutrophils. 
Legend for figures 5.1, 5.2 and 5.3. 
The results show the overall mean (and SEM) for each group.  Negative control is RPMI 
1640 (Sigma-Aldrich), positive control is 10 -7M fMLP (Sigma-Aldrich).    
* = significant difference compared with healthy controls (HC), $ = significant 
difference from patients with A1ATD. 
 
 *$                         *$ 
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The overall migratory pattern seen with the Under Agarose assay appeared to suggest 
that neutrophils isolated from patients with COPD spread out more during migration 
(with more movement both towards and away from the chemotactic stimulus) than 
neutrophils isolated from healthy controls and patients with A1ATD.   There were no 
clear differences in migratory patterns between patients with A1ATD and healthy 
controls.  The Modified Dunn chamber was used to explore these differences further. 
 
5.3.3 Modified Dunn Assay: Results 
5.3.3.1 Migratory differences between healthy smokers and non smokers 
 
The Under Agarose assay experiments included non-smoking healthy controls and ex-
smoking patients with COPD and A1ATD.  There were clear migratory differences 
between patients with COPD and the other groups, however, the COPD group also had 
greater smoking exposure (although this was not significantly different between COPD 
and A1ATD patients).  In order to explore the impact of smoking on neutrophil 
migration,  healthy never smokers and matched healthy smokers (n=6 in each group) 
were recruited, and neutrophil migratory patterns were explored.  
Baseline characteristics 
 
Demographic data for the “healthy smokers” and healthy non smokers are shown in table 
5.3. The results shown are for post-bronchodilator forced expiratory volume in one second 
(FEV1) expressed as a percentage of the value predicted for the patient’s age, gender and 
height (British Thoracic Society 1994) and the ratio of FEV1 to forced vital capacity 
(FEV1/FVC). 
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Table 5.3. Demographic data for healthy never smokers and smokers 
 
Healthy never 
smokers 
Healthy smokers 
 
N 6 6 
Age (years) 58 (53 - 68) 62 (56 - 65) 
Male 3 2 
Smoking status All never All current 
Pack years 0 26 (15 - 47) 
FEV1 2.46 (2.1- 2.8) 2.63 (2.4 - 3.1) 
FEV1 % 
predicted 98 (94 – 108) 106 (100 - 111) 
FEV1/FVC 82 (75 - 85) 80 (78 - 83) 
BMI 26 (21 - 33) 23 (21 - 29) 
 
Legend.  Age is presented as the mean (with the range in parenthesis).  Gender is the 
number of males in each group. The remaining data is presented as the median (with the 
interquartile range in parentheses).   Healthy non-smokers differed from healthy smokers 
only in terms of smoking exposure.  There were no other differences between groups.  
 
Migratory patterns of neutrophils from healthy never smokers and healthy smokers   
Figure 5.4a shows pathways of neutrophil migration for a healthy non-smoker and figure 
5.4b for a healthy smoker. 
 
Figure 5.4a.  Migratory pathways of neutrophils isolated from a non-smoking healthy 
control. 
See below for legend 
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Figure 5.4b   Migratory pathways of neutrophils isolated from a smoking healthy 
control. 
Legend. Each image is a photograph taken at the end of migration, with migratory 
pathways for each neutrophil added using digital tagging.  The large arrow at the top of 
each image is the source of the chemoattractant (IL-8 10nM).  The small arrows show the 
neutrophils migratory pathway.  The neutrophil  starting position is the beginning of the 
small arrows, the arrow tip represents the cells orientation at the end of migration. 
There were no significant differences in the migratory pathways of cells from either group. 
 
When individual migratory parameters were studied, there were no migratory differences 
in circulating neutrophils from age and gender matched healthy non smokers and the 
“healthy smokers”, suggesting that smoking per se does not effect neutrophil migration in 
this assay  (see Figure 5.5).   The mean chemokinesis (speed) was 4.28 + 0.4µm/min (non-
smoker) Vs. 4.30 + 0.4 µm/min (smoker), mean chemotaxis (velocity) was 1.09 + 
0.1µm/min (non-smoker) Vs  1.2 + 0.3 µm/min (smoker), persistence was 0.28 + 0.04 
(non-smoker) Vs 0.38 + 0.06 (smoker) and chemotactic accuracy was 0.21 + 0.05 (non 
smoker) Vs. 0.22 + 0.06 (smoker), respectively.  
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Figure 5.5:  Differences in migratory dynamics of peripheral neutrophils from 
healthy non smokers and healthy smokers 
Legend:  Each data point represents the mean migratory parameter for one individual, 
taken from the analysis of 10 neutrophils with each experiment repeated three times.  
Chemokinesis is the random speed of movement in any direction (measured in 
µm/minute), chemotaxis is the velocity of movement towards the chemoattractant 
(measured in µm/minute).  Persistence is a measure of the number of changes of 
direction made by a cell during migration (scored between 0 and 1, the higher the score, 
the less directional changes).  Accuracy is a vector analysis of the accuracy of cell 
migration, with 1 equalling movement straight up the chemoattractant gradient, and -1 
equalling movement in the opposite direction to the chemoattractant gradient. The bar 
represents the overall group mean.  There were no differences in migratory parameters 
in neutrophils isolated from healthy non smokers (HC) and healthy smokers (HS). 
 
 
5.3.3.2 Migratory differences between patients with COPD, healthy controls  and 
patients with A1ATD 
 
Baseline characteristics 
Demographic data for the COPD patients with and without A1ATD and healthy controls 
are shown in Table 5.4. The results shown are for postbronchodilator forced expiratory 
volume in one second (FEV1) expressed as a percentage of the value predicted for the 
patient’s age, gender and height (British Thoracic Society 1994) and the ratio of FEV1 to 
vital capacity (FEV1/FVC).   
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Table 5.4. Demographic data for COPD patients, healthy controls and patients with 
A1ATD. 
  COPD Healthy subjects A1ATD 
N 12 12 12 
Age (years) 60 (55 - 68) 59 (53 - 68) 53 (45 – 67) 
Gender (Male) 7 5 7 
Smoking status  All ex-smokers Mixed All ex-smokers 
Pack years 36 (24 - 43)  13 (0 - 47) * 29 (15 – 38)   
FEV1 (l) 0.96 (0.8 - 1.1)   2.54 (2.5 - 2.9) * 1.2 (0.9 – 1.6)  
FEV1 % predicted 44 (39 - 49)  101 (94 – 111) * 41 (34 – 49)  
FEV1 /FVC 38 (31 - 47)  79 (75 - 83) * 42 (35 – 43)  
BMI (kg/m2) 26 (24 - 28) 24 (21 - 33) 25 (23 – 27) 
Receiving inhaled steroids 
Receiving theophyllines 
Receiving long acting β2 
agonist 
Bacterial colonization 
            83%  
0% 
75% 
 
0% 
           0% * 
           0% 
0% * 
 
N/A 
 
83% 
           0% 
83% 
 
           0%  
 
Legend 
Age is presented as the mean (with the range in parenthesis).  Gender is the number of 
males in each group. Patients receiving listed medications are denoted as a percentage of 
the group.  The remaining data is presented as the median (with the interquartile range in 
parentheses).   Healthy subjects differed significantly from both patient groups in all 
lung function, smoking and medication parameters.  
* = significant difference from COPD and A1ATD groups (p < 0.05) 
 
Chemotaxis towards IL-8 
 
Figure 5.6, 5.7 and 5.8 provide examples of the cell migratory tracks that were recorded 
for a representative subjects in each group.    
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Figure 5.6.  Tracks of neutrophil migration from a patient with COPD 
 
Figure 5.7.  Tracks of neutrophil migration from a healthy control 
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Figure 5.8.  Tracks of neutrophil migration from a subject with A1ATD 
Figure 5.6 – 5.8:  Tracks of neutrophil migration from a subject with COPD,  a 
healthy control and a subject with COPD due to A1ATD. 
The images show the final neutrophil positions within the Dunn chemotaxis chamber 
following 20 minutes of phase time lapse recording.  The large white arrow at the top of 
each picture represents the direction of the source of the chemotactic signal (here IL-8 at 
a concentration of 100nM for all figures).  The tracks (shown in white) indicate the path 
of migration for each cell analysed:  each track begins where the cell was positioned at 
the start of recording and ends where the cell was positioned at the end of recording. The 
arrow at the end of each track (again shown in white) indicates the last direction of 
movement. 
 
Figure 5.6: Tracks of neutrophil migration from a subject with COPD   
This picture is representative of all recordings taken of neutrophils from patients with 
COPD across all concentrations.  In this instance, mean cell speed was 5.12µm/min, 
mean velocity was -1.09µm/min, mean persistence was 0.43 and mean chemotactic 
index was -0.19.   
 
Figure 5.7: Tracks of neutrophil migration from an age and gender matched 
healthy control  This picture is representative of all recordings taken of neutrophils 
from healthy controls across all concentrations.  In this instance, mean cell speed was 
3.77µm/min, mean velocity was 2.14µm/min, mean persistence was 0.34 and mean 
chemotactic index was 0.49.   
 
Figure 5.8: Tracks of neutrophil migration from a patient with A1ATD matched 
for FEV1  
This picture is representative of all recordings taken of neutrophils from patients with 
A1ATD across all concentrations.  In this instance, mean cell speed was 3.04 µm/min, 
mean velocity was 1.6µm/min, mean persistence was 0.38 and mean chemotactic index 
was 0.47 
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Speed of migrating neutrophils 
Circulating neutrophils from patients with COPD moved with significantly greater speed 
(chemokinesis) than both healthy controls (5.91µm/min + 0.17 Vs. 4.37µm/min + 0.14, p 
< 0.0001) and the disease-matched patients with A1ATD (3.26µm/min + 0.16, p < 
0.0001); summarised in figure 5.9. 
 
 
Figure 5.9. Comparisons of average speed of migrating neutrophils from patients 
with COPD, age matched controls and patients with A1ATD: IL8 
Legend: Measurements were taken from 10 cells from each individual (migrating in the 
presence of a chemotactic gradient formed from 10nM of IL-8). Each experiment was 
repeated three times and the average results for each subject were calculated, and an 
overall average was used for comparisons between groups.  Each data point represents 
the average migratory parameter for one individual. * = significant difference from 
COPD neutrophils (see text). 
 
Velocity of migrating neutrophils  
COPD neutrophils demonstrated a decreased velocity (directed speed movement or 
chemotaxis) compared with healthy controls (0.87µm/min + 0.16 Vs. 1.43µm/min + 0.12, 
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p = 0.04) but not compared to the A1ATD patients (1.1µm/min + 0.26, p = 0.8); figure 
5.10.    
 
 
Figure 5.10. Comparisons of average velocity of migrating neutrophils from 
patients with COPD, age matched controls and patients with A1ATD: IL8 
Legend: Measurements were taken from 10 random cells from each individual 
(migrating in the presence of a chemotactic gradient formed from 10nM of IL-8). Each 
experiment was repeated three times and the average results for each subject were 
calculated, and an overall average was used for comparisons between groups.  Each data 
point represents the average migratory parameter for one individual. * = significant 
difference from COPD neutrophils (see text). 
 
The persistence of migrating neutrophils 
There were no differences in the number of changes of direction made by circulating 
COPD neutrophils during migration compared to both control groups (they displayed the 
same degree of directional persistence);  COPD mean persistence 0.28 + 0.05; Healthy 
control mean persistence 0.32 + 0.04; A1ATD mean persistence 0.28 + 0.05.. 
 
 
   * 
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Chemotactic Accuracy 
Neutrophils from patients with COPD were significantly less accurate during migration 
(displaying a lower chemotactic index) compared with the healthy controls (0.15 + 0.02 
Vs. 0.27 + 0.02, p = 0.006) and patients with A1ATD (0.26 + 0.03, p = 0.04), summarised 
in figure 5.11.  
 
Figure 5.11. Comparisons of average chemotactic accuracy of migrating neutrophils 
from patients with COPD, age matched controls and patients with A1ATD: IL8 
Legend: Measurements were taken from 10 random cells from each individual 
(migrating in the presence of a chemotactic gradient formed from 10nM of IL-8). Each 
experiment was repeated three times and the average results for each subject were 
calculated, and an overall average was used for comparisons between groups.  Each data 
point represents the average migratory parameter for one individual. * = significant 
difference from COPD neutrophils (see text). 
 
These data show that neutrophils isolated from patients with COPD clearly have 
movement differences involving excessive, continuous migration, as demonstrated by their 
increased speed of migration, coupled with a reduction in velocity and chemotactic 
accuracy.   Knowing the speed and distance of the neutrophil migratory tracks enabled a 
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theoretical comparison of the potential lung damage neutrophils could produce if 
migratory patterns  in vivo  resembled those seen in vitro.   
 
5.3.4 Model of lung damage in COPD and A1ATD 
The observations included in the current study are consistent with a substantial body of 
work implicating the neutrophil in the pathogenesis of COPD and provide a potential 
model incorporating the physiological effects of neutrophil proteinases and the 
widespread damage seen in lung tissue.   During activation, it is known that a high 
proportion of neutrophil proteinases are expressed on the neutrophil membrane (Owen, 
Campbell et al. 1995; Owen, Campbell et al. 1997; Campbell, Campbell et al. 2000), 
polarising towards the leading edge of the neutrophil as it migrates (Cepinskas, Sandig 
et al. 1999). A proportion of the proteinase is left behind as the cell moves on (Clayton, 
Evans et al. 1998; Cepinskas, Sandig et al. 1999) and it has been clearly demonstrated 
that an area of obligate enzyme activity (or “collateral damage”) always exists following 
the secretion of free NE from activated neutrophils until concentrations have decreased 
by diffusion to match the concentration of surrounding proteinase inhibitors (Liou and 
Campbell 1996; Campbell, Campbell et al. 1999).   This explains the excess lung 
damage that occurs during neutrophil migration in A1ATD where the low level of 
antitrypsin results in a wider area of obligate enzyme activity around a normal migrating 
neutrophil. 
 
The more circuitous migratory routes taken by COPD neutrophils (as shown here) would 
increase the potential for collateral damage by a different mechanism, as more NE would 
be released during the lengthier journey to the source of inflammation, thereby increasing 
the area of obligate enzyme activity.  
203 
 
Furthermore, the presence of this extra NE, and any resultant tissue and cell damage, 
would also increase the secretion of other pro-inflammatory mediators such as LTB4 and 
IL-8 (Hubbard, Fells et al. 1991), amplifying the migration of inflammatory cells 
(including more neutrophils and macrophages) into the surrounding tissue with their 
resultant pro-inflammatory interactions (Itoh and Nagase 1995; Ferry, Lonchamp et al. 
1997),  
 
Diffusion analysis predicts that the obligate catalytic activity (excess of local NE over 
inhibitor concentration) extends to 1.33 µm from the site of granule extrusion in subjects 
with normal plasma levels of α1 antitrypsin, and 3.29 µm from the site of granule 
extrusion in subjects with A1ATD and reduced levels of A1AT (Liou and Campbell 
1995). Measurements from our data suggest that the average diameter of a polarised 
migrating neutrophil is 3µm. The average migratory distances of neutrophils were 
significantly greater in COPD than in health (0.98 µm + 0.03 Vs. 0.72 µm + 0.02 in ten 
seconds) or A1ATD (0.54µm in ten seconds + 0.03).   
 
Using a simplistic mathematical model, and applying the formula distance x (πr2), where r 
equals the average radius of a cyclindrical neutrophil including an allowance for obligate 
catalytic activity based on the calculations by Liou et al (Liou and Campbell 1995), the 
theoretical volume of lung damage in ten seconds of a migrating neutrophil in COPD is 
76µm3 compared to 56µm3 in health.  If one accepts that neutrophils are releasing 
proteinases throughout their migratory tracks in order to penetrate through tissue, these 
data suggest that the COPD neutrophil would cause approximately 30% more damage 
compared to control cells and this may explain the increased susceptibility of such 
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individuals to develop COPD features.   In A1ATD there is also an increased potential for 
tissue damage, with the theoretical volume of lung damage in ten seconds of a migrating 
neutrophil in A1ATD being 110µm3 compared to 56µm3 in health (an increase of 90%), 
because of the low prevailing concentration of A1AT rather than abnormal migratory 
function.  
5.3.5 Migration towards GROα  
 
To determine if migratory patterns seen were selectively dependent on CXCR1 or 
CXCR2, similar migratory studies were performed on a smaller sample of patients with 
COPD compared to healthy controls and patients with A1ATD  (n=6 per group), using 
GROα as the chemoattractant.  
5.3.5.1 Baseline characteristics 
 
Demographic data for the COPD patients, healthy controls and patients with A1ATD are 
shown in Table 5.5. The results shown are for postbronchodilator forced expiratory 
volume in one second (FEV1) expressed as a percentage of the value predicted for the 
patient’s age, gender and height (British Thoracic Society 1994) and the ratio of FEV1 to 
vital capacity (FEV1/FVC). 
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Table 5.5. Demographic data for COPD patients,  healthy controls and patients 
with A1ATD  
 
 
 COPD HC A1ATD 
N 6 6 6 
Age (years) 62 (57 - 66) 60 (55 – 64) 59 (54 – 65) 
Gender (Male) 4 4 3 
Smoking status  All ex-smokers Mixed All ex-smokers 
Pack years 37 (31 - 53) 16 (0 – 29) * 28 (20 – 36) 
FEV1 (l) 0.84 (0.7 – 1.0) 2.15 (2.0 – 2.7) * 0.96 (0.8 – 1.2) 
FEV1 % predicted 46 (41 - 50) 91 (85 – 106) * 50 (46 – 52) 
FEV1 /FVC 52 (36 - 59) 81 (76 – 85) * 60 (40 – 66) 
BMI (kg/m2) 22 (19 - 27) 24 (21 – 32) 21 (20 – 23) 
Receiving inhaled steroids 100% 0% * 100% 
Receiving theophyllines 0% 0% * 0% 
Receiving long acting β2 agonist 66% 0% * 50% 
Receiving anti-cholinergics 50% 0% * 50% 
Bacterial colonization 0% N/A N/A 
 
Legend 
Age is presented as the mean (with the range in parenthesis).  Gender is the number of 
males in each group. Patients receiving listed medications are denoted as a percentage of 
the group.  The remaining data is presented as the median (with the interquartile range in 
parentheses).   Healthy subjects differed significantly from COPD and A1ATD patients 
in all lung function, smoking and medication parameters.  
* = significant difference from COPD (p < 0.05) 
 
  
 Speed of migrating neutrophils 
Circulating neutrophils from patients with COPD moved with significantly greater speed 
(chemokinesis) in gradients of GROα compared to healthy controls (3.97 µm/min + 0.13 
Vs. 2.34µm/min + 0.2, p = 0.0001) and patients with A1ATD (3.01µm/min + 0.2, 
p=0.008); summarised in figure 5.12. 
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Figure 5.12. Comparisons of average speed of migrating neutrophils from patients 
with COPD, age matched controls and patients with A1ATD: GROα   
Legend: Measurements were taken from 10 cells from each individual (migrating in the 
presence of a chemotactic gradient formed from 100nM of GROα). Each experiment 
was repeated three times and the average results for each subject were calculated, and an 
overall average was used for comparisons between groups.  Each column represents the 
average migratory speed and the error bar is the standard error.  * = significant 
difference from COPD neutrophils (see text). 
 
Velocity of migrating neutrophils  
COPD neutrophils demonstrated a decreased velocity (directed speed movement or 
chemotaxis) compared with healthy controls (0.21µm/min + 0.2 Vs. 0.32 µm/min + 0.1, p 
= 0.02) and patients with A1ATD (0.35 + 0.1, p = 0.006); see figure 5.13.    
       *                      * 
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Figure 5.13. Comparisons of average velocity of migrating neutrophils from patients 
with COPD, age matched controls and patients with A1ATD: GROα  
Legend: Measurements were taken from 10 random cells from each individual 
(migrating in the presence of a chemotactic gradient formed from 100nM of GROα). 
Each experiment was repeated three times and the average results for each subject were 
calculated, and an overall average was used for comparisons between groups.  Each 
column represents the mean velocity and the error bars are the standard error. * = 
significant difference from COPD neutrophils (see text). 
 
The persistence of migrating neutrophils 
There were no differences in the number of changes of direction made by circulating 
COPD neutrophils during migration compared to the control groups (they displayed the 
same degree of directional persistence); COPD mean persistence 0.17 + 0.03; healthy 
control mean persistence 0.19 + 0.1; patients with A1ATD 0.19 + 0.06. 
 
Chemotactic Accuracy 
Neutrophils from patients with COPD were significantly less accurate during migration 
(displaying a lower chemotactic index) compared with the healthy controls (0.03 + 0.03 
 *                       * 
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Vs. 0.21 + 0.05, p = 0.004) and patients with A1ATD (0.25 + 0.08, p < 0.0001), 
summarised in figure 5.14.  
 
Figure 5.14. Comparisons of average chemotactic accuracy of migrating neutrophils 
from patients with COPD, age matched controls and patients with A1ATD: GROα  
Legend: Measurements were taken from 10 random cells from each individual 
(migrating in the presence of a chemotactic gradient formed from 100nM of GROα). 
Each experiment was repeated three times and the average results for each subject were 
calculated, and an overall average was used for comparisons between groups. Each 
column is the mean chemotactic index and the error bars are the standard error. * = 
significant difference from COPD neutrophils (see text). 
 
These data also show that neutrophils isolated from patients with COPD are clearly 
different comprising excessive but inaccurate migration, as demonstrated by their 
increased speed of migration, coupled with a reduction in velocity and chemotactic 
accuracy towards GROα.   There was no difference in migration between healthy controls 
and patients with A1ATD.  These data gave the same pattern of results as was seen with 
IL-8.  
 
 
     *                       * 
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5.4 Discussion 
 
This body of work proposes that lung damage in COPD could be driven by aberrant 
migration in COPD, and that the migrational differences seen in this disease cannot be 
explained by cigarette smoke, lung inflammation or its treatment per se, but instead are 
likely to represent an intrinsic flaw with the neutrophil in this patient population.  This 
work also suggests that the migrational differences seen in COPD are not purely an 
expression of advanced ageing, since they differ from the patterns of ageing neutrophils 
seen in the previous chapter.  
 
The current study describes clear differences in the migratory behaviour of neutrophils 
from patients with COPD compared with two control groups; age and gender matched 
healthy subjects, and patients with A1ATD with COPD due to a genetic deficiency of  
alpha 1-antitrypsin, but with a similar severity of lung disease.    
 
The under agarose studies demonstrated that neutrophils from patients with COPD 
(without A1ATD) displayed greater chemotaxis and chemokinesis than either control 
group, when migrating in the presence of IL-8 and fMLP.  It appeared that the 
neutrophils were spreading out further during their migration, both towards and away 
from the chemotactic source.    The net chemotactic movement (chemotaxis – 
chemokinesis) however was not different. 
 
Previous studies have reported that neutrophils from patients with A1ATD display a 
greater chemotactic differential (chemotaxis – chemokinesis) than patients with usual 
COPD, when migrating towards their own sputum  (Woolhouse, Bayley et al. 2002).  
However, the A1ATD sputum samples contained greater concentrations of both IL-8 
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and LTB4 than those from the PiM COPD patients, suggesting that migratory 
differences could have been driven by increased mediator content.  There have been no 
other studies directly commenting on the migratory differences between COPD and 
A1ATD using this methodology.  To further explore the migratory differences seen, 
individual cells were studied using the modified Dunn Chamber. 
 
Firstly, using this assay in smoking and non smoking healthy controls who were age 
matched to the COPD group, established that active smoking does not influence 
neutrophil migration.   Secondly, it was shown that neutrophils from the COPD patients 
displayed clear differences in their migratory dynamics compared to other controls 
groups.  The cells were faster in their migratory speed but less accurate (exhibiting a 
lower velocity and chemotactic index)  than both the healthy controls and patients with 
A1ATD.   Overall the data suggests cells from COPD patients move more randomly in 
the presence of a chemotactic gradient, as demonstrated by the results of both the 
agarose and Dunn chamber method. 
 
When migratory pathways were mapped out, a rudimentary volume of tissue damage 
(allowing for theories of quantum proteolysis) per neutrophil was calculated.  COPD 
neutrophils had the capacity to cause 30% more tissue damage than healthy controls 
(due to convoluted migratory tracks but a normal area of obligate damage), while 
A1ATD neutrophils had the capacity to cause 90% more damage (due to less regulated 
proteolysis in the presence of normal migration).  Interestingly, when one compares 
studies of FEV1 decline, the approximate annual decline in absolute FEV1 in healthy 
subjects  (age matched to the COPD patients included in this study) is 45ml/year 
(Fletcher and Peto 1977; Kerstjens, Rijcken et al. 1997).  Studies of COPD have given 
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variable results, but in patients with similar characteristics to those included in this body 
of work, the average annual decline in absolute FEV1 ranges from 59 – 74 ml/year  
(Burge, Calverley et al. 2000; Simmons, Connett et al. 2005; Makris, Moschandreas et 
al. 2007) and in patients with A1ATD and moderate severity airflow obstruction, the 
decline is approximately 90ml/year (Dawkins, Dawkins et al. 2009).  This equates to a 
45% increase in FEV1 decline in COPD and a 100% increase in FEV1 decline in 
A1ATD, compared to that seen in health.  These figures are similar to the estimated 
increased potential for tissue damage given above using migratory tracks, suggesting a 
common paradigm of neutrophil mediated damage in both groups. 
 
The current study included patients with COPD related to a genetic anti-proteinase 
deficiency (A1ATD), in order to determine any impact of lung disease alone or its 
treatment on neutrophil migration.  In the current study, cells from these A1ATD 
patients had similar migratory parameters to healthy controls. Previously, neutrophils 
from patients with A1ATD also displayed overall adhesion and migratory patterns under 
flow conditions that were the same as healthy controls (Woolhouse, Bayley et al. 2005). 
In the same study, neutrophils from matched COPD patients showed enhanced adhesion 
and migration consistent with the findings of the current study. On the other hand, 
neutrophils from patients with bronchiectasis (another more marked inflammatory lung 
disease) also had normal chemotactic responses (Burnett, Chamba et al. 1987).  
Together, these data suggest that lung inflammation or severity per se does not alter the 
mechanics of circulating neutrophil migration.  In the current study, the patients with 
A1ATD were also matched for smoking status, medication, the absence of bacterial 
colonisation and lung function, suggesting that the differences seen in migration cannot 
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be accounted for any of these factors, and hence are likely to be central to the 
pathophysiology of COPD. 
 
Of note, the migratory parameters measured in neutrophils from the healthy controls 
throughout this series of experiments (and in particular when using the modified Dunn 
chamber) did not closely resemble those seen in the healthy elderly subjects in the 
preceding chapter (with both velocity and chemotactic index being higher when 
migrating in gradients of IL-8). Nor did they closely resemble those from younger 
subjects (as they demonstrated reduced persistence), and instead were a  mixture of both.  
Subjects in this body of work were age matched to the COPD patient group, and were 
much younger than the elderly subjects included in the experiments described in chapter 
4.  It is likely that any age-related changes in neutrophil behaviour develop progressively 
rather than suddenly, although there is no published data to confirm this.  If patterns of 
migration documented in this younger group are representative, it appears as though 
persistence is the first parameter to change with age (with cells making more directional 
changes during migration), with velocity altering at a later stage. Interestingly, 
neutrophil migratory behaviour in COPD does not appear to be advanced ageing, as 
there were notable differences in the dynamics or migration (namely, the increased 
speed). 
 
In conclusion, the current study presents clear differences in migratory behaviour of 
circulating neutrophils in COPD compared with healthy age matched controls and 
disease-matched patients with A1ATD.  Cells from COPD patients migrated with 
greater speed, but with less accuracy towards both IL-8 and GRO, and changes seen 
could not be explained by smoking, inflammation, bacterial colonisation or treatment 
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regimes.  The findings are in keeping with theories of bystander cell and tissue damage 
in COPD and provide an important insight into potential mechanisms of the increased 
lung damage noted in this disease.  In order to study these differences further, analysis 
of the structural properties of migratory neutrophils was undertaken (see chapter 6).  
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6 Mechanisms of aberrant migration:  Pseudopod 
formation in COPD 
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6.1 Brief Introduction 
 
Work described in chapter 5 found clear differences in the migratory dynamics of 
circulating neutrophils from patients with COPD, namely increased speed of movement 
but decreased accuracy, when migrating in the presence of chemotactic gradients. 
 
As described previously, neutrophil movement occurs via the formation of locally 
protruding actin-rich pseudopods while retracting other regions of the cell body 
(Devreotes and Janetopoulos 1988).   In order to achieve this, directed neutrophil 
chemotaxis begins with cell polarisation, where, following stimulation, neutrophils 
acquire polarity through a self-organising process involving positive “frontness” and 
negative “backness” feedback loops. The leading edge is composed of F-actin rich 
lamellipodia, and highly polarized distributions of lipids that are up-regulated during 
cell alignment (including PIP3,, Cdc42, PAK1 and Akt).  “Backness” is enhanced by 
inhibiting the formation of a leading edge and with the development of a uropod.  This 
is achieved by actin-myosin II meshworks, regulated by Rho-A and PTEN. In keeping 
with the role of the leading and trailing edge of the neutrophil, receptors for 
chemoattractants are redistributed to pseudpods (Gomez-Mouton, Lacelle et al. 2001) 
and those for adhesion (such as PSGL-1 and ICAM-3) are redistributed to the uropod  
(Fais and Malorni 2003).  
 
No studies to date have examined the structural nature of individual migrating cells in 
COPD to determine if differences in migratory behaviour equate to differences in 
migratory structure.  Neutrophils (as with most eukaryote cells) randomly protrude actin-
rich pseudopods at the leading edge of the cell and sustain those pseudopods that are best 
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placed in chemotactic gradients (Andrew and Insall 2007).  The direction of chemical 
gradients are believed to be perceived by receptor occupancy, and those pseudopodia 
orientated towards the gradient are maintained, determining the direction of migration 
(Andrew and Insall 2007).  
 
Most studies of cellular migration have focused upon Dictyostelium cells, and caution 
must be applied when making comparisons, however, studies of mutated Dictyostelium 
strains demonstrate that abnormally increased formation of pseudopodia is associated with 
less migration (Weber 2006).   Differences in pseudopodia generation are likely, therefore, 
to be a determinant of migratory dynamics. 
 
The aims of the present study were to examine, in quantitative detail, pseudopod formation 
in subjects with COPD, compared to non smoking healthy subjects, smoking subjects with 
normal lung function and no respiratory symptoms (so called “healthy smokers”) and 
patients with A1ATD matched for lung disease, severity and treatment.  
 
Once again, the control groups were carefully selected and specifically included patients 
with A1ATD as these patients can be selected with the same degree of functional 
impairment, cigarette exposure and similar pulmonary inflammation and therapy to 
usual COPD (all of which may influence results).  Thus, if pseudopod formation in 
A1ATD resembles health more than COPD, it could be surmised that any differences 
were not due to the presence of pulmonary and systemic inflammation or lung disease 
alone. 
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6.2 Experiments 
 
6.2.1 Study subjects 
 
COPD patients had moderate to severe disease defined by GOLD criteria (Pauwels, Buist 
et al. 2001).  They were ex-smokers, aged between 50 and 70.  All patients were clinically 
stable for at least eight weeks prior to recruitment with no changes in medication.  
Alternative and concomitant disease was excluded clinically, physiologically and 
radiologically.   
 
Controls consisted of age and gender matched healthy volunteers and patients with 
A1ATD.  The A1ATD patients were ex-smokers and matched for the severity of airflow 
obstruction, age, gender, bacterial colonisation and medications.  Healthy volunteers were 
divided into two groups.  The first had never smoked, had no evidence of chronic disease 
(including lung disease)  and were medication free.  The second group of healthy controls 
were current smokers who had no evidence of lung disease (or other co-morbidities) and 
were also medication free, the so called “healthy smokers”. These two control groups were 
chosen as comparisons with healthy controls would allow an understanding of differences 
from normal, including the effects of smoking and comparisons with patients with A1ATD 
would differentiate the effects of pulmonary inflammation and lung disease per se. 
 
6.2.2 Isolation of blood neutrophils 
 
Neutrophils were isolated from the whole blood as described previously (methods 2.5.7) 
The neutrophils (>95% pure, > 97% viable, by exclusion of trypan blue) were resuspended 
in buffer (RPMI 1640 medium (Flow Laboratories, Rickmansworth, UK) containing 
0.15% bovine serum albumin (Sigma-Aldrich, UK). 
218 
6.2.3 Assessment of pseudopod formation  
6.2.3.1 Modified Dunn Chamber 
 
Pseudopod formation was assessed using a modification of the Dunn chamber and DIC 
time lapse recordings.  Full methodological details are included in the methods (section 
2.7.2). Each subject’s neutrophils were studied with a negative control (assay buffer, see 
above) and with IL-8 10-7M (concentrations were chosen following appropriate dose 
response experiments, see 4.3.3.3).    
 
Analysis of pseudopods 
The java software ImageJ (Wayne Rasband, NIH, Bethsada) was used to outline 
individual pseudopods of time lapse images using plug-ins developed by Natasha 
Andrew (Biosciences, University of Birmingham), as described in sectin 2.7.2.3.  In 
brief, pseudopods were defined as being granule free regions of the cell that had some 
protrusive activity.  New pseudopods were defined as “daughter” or “new lateral” 
pseudopods.  Daughter pseudopods were identified after having split from the parent 
pseudopod (noted when a granular region divided a granule free area into two regions), 
sharing pixels with their parents in the previous frame.  Any new pseudopod that did not 
have a parent defined by this criterion was defined as a new lateral pseudopod.  
 
Pseudopod formation was firstly compared between healthy non-smokers and “healthy 
smokers” (n=6 for each group).  With this as a background, it was then assessed in patients 
with COPD, healthy controls and patients with A1ATD (n=12 for each group).   
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6.2.4 Statistical analysis 
 
Pseudopod generation between groups was compared using the mean data of 5 random 
cells per experiment, with each experiment being repeated three time for each subject.  
Differences in pseudopod generation were compared using an Independent t test. A p 
value of less than 0.05 was considered to be statistically significant.   
 
Sample size calculations were carried out following a pilot study to assess inter and 
intra patient variability in pseudopod generation.  Based upon a two group parallel 
comparison, the inclusion of 6 subjects to each arm provided an 80% power of 
detecting a 30% change in pseudopod formation at the 5% level of significance 
between healthy smokers and non smokers and the inclusion of 12 subjects to each 
arm provided an 80% power of detecting 20% change in pseudopod formation at the 
5% level of significance between patients with COPD, healthy controls and patients 
with A1ATD (both as described in section 2.9). 
 
 
6.3 Results 
 
6.3.1 Validation 
 
A pilot study of healthy volunteers determined that there was little intra or inter-subject 
variability in pseudopod formation on neutrophils migrating towards IL-8.  Power 
calculations were performed to determine the numbers needed to confirm a 50 – 25% 
change in pseudopod formation with 80% power and at the 5% significance level, using 
the mean of data from 5 cells per subject, with each experiment repeated in triplicate.  
Table 6.1 summarises the mean pseudopod formation in healthy subjects, the variation 
in inter-patient pseudopod formation and the number of subjects required in each group.  
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six  participants were recruited to study differences in healthy controls and 12 subjects 
were recruited to study differences in COPD and A1ATD, to provide the maximum 
opportunity to see differences in migration. 
 
Table 6.1.  The numbers needed in a parallel design study to detect varying 
difference in neutrophil pseudopod formation between groups 
 
Mean new pseudopod generation (per minute)           6.9 
SEM 0.24 
Co-efficient of variation 8.5% 
  
Number of subjects needed to detect:  
50% difference in pseudopod formation 2 
40% difference in pseudopod formation 3 
30% difference in pseudopod formation 4 
20% difference in pseudopod formation 6 
10% difference in pseudopod formation 12 
  
 
6.3.2 Smoking and Non smoking health controls  
 
Pseudopod formation was studied in non healthy and “healthy smokers” to assess the 
effect of active smoking on pseudopod generation, both when cells were quiescent and 
activated in chemotactic gradients of IL-8 (10nM).  
6.3.2.1 Baseline characteristics 
 
Demographic data for the “healthy smokers” and healthy non smokers (who had never 
smoked) are shown in table 6.2. The results shown are for postbronchodilator forced 
expiratory volume in one second (FEV1) expressed as a percentage of the value predicted 
for the patient’s age, gender and height (British Thoracic Society 1994) and the ratio of 
FEV1 to forced vital capacity (FEV1/FVC).  Subjects were recruited if they had no chronic  
disease, were on no medication, were symptom free and had no evidence of pathology on 
physical examination or spirometry. 
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Table 6.2.  Pseudopod extension. Demographic data for healthy never smokers and 
smokers 
 Healthy never smokers Healthy smokers 
N 6 6 
Age (years) 61 (56 - 69) 63 (58 – 71) 
Male 3 3 
Smoking status All never All current 
Pack years 0 36 (20 – 46) 
FEV1 2.51 (2.3- 2.9) 2.49 (2.3 – 3.2) 
FEV1 % predicted 93 (90 - 106) 96 (92 – 110) 
FEV1/FVC 81 (73 - 86) 83 (76 – 86) 
BMI 26 (23 – 30) 25 (22 – 29) 
 
Legend.  Age is presented as the mean (with the range in parenthesis).  Gender is the 
number of males in each group. The remaining data is presented as the median (with the 
interquartile range in parentheses).   Healthy non-smokers differed from healthy smokers 
only in terms of smoking exposure.  There were no other differences between groups.  
 
 
6.3.2.2 Pseudopod generation 
Figure 6.1 depicts typical pseudopodia on a neutrophil from a healthy control, migrating 
towards IL-8.   Pseudopods shown in figure 6.1 are typical for those counted throughout 
this body of work.   There are some differences in appearances of these pseudopods and 
those shown in other works (for example, Andrew et al, 2007).  This is due to differences 
in filming techniques (those shown in the Andrew paper were filmed under agar), 
differences in focusing (with films included in this thesis being focused higher than the 
substratum, which emphasises the cell body rather than the pseudopod), and differences in 
cell types (with current observations suggesting that neutrophil pseudopodia being less 
substantial than those seen in migrating Dictyostelium cells.  
 
There were no differences in pseudopod generation between healthy non-smokers and 
healthy smokers, either in the presence of the negative control (quiescent cells) or in the 
presence of IL-8 10nM, indicating that smoking per se does not effect neutrophil 
pseudopod projection (see figure 6.2). 
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Figure 6.1:  Pseudopod structure 
Legend:  This is an example of a DIC image of a migrating peripheral neutrophil from a 
healthy control.  The image has then been enlarged (on the right) and the pseudopods on 
the leading edge of the cell have been outlined.  Pseudopods (pseudopodia) are 
temporary projections of eukaryotic cells.  Pseudopodia extend and contract by the 
reversible assembly of actin subunits into microfilaments, while filaments near the cell’s 
end interact with myosin which causes contraction, the combination propels the cell 
forward. Pseudopodia are thought to be retracted or maintained depending on their 
orientation in a chemical gradient. 
 
When inactive, mean cellular pseudopod extension was 5.4 + 0.4 per minute for healthy 
non-smokers and 5.0 + 0.3 per minute for healthy smokers.  In the presence of a 
chemotactic gradient of IL-8, mean cellular pseudopod extension increased to 7.0 + 0.5 per 
minute for healthy non-smokers (p = 0.002) and 7.2 + 0.3 per minute for healthy smokers 
(p=0.001).   
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Figure 6.2. Pseudopodia formation on neutrophils from healthy non-smokers and 
healthy current smokers. 
Legend:  Pseudopodia formation per minute by in neutrophils isolated from healthy 
non-smokers (HC) and healthy smokers (HS) when cells were quiescent (negative 
control) or activated (IL-8).  Each data point is the mean pseudopod count per individual 
over 20 minutes of filming. IL-8 increases pseudopod formation (see text) but there were 
no differences between groups.  
 
As pseudopod formation was the same in healthy smokers and non-smokers, it was 
surmised that smoking per se does not alter pseudopod formation during neutrophil 
migration towards IL-8.  
 
6.3.3 Pseudopod formation in neutrophils isolated from patients with 
COPD, A1ATD and healthy controls 
 
Pseudopod formation was then studied in patients with COPD, A1ATD and compared to 
the healthy controls to see if there were differences both when cells were quiescent and 
activated. 
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6.3.3.1 Baseline characteristics 
 
Demographic data for the COPD patients with and without A1ATD and healthy controls 
are shown in Table 6.3. The results shown are for postbronchodilator forced expiratory 
volume in one second (FEV1) expressed as a percentage of the value predicted for the 
patient’s age, gender and height (British Thoracic Society 1994) and the ratio of FEV1 to 
vital capacity (FEV1/FVC).  
 
Table 6.3. Demographic data for COPD patients, healthy controls and patients with 
A1ATD. 
  COPD Healthy subjects A1ATD 
N 12 12 12 
Age (years) 60 (55 - 68) 59 (53 - 68) 53 (45 - 67) 
Gender (Male) 7 5 7 
Smoking status  All ex-smokers Never and current All ex-smokers 
Pack years 36 (24 - 43)  13 (0 - 47) * 29 (15 – 38)   
FEV1 (l) 0.96 (0.8 - 1.1)   2.54 (2.5 - 2.9) * 1.2 (0.9 - 1.6)  
FEV1 % predicted 44 (39 - 49)  101 (94 – 111) * 41 (34 – 49)  
FEV1 /FVC 38 (31 - 47)  79 (75 - 83) * 42 (35 – 43)  
BMI (kg/m2) 26 (24 - 28) 24 (21 - 33) 25 (23 – 27) 
Receiving inhaled steroids 
Receiving theophyllines 
Receiving long acting β2 
agonist 
Bacterial colonisation 
            83%  
0% 
75% 
 
0% 
           0% * 
           0% 
0% * 
 
N/A 
 
83% 
           0% 
83% 
 
           0%  
 
Legend 
Age is presented as the mean (with the range in parenthesis).  Gender is the number of 
males in each group. Patients receiving listed medications are denoted as a percentage of 
the group.  The remaining data is presented as the median (with the interquartile range in 
parentheses).   Healthy subjects differed significantly from both patient groups in all 
lung function, smoking and medication parameters.  
* = significant difference from COPD and A1ATD groups (p < 0.05, see text for values) 
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6.3.3.2 Pseudopod formation 
 
Pseudopod generation was studied when cells were quiescent and activated. In total, 
peripheral neutrophils from healthy controls produced 5.1 + 0.2 pseudopods per minute 
when the cells were quiescent (negative control), which increased to 7.1 + 0.3 pseudopods 
per minute in the presence of 10nM IL-8 (p =0.001).    
 
When quiescent, neutrophils from patients with COPD produced less pseudopods per 
minute than those from healthy control (3.9 + 0.1 pseudopods per minute, p < 0.0001).  
There was no significant difference compared with patients with A1ATD (4.1 + 0.1 
pseudopods per minute, p = 0.06).   
 
However, when activated and migrating towards IL-8, neutrophils from patients with 
COPD did not increase the rate of pseudopod formation compared with quiescent cells.  
COPD neutrophils produced significantly less pseudopods while migrating than cells from 
healthy controls (3.9 + 0.1 Vs 7.1 + 0.3 pseudopods per minute, p < 0.0001) and cells from 
patients with A1ATD (4.9 + 0.1 pseudopods per minute, p =0.0001).  See Figure 6. 3. 
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Figure 6.3.  Pseudopodia formation on neutrophils from patients with COPD, 
healthy controls and patients with A1ATD. 
Legend.  Pseudopodia formation per minute are shown for each individual for each 
subject group when cells were quiescent (negative control) or activated (IL-8).  Each 
data point is the mean pseudopod count per individual over 20 minutes of filming.   * = 
significant difference from HC cells.  ** = significant difference from A1ATD cells.  
COPD neutrophils produced less pseudopodia than cells from healthy controls when 
quiescent (p < 0.0001),  and less than cells from healthy controls and patients with 
A1ATD when activated (p < 0.0001 and p=0.0001, respectively). 
 
 
6.4 Discussion 
 
Circulating neutrophils isolated from subjects with COPD display clear differences in 
migratory behaviour compared with control groups. This series of experiments also 
suggest that they display different structural qualities during migration. Pseudopod 
counts were lower on COPD neutrophils compared with healthy controls both when 
quiescent and when activated.  As stated, it is known that some mutated Dictyostelium 
strains demonstrate abnormally increased pseudopodia formation and that this is 
associated with less migratory speed (Weber 2006).  It is therefore possible that the 
reverse is also true, and that fewer pseudopods on neutrophils might be consistent with 
*           ** 
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faster migratory speed.    Pseudopod generation is limited by enzymatic reactions in the 
signalling pathway (Zhelev, Alteraifi et al. 2004), suggesting a defect within this 
pathway in COPD patients might explain the increased speed of migration. 
 
It is generally accepted that pseudopods are also a means by which motile cells 
experience their surroundings and orientate themselves via receptor occupancy (Andrew 
and Insall 2007). It is known that pseudopod extension frequency increases with 
chemoattractant mediators in a dose dependent manner (Zhelev, Alteraifi et al. 2004)  
Fewer pseudopods would reduce chemotactic sensitivity, due to a smaller surface area 
for receptor binding. This would result in less points of comparison to ascertain the 
origin of a chemotactic signal accurately (both spatially or temporally) by pro-
inflammatory receptor occupancy around the cell (Jin and Hereld 2006; Levine and 
Rappel 2006).   This therefore might represent the mechanism of reduced migratory 
accuracy. 
 
It is likely that the differences in pseudopod formation are unique to COPD.  Studies of 
healthy smokers and non-smokers demonstrate that pseudopod formation is not altered 
by smoking.   Furthermore, comparison of activated neutrophils between patients with 
COPD and A1ATD suggest that differences seen are not driven by lung disease alone, 
the treatment of lung disease or the presence of inflammation, as these were comparable 
between groups.    
 
It is known that patients with A1ATD often have higher concentrations of inflammatory 
mediators in their sputum (such as IL-8 and LTB4) compared to matched patients with 
COPD (Woolhouse, Bayley et al. 2002).  The presence of inflammation may effect 
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pseudopod development when cells are quiescent, as there was no difference in 
pseudopod formation between patients with A1ATD and COPD in the presence of a 
negative control, and both groups displayed significantly less pseudopod formation than 
age and gender matched healthy controls.  
 
One hypothesis of immunosenescence is that changes in immune function with 
advanced ageing are driven by raised systemic inflammation (termed “inflammaging” 
(Giunta 2006)).  It is known that patients with COPD and A1ATD have increased 
pulmonary inflammation (Sapey, Bayley et al. 2008) and there is some evidence that this 
is associated with increased systemic inflammation (for example, a raised high 
sensitivity CRP (Sapey, Bayley et al. 2008) although evidence for a direct “over spill” 
from lung to plasma remains mixed (Sapey, Ahmad et al. 2009).  It is possible that the 
presence of continued low-grade inflammation in COPD and A1ATD may reduce 
pseudopod formation by adaptive mechanisms (preventing neutrophils from migrating 
and degranulating where there is no specific inflammatory trigger, a process which 
would limit unnecessary bystander tissue damage).  However, if anything, the airway 
inflammation in A1ATD is greater than in COPD in the stable state (Woolhouse, Bayley 
et al. 2002), suggesting that this alone does not explain the results for COPD 
neutrophils.  Furthermore, in the presence of an over-riding inflammatory source (here, 
IL-8), A1ATD neutrophils (unlike COPD cells) are able to increase pseudopod 
formation (although to a lesser degree than cells from healthy controls), perhaps 
enabling more accurate migration.  In the presence of IL-8, the COPD neutrophils did 
not increase pseudopod formation, suggesting that there is an underlying problem with 
migratory processes.   In order to study these differences further, analysis of some of the 
components of the migratory pathway was undertaken. 
229 
 
 
 
 
 
 
 
 
 
 
 
 
 
7 Mechanism of aberrant migration. Surface expression of 
CXCR1 and CXCR2 and the affects of inhibition of CXCR1 
and CXCR2 in COPD 
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7.1 Brief Introduction 
 
Previous studies in the current thesis have described clear differences in migratory 
parameters in neutrophils isolated from patients with COPD, as well as the presence of 
structural differences (with reduced pseudopod formation).  Migration is controlled by a 
pathway, which begins with chemoattractant receptor occupancy at the leading edge of 
the cell, and through a series of complex interactions, ends with myosin and actin 
mobilisation (outlined in greater depth in the main introduction).  During polarisation, 
receptors for chemoattractants are mobilised to pseudopods at the leading edge of the 
cell (Gomez-Mouton, Lacelle et al. 2001). 
 
IL-8 is a member of the ELR+ CXC subfamily of chemokines. These have the 
characteristic ability to specifically recruit neutrophils into inflamed tissue.  Recruitment 
from the bronchial circulation (although perhaps not from the pulmonary circulation) 
requires rolling, adhesion and transmigration, which is initiated by the expression of 
immobilized ELR+ chemokines on the surface of the endothelium (Rainger, Fisher et al. 
1997).   
 
CXCR1 and CXCR2 are specific receptors on the cellular surface for the ELR+ 
chemokines (Holmes, Lee et al. 1991; Murphy and Tiffany 1991).   Both receptors bind 
IL-8 with high and similar affinity, whereas CXCR2 binds the remaining ELR+ with 
high affinity, with minimal binding from CXCR1 (Lee, Hpruk et al. 1992).   In both 
cases, down stream signalling is initiated once the receptor-ligand complex is 
internalised via clathrin-mediated endocytosis (Signoret, Hewlett et al. 2005). The 
binding of ligand results in phosphorylation of Ser and Thr residues in the intracellular 
loops and the C-terminus of the chemokine receptor by G-protein-coupled receptor 
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kinases (GRKs) which results in the uncoupling of the G protein subunits from the 
receptor and receptor desensitization in some cases (Ferguson 2001). 
 
 
Phosphorylation of these residues is important for the recruitment of adaptor molecules 
that link the receptor to a lattice of clathrin that facilitates receptor internalization. The 
association of receptors with these adaptor molecules results in recruitment of clathrin 
and formation of clathrin-coated pits which pinch-off from the membrane through the 
action of dynamin and become clathrin-coated vesicles (Barlic, Khandaker et al. 1999; 
Colvin, Campanella et al. 2004).   The clathrin-coated vesicle is then uncoated and the 
receptor-ligand complex enters the early endosome. The receptor can either enter the 
recycling compartment and traffic back to the plasma  membrane to bind ligand, or enter 
the late endosome where it will be sorted to the lysosome for degradation (Neel, 
Lapierre et al. 2008). 
 
Prior studies show that the length of stimulation with ligand plays a role in the 
recycling/degradation sorting decision (Signoret, Pelchen-Matthews et al. 2000; Fan, 
Lapierre et al. 2003; Neel, Schutyser et al. 2005). Initially, following CXCL8 
stimulation of CXCR1 or CXCR2, the receptor enters the recycling compartment; 
however, following extended periods of stimulation, the receptor enters the late 
endosome and lysosome (Fan, Lapierre et al. 2003). The ability of internalised CXCR2 
to recycle is crucial for continued gradient sensing and chemotactic response to ligand. 
When CXCR2 recycling is inhibited, chemotaxis and signaling are impaired (Fan, 
Lapierre et al. 2003; Fan, Lapierre et al. 2004). 
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Although both receptors have been characterised, their roles in mediating biological 
effects has not been well defined, including their role in  IL-8 mediated cell chemotaxis.  
Indeed, studies have produced contradictory results as to the composite role of each 
receptor in migration.  Loetscher et al, monitored the migration of Jurkat cell lines that 
expressed CXCR1 or CXCR1 and CXCR2.  There was an unquantified degree of 
migration towards IL8 in the absence of CXCR2, that was not seen when GROα or 
NAP-2 were used as migratory stimulants, suggesting that CXCR2 is not necessary for 
migration towards IL-8 in this cell line  (Loetscher, Seitz et al. 1994).    Chuntharapai et 
al semi-quantified the surface expression of CXCR2 on neutrophils following migration 
towards IL-8, and concluded that reduced expression was evidence of a role of CXCR2 
in migration (Chuntharapai and Kim 1995).  Quan et al utilised a CXCR1 monoclonal 
antibody and found reduced migration under agarose towards IL-8, but did not assess 
CXCR2 (Quan, Martin et al. 1996).   Ben-Barach described increased phosphorylation  
of neutrophil CXCR2 following stimulation with IL-8, and suggested that this was 
suggestive of its’ importance in migration, but did not assess CXCR1 (Ben-Barach, 
Grimm et al. 1997).  Finally, Godaly et al treated epithelial layers with antibodies to 
CXCR1 or CXCR2  and found that only epithelial cells treated with CXCR1 decreased 
neutrophil migration when the epithelial cells were stimulated with IL-8.  The authors 
suggested that this demonstrated a role for CXCR1 but not CXCR2 in neutrophil 
migration (Godaly, Hang et al. 2000).  However, this oft cited conclusion is flawed. The 
antibodies were not incubated with the migrating cells, but with the static epithelial 
cells, and so what was being tested was the affect of antiCXCR1 and antiCXCR2 on the 
epithelial cell response to IL-8 (perhaps altering autocrine expression of chemokines and 
adhesion molecules), not  neutrophil migration.  The authors then showed that 
neutrophils from an IL-8 receptor homolog knock out mice (mice do not possess 
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CXCR1 and CXCR2) did not migrate towards IL-8, but here there could be no 
differentiation between receptor types (Godaly, Hang et al. 2000).  To date, therefore, 
there have been no erudite studies of the role of CXCR1 or CXCR2 on neutrophil 
migration. 
 
IL8 and CXCR2 expression appears to vary with chronic disease, for example, 
expression appears to be increased in inflammatory bowel disease (Banks, Bateman et 
al. 2003) and cystic fibrosis (Hay and Sarau 2001)  In pulmonary secretions from 
patients with COPD, IL8 has been shown to account for 30% of the chemotactic activity 
of sputum (Woolhouse, Bayley et al. 2002) and  IL8 concentrations correlate with 
neutrophil numbers in sputum (see section 4.7.7), airflow obstruction (see section 4.7.8), 
and progression of emphysema (Parr, White et al. 2006).    
 
There have been some studies measuring CXCR1 and 2 receptors on neutrophils in 
COPD, but results have been contradictory.  A study by Pignatti et al (Pignatti, Moscato 
et al. 2005) found lower expression of CXCR2 on the surface of neutrophils from 13 
patients with COPD compared with those with neutrophilic asthma and healthy controls.   
A study by Yamagata et al (Yamagata, Sugiura et al. 2007), found higher median 
fluorescent intensity for CXCR1, but not CXCR2 in 16 patients with COPD compared 
with healthy controls.   Differences may be explained by the heterogeneity of COPD as a 
disease, but certainly the numbers included would only be sufficient to determine a 30% 
change in CXCR1 expression and a 50% change in CXCR2, based upon the power 
calculations included in this thesis (see section 4.3.5.1). 
   
Potentially differences in pseudopod formation may alter CXCR1 and CXCR2 surface 
expression or the ability to recycle receptors following stimulation with their ligand.  We 
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hypothesise that a reduction in pseudopod formation may lead to reduced surface 
receptor expression in COPD (including surface expression of the receptors CXCR1 and 
CXCR2) as a direct consequence of the reduced pseudopod surface area.  If this were the 
case, it would be predicted that a CXCR2 or CXCR1 antagonist would have differential 
effects in COPD compared with age matched controls towards CXC chemokines or 
sputum if perception of receptor occupancy is altered by the migratory or structural 
differences seen.  
 
The current studies aimed to explore the functional role of CXCR receptors in neutrophil 
chemotaxis in COPD and age and gender matched healthy subjects (including smoking 
and non smoking healthy controls).  CXCR1 and 2 receptors were measured on the 
surface of circulating neutrophils taken from these groups, to determine if there was any 
disparity in surface expression when quiescent and activated.  Migrational studies were 
performed utilising the ELR+ chemokines IL-8 and GROα, their respective monoclonal 
antibodies, sputum and following specific inhibition of  CXCR1 and CXCR2.  
 
7.2 Experiments 
 
7.2.1 Study subjects 
Healthy controls consisted of healthy volunteers, age and gender matched to the COPD 
group, who had never smoked, had no evidence of chronic disease and were medication 
free.   Healthy smokers were subjects matched to healthy controls, but had a significant 
smoking history 
 
COPD patients had moderate to severe disease defined by GOLD criteria (Pauwels, Buist 
et al. 2001).  They were ex-smokers, aged between 50 and 70.  All patients were clinically 
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stable for at least eight weeks prior to recruitment with no changes in medication.  
Alternative and concomitant disease was excluded clinically, physiologically and 
radiologically.  Patients had normal circulating levels of A1AT and were PiMM genotype. 
 
7.2.2 Isolation of blood neutrophils 
 
Neutrophils were isolated from the whole blood as described previously (general methods 
2.5.7, (Mikami, Llewellyn-Jones et al. 1998)).  The neutrophils (>95% pure, > 97% viable, 
by exclusion of trypan blue) were resuspended in sterile buffer (RPMI 1640 medium 
(Flow Laboratories, Rickmansworth, UK) containing 0.15% bovine serum albumin 
(Sigma-Aldrich, UK) for migrational studies or PBS for semi-quantification of surface 
receptors by flow cytometry (see section 2.8). 
 
7.2.3 Flow Cytometry 
 
CXCR1 and CXCR2 receptor expression on isolated neutrophils was measured as 
described in section 2.8 of the general methods.  All measurements for an individual 
were carried out in triplicate, and a median result used for each subject.  
 
Anti-CXCR1 (IgG2A stock concentration 50 µg/ml) diluted to 2ng/ml in 2% BSA PBS, 
Anit-CXCR2 (IgG2A stock concentration 50 µg/ml) diluted to 3ng/ml in 2% BSA PBS 
and an isotype matched irrelevant FITC labelled IgG2A  (stock concentration 200 µg/ml), 
diluted to 2ng/ml in 2% BSA PBS, was used as a control. All were incubated on ice for 
20 minutes and the resuspended cells were read on FACS within twenty minutes of 
preparation. Samples from COPD patients and healthy subjects were read at the same 
time point to allow comparison of receptors.    
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CXCR1 and 2 receptor expression over time was assessed by measuring the receptors at 
3 time points (Time zero, 1 hour, and 2 hours).  The effects of cell stimulation on 
CXCR1 and 2 expression were investigated by measuring receptor surface expression  
following neutrophil incubation with three concentrations of IL-8 (1, 10 and 100nM) 
and a negative control (RPMI 1640).  The dose range and exposure time were chosen 
following appropriate validatory experiments (as detailed in section 4.3.5). 
 
7.2.4 Neutrophil Chemotaxis 
7.2.4.1 Modified Dunn Chamber 
 
Neutrophil chemotaxis was measured using a modification of the Dunn chamber.  Full 
methodological details are included in the general methods (section 2.7.2). Chemotaxis 
was assessed as described in general methods (section 2.7.2). 
 
7.2.4.2 Chemo-attractants and antagonists 
 
Neutrophils migrated in gradients of a negative control (RPMI (Sigma-Aldrich)), IL-8 
(RnDSystems) (10nM) and IL-8 (at the stated dose) that had been preincubated for 45 
minutes at room temperature with IL-8 monoclonal antibody (RnDSystems)  (1.6µM).  
Studies were also performed with GROα (RnDSystems) (100nM), GROα that had been 
pre-incubated for 45 minutes at room temperature with GROα monoclonal antibody 
(RnDSystems) (1.6µM) and sputum from patients with COPD.  Neutrophils then 
migrated towards IL-8 (10nM), GROα (100nM) and sputum sol phase both before and 
following neutrophil incubation with CXCR2 antagonist (kindly provided by 
AstraZeneca) at two concentrations, 5nM and 500nM for 45 minutes at room 
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temperature.  All doses were chosen following appropriate initial dose response 
experiments. 
 
Neutrophils then migrated towards IL-8, GROα (concentrations as above) and sputum 
sol phase before and following 45 minute incubation with CXCR1 and CXCR2 
antibodies (both at 1.6µM). 
 
7.2.4.3 Sputum collection and processing 
 
Sputum samples were collected from 15 patients with moderate to severe COPD 
(according to GOLD criteria). Patients were daily sputum producers with a history of 
chronic bronchitis as defined by the MRC criteria (Medical Research Council. 1965)and 
were current or ex-smokers. All patients were confirmed to have obstructive airways 
disease at screening by spirometric measurements and had stable symptoms of COPD 
for at least eight weeks prior to recruitment with no changes in medications during this 
time.  Alternative and concomitant lung disease were excluded clinically and by high 
resolution computed tomography.  
 
Sputum was collected and processed as described in the general methods (section 2.4 
and 2.5).  All sol samples were pooled, and the same pool of sputum sol was used 
throughout all studies.  Sputum was diluted in RPMI (Sigma-Aldrich) following 
appropriate initial dose response experiments. 
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7.2.4.4 Mediator measurement 
 
Concentrations of IL-8 and GROα were measured in triplicate in the pooled sputum sol 
samples using commercially available ELISA kits that had been validated previously 
(see section 2.6).   
 
7.2.5 Statistical analysis 
 
Differences in CXCR1 and 2 surface expression were compared using a Mann 
Whitney U test. A p value of less than 0.05 was considered to be statistically 
significant.  Migrational differences seen using the Modified Dunn Chamber were 
compared using the mean data of 10 cells per experiment, per subject.  Differences in 
chemotaxis criteria were compared using an Independent t test.  
 
For CXCR1 and 2 surface expression, sample size calculations were based upon a two 
group parallel comparison, to provide an 80% power of detecting a 20% change of 
expression in CXCR1 and a 25% change of expression in CXCR2 at the 5% level of 
significance (both as described in section 2.9). For the Modified Dunn chamber, 
sample size calculations were based upon a two group parallel comparison, to provide 
an 80% power of detecting a 25% change in mean speed at the 5% level of 
significance.    
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7.3 Results 
 
7.3.1 Baseline characteristics 
 
Demographic data for healthy smoking and non-smoking subjects is shown in table 7.1. 
Demographic data for patients with COPD and age and gender matched healthy controls 
is shown in Table 7.2. 
 
Table 7.1.  Demographic data for healthy controls 
  
Healthy non 
smoking subjects 
Healthy smoking 
subjects 
N 12 12 
Age (years) 58 (53 - 71) 64 (55 – 76) 
Gender (Male) 5 6 
Smoking status  All never smokers All ex or current 
Pack years 0  19 (12 – 26) * 
FEV1 (l) 2.34 (2.2 – 2.7)   2.48 (2.2 – 2.9)  
FEV1 % predicted 101 (89 – 106)  94 (90 – 103)  
FEV1 /FVC 82 (76 – 93)  81 (70 – 85)  
BMI (kg/m2) 23 (19 – 27) 24 (21 – 30) 
   
Legend 
Age is presented as the mean (with the range in parenthesis).  Gender is the number of 
males in each group. The remaining data is presented as the median (with the 
interquartile range in parentheses).   Healthy smoking subjects differed significantly 
from non smoking subjects in smoking history alone.  * = significant difference from 
non smoking subjects (p < 0.05) 
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Table 7.2.  Demographic data for COPD patients and healthy controls 
  COPD Healthy subjects 
N 20 20 
Age (years) 66 (55 - 74) 69 (57 – 78) 
Gender (Male) 10 10 
Smoking status  All ex-smokers Mixed 
Pack years 38 (22 - 47)  18 (0 – 35) * 
FEV1 (l) 1.04 (0.8 - 1.3)   2.48 (2.6 – 2.9) * 
FEV1 % predicted 47 (38 - 51)  96 (92 – 107) * 
FEV1 /FVC 42 (31 - 52)  78 (74 – 82) * 
BMI (kg/m2) 28 (23 - 32) 27 (21 – 34) 
Receiving inhaled steroids 
Receiving theophyllines 
Receiving long acting β2 agonist 
Receiving anti-cholinergics 
Bacterial colonization 
           95%  
0% 
80% 
75% 
0% 
           0% * 
           0% 
           0% * 
           0% *  
            N/A 
 
Legend 
Age is presented as the mean (with the range in parenthesis).  Gender is the number of 
males in each group. Patients receiving listed medications are denoted as a percentage of 
the group.  The remaining data is presented as the median (with the interquartile range in 
parentheses).   Healthy subjects differed significantly from COPD patients in all lung 
function, smoking and medication parameters.  
* = significant difference from COPD (p < 0.05) 
 
7.3.2 CXCR1 and CXCR2 receptor surface expression  
7.3.2.1 Validation  
 
Dose response experiments determined that antiCXCR1 2ng/ml and antiCXCR2 3ng/ml 
were the most appropriate to measure surface expression of CXCR1 and CXCR2 (see 
section 4.3.5). Time course experiments determined that neutrophil CXCR1 and CXCR2 
expression was greatest immediately following neutrophil isolation (0 Hour).  
Neutrophil surface expression of both receptors then decreased in a time dependent 
manner. In light of these results, expression was measured at the same time in 
neutrophils isolated from COPD patients and healthy subjects, as soon as the neutrophils 
were isolated, and not longer than 20 minutes from preparation.   
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7.3.2.2 Quiescent CXCR1 and CXCR2 expression 
 
CXCR1 and CXCR2  surface receptors were semi-quantified on neutrophils isolated 
from  smoking and non smoking healthy controls to assess the impact of smoking 
behaviour on expression.   There was no significant difference in surface expression 
between these two groups, suggesting that smoking alone has no impact upon surface 
expression (healthy non smoker, CXCR1 MFI 50, IQR 34 – 58, healthy smoker CXCR1 
MFI 52, IQR 36 – 66: healthy non smoker CXCR2 MFI 38, IQR 26 – 46, healthy 
smoker CXCR2 MFI 41, IQR 35 – 51).  See Figure 7.1 and 7.2.  
 
Figure 7.1 Median CXCR1 surface expression 
Legend. Data is the median fluorescence intensity for each of 12 healthy non smoking 
and 12 healthy smoking subjects in anti-human CXCR1.  The group medians are shown 
as the horizontal line. 
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Figure 7.2 Median CXCR2 surface expression 
Legend. Data is the median fluorescence intensity for each of 12 healthy non smoking 
and 12 healthy smoking subjects in anti-human CXCR2.  The group medians are shown 
as the horizontal lines. 
  
 
There was significantly less CXCR1 expression in COPD compared with age and gender 
matched healthy controls (median MFI (inter-quartile range), Healthy subjects 49 (32 – 
68), COPD patients 33 (22 – 45), p=0.02).  See figure 7.3. 
 
243 
Figure 7.3 Median CXCR1 surface expression in COPD 
Legend. Data is the median fluorescence intensity for each of 20 healthy controls and 20 
COPD patients in anti-human CXCR1.  The group median value is shown as the 
horizontal line.  Data from one healthy control is not included due to a technical error. 
 
 
 
There was also significantly less CXCR2 expression in COPD compared with age and 
gender matched healthy controls (median MFI (inter-quartile range), Healthy subjects 40 
(30 – 51), COPD patients 27 (21 – 34), p=0.01).  See figure 7.4. 
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Figure 7.4 Median CXCR2 surface expression in COPD 
Legend. Data is the median fluorescence intensity for each of 20 healthy controls and 20 
COPD patients in anti-human CXCR2.  The group median value is shown as the 
horizontal line. 
 
7.3.2.3 CXCR1 and CXCR2 receptor expression over time. 
 
In order to assess the time course of CXCR1 and CXCR2 surface expression on 
quiescent cells, neutrophils were incubated in a negative control (RPMI) and surface 
expression of receptors was semi-quantified over three time points (time zero, one hour 
and two hours).  There was a decline in surface expression of both receptors in a time 
dependent manner, however there was no evidence of differential changes in receptor 
expression between patients with COPD and healthy controls.  See table 7.3 and figures 
7.5 and 7.6. 
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Table 7.3.  Changes in surface expression in CXCR1 and CXCR2 in quiescent cells 
over time in COPD.  
 CXCR1 
 Time 0 1 hour 2 hours   
Healthy controls 43 (39 - 46) 25 (20 - 26) 14 (13 - 17)   
COPD 28 (25 - 29) 14 (12 - 15) 6 (5 - 8)   
     
 CXCR2 
 Time 0 1 hour 2 hours   
Healthy controls 48 (42 - 55) 39 (34 - 40) 24 (20 - 27)   
COPD 29 (26 - 31) 16 (15 - 18) 10 (9 - 11)   
 
 
Legend. Data is the median fluorescence intensity for  20 healthy controls and 20 COPD 
patients in anti-human CXCR1 and CXCR2 following incubation with a negative 
control over three time points. The inter-quartile range is shown in parentheses. 
 
 
 
 
 
Figure 7.5 Median CXCR1 surface expression  over time in COPD 
Legend. Data is the median fluorescence intensity for 20 healthy controls and 20 COPD 
patients in anti-human CXCR1 over three time points (time 0, 1 hour and 2 hours).  The 
interquartile range is shown as the vertical bars. 
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Figure 7.6 Median CXCR2 surface expression over time in COPD 
Legend. Data is the median fluorescence intensity for  20 healthy controls and 20 COPD 
patients in anti-human CXCR2 over three time points (time 0, 1 hour and 2 hours. The 
interquartile range is shown as the vertical bars. 
 
 
7.3.2.4 CXCR1 and CXCR2 receptor expression when activated by IL-8 
 
In order to assess the impact of cell activation on CXCR1 and CXCR2 surface 
expression, cells were incubated in three concentrations of IL-8 or a negative control and 
surface expression of receptors was semi-quantified.  There was a decline in surface 
expression of both receptors in a dose dependent manner with increasing concentrations 
of IL-8, however there was no evidence of differential changes in receptor expression 
between patients with COPD and healthy controls.  See table 7.4 and figures 7.7 and 7.8. 
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Table 7.4.  Changes in surface expression in CXCR1 and CXCR2 in quiescent and 
activated cells in COPD.  
 
 CXCR1 
 Negative control IL8 1nM IL8 10nM IL8 100nM 
Healthy controls 43 (39 - 46) 31 (28 - 32) 23 (21 - 25) 10 (8 - 11) 
COPD 28 (25 - 29) 14 (13 - 16) 10 (9 – 11) 6 (5 - 7_ 
     
 CXCR2 
 Negative control IL8 1nM IL8 10nM IL8 100nM 
Healthy controls 48 (42 - 55) 36 (32 - 38) 18 (16 - 17) 11 (10 - 12) 
COPD 29 (27 - 31) 14 (13 - 15) 10 (9 – 11) 5 (5 - 6) 
 
Legend. Data is the median fluorescence intensity for  20 healthy controls and 20 COPD 
patients in anti-human CXCR1 and CXCR2 following incubation with three 
concentrations of IL-8 and a negative control. The interquartile range is shown in 
parentheses. 
 
 
 
 
Figure 7.7 Median CXCR1 surface expression in COPD following cell activation 
Legend. Data is the median fluorescence intensity for of 20 healthy controls and 20 
COPD patients in anti-human CXCR1 when incubated in negative control (RPMI) or 
three concentrations of IL-8 (1nM, 10nM, 100nM).  The inter-quartile range is shown as 
the vertical bars. 
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Figure 7.8 Median CXCR2 surface expression in COPD following cell activation 
Legend. Data is the median fluorescence intensity for of 20 healthy controls and 20 
COPD patients in anti-human CXCR2 when incubated in negative control (RPMI) or 
three concentrations of IL-8 (1nM, 10nM, 100nM).  The inter-quartile range is shown as 
the vertical bars. 
 
There are clear differences in initial CXCR1 and CXCR2 surface expression in patients 
with COPD compared with healthy controls, which may exacerbate flaws in migration, 
potentially due to a reduced ability to utilise receptor occupancy in the detection of a 
chemoattractant gradient.  In order to study this further, monoclonal antibodies for IL8, 
GROα and a CXCR2 antagonist were used to look for differential effects during 
migration to these chemokines or sputum.    
 
7.3.3 The affects of IL-8 and GROα  antibodies and a CXCR2 antagonist: 
validation 
 
Dose response experiments for increasing concentrations of IL-8, GROα (see section 
4.3.3.3.) and increasing dilutions of sputum sol phase were performed to establish the 
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concentrations where neutrophil chemotaxis was maximal.  Dose response experiments 
were performed for chemokine antibodies (anti-IL-8 with IL-8, and anti-GROα with 
GROα) to establish the concentration where chemotaxis to the pure chemoattractant was 
maximally inhibited.  Dose response experiments were also performed on neutrophils 
pre-incubated with increasing concentrations of the CXCR2 antagonist to establish doses 
where chemotaxis inhibition was initiated and where it could be fully inhibited  (see 
section 4.3.3.3.). 
 
The dose response to varying dilutions of pooled sputum sol phase from COPD patients 
is shown in Figure 7.9.  For this pooled sputum, maximal chemotaxis was achieved 
when sputum was diluted 1 in 2 in RPMI.  This dilution was used for all subsequent 
experiments. 
 
Figure 7.9.  The chemotactic response of increasing dilutions of pooled sputum 
from COPD patients 
Legend.  The results shown are the mean (and SEM) values of six experiments.  
Negative control is RPMI (Sigma-Aldrich).  Migration is assessed in the presence of 
increasing dilutions of pooled sputum sol phase (diluted in RPMI).  
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The neutrophil chemotactic response was inhibited maximally towards IL-8 when an IL-
8 antibody concentration of 1.6µM  was used.  See figure 7.10. 
 
Figure 7.10. The chemotactic response of neutrophils towards IL-8 mixed with 
increasing concentrations of antihuman IL-8 antibody. 
Legend.  The results shown are the mean (and SEM) values of six experiments.  
Negative control is buffer (RMPI (Sigma-Aldrich).  Positive control is fMLP (Sigma-
Aldrich) 10 -7 M. IL-8 10nM is migration in the presence of  IL-8 alone, while 
concentrations of 20 – 0.006µM represents migration in the presence of IL-8 (10nM) 
and the given concentration of IL-8 antibody. 
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The neutrophil chemotactic response was inhibited maximally towards GROα when a 
GROα antibody concentration of 1.6µM was used.  See figure 7.11. 
 
Figure 7.11. The chemotactic response of neutrophils towards GROα mixed with 
increasing concentrations of anti-human GROα  antibody 
Legend.  The results shown are the mean (and SEM) values of six experiments.  
Negative control is buffer (RMPI (Sigma-Aldrich).  Positive control is fMLP (Sigma-
Aldrich) 10 -7 M. GROa 100nM is migration in the presence of GROα alone, while 
concentrations of 20 – 0.006µM represents migration in the presence of GROα (100nM) 
and the given concentration of GROα antibody. 
 
 
Validatory experiments using both the specific and isotype matched but irrelevant 
antibodies (Anti-human goat IgG  for both IL-8 and GROα, RnD Systems) were 
performed to ensure that the presence of antibody alone did not effect migration to either 
chemokines or sputum.  There was no evidence of non-specific antibody effects on 
neutrophil migration (see figure 7.12).  Cross-reactivity experiments were performed 
with the IL-8 and GROα antibody to assess the specificity of each antibody to its’ ligand 
compared with the other CXC chemokines.  There was no cross-reactivity between IL-8 
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antibody and GROα, and only minimal cross-reactivity between GROα antibody and 
IL-8 (< 10%).  See figure 7.13. 
 
 
Figure 7.12. The chemotactic response of neutrophils towards IL-8, GROα  or 
sputum mixed with specific or irrelevant anti-human antibodies. 
 
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 is 
migration in the presence of IL-8 alone (10nM), IL-8 + IL-8 antibody is migration 
towards IL-8 (10nM) mixed with IL-8 antibody (1.6µM). Ab alone is migration in the 
presence of the antibody alone (either the IL-8 and GROα antibodies or the irrelevant).  
IL-8 + irrelevant is IL-8 (10nM) mixed with the irrelevant antibody (1.6µM).  Similar 
nomenclature is used for GROα and sputum studies. 
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Figure 7.13. The chemotactic response of neutrophils towards IL-8 and GROα 
mixed with IL-8 and GROα anti-human antibodies. 
 
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 is 
migration in the presence of IL-8 alone (100nM), IL-8 + IL-8 antibody is migration 
towards IL-8 (10nM) mixed with IL-8 antibody (1.6µM).  IL-8 + GROα antibody is 
migration towards IL8 (10nM) mixed with GROα antibody (1.6µM).  Similar 
nomenclature is used for GROα studies, except that 100nM of GROα was used. 
 
The neutrophil chemotactic response was partially inhibited following incubation with 
5nM CXCR2 antagonist and maximally inhibited following incubation with 500nM 
CXCR2 antagonist, towards IL-8 and GROα, and so both concentrations were used for 
migratory studies.   Two concentrations were chosen to look for differential effects of 
the antagonist in the two groups, as there were clear differences in CXCR2 receptor 
surface expression.  See section 4.3.3.3. 
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7.3.4 The affects of IL-8 and GROα  monoclonal antibodies and a CXCR2 
antagonist: Results 
7.3.4.1 Baseline characteristics 
Healthy controls and COPD 
 
Demographic data for the COPD patients and healthy controls are shown in Table 7.2.  
Pooled sputum was collected from patients with COPD and a known chronic bronchitis 
phenotype. These samples were used to obtain a sol phase, which was then pooled.  The 
demographic data of these patients is described in Table 7.5. 
 
Table 7.5.  Demographic data of COPD patients whose sputum samples formed the 
pooled sputum sol. 
    
N 15 
Age 65 (56 - 78) 
Male  6 (40%) 
Stable state FEV1 (% predicted) 40 + 8.3 
Stable state FEV1/VC (%) 42 + 11 
Current smokers 6 (40%) 
Inhaled corticosteroids 11 (73 %) 
Inhaled long acting B2 agonists 
Inhaled anti-cholinergics 
6 (40%) 
5 (33%) 
Theophyllines 0 
Sputum bacterial load > 107 (cfu/ml) 0  
  
Legend.  Age is presented as the mean age (with the range in parenthesis).  Gender is 
the number of males in each group. Patients receiving inhaled steroids, theophyllines, 
anticholinergics or long acting beta 2 agonists are denoted as a number (with percentage 
of the group in parentheses).  The remaining data is presented as the mean with the 
standard deviation. 
 
7.3.4.2 Concentrations of mediators in pooled sputum 
 
Concentrations of IL-8 and GROα were measured (in triplicate) in the pooled sputum 
samples to compare the concentrations present in these biological samples to those used 
in the chemotaxis assay.  Furthermore, it was necessary to ensure that concentration of 
each monoclonal antibody was sufficient to inhibit the IL-8 and GROα present in the 
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pooled sputum sol.   The median of the three samples is given with the range.  There was 
6.8nM of IL-8 (range 6.4 – 7.3nM) and 29nM of GROα (range 25 – 32nM) in the 
pooled sputum.  10nM of IL-8 and 100nM of GROα was found to be the optimal 
concentrations of the chemokines for the chemotaxis assays, therefore the concentrations 
of the antibodies and the CXCR2 antagonist would be sufficient to inhibit the IL-8 and 
GROα present in the pooled sputum.  
7.3.4.3 The affect of a CXCR2 antagonist in neutrophil migration towards IL-8 in 
COPD 
 
Speed of migration (Chemokinesis) 
 
In the control group, there was a significant increase in speed of migration in IL-8 
compared with negative control  (RPMI 2.3 µm/min + 0.2 Vs IL-8 3.2 + 0.3, p < 0.0001) 
but incubating IL-8 with the IL-8 antibody significantly reduced overall migratory speed 
to that seen with the negative control.  There was no difference in the speed of 
neutrophils migrating towards IL-8 after treatment with the CXCR2 receptor antagonist 
at the lower concentration (untreated cells 3.2 + 0.3 Vs treated cells 3.0 + 0.1) and a 
trend towards a decrease in speed when neutrophils were incubated with the higher 
concentration (2.5 + 0.2, p=0.06), a reduction of  20%.     
 
In the COPD group, there was a significant difference in speed of migration in IL-8 
compared with negative control  (RPMI 3.0 µm/min + 0.3 Vs. IL-8 6.2 + 0.6, p < 
0.0001) but incubating IL-8 with the IL-8 antibody significantly reduced overall 
migratory speed to that seen with the negative control. Following treatment with the 
CXCR2 receptor antagonist, there was a significant decrease in the speed of neutrophils 
from COPD patients migrating in IL-8  at the lower concentration (untreated cells 
6.2µm/min + 0.6 Vs. treated cells 4.6µm/min + 0.6, p=0.01), by approximately 25%.  
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There was no further reduction using the higher concentration of  the CXCR2 antagonist 
(3.8 + 0.3).  
 
As seen in previous studies, COPD neutrophils migrated with greater speed than those 
from healthy controls (MD 3.02, CI 1.2 – 3.8, p=0.0002).  The monoclonal antibody 
reduced migratory speed to baseline levels in both groups. The CXCR2 antagonist was 
not as efficacious and reduced migratory speed by approximately 25% in both groups, 
however, a lower dose was required to achieve this in COPD.   See figure 7.14.  
 
Figure 7.14.  The affect of an IL-8 antibody and CXCR2 antagonist on the speed of 
migration of neutrophils in the presence of IL-8   
Legend.   The figure describes the mean speed for each condition (with SEM).  On the 
horizontal axis, control is RPMI (Sigma-Aldrich), IL8 is migration in shallow gradients 
of this chemokine (10nM).  IL-8 plus ab is migration in shallow gradients of IL-8 mixed 
with IL-8 monoclonal antibody. IL-8 plus CXCR2 antagonist is neutrophil migration 
towards IL-8 following neutrophil incubation with the CXCR2 receptor antagonist at the 
two given concentrations.  * = significant difference from IL-8 alone. 
 
 
 
 
 
 
 *    * 
 * 
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Velocity of migration (Chemotaxis). 
 
In the control group there was a significant increase in migratory velocity towards IL-8 
compared with the control (RPMI 0.01 µm/min + 0.06 Vs IL-8 1.56 µm/min + 0.39, 
p<0.0001). The velocity of neutrophils migrating towards IL-8 was reduced to control 
levels when mixed with its’ antibody.  Pre-incubating neutrophils with the 5nM CXCR2 
antagonist also reduced the velocity of migration towards IL-8 (to 0.82 µm/min + 0.26, 
p=0.009) by approximately 46%.    There was a further reduction in chemotaxis (62%) 
using 500nM of the CXCR2 antagonist (reduced to 0.58 + 0.4, p=0.03). 
 
In the COPD group there was a significant increase in velocity towards IL-8 compared 
with the control (RPMI 0.2µm/min + 0.3 Vs IL8 1.1µm/min + 0.3, p=0.001). The 
velocity of neutrophils migrating towards IL-8 was reduced to control levels when 
mixed with its’ antibody.  Pre-incubating neutrophils with the 5nM CXCR2 antagonist 
significantly reduced chemotaxis (65%) (to 0.37 µm/min + 0.3, p=0.002). There was no 
further reduction in chemotaxis using the higher concentration of the CXCR2 antagonist 
(0.3 µm/min + 0.2). 
 
As seen in previous studies, COPD neutrophils migrated with less velocity than those 
from healthy controls (HC 1.6µm/min  + 0.4 Vs. COPD 1.1µm/min + 0.3, p=0.01).  The 
IL-8 monoclonal antibody reduced velocity to baseline levels in both groups.  The 
CXCR2 antagonist also reduced velocity in both groups, but to a lesser degree.   Again, 
COPD neutrophils differentially responded to a lower dose of the CXCR2 antagonist.  
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See figure 7.15.                     . 
 
Figure 7.15.  The affect of an IL-8 antibody and CXCR2 antagonist on the velocity 
of neutrophils towards IL-8   
Legend.   The figure describes the mean velocity for each condition (with SEM).  On 
the horizontal axis, control is RPMI (Sigma-Aldrich), IL8 is migration in shallow 
gradients of this chemokine (10nM).  IL-8 plus ab is migration in shallow gradients of 
IL-8 mixed with IL-8 monoclonal antibody. IL-8 plus CXCR2 antagonist is neutrophil 
migration towards IL-8 following neutrophil incubation with the CXCR2 receptor 
antagonist at the given concentration. * = significant difference from IL-8 alone. 
 
 
Directional persistence 
 
In the healthy controls, directional persistence of neutrophils migrating towards IL-8 
was reduced to levels comparable to baseline in the presence of the IL-8 antibody 
(Control 0.05 + 0.01, IL-8 0.36 + 0.09, IL-8 + IL-8 antibody 0.05 + 0.04, p<0.0001. Pre-
incubation of neutrophils with the CXCR2 antagonist reduced directional persistence 
when migrating towards IL-8 both at 5nM (to 0.18 + 0.04, p  = 0.04, by 50%), and at 
500nM (to 0.13 + 0.05, p=0.02, by 63%).  
 
   *    *            *    *            *    * 
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In the COPD group, directional persistence of neutrophils migrating towards IL-8 was 
reduced to levels comparable with baseline in the presence of the IL-8 antibody (Control 
0.07 + 0.1, IL-8 0.29 + 0.11, IL-8 + IL-8 antibody 0.006 + 0.09, p=0.005).  Pre-
incubation of neutrophils with the 5nM CXCR2 antagonist also reduced directional 
persistence (to 0.004 + 0.07, p < 0.0001).  The 500nM CXCR2 antagonist had no further 
affect on persistence. 
 
As seen in previous studies, COPD neutrophils migrated with similar persistence to 
those from healthy controls (HC 0.36  + 0.09 Vs. COPD 0.29  + 0.11).  The monoclonal 
antibody reduced persistence to baseline levels in both groups. The CXCR2 antagonist 
reduced persistence to baseline levels in COPD neutrophils, but not in neutrophils from 
healthy controls (5nM:  difference in percent, healthy controls 50% + 7, COPD 98% + 
12, p <0.001).  See figure 7.16.  
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Figure 7.16.  The affect of an IL-8 antibody and CXCR2 antagonist on the 
directional persistence of neutrophils towards IL-8   
Legend.   The figure describes the mean persistence for each condition (with SEM).  On 
the horizontal axis, control is RPMI (Sigma-Aldrich), IL8 is migration in shallow 
gradients of this chemokine (10nM).  IL-8 plus ab is migration in shallow gradients of 
IL-8 mixed with IL-8 monoclonal antibody. IL-8 plus CXCR2 antagonist is neutrophil 
migration towards IL-8 following neutrophil incubation with the CXCR2 receptor 
antagonist at the given concentration. * = significant difference from IL-8 alone. 
 
Chemotactic Index  
In the healthy controls, the addition of IL-8 monoclonal antibody completely reversed 
the chemotactic index of neutrophils migrating towards IL-8 to control levels (Control 
0.02 + 0.02, IL-8 0.4 + 0.07, IL-8 + IL-8 antibody 0.01 + 0.02, p<0.0001). Pre-
incubation of neutrophils with the 5nM CXCR2 antagonist also reduced the chemotactic 
index (52%) towards IL-8 (to 0.2 + 0.04, p=0.002), with a further reduction  (69%) 
using the 500nM CXCR2 antagonist (0.12 + 0.02, p=0.03). 
 
In the COPD group, the addition of IL-8 antibody completely reversed the chemotactic 
index of neutrophils migrating towards IL-8 to control levels (Control 0.01 + 0.06, IL-8 
  *   *              *     *            *   * 
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0.22 + 0.05, IL-8 + IL-8 antibody 0.01 + 0.02, p=0.005). Pre-incubation of neutrophils 
with the 5nM CXCR2 antagonist reduced the chemotactic index (70%) towards IL-8 (to 
0.07 + 0.03, p=0.007) with no further decrease using the 500nM CXCR2 antagonist 
(0.06 + 0.02).  
 
As seen in previous studies, COPD neutrophils migrated with less accuracy than those 
from healthy controls (HC 0.4  + 0.07 Vs. COPD 0.22  + 0.05, p=0.002). The IL-8 
antibody reduced the accuracy of migration to baseline levels, but this was not achieved 
by the CXCR2 antagonist.  Treating cells with 5nM CXCR2 antagonist reduced the 
accuracy of neutrophils in COPD patients more than was seen with healthy controls  
(difference in percent, healthy controls 52% + 6, COPD 69% + 11, p <0.01), but not to 
comparable levels.  See Figure 7.17.  
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Figure 7.17.  The affect of an IL-8 antibody and CXCR2 antagonist on the overall 
accuracy of neutrophils towards IL-8   
Legend.   The figure describes the mean chemotactic index for each condition (with 
SEM).  On the horizontal axis, control is RPMI (Sigma-Aldrich), IL8 is migration in 
shallow gradients of this chemokine (10nM).  IL-8 plus ab is migration in shallow 
gradients of IL-8 mixed with IL-8 monoclonal antibody. IL-8 plus CXCR2 antagonist is 
neutrophil migration towards IL-8 following neutrophil incubation with the CXCR2 
receptor antagonist at the given concentrations. * = significant difference from IL-8 
alone. 
 
 
In summary, neutrophils from patients with COPD moved with greater speed, but less 
accuracy than those from healthy controls, mirroring the results of the previous chapters.  
In both groups, mixing IL-8 with its monoclonal antibody reduced the speed, velocity, 
directional persistence and accuracy of migration to baseline levels, effectively 
abrogating the affect of the chemokine.     The CXCR2 antagonist was not as effective, 
having a smaller affect on chemokinesis (random speed), chemotaxis (directed speed or 
velocity) and overall accuracy of movement.    The residual migration could be due to 
the binding of IL-8 to CXCR1 (which the antagonist would not inhibit) or by a partial 
efficacy of the CXCR2 antagonist (although doses chosen were based upon dose 
*    *              *      *           *      * 
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response experiments).   There were differential effects between COPD and controls, in 
that COPD neutrophils responded to a lower concentration of CXCR2 antagonist 
compared with those from healthy controls.  This is in keeping with a lower surface 
expression of CXCR2.  To further assess the role of CXCR2, migrational studies were 
repeated using GROα, which preferentially binds to CXCR2.  
 
7.3.4.4 The affect of a CXCR2 antagonist in neutrophil migration towards GROα  
in COPD 
 
Speed of migration (Chemokinesis) 
 
In the control group, there was a small but significant increase in speed of migration in 
shallow gradients of GROα compared with the negative control  (RPMI 2.3 µm/min + 
0.2 Vs GROα 2.9 + 0.2, p =0.04). Incubating GROα with the GROα antibody and 
incubating neutrophils with the higher concentration of the CXCR2 antagonist reduced 
this to control levels (GROα antibody, 2.3 µm/min + 0.2, p 0.03; CXCR2 5nM, 
2.5µm/min + 0.2: CXCR2 500nM, 2.2µm/min + 0.3, p=0.01).    
 
In the COPD group, there was an increase in speed of migration with GROα compared 
with negative control  (RPMI 3.0 µm/min + 0.3 Vs. GROα 4.4 + 0.2, p = 0.003).  
Incubating GROα with the GROα antibody reduced overall migratory speed to control 
levels (GROα Ab 3.0µm/min + 0.1, p=0.004). There was a decrease in speed following 
treatment with 5nM CXCR2 receptor antagonist (untreated cells 4.4 µm/min + 0.2 Vs. 
treated cells 2.8 µm/min + 0.4, p=0.001).  There was no additional affect with 500nM 
CXCR2 antagonist (2.7µm/min + 0.3). 
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As seen in previous studies, COPD neutrophils migrated with greater speed (were more 
chemokinetic) than those from healthy controls (average difference 1.9µm/minute,  CI 
0.7 – 2.4, p=0.001).  The GROα antibody reduced speed to baseline levels in both 
groups, as did the CXCR2 antagonist, however a differential effect was seen, with 
COPD cells responding maximally  to a lower concentration. See Figure 7.18. 
 
 
 
Figure 7.18.  The affect of a GROα  antibody and CXCR2 antagonist on the speed 
of migration of  neutrophils in the presence of GROα    
Legend.   The figure describes the mean speed for each condition (with SEM).  On the 
horizontal axis, RPMI is the negative control, GROa is migration in shallow gradients of 
this chemokine (100nM).  GROa plus ab is migration in shallow gradients of GROa 
mixed with GROa monoclonal antibody. GROa plus CXCR2 antagonist is neutrophil 
migration in the presence of GROa following neutrophil incubation with the CXCR2 
receptor antagonist at the given concentration.  * = significant difference from GROα 
alone. 
 
 
Velocity of migration (Chemotaxis) 
 
In the control group there was a significant increase in velocity (chemotaxis) towards 
GROα compared with the control (RPMI 0.03 µm/min + 0.01 Vs GROα 0.38µm/min + 
0.07, p=0.002). This was reduced to control levels when GROα was mixed with its’ 
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antibody. Pre-incubating neutrophils with 5nM CXCR2 antagonist reduced the velocity 
of migration towards GROα (50%) (to 0.2 µm/min + 0.01, p=0.01).   The 500nM 
CXCR2 antagonist reduced this further to baseline (0.03µm/min + 0.08 (p = 0.02))  
 
In the COPD group there was a significant increase in velocity towards GROα 
compared with the control (RPMI 0.02µm/min + 0.02 Vs GROα 0.14µm/min + 0.01, 
p=0.03). This was reduced to control levels when mixed with its’ antibody. Pre-
incubating neutrophils with 5nM CXCR2 antagonist significantly reduced the velocity 
of migration towards GROα to baseline (to 0.04 µm/min + 0.02, p=0.01).  The 500nM 
CXCR2 antagonist did not reduce this further (0.01µm/min + 0.03). 
 
As seen in previous studies, COPD neutrophils migrated with less velocity than those 
from healthy controls (HC 0.38µm/min  + 0.01 Vs. COPD 0.14µm/min + 0.01, 
p=0.008).  Mixing GROα with its monoclonal antibody could reduce the velocity to 
baseline levels in both groups. The CXCR2 antagonist also reduced chemokinesis to 
baseline in both groups, although neutrophils from healthy controls required a higher 
dose of the antagonist.   See figure 7.19.  
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Figure 7.19.  The affect of a GROα  antibody and CXCR2 antagonist on the 
chemotaxis of neutrophils towards GROα   
Legend. The figure describes the mean velocity for each condition (with SEM).  On the 
horizontal axis, control is RPMI (Sigma-Aldrich), GROα is migration in shallow 
gradients of this chemokine (100nM).  GROa plus ab is migration in shallow gradients 
of GROα mixed with GROα monoclonal antibody. GROa plus CXCR2 antagonist is 
neutrophil migration towards GROα following neutrophil incubation with the CXCR2 
receptor antagonist at the given concentration. * = significant difference from GROα 
alone. 
 
Directional persistence 
 
In the healthy controls, the directional persistence of neutrophils migrating towards 
GROα was reduced to baseline levels when GROα was incubated with the GROα 
monoclonal antibody (Control 0.07 + 0.01, GROα 0.14 + 0.009, GROα with GROα 
antibody 0.05 + 0.01, p=0.009). Pre-incubation of neutrophils with 5nM CXCR2 
antagonist reduced the directional persistence when migrating towards GROα (34%) (to 
0.09 + 0.01), with a further reduction using the higher concentration of CXCR2 
antagonist  (0.06 + 0.02, p=0.02) to baseline.  
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In the COPD group, directional persistence of neutrophils migrating towards GROα was 
reduced to baseline when GROα was incubated with the GROα monoclonal antibody 
(Control 0.07 + 0.01, GROα 0.16 + 0.03, GROα + GROα antibody 0.06 + 0.01, 
p=0.04). Pre-incubation of neutrophils with 5nM CXCR2 antagonist reduced directional 
persistence (to 0.08 + 0.002, p = 0.03) to baseline levels, but there was no further 
reduction with the higher concentration of the antagonist (0.06 + 0.02). 
 
As seen in previous studies, COPD neutrophils migrated with similar persistence to 
those from healthy controls (HC 0.14  + 0.09 Vs. COPD 0.16  + 0.03).  The monoclonal 
antibody and CXCR2 antagonist reduced persistence to baseline in both groups, 
however, cells from healthy controls required a higher dose of antagonist to achieve this. 
See figure 7.20.  
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Figure 7.20.  The affect of a GROα  antibody and CXCR2 antagonist on the 
directional persistence of neutrophils towards GROα    
Legend. The figure describes the mean persistence for each condition (with SEM).  On 
the horizontal axis, RPMI (Sigma-Aldrich) is the negative control, GROa is migration in 
shallow gradients of this chemokine (100nM).  GROa plus ab is migration in shallow 
gradients of GROα mixed with GROα monoclonal antibody. GROa plus CXCR2 
antagonist is neutrophil migration towards GROa following neutrophil incubation with 
the CXCR2 receptor antagonist.  * = significant difference from GROα alone. 
 
Chemotactic Index  
In the healthy controls, the addition of GROα monoclonal antibody reduced the 
chemotactic index of neutrophils migrating towards GROα to control levels (Control 
0.02 + 0.002, GROα 0.13 + 0.02, GROα +  GROα antibody 0.02 + 0.003, p=0.012). 
Pre-incubation of neutrophils with 5nM CXCR2 antagonist also reduced the migrational 
accuracy towards GROα (to 0.07 + 0.01, p=0.02), but 500nM CXCR2 were required to 
reduce this to  baseline (0.03 + 0.01). 
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In the COPD group, GROα did not significantly increase migrational accuracy 
compared with the negative control (Control 0.02 + 0.009, GROα 0.03 + 0.003, GROα 
+ GROα antibody 0.009 + 0.001).  
 
As seen in previous studies, COPD neutrophils migrated with less accuracy than those 
from healthy controls (HC 0.13  + 0.002 Vs. COPD 0.03  + 0.003, p=0.008).   In healthy 
controls, both the monoclonal antibody and CXCR2 antagonist (at the higher 
concentration) could reduce accuracy to baseline levels. The effect of a CXCR2 
antagonist on migratory accuracy in COPD could not be evaluated as GROα did not 
significantly increase accuracy from baseline in the COPD group.  See figure 7.21. 
 
Figure 7.21.  The affect of a GROα antibody and CXCR2 antagonist on the overall 
accuracy of neutrophils towards GROα    
Legend. The figure describes the mean chemotactic index for each condition (with 
SEM).  On the horizontal axis, control is RPMI (Sigma-Aldrich), GROa is migration in 
shallow gradients of this chemokine (100nM).  GROa plus ab is migration in shallow 
gradients of GROα mixed with GROα monoclonal antibody. GROa plus CXCR2 
antagonist is neutrophil migration towards GROα following neutrophil incubation with 
the CXCR2 receptor antagonist at the given concentration.   * = significant difference 
from GROα alone. 
 
   *    *           *                   * 
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In summary, COPD neutrophils also displayed greater speed, but reduced accuracy 
when migrating towards GROα compared with control cells.   Here, the CXCR2 
antagonist was as effective in abrogating migration as the monoclonal antibody, 
suggesting that migration towards GROα is CXCR2 dependent, and that the antagonist 
is effective in abrogating this effect.  This data is supportive of the liklihood that the 
residual migration seen towards IL-8 in the previous experiments was CXCR1 
dependent.  When studying this residual IL-8 response, we would predict that 40% of 
the migratory response to IL-8 in health and 25% of the migratory response to IL-8 in 
neutrophils from patients with COPD (measured by velocity, directional persistence or 
accuracy) is CXCR1 dependent, if the receptors exert separate affects.   However,  
specific inhibition of CXCR1 would be required to confirm this hypothesis.  Again, in 
the current series of experiments, COPD neutrophils responded to a lower dose of the 
CXCR2 antagonist than controls, which would be consistent with lower surface 
expression of CXCR2, shown earlier in this chapter. 
 
7.3.4.5 The affect of a CXCR2 antagonist in neutrophil migration towards sputum 
in COPD 
 
Speed of migration (Chemokinesis) 
 
There was a significant increase in the speed of healthy control neutrophil movement in 
the presence sputum compared with the negative control (RPMI 2.3 µm/min + 0.2; 
Sputum 3.14 µm/min + 0.1, p=0.04).  However, the addition of IL-8 and GROα 
antibody and incubation with either concentration of the CXCR2 antagonists did not 
significantly reduce this speed of movement (IL-8 ab; 3.1 + 0.3; GROα ab 2.9 + 0.07, 
CXCR2 5nM 2.9 + 0.2; CXCR2 500nM 2.7 + 0.3). 
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When COPD neutrophils migrated in shallow gradients of sputum, there was an increase 
of speed in comparison with cells from healthy controls (3.14 µm/min + 0.1 Vs. 5.31 
µm/min + 0.6, p=0.0001).  Again the addition of IL8 antibody (5.2µm/min + 0.7) and 
GROα antibody (5.2µm/min + 0.3) did not significantly affect the speed of movement, 
nor did 5nM (4.8 µm/min + 0.1) or 500nM (4.7µm/min + 0.3) of the CXCR2 antagonist.  
See figure 7.22. 
 
Figure 7.22.  The affect of an IL-8 and GROα  antibody and CXCR2 antagonist on 
the overall speed of neutrophils migrating in gradients of sputum   
Legend. The figure describes the mean speed for each condition (with SEM).  On the 
horizontal axis, control is RPMI (Sigma-Aldrich), sputum is migration in sputum sol 
phase, Sputum plus ab is migration in shallow gradients of sputum mixed with the 
named monoclonal antibody. Sputum plus CXCR2 antagonist is neutrophil migration 
towards sputum sol phase following neutrophil incubation with the CXCR2 receptor 
antagonist at the given concentration.  
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Velocity (Chemotaxis) 
 
There was a significant increase in the velocity of healthy control neutrophil movement 
in the presence sputum compared with the negative control (RPMI 0.01 µm/min + 0.2; 
Sputum 1.44 µm/min + 0.1, p=0.002).  The addition of IL-8 antibody reduced velocity 
by 56% (to 0.63 µm/min + 0.05, p=0.004) and GROα antibody by 30 % (to 1µm/min + 
0.08, p=0.04).  Incubation with 5nM CXCR2 antagonist did not alter the velocity, but 
there was a significant reduction of 42% using 500nM (CXCR2 5nM 1.29 µm/min  + 
0.02: CXCR2 500nM 0.8µm/min + 0.08, p = 0.003). 
 
When COPD neutrophils migrated in sputum, velocity of movement was reduced in 
comparison with cells from healthy controls (Controls 1.44 µm/min + 0.06 Vs. COPD 
1.1µm/min + 0.06, p=0.001).  The addition of IL8 antibody reduced velocity by 58% (to 
0.4µm/min + 0.02, p=0.002) as did GROα antibody (by 28%, 0.8µm/min + 0.02, 
p=0.02).   There was a significant decrease of 41% following incubation with 5nM 
CXCR2 antagonist, with no further changes seen using 500nM (5nM 0.64µm/min + 
0.03, p = 0.006, 500nM 0.55µm/min + 0.1).  See figure 7.23. 
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Figure 7.23.  The affect of an IL-8 and GROα  antibody and CXCR2 antagonist on 
the overall velocity of neutrophils migrating towards sputum   
Legend. The figure describes the mean velocity for each condition (with SEM).  On the 
horizontal axis, control is RPMI (Sigma-Aldrich), sputum is migration in sputum sol 
phase, Sputum plus ab is migration towards sputum mixed with the named monoclonal 
antibody. Sputum plus CXCR2 antagonist is neutrophil migration towards sputum sol 
phase following neutrophil incubation with the CXCR2 receptor antagonist at the given 
concentration. * = significant difference from sputum alone. 
 
Persistence 
There were no differences in the directional persistence of neutrophils from healthy 
controls or patients with COPD migrating in sputum (controls: 0.42 + 0.01 Vs COPD 
0.37 + 0.08).  The addition of IL-8 antibody reduced persistence by 18% in healthy 
controls (to 0.34 + 0.01, p=0.04) and by 17% in COPD (to 0.31 + 0.07, p=0.04).  The 
addition of GROα antibody did not significantly reduce persistence in either group.  
Incubation with 5nM CXCR2 antagonist decreased persistence by 12% in COPD 
neutrophils (to 0.32 + 0.02, p=0.02), but there was no further decrease using 500nM 
(0.34 + 0.03).  A similar decrease in persistence was not seen until 500nM of the 
CXCR2 antagonist was used in healthy controls (13% reduction, to 0.36 + 0.04, p=0.04)   
See figure 7.24. 
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Figure 7.24.  The affect of an IL-8 and GROα  antibody and CXCR2 antagonist on 
the persistence of neutrophils migrating in gradients of sputum   
Legend. The figure describes the mean migratory parameter for each condition (with 
SEM).  On the horizontal axis, control is RPMI (Sigma-Aldrich), sputum is migration in 
sputum sol phase, Sputum plus ab is migration towards sputum mixed with the named 
monoclonal antibody. Sputum plus CXCR2 antagonist is neutrophil migration towards 
sputum sol phase following neutrophil incubation with the CXCR2 receptor antagonist 
at the given concentration.  * = significant difference from sputum alone.  
 
Chemotactic Index (Migratory accuracy) 
Neutrophils from patients with COPD migrated with less accuracy towards sputum 
compared with those from healthy controls (Controls: 0.46 + 0.01 Vs COPD: 0.16 + 
0.08, p=0.002). The addition of IL-8 antibody reduced migratory accuracy by 52% in 
healthy controls (to 0.23 + 0.02, p=0.003) and by 55% in COPD neutrophils (to 0.07 + 
0.02, p=0.004). The addition of GROα antibody reduced accuracy by 28% in healthy 
control neutrophils (to 0.33 + 0.06, p=0.009) and by 25% in COPD (to 0.12 + 0.04, 
p=0.01).  Incubation with 5nM CXCR2 antagonist decreased accuracy by 39% in COPD 
neutrophils (to 0.1 + 0.01, p=0.008), but there was no further decrease using 500nM 
(0.09 + 0.06).  A significant decrease in accuracy was not seen until 500nM of the 
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CXCR2 antagonist was used in healthy controls (54% reduction, to 0.21 + 0.01, 
p=0.004).  See figure 7.25.   
 
Figure 7.25.  The affect of an IL-8 and GROα  antibody and CXCR2 antagonist on 
the chemotactic index of neutrophils migrating in gradients of sputum   
Legend. The figures describes the mean chemotactic index for each condition (with 
SEM).  On the horizontal axis, control is RPMI (Sigma-Aldrich), sputum is migration in 
sputum sol phase, Sputum plus ab is migration towards sputum mixed with the named 
monoclonal antibody. Sputum plus CXCR2 antagonist is neutrophil migration towards 
sputum sol phase following neutrophil incubation with the CXCR2 receptor antagonist 
at the given concentration. * = significant difference from sputum alone 
 
In summary, blocking the affects of IL-8 and GROα in the migratory response to 
sputum (using either monoclonal antibodies or the antagonist) did not alter 
chemokinesis.  However, the IL-8 antibody reduced the velocity and accuracy of 
migration by approximately 50% in both groups, again emphasizing the importance of 
this chemokine in the migratory drive of neutrophils.  Abrogating GROα reduced 
velocity and accuracy by a smaller amount (28%).  Abrogating the CXCR2 receptor 
(which should specifically target migration caused by GROα, NAP-2, ENA 78 and a 
proportion of migration caused by IL-8) reduced migration by approximately 50% in 
   *   *           *   *               *          *    *  
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healthy controls and 40% in patients with COPD.   Again, a lower dose of the CXCR2 
antagonist was required in COPD, and this, coupled with the observation that the 
CXCR2 antagonist had less of an effect in migration towards sputum in COPD would be 
consistent with lower surface expression of the receptors in this group.  
 
 
It was interesting to note that the increased speed of migration, reduced velocity and 
reduced accuracy of COPD neutrophils towards sputum was still present following the 
addition of IL-8 antibody, GROα antibody or the CXCR2 antagonist.  Sputum contains 
other mediators that act independently of CXCR1 or CXCR2 receptors (including, for 
example, LTB4).  That these migratory differences are still present when CXCR1 and 2 
receptors (or their ligands) are blocked, strongly suggests that this phenomenon is not 
specific to CXCR1 or 2, and is a more generalised defective response, perhaps localised 
at a common downstream pathway of  these specific receptors.     
 
To identify the differential affects of CXCR1 and CXCR2 inhibition on neutrophil 
migration in COPD, studies were repeated using CXCR1 and CXCR2 monoclonal 
antibodies.  Monoclonal antibodies were used, as there was no small molecule 
antagonist of CXCR1 available at the time of study, and it was felt important to compare 
like with like. 
 
7.3.5 The affects of CXCR2 and CXCR1 monoclonal antibodies: validation 
 
Dose response experiments were performed for anti-CXCR2 (RnD Systems, UK) and 
anti-CXCR1 (RnD Systems, UK) with IL-8 to establish the concentration where 
chemotaxis was maximally inhibited.     1.6µm was found to be the most effective 
antibody concentration for both antibodies (see figures 7.26 and 7.27). Validation 
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experiments carried out by RnDSystems, UK have previously confirmed that these 
antibodies do not cross-react.   Both antibodies are IgG2a and an irrelevant IgG2a 
antibody was used to assess any non-specific migrational affects caused by the presence 
of antibody alone.  There were no changes in migration following incubation with the 
irrelevant IgG2a antibody, see figure 7.28. 
Figure 7.26. The chemotactic response of neutrophils towards IL-8 after incubation 
with increasing concentrations of anti human CXCR2 antibody. 
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 
10nM is migration in the presence of IL-8 alone, while concentrations of 16 – 0.06µM 
represents migration in the presence of IL8 (10nM) following neutrophil incubation with 
the given concentration of CXCR2 antibody. 
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Figure 7.27. The chemotactic response of neutrophils towards IL-8 after incubation 
with increasing concentrations of anti human CXCR1 antibody. 
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 
10nM is migration in the presence of  IL-8 alone, while concentrations of 16 – 0.06µM 
represents migration in the presence of IL8 (10nM) following neutrophil incubation with 
the given concentration of CXCR1 antibody 
 
 
Figure 7.28. The chemotactic response of neutrophils towards IL-8 after incubation 
with anti human CXCR1 or CXCR2 antibody or a matched irrelevant antibody. 
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 
10nM is migration in the presence of  IL-8 alone, CXCR2, CXCR1 and Irrelevant is 
migration in the presence of IL8 (10nM) following neutrophil incubation with the named  
(CXCR1, CXCR2, Irrelevant). 
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7.3.6 The affects of CXCR2 and CXCR1 monoclonal antibodies: results 
7.3.6.1 CXCR2 
 
Speed of migration (Chemokinesis) 
 
As seen with the small molecule CXCR2 antagonist, when neutrophils from healthy 
controls were incubated with the CXCR2 antibody, there was a significant reduction in 
the speed of movement in IL-8 (IL-8 3.6 µm/min + 0.2; IL-8 + CXCR2 Ab 2.5µm/min + 
0.2, p = 0.01) and GROα (GROα 3.0µm/min + 0.2; GROα + CXCR2 Ab 2.2µm/min 
+0.1, p=0.04).  However,  the CXCR2 antibody did not reduce the speed of migration 
towards sputum (Sputum 3.1µm/min + 0.2; Sputum + CXCR2 Ab 2.7µm/min  + 0.2). 
 
With neutrophils from COPD patients, a similar pattern was seen, with a reduction in 
speed towards the chemokines (IL-8, 6.2µm/min + 0.4; IL8 + CXCR2 Ab, 4.2 µm/min + 
0.2, p=0.008: GROα, 4.4µm/min + 0.2; GROα + CXCR2 Ab, 3.0µm/min + 0.1, p = 
0.009).   Incubation with the CXCR2 antibody did not significantly affect the speed of 
movement in gradients of sputum (Sputum, 5.3µm/min + 0.1; Sputum + CXCR2 Ab, 
4.6µm/min + 0.1).   COPD neutrophils were faster compared with those from healthy 
controls, see figure 7.29, but there were no differential affects using the small molecule 
antagonist or the CXCR2 antibody.   
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Figure 7.29. The chemokinetic response of neutrophils towards IL-8, GROα  and 
sputum after incubation with anti human CXCR2 antibody.  
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 
10nM is migration in the presence of  IL-8 alone, IL8 + CXCR2 Ab is in the presence of 
IL8 (10nM) following incubation with the  antibody.  The nomenclature is the same for 
GROα (100nM) and Sputum (2:1 dilution). * = significant difference from 
chemoattractant alone. 
 
 
Velocity (Chemotaxis) 
 
As seen with the small molecule CXCR2 antagonist, when neutrophils from healthy 
controls were incubated with the CXCR2 antibody, there was a significant reduction in 
the velocity of movement towards IL-8 of approximately 40% (IL-8 1.6 µm/min + 0.2; 
IL-8 + CXCR2 Ab 0.9µm/min + 0.1, p = 0.009) and GROα by approximately 90% 
(GROα 0.4µm/min + 0.2; GROα + CXCR2 Ab 0.02µm/min +0.01, p=0.02).  The 
CXCR2 antibody also reduced chemotaxis towards sputum by 50% (Sputum 1.4µm/min 
+ 0.1; Sputum + CXCR2 Ab 0.7µm/min  + 0.1, p=0.008). 
 
With neutrophils from COPD patients, a similar pattern was seen, with a reduction in 
velocity towards the chemokines (IL-8, 1.1µm/min + 0.1; IL8 + CXCR2 Ab, 0.3 
 *   *                       *  *        
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µm/min + 0.1, p=0.006: GROα, 0.14µm/min + 0.2; GROα + CXCR2 Ab, 0.003µm/min 
+ 0.1, p = 0.03).   There was also a significant reduction in velocity towards sputum 
(Sputum, 1.1µm/min + 0.1; Sputum + CXCR2 Ab, 0.5µm/min + 0.1, p=0.008). Once 
again, COPD neutrophils had less velocity compared to those from healthy controls, (see 
figure 7.30).   
 
Figure 7.30. The velocity of neutrophils towards IL-8, GROα  and sputum after 
incubation with anti human CXCR2 antibody.  
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 
10nM is migration towards IL-8 alone, IL8 + CXCR2 Ab is towards IL8 (10nM) 
following incubation with the  antibody (1.6µM).  The nomenclature is the same for 
GROα (100nM) and Sputum (2:1 dilution).  * = significant difference from 
chemoattractant alone.  
 
 
Persistence 
 
 
As seen with the small molecule CXCR2 antagonist, when neutrophils from healthy 
controls were incubated with the CXCR2 antibody, there was a significant reduction in 
the persistence of movement towards IL-8 of approximately 55% (IL-8 0.36 + 0.1; IL-8 
+ CXCR2 Ab 0.16 + 0.1, p = 0.01) and GROα to baseline levels (GROα 0.14 + 0.1; 
GROα + CXCR2 Ab 0.06 +0.01, p=0.03).  The CXCR2 antibody did not reduce 
   *   *                     *   *                       *   * 
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directional persistence towards sputum (Sputum 0.4 + 0.1; Sputum + CXCR2 Ab 0.3  + 
0.1). 
 
With neutrophils from COPD patients, a similar pattern was seen, with a reduction in 
persistence towards the chemokines to baseline levels (IL-8, 0.3 + 0.1; IL8 + CXCR2 
Ab, 0.03 + 0.1, p=0.004: GROα, 0.16 + 0.1; GROα + CXCR2 Ab, 0.06 + 0.1, p = 0.04).   
However, the CXCR2 antibody did not alter persistence towards sputum (Sputum, 0.37 
+ 0.1; Sputum + CXCR2 Ab, 0.3 + 0.1). Once again, there were no differences in the 
persistence of neutrophils from COPD patients or controls, (see figure 7.31).  There 
were also no differential affects using the CXCR2 antibody.   
Figure 7.31. The persistence of neutrophils towards IL-8, GROα and sputum after 
incubation with anti human CXCR2 antibody.  
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 
10nM is migration towards IL-8 alone, IL8 + CXCR2 Ab is towards IL8 (10nM) 
following incubation with the  antibody (1.6µM).  The nomenclature is the same for 
GROα (100nM) and Sputum (2:1 dilution). * = significant difference from 
chemoattractant. 
 
 
 
 
 *   *                     *   *                      *    * 
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Chemotactic Index (Accuracy) 
 
As seen with the small molecule CXCR2 antagonist, when neutrophils from healthy 
controls were incubated with the CXCR2 antibody, there was a significant reduction in 
the chemotactic index of neutrophils migrating towards IL-8 (64%) (IL-8 0.41 + 0.1; IL-
8 + CXCR2 Ab 0.15 + 0.1, p = 0.009) and GROα by approximately 71% (GROα 0.13 + 
0.1; GROα + CXCR2 Ab 0.03 +0.01, p=0.01).  The CXCR2 antibody also reduced the 
accuracy of migration towards sputum by 56% (Sputum 0.46 + 0.1; Sputum + CXCR2 
Ab 0.20 + 0.1). 
 
With neutrophils from COPD patients, there was a reduction in accuracy towards IL-8, 
but as there was no increase in accuracy in the presence of GROα compared to baseline, 
the affect of the antibody could not be assessed (Control 0.02 + 0.1; IL-8, 0.22 + 0.1; 
IL8 + CXCR2 Ab, 0.05 + 0.1, p=0.004: GROα, 0.02 + 0.1; GROα + CXCR2 Ab, 0.004 
+ 0.1).   There was a significant reduction in accuracy of movement towards sputum 
(Sputum, 0.17 + 0.1; Sputum + CXCR2 Ab, 0.09 + 0.1, p=0.02). Once again, COPD 
neutrophils were less accurate compared to those from healthy controls, (see figure 
7.32), but there were no differential affects using the small molecule antagonist or the 
CXCR2 antibody. 
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Figure 7.32. The chemotactic index of neutrophils towards IL-8, GROα  and 
sputum after incubation with anti human CXCR2 antibody.  
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 
10nM is migration towards IL-8 alone, IL8 + CXCR2 Ab is towards IL8 (10nM) 
following incubation with the  antibody (1.6µM).  The nomenclature is the same for 
GROα (100nM) and Sputum (2:1 dilution). * = significant difference from 
chemoattractant. 
 
7.3.6.2 CXCR1 
 
Speed of migration (Chemokinesis) 
 
When neutrophils from healthy controls were incubated with the CXCR1 antibody, there 
was a significant reduction in the speed of movement of approximately 25% in IL-8 (IL-
8 4.8 µm/min + 0.2; IL-8 + CXCR1 Ab 3.6µm/min + 0.2, p = 0.04). There was no 
significant reduction towards GROα (GROα 4.2µm/min + 0.2; GROα + CXCR1 Ab 
4.1µm/min +0.1) nor towards sputum (Sputum 4.3µm/min + 0.2; Sputum + CXCR1 Ab 
4.3µm/min  + 0.2). 
 
With neutrophils from COPD patients, a similar pattern was seen, with a 22% reduction 
in speed towards IL-8 (IL-8, 5.3µm/min + 0.4; IL8 + CXCR1 Ab, 4.1 µm/min + 0.2, 
   *   *                       *   *                       *   * 
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p=0.03), but no significant reduction towards GROα, (4.8µm/min + 0.2; GROα + 
CXCR1 Ab, 4.7µm/min + 0.1) or sputum (Sputum, 4.9µm/min + 0.1; Sputum + CXCR1 
Ab, 4.6µm/min + 0.1).   Once again, COPD neutrophils were faster compared with those 
from healthy controls, see figure 7.33, but there were no differential affects using the 
CXCR1 antibody.   
 
 
 
Figure 7.33. The chemokinetic response of neutrophils towards IL-8, GROα  and 
sputum after incubation with anti human CXCR1 antibody.  
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8  is 
migration in the presence of  IL-8 alone, IL8 + CXCR1 Ab is in the presence of IL8 
(10nM) following neutrophil incubation with the  antibody.  The nomenclature is the 
same for GROα (100nM) and Sputum (2:1 dilution).  * = significant difference from 
chemoattractant alone. 
 
 
Velocity (Chemotaxis) 
 
When neutrophils from healthy controls were incubated with the CXCR1 antibody, there 
was a significant reduction in the velocity of movement towards IL-8 of approximately 
40% (IL-8 1.9 µm/min + 0.2; IL-8 + CXCR1 Ab 1.1µm/min + 0.1, p = 0.001).  The 
CXCR1 antibody did not alter velocity towards GROα (GROα 1.2µm/min + 0.2; GROα 
 *   * 
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+ CXCR1 Ab 1.3µm/min +0.01), however, the CXCR1 antibody reduced velocity 
towards sputum by 20% (Sputum 1.2µm/min + 0.2; Sputum + CXCR1 Ab 0.9µm/min  + 
0.1, p=0.04). 
 
With neutrophils from COPD patients, a similar pattern was seen, with a 30% reduction 
in velocity towards IL-8 (IL-8, 0.5µm/min + 0.1; IL8 + CXCR1 Ab, 0.3 µm/min + 0.1, 
p=0.03) but not GROα (GROα, 0.6µm/min + 0.2; GROα + CXCR1 Ab, 0.5µm/min + 
0.1).   There was a significant reduction in velocity towards sputum (Sputum, 
0.6µm/min + 0.1; Sputum + CXCR1 Ab, 0.4µm/min + 0.1, p=0.04). Once again, COPD 
neutrophils had less velocity towards all chemoattractants than those from healthy 
controls, (see figure 7.34), but there were no differential affects using the CXCR1 
antibody.   
 
Figure 7.34. The velocity of neutrophils towards IL-8, GROα  and sputum after 
incubation with  CXCR1 antihuman antibody.  
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8 is 
migration towards IL-8 alone, IL8 + CXCR1 Ab is towards IL8 (10nM) following 
incubation with the  antibody (1.6µM).  The nomenclature is the same for GROα 
(100nM) and Sputum (2:1 dilution). * = significant difference from chemoattractant 
alone. 
   *  * 
*  * 
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Persistence 
 
When neutrophils from healthy controls were incubated with the CXCR1 antibody, there 
was a small but significant reduction in the persistence of movement towards IL-8 of 
approximately 20% (IL-8 0.35 + 0.1; IL-8 + CXCR1 Ab 0.27 + 0.1, p = 0.04).  CXCR1 
antibody did not change persistence towards GROα (GROα 0.34 + 0.1; GROα + 
CXCR1 Ab 0.32 +0.1) or sputum (Sputum 0.4 + 0.1; Sputum + CXCR1 Ab 0.4  + 0.1). 
 
With neutrophils from COPD patients, a similar pattern was seen, with a small reduction 
in persistence towards IL- 8 (IL-8, 0.3 + 0.1; IL8 + CXCR2 Ab, 0.2 + 0.1, p=0.04) but 
the CXCR1 antibody did not change persistence towards GROα (GROα, 0.3 + 0.1; 
GROα + CXCR1 Ab, 0.3 + 0.1) or towards sputum (Sputum, 0.2 + 0.1; Sputum + 
CXCR2 Ab, 0.2 + 0.1). Once again, there were no differences in the persistence of 
neutrophils from COPD patients or controls, (see figure 7.35).  
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Figure 7.35. The persistence of neutrophils towards IL-8, GROα  and sputum after 
incubation with anti human CXCR1 antibody.  
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8  is 
migration towards IL-8 alone, IL8 + CXCR1 Ab is towards IL8 (10nM) following 
incubation with the  antibody (1.6µM).  The nomenclature is the same for GROα 
(100nM) and Sputum (2:1 dilution). * = significant difference from chemoattractant 
alone. 
 
 
 
Chemotactic index (Accuracy) 
 
When neutrophils from healthy controls were incubated with the CXCR1 antibody, there 
was a significant reduction in the accuracy of movement towards IL-8 of approximately 
30% (IL-8 0.25 + 0.1; IL-8 + CXCR1 Ab 0.18 + 0.1, p = 0.03).  The CXCR1 antibody 
did not affect the accuracy of migration towards GROα (GROα 0.21 + 0.1; GROα + 
CXCR1 Ab 0.23 +0.01) but it did reduce the accuracy of migration towards sputum by 
20% (Sputum 0.27 + 0.1; Sputum + CXCR1 Ab 0.19 + 0.1, p=0.02). 
 
*  * 
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With neutrophils from COPD patients, similar patterns were seen, with a reduction in 
accuracy towards IL-8 of 20% (IL-8, 0.14 + 0.1; IL8 + CXCR1 Ab, 0.09 + 0.1, p=0.04)  
The CXCR1 antibody did not reduce accuracy towards GROα (GROα, 0.12 + 0.1; 
GROα + CXCR1 Ab, 0.11 + 0.1).   There was a significant reduction in accuracy of 
movement towards sputum of 50% (Sputum, 0.16 + 0.1; Sputum + CXCR1 Ab, 0.07 + 
0.1, p=0.002). Once again, COPD neutrophils were less accurate compared to those 
from healthy controls, (see figure 7.36).  
 
 
 
Figure 7.36. The chemotactic index of neutrophils towards IL-8, GROα  and 
sputum after incubation with anti human CXCR1 antibody.  
Legend.  The results shown are the mean (and SEM) values of six experiments. IL-8  is 
migration towards IL-8 alone, IL8 + CXCR1 Ab is towards IL8 (10nM) following 
neutrophil incubation with the  antibody (1.6µM).  The nomenclature is the same for 
GROα (100nM) and Sputum (2:1 dilution). * = significant difference from 
chemoattractant alone. 
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7.3.6.3 Comparing the affects of CXCR1 and CXCR2 antibodies in neutrophil 
migration from healthy controls 
 
IL-8 
Data from these studies suggest that CXCR1 accounted for 25%  + 3 of neutrophil 
chemokinesis with  IL-8, while CXCR2 accounted for 30% + 5.  Neutrophils are not 
static, even in the absence of a chemoattractant,  and a combination of  CXCR1 and 
CXCR2 inhibition exerting these effects would reduce movement to baseline levels.  
Inhibition of both receptors decreased chemotaxis towards IL-8 by 40% (CXCR1, + 9%, 
CXCR2 + 8%), suggesting an equally important role for CXCR1 and CXCR2, and 
again, a combination of the two should theoretically reduce chemotaxis to baseline.  
CXCR2 appeared differentially important in directional persistence (with a 56% + 7  
increase in directional change Vs. a 20% + 4 increase for CXCR1, p=0.04) and overall 
accuracy (with a 64% + 11 reduction in chemotactic index Vs. 30% + 6 reduction with 
CXCR1, p=0.02) but again, the receptors in combination should reduce both parameters 
to baseline. 
 
GROα  
As expected, given the preferential binding of GROα to CXCR2, inhibition of CXCR1 
had no affects on migration towards GROα.    CXCR2 inhibition reduced all parameters 
to baseline levels, confirming that GROα mediated migration is via CXCR2. 
 
Sputum 
Speed or chemokinesis in the presence of sputum was not altered by CXCR1 or CXCR2 
inhibition, suggesting that neither of the receptors are of predominant importance for 
non-directional movement.  There was a significant decrease in velocity, but CXCR2 
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inhibition had a greater affect compared to CXCR1 (49% + 4 Vs 19% + 5, p=0.03).   
Neither antibody altered directional persistence towards sputum.   However, although 
anti-CXCR1 reduced overall accuracy of migration towards sputum, it did so less than 
CXCR2 (30% + 6 Vs. 56% + 8, p=0.01). 
 
7.3.6.4 Comparing the affects of CXCR1 and CXCR2 antibodies in neutrophil 
migration from patients with COPD 
 
In patients with COPD, similar patterns of the migratory affects of inhibiting CXCR1 or 
CXCR2 were seen.  There was a significant and similar reduction in IL-8 mediated 
chemokinesis following CXCR1 and CXCR2 inhibition, reducing speed to baseline.  
This was not seen with GROα or sputum driven chemokinesis.  In COPD,  as with 
controls, inhibition of CXCR2 had a greater affect on neutrophil velocity (68% + 10% 
Vs 30% + 4, p=0.009), persistence (86% + 16 Vs 19% + 3, p=0.007) and accuracy 74% 
+ 9 Vs. 35% + 12, p=0.04) driven by IL-8, compared to CXCR1 inhibition. This 
confirmed that CXCR2 is more important in accurate and efficient migration towards 
IL-8.  A similar pattern was seen in migration towards sputum, with no significant 
reduction of chemokinesis or persistence with either antibody, but a greater reduction in 
velocity with CXCR2 inhibition compared with CXCR1 inhibition (53% + 9 Vs. 28% + 
10, p=0.03), although not chemotactic index (CXCR2 inhibition 44% + 5 Vs CXCR1 
inhibition 54% + 7).   As seen with neutrophils from healthy controls, CXCR2 inhibition 
reduced all migration mediated by GROα to baseline levels, while CXCR1 inhibition 
did not.     
 
In summary, theoretically, in health and in COPD, a combination of CXCR1 and 
CXCR2 would reduce all migratory parameters towards IL-8 to baseline, and reduce 
chemotaxis and accuracy of migration towards sputum by 65 – 70%.   Here, both 
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receptors seem able to moderate migration, as neither inhibitor alone was able to stop it 
completely. However, CXCR1 inhibition altered migration less than CXCR2., 
suggesting that CXCR2 is the predominant migratory receptor involved in migration to 
airway secretions.   
 
There were no significant differential affects between the responses of healthy controls 
and patients with COPD, and neither antibody altered migratory dynamics of neutrophils 
from healthy controls to resemble those from  patients with COPD. 
7.4 Discussion 
 
These data describe further differences in circulating neutrophils from patients with 
COPD compared with those isolated from healthy controls.  Firstly, COPD neutrophils 
expressed significantly less CXCR1 and CXCR2 receptors on their surface compared 
with healthy controls, and these differences remained both over time and when cells 
were activated.   There were no differences in surface expression of either receptor on 
neutrophils from healthy smokers and non-smokers, suggesting that expression is 
independent of smoking status. These differences are not necessarily specific to COPD, 
as the healthy controls also differ in terms of their medications,  inflammatory burden 
and lung function, all of which may alter the expression of receptors involved in 
migration.  However, it is interesting that in some inflammatory conditions (including 
inflammatory bowel disease (Banks, Bateman et al. 2003) and Behçets eye disease 
(Qiao, Sonoda et al. 2005)) CXCR2 expression is increased, and so down-regulation of 
CXCR2 is not a universal response to inflammation. 
 
It is also interesting that receptor numbers are reduced in COPD when in a previous 
chapter it was established that pseudopod counts were reduced in neutrophils from this 
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patient population.  It is known that the receptors for chemoattractants are localised to 
the leading edge of a cell, and expressed on pseudopods (Weber 2006).  Although no 
causal link can be established, it could be hypothesised that reduced receptor expression 
may be linked with reduced pseudopod formation, and might, in combination, explain 
the decreased accuracy of migration due to a reduced ability to compare sites of receptor 
occupancy.   
 
There have been three previous studies of CXCR1 and CXCR2 expression in COPD, 
one reporting reduced expression of CXCR2  (Pignatti, Moscato et al. 2005), one 
describing increased expression of CXCR1 but not CXCR2 (Yamagata, Sugiura et al. 
2007)  and one describing no difference between groups, although there was a trend 
towards a decrease in CXCR2 (Traves, Smith et al. 2004).   In all studies, a wide range 
of COPD patients were included, rather than the more homogenous patient group 
included in the current thesis, and it may be that different phenotypes of patients or 
differing disease severities may affect receptor expression.  Further studies of a wider 
group of highly characterised patients, in larger numbers would be required to examine 
this.    
 
It is also overly simplistic to assume that receptor expression on quiescent neutrophils 
equates to receptor function, given the complex nature of receptor recycling and 
degradation.  Studies of surface expression when cells were activated, and studies of 
expression over time, were undertaken to start to explore functional differences in 
CXCR1 and 2, and no differential affects were seen.  To explore this further, studies of a 
CXCR2 small molecule antagonist and CXCR1 and CXCR2 monoclonal antibodies 
were undertaken. 
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To summarise the migratory components of these studies, neutrophils from patients with 
COPD moved with greater speed, but less accuracy towards IL-8, GROα and sputum.  
This remained even in the presence of CXCR1 or CXCR2 inhibition.   Incubating the 
IL-8 monoclonal antibody with IL-8 or the GROα antibody with GROα reduced all 
facets of migration towards the chemokines to baseline levels in both groups.  Inhibition 
of CXCR2 by the CXCR2 antagonist or antibody also reduced all migratory parameters 
to baseline when used with GROα (in keeping with its preferential binding to CXCR2), 
but not when used with IL-8 where inhibition of CXCR2 achieved only a 25% reduction 
in chemokinesis, but approximately a 40 - 60% reduction in chemotaxis, persistence and 
accuracy.    Inhibition of CXCR1 also reduced chemokinesis towards IL-8 by 25%, but 
reduced persistence and accuracy of migration to a lesser degree (20 – 30%) 
 
None of the chemokine specific antibodies, the receptor antibodies nor the antagonist 
reduced the speed of movement (chemokinesis) in sputum, suggesting that CXCR1 and 
CXCR2 are not important components of non specific cell activation and random 
movement in this biological fluid.   However, it is likely that these receptors have a role 
in directed migration, as chemotaxis and overall accuracy could be reduced by 50% 
following inhibition of IL-8 and 30% following inhibition of GROα.  CXCR2 inhibition 
reduced the chemotaxis and overall accuracy by approximately 50%, while CXCR1 
inhibition reduced chemotaxis and accuracy by 20 – 30% . 
 
These data allow some comment about the specific role of CXCR1 and CXCR2 in 
neutrophil migration. It is apparent that both receptors are required for accurate 
migration, but not chemokinesis.  However, that CXCR2 signalling accounts for a 
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greater proportion of directed cell movement  (approximately 60% CXCR2 compared 
with 30% CXCR1) suggests that it is the dominant receptor in neutrophil migration.  
 
It is known that CXCR2 is of fundamental important in neutrophil recruitment to areas 
of inflammation and infection, as demonstrated in vitro and in vivo in animal studies 
(Del Rio, Bennouna et al. 2001; Farooq, Stillie et al. 2009). The role of CXCR1 is less 
clear, but CXCR1 has been associated with bacterial killing, the respiratory burst and the 
release of α defensins by neutrophils from subjects with cystic fibrosis and COPD 
although CXCR2 was not associated with these functions (Hartl, Latzin et al. 2007).  It 
has also been hypothesised that these closely related G protein receptors are involved in 
cross-talk, as the down-regulation seen in surface expression on neutrophils following 
activation, is reduced when both receptors are present (Attal, Cohen-Hillel et al. 2007).  
In addition  the CXCR2 carboxyl terminus phosphorylation sites are required for 
inducing inhibition of CXCR1 down-regulation, and vice versa (Attal, Cohen-Hillel et 
al. 2007).    Certainly, the data included in the current chapter provides some evidence of 
synergistic actions in migration, as neutrophil migration should theoretically only be 
maximal towards IL-8 when both receptors  are available.  
 
It is interesting to note that inhibiting CXCR1 and CXCR2 on neutrophils from healthy 
controls did not produce a COPD phenotype, because although this reduced the accuracy 
of migration, it did not increase migratory speed.  This suggests that the defect in COPD 
migration is not only caused by a lack of or impaired function of CXCR1 and CXCR2 
receptors. Indeed, the fact that neutrophils isolated from COPD patients continued to 
display excessive speed but reduced accuracy of migration towards sputum, even when 
IL-8 and GROα were abrogated, and following inhibition of  CXCR1 and CXCR2  
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demonstrates very clearly that the aberrant migration is not purely dependent upon 
CXCR1 and CXCR2 signalling,  This suggests very strongly that the defect involves a 
wider range of chemoattractants (sputum will contain a variety of other chemoattractants 
including LTB4) and hence is likely to be due to an alteration in downstream signalling, 
in a shared component of the migratory pathway.   In order to study this further, the last 
series of studies have focused upon the common migratory pathway, in particular on 
phosphoinositide-3-kinase (PI3K).  
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8 Mechanism of aberrant migration.  
Phosphoinositide 3-Kinase inhibition 
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8.1 Brief Introduction 
 
Data described in previous chapters have consistently demonstrated that neutrophils 
from  patients with COPD migrate with increased speed but reduced accuracy towards 
IL-8, GROα and sputum and with reduced pseudopod formation.   This was associated 
with  reduced surface expression of CXCR1 and CXCR2, but did not seem to be 
attributable to the decrease in  expression of these receptors  alone.  Firstly,  because the 
aberrant migration towards sputum was seen when IL-8 and GROα were blocked by 
monoclonal antibodies, suggesting that other pathways may be involved, and secondly 
because inhibiting CXCR1 and CXCR2 in healthy controls did not produce a “COPD” 
migration phenotype.  
 
Although further studies of CXCR1 and CXCR2 expression, placement and recycling 
are warranted, pro-migratory ligands act via phosphoinositide 3 kinase (PI3K).  PI3Ks 
are a family of related enzymes that play a pivotal role in cellular regulatory 
mechanisms, by phosphorylating the 3’-OH position of phosphoinositide lipids, 
generating lipid second messengers.     
 
The PI3K family is divided into three classes, termed I, II and III.  All class I members 
are heterodimers consisting of a catalytic subunit and a non-catalytic subunit.  They 
phosphorylate phosphatidylinositol (PI), phosphatidylinositol-4-mono-phosphate (PIP) 
and phosphatidylinositol-4,5- bisphosphate (PIP2 ) in vitro, but have a strong preference 
for PIP2 in vivo.  Class one members are further subdivided into class1A and 1B PI3Ks.  
Class 1A consist of three isoforms (p100α, p110γ and p100δ) whereas the only class1B 
member is p110γ.   Class1A are commonly activated by tyrosine-kinases, which 
generate docking sites for the p85/p55 adapter subunits by phosphorylating tyrosines 
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within the p85/p55 consensus binding motifs on a large number of proteins (Cantrell 
2001).  In contrast, the class 1B member (p110γ) is activated by G-protein-coupled 
receptors (GPCRs) (Foster, Traer et al. 2003), such as CXCR1 and CXCR2, but also 
including the receptors for LTB4, fMLP, and C5a. 
 
All class 1 PI3Ks are further activated by the small GTPase, Ras via a direct interaction 
between Ras-GTP and the catalytic p110 gamma subunits (Suire et al, 2006).  Effectors 
of class 1 PI3Ks are pleckstrin-homology domain containing proteins such as Akt/PKB, 
BTK, TEC, ITK and small GTPases (e.g. Cdc42, Rac or Ras).  The action of PI3Ks is 
antagonised by the phosphatidyl-inositol-3,4,5-trisphosphate phosphatases SHIP and 
PTEN (Foster, Traer et al. 2003).   
 
PI3K gamma is predominantly expressed in haematopoietic cells, and is important in 
cell migration (Faerrandi, Ji et al. 2003; Del Prete, Vermi et al. 2004).   In Dictyostelium, 
studies of pi3k1- and pi3k2- double knock-out cells have suggested that PI3K is 
important in regulating cell speed and locomotion (Kolsch, Charest et al, 2008) and is 
involved in directional sensing in shallow gradients of chemoattractants (although in 
steep gradients, other pathways may be sufficient to allow migration) (Hoeller and Kay, 
2007).  Importantly, Class 1 PI3K knock out strains of Dictyostelium are still able to 
migrate, but show reduced speed (Hoeller and Kay, 2007).  
 
PI3Kγ is believed to orientate the cell by initiating and maintaining the leading edge 
(cell polarity) (Wang, Herzmark et al. 2002), allowing directed motility by the formation 
of pseudopodia (Wu 2005).  Cell migration involves local production and degradation of 
phosphatidylinositol (3,4,5) trisphosphate (PtdIns(3,4,5)P3) at the plasma membrane, 
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resulting in a net accumulation of PtdIns(3,4,5)P3  at the leading edge of the cell, leading 
ultimately to actin polymerization, with the formation of pseuodopodia.  PtdIns(3,4,5)P3 
accumulation at the leading edge is PI3kγ dependent (Ferguson et al, 2007: Nishio et al, 
2007), as is stabilisation of the leading edge (Sasaki et al, 2004). 
 
 PI3Kγ probably controls pseudopod generation by the localisation of PtdIns(3,4,5)P3 
signalling, however PI3K is not responsible for pseudopod placement. Instead it is likely 
that PTEN suppresses lateral pseudopods (by degrading PtdIns(3,4,5)P3) maintaining 
migratory direction (Wessels et al, 2007), and helping prevent the migrating cell from 
“going off track”.   The balance of activity between PI3K and PTEN may establish 
gradients of PtdIns(3,4,5)P3 in chemotaxing cells, that can facilitate (PI3K) or suppress 
(PTEN) pseudopod generation in accordance with chemotactic stimuli.  
 
A study of pten- mice by Subramanian et al (2007) suggested that neutrophils without 
PTEN activity had enhanced PtdIns(3,4,5)P3 levels, Akt phosphorylation and actin 
polymerization, with increased speed of migration, but the cells also had directional 
migratory defects (Subramanian et al, 2007), potentially due to a lack of lateral 
pseudopod suppression.  SHIP1 (Src homology 2 domain-containing inositol-5-
phosphatase 1) is also believed to be important in PtdIns(3,4,5)P3 degradation (perhaps 
especially so in human neutrophils), but in recent studies of neutrophils lacking SHIP1, 
migration was slower (in contrast to neutrophils deplete in PTENS), with reduced 
cellular polarity (Nishio et al, 2007). 
 
Therefore, PtdIns(3,4,5)P3 signalling via PI3K and inhibition of signalling via PTEN/ 
SHIP1 does not affect the sensing of a chemotactic stimuli or gradient, but will affect the 
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speed of migration and potentially the overall efficiency of migration due to effective 
sustainment of aligned pseudopodia and the suppression of unaligned lateral 
pseudopodia.  It is unclear whether over-activity or under-activity of either enzyme 
would change rate of pseudopod formation. 
 
Neutrophils from patients with COPD have displayed increased speed but reduced 
accuracy of migration towards chemoattractants in shallow gradients (as shown in 
previous chapters).  This could be consistent with an alteration in PtdIns(3,4,5)P3 
signalling. 
  
The PI3 kinase Class 1 inhibitor, LY294002, has been shown to reduce chemokinesis 
and chemotaxis towards IL-8 in the Boyden chamber assay using neutrophils from 
healthy young controls (Knall, Worthen et al. 1997).  Furthermore, studies by Andrew et 
al suggest that LY294002 reduces the efficiency of migration without removing the 
ability to chemotax up chemotactic gradients, potentially by altering pseudopod 
placement on the leading edge (Andrew and Insall 2007).    
 
Differences in PI3K/PTEN activity could be a potential mechanism for the migratory 
differences seen in COPD, however, the affects of a PI3K Class 1 inhibitor has not been 
assessed in COPD, compared with healthy controls and patients with A1ATD.  
 
The studies included in this chapter aimed to determine whether a PI3K inhibitor 
(LY294002) had differential affects in neutrophil migration in COPD. 
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8.2 Experiments 
 
8.2.1 Study subjects 
 
Healthy controls consisted of healthy volunteers, age and gender matched to the COPD 
group, who had never smoked, had no evidence of chronic disease and were medication 
free.    COPD patients had moderate to severe disease defined by GOLD criteria (Pauwels, 
Buist et al. 2001).  They were ex-smokers, aged between 50 and 70.  All patients were 
clinically stable for at least eight weeks prior to recruitment with no changes in 
medication.  Alternative and concomitant disease was excluded clinically, physiologically 
and radiologically.  Patients had normal circulating levels of A1ATD and were PiMM 
genotype.  Patients with A1ATD (PiZ) were matched for age, gender, lung physiology and 
treatments to patients with usual COPD.   
8.2.2 Isolation of blood neutrophils 
 
Neutrophils were isolated from the whole blood as described previously (general methods 
2.5.7) (Mikami, Llewellyn-Jones et al. 1998).  The neutrophils (>95% pure, > 97% viable, 
by exclusion of trypan blue) were resuspended in sterile buffer (RPMI 1640 medium 
(Flow Laboratories, Rickmansworth, UK) containing 0.15% bovine serum albumin 
(Sigma-Aldrich, UK) for migrational studies. 
8.2.3 Neutrophil Chemotaxis 
8.2.3.1 Modified Dunn Chamber 
 
Neutrophil chemotaxis was measured using a modification of the Dunn chamber.  Full 
methodological details are included in the general methods (section 2.7.2). Chemotaxis 
was assessed as described in general methods (section 2.7.2). 
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8.2.3.2 Chemo-attractants and antagonists 
 
In both assays, neutrophils migrated in gradients of a negative control (RPMI (Sigma-
Aldrich)) and IL-8 (RnDSystems) (10nM). Subsequently, neutrophils were pre-
incubated the type 1 PI3 kinase inhibitor, LY294002 (SABiosciences, tebu-bio, 
Peterborough, UK) (1nM) made up with buffer (RPMI 1640 medium (Flow 
Laboratories, Ricksmansworth, UK), at room temperature for 45 minutes. The pre-
treated neutrophils were studied in gradients of IL-8 (10nM) or control buffer as before.  
Concentrations of LY294002 were chosen following appropriate dose response 
experiments to slow but not prevent migration. Chemotaxis was assessed as described in 
general methods (section 2.7.2).   
8.2.4 Statistical analysis 
 
Migrational differences seen using the Modified Dunn Chamber were compared using 
the mean data of 10 cells per experiment, per subject.  Differences in chemotaxis 
criteria were compared using an Independent t test. Sample size calculations were 
based upon a two group parallel comparison, to provide an 80% power of detecting a 
25% change in mean speed at the 5% level of significance.    
 
8.3 Results 
 
8.3.1 The affect of a type 1 PI3 Kinase inhibitor on neutrophil migration 
8.3.1.1 Validation. 
 
Initially, neutrophilic adherence and migration was assessed in the presence of 
increasing concentrations of LY294002 by determination of the percentage of cells that 
had adhered to the coverslip (compared with cells that had not) and the percentage of 
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adhered cells that were able to migrate towards IL-8.  Using this data, dose response 
experiments were performed with increasing concentrations of LY294002 to establish 
concentrations where migration was decreased, but not inhibited. 
 
LY294002 appeared to profoundly effect neutrophil adherence to coverslips and 
migration at concentrations over 1µM (see figure 8.1). Dose responses to assess the 
effects of LY294002 on migratory speed were limited to a dosing range of 1nM to 1µM 
in view of the above results.  Neutrophil migratory speed was slowed, but not fully 
inhibited when neutrophils were pre-incubated with LY294002 concentrations of 1nM, 
0.01µM and 0.1µM (see figure 8.2a). Further dose responses were carried out using 
neutrophils isolated from patients with COPD.   These data showed that COPD 
neutrophils migrated with reduced speed at concentrations of LY294002 of 1nM, and 
that this effect was more pronounced than seen with neutrophils isolated from healthy 
controls.  Given that this seemed to be a differential affect, a concentration of 1nM was 
utilised for further experiments.  
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Figure 8.1.  The affects of incubation with increasing doses of LY294002 on 
neutrophil adherence and migration 
Legend:  The graph demonstrates the effect of increasing concentrations of LY294002 
on neutrophil adherence and migration to IL-8. Adherent cells = adherent cells/ total 
number of cells per field x 100.  Migrating cells = number of migrating neutrophils / 
adherent neutrophils per field x 100.   On the x axis, IL-8 represents naïve neutrophils, 
while 0.001 – 50 represents neutrophils pre-treated with the corresponding concentration 
of LY294002 (µM). The results shown are the mean (and SEM) of 6 experiments. 
 
Figure 8.2a. The speed of migrating neutrophils from healthy controls pre-
incubated in increasing concentrations of LY294002 
Legend:  Neutrophils migrated in shallow gradients of 10nM IL-8.  On the x axis, 
negative control is RPMI buffer, IL-8 is migration of naive neutrophils towards IL-8, 
0.001 – 1 represent increasing concentrations of LY294002 (in µM).  The results shown 
are the mean (and SEM) values of six experiments. 
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Figure 8.2b. The speed of migrating neutrophils from patients with COPD pre-
incubated in increasing concentrations of LY294002 
Legend:  Neutrophils migrated in shallow gradients of 10nM IL-8.  On the x axis, 
negative control is RPMI buffer, IL-8 is migration of naive neutrophils towards IL-8, 
0.001 – 1 represent increasing concentrations of LY294002 (in µM).  The results shown 
are the mean (and SEM) values of six experiments 
 
 
The affects of LY294002 on neutrophil migration in COPD 
 
Migrational studies and comparisons of PI3K expression were conducted on neutrophils 
isolated from 6 patients with COPD and 6 age and gender matched healthy controls.  
Demographic data is presented in Table 8.1.  
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Table 8.1:  Demographic data for COPD patients, healthy controls, healthy 
smokers and patients with A1ATD for studies of LY294002 
 COPD HC HS A1ATD 
N 6 6 6 6 
Age (years) 62 (57 - 66) 60 (55 – 64) 58 (55 - 61) 59 (54 – 65) 
Gender (Male) 4 3 3 3 
Smoking status  All ex-smokers Never * Current All ex-smokers 
Pack years 29 (24 - 35 ) 0 * 25 (18 - 29) 24 (19 – 30) 
FEV1 (l) 0.97 (0.8 – 1.1) 2.25 (2.0 – 2.7) * 1.98 (1.8 - 2.5) * 
1.02 (0.7 – 1.3) 
FEV1 % predicted 49 (43 - 54) 91 (85 – 106) * 90 (84 - 101) * 
51 (46 – 53) 
FEV1 /FVC 56 (44 - 58) 81 (76 – 85) * 78 (76 - 83)* 
58 (51 – 63) 
BMI (kg/m2) 21 (20 - 22) 21 (20 – 22) 22 (20 - 23) 22 (20 – 23) 
Inhaled steroids 83% 0% * 0% * 66% 
Theophyllines 0% 0% * 0% * 0% 
Long acting b2 agonist 50% 0% * 0% * 50% 
Anti-cholinergics 50% 0% * 0% * 50% 
Bacterial colonisation 0% N/A N/A 0% 
 
Legend.  Age is presented as the mean age (with the range in parentheses).  Gender is 
the number of males in each group. The remaining data is presented as the median (with 
the interquartile range in parentheses).   Healthy non-smoking controls (HC) and healthy 
smokers (HS) differed from COPD patients in terms of lung function and treatments.  
There were no other differences between groups.  
* = significant difference from COPD patients (p < 0.05) 
 
 
Speed (Chemokinesis) 
Pre-incubation with LY294002 significantly reduced the speed of migrating COPD 
neutrophils from 4.8 + 0.2 µm/min to 2.4 + 0.5 µm/min (p = 0.001) without slowing cells 
from healthy controls (unaltered at 3.7 + 0.4 µm/min), healthy smokers (from 3.6 + 0.2 to 
3.4 + 0.3 µm/min) or patients with A1ATD (from 3.5 + 0.2 to 3.4 + 0.2 µm/min), see 
figure 8.3.  
 
308 
 
Figure 8.3.  Speed of neutrophils pre-incubated with the PI3K inhibitor LY294002. 
Legend. For graphs 8.3 – 8.5 measurements were taken from 10 cells from each 
individual (migrating in the presence of a chemotactic gradient formed from 10nM of 
IL-8). Neutrophils are migrating in IL-8 alone (naïve cells), or in IL-8 following 
incubation with LY294002.  Each experiment was repeated three times and the average 
results for each subject were calculated, and an overall average was used for 
comparisons between groups.  The mean data per group is shown with standard error 
bars.    HC = healthy non-smoking, HS = healthy-smoking.  For graph 8.3: a significant 
reduction in speed following treatment with LY294002 is annotated * where p < 0.05.  
 
 
Velocity (Chemotaxis) 
LY294002 increased the velocity of neutrophils from COPD patients (from 0.5 + 
0.1µm/min to 0.9 + 0.1 µm/min p = 0.03) while decreasing the velocity of  healthy 
controls (from 1.2 + 0.1 µm/min to 0.8 + 0.1 µm/min, p=0.03) and  healthy smokers (1.3 + 
0.4 µm/min to 0.7 + 0.3 µm/min, p=0.02), with a trend towards a reduction in patients with 
A1ATD (from 1.1 + 0.1 µm/min to 0.8 + 0.1 µm/min, p=0.06). See figure 8.4. 
 
 
 
 
 
 
 
     * 
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Figure 8.4.  Velocity of neutrophils pre-incubated with the PI3K inhibitor LY294002. 
Legend. See legend for graph 8.3.  Neutrophils are migrating towards IL-8 alone (naïve 
cells), or towards IL-8 following incubation with LY294002. * = significant decrease 
from naïve cells. ** = significant increase from naïve cells. 
 
 
Persistence 
The PI3kinase inhibitor did not alter the directional persistence of neutrophils from 
patients with COPD (naïve cells 0.43 + 0.08, treated cells 0.48 + 0.06),  healthy controls 
(naïve cells 0.44 + 0.01, treated cells 0.41 + 0.05), healthy smokers (naïve cells 0.36 + 
0.03, treated cells 0.35 + 0.04), or patients with A1ATD (naïve cells 0.39 + 0.04, treated 
cells 0.37 + 0.06).   
 
Chemotactic Accuracy 
LY294002 significantly increased the chemotactic index of COPD neutrophils compared 
with untreated cells (from 0.2 + 0.06 to 0.3 + 0.01, p=0.03), while there was a trend 
towards a decrease in chemotactic index following incubation with the PI3 kinase inhibitor 
in healthy controls (from 0.29 + 0.06 to 0.22 + 0.05, p=0.06), healthy smokers (from 0.31 
  *                  *                 ** 
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+ 0.02 to 0.27 + 0.04, p=0.09) and patients with A1ATD (from 0.28 + 0.07 to 0.22 + 0.06, 
p=0.07) as summarised in figure 8.5. 
 
 
Figure 8.5.  Chemotactic Accuracy of neutrophils pre-incubated with the PI3K 
inhibitor LY294002. 
Legend. See legend for graph 8.3.  Neutrophils are migrating towards IL-8 alone (naïve 
cells), or towards IL-8 following incubation with LY294002. * = significant decrease in 
chemotactic index from naïve cells. ** = significant increase in chemotactic index from 
naïve cells. 
 
 
Figure 8.6 and 8.7 provide representative examples of the circulating neutrophils 
migratory tracks that were recorded for an individual COPD patient both with and without 
pre-incubation with LY294002 in response to IL-8.    
 
 
** 
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Figure 8.6 
 
 
Figure 8.7 
Figures 8.6 and 8.7  Tracks of neutrophil migration from a subject with COPD, 
with and without neutrophil incubation with the PI3 Kinase Inhibitor, LY294002. 
Legend.  The images show the final neutrophil positions within the Dunn chemotaxis 
chamber following 20 minutes of phase time lapse recording.  The large white arrow at 
the top of each picture represents the direction of the source of the chemotactic signal 
(here IL-8 at a concentration of 10nM for all figures). In Figure 8.6, mean cell speed was 
5µm/min, mean velocity was -1µm/min, mean persistence was 0.43 and mean 
chemotactic index was -0.19. In Figure 8.7, (treated with LY294002) mean cell speed 
was 1.97 µm/min, mean velocity was 0.63 µm/min, mean persistence was 0.48 and 
mean chemotactic index was 0.373. 
 
In summary, there were no differences in the migratory patterns seen between patients 
with A1ATD and healthy controls.   The addition of LY294002 to COPD neutrophils 
reduced migratory speed to levels below those seen in the healthy controls (p = 0.0001 for 
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both).  The inhibitor increased migratory velocity to that of healthy controls.  Furthermore, 
although treating cells with the inhibitor did not alter migratory persistence, it enhanced 
overall chemotactic accuracy to levels comparable to healthy controls.   See Table 8.2. 
 
Table 8.2: A comparison of migratory parameters in 6 patients with COPD (with 
and without incubation with LY294002) and 6 healthy subjects 
 
  Healthy COPD without LY294002 
  Controls Inhibitors  
Speed 3.66 (0.2) 4.88 (0.1) * 2.44 (0.5)  ± 
Velocity 1.18 (0.1)    0.46  (0.1) *     1.0   (0.1)  ± 
Persistence 0.44 (0.1)    0.43  (0.01)     0.48 (0.1)  
Chemotactic Index 0.29 (0.1) 0.17 (0.1) * 0.30 (0.1)  ± 
 
Legend. The table compares the untreated and treated circulating neutrophils from 
patients with COPD with age and gender matched healthy controls. The mean data for 
each group is displayed (with the SEM in parentheses).  Neutrophils migrated in the 
presence of a chemotactic gradient formed using 10nM IL-8.  Speed and velocity are 
measured in µm/minute. Persistence is scaled from 0 to 1, where 1 equates to no change 
of cell orientation during migration (no change of direction) and 0 equates to many 
changes in cell orientation (see text).  Chemotactic Index is measured from -1 to 1, 
where 1 equates to direct movement towards the chemoattractant source and -1 equates 
to direct movement away from the chemoattractant source. * = significant difference (p 
< 0.05) in comparison with neutrophils from healthy controls.   ± = significant difference 
(p < 0.05) in comparison with untreated neutrophils from patients with COPD. 
 
 
This series of experiments suggested that the PI3 kinase inhibitor was able to change the 
migratory dynamics of COPD  neutrophils, so that they now resembled those from 
healthy controls.  
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8.4 Discussion   
 
The studies included in this chapter once again demonstrate that neutrophils isolated 
from patients with COPD display altered migratory dynamics compared with those from 
healthy controls:  namely an increase in speed of migration and a decrease in 
chemotactic accuracy.   Previous work has also described that pseudopodia counts were 
lower on COPD neutrophils compared with healthy controls both when quiescent and 
when activated, a finding that could be consistent with the enhanced speed but reduced 
accuracy of migration (Weber 2006).  Pseudopod generation is altered by enzymatic 
reactions in the signalling pathway (Zhelev, Alteraifi et al. 2004), suggesting that a 
defect within this pathway in COPD patients might explain the increased speed of 
migration.  
 
Incubation of COPD neutrophils with a Type 1 PI3 Kinase inhibitor altered migratory 
dynamics, so that they resembled those from healthy controls.  Migratory speed was 
reduced, but accuracy was increased, both in terms of migratory velocity and 
chemotactic index (a vector analysis of migration).  
 
LY294002 was chosen as it has its’ main actions on the pathway that drives migration, 
non selectively inhibiting all Class 1 sub types (El-Kholy, MacDonald et al. 2003).  PI 3-
kinase is central to neutrophil chemotaxis (Knall, Worthen et al. 1997; Sasaki, Irie-
Sasaki et al. 2000), in particular for directed migration through cell polarisation (Sadhu, 
Masinovsky et al. 2003).  It is activated by multiple extracellular stimuli and acts via the 
intracellular localisation of proteins such as AKT and thus F-actin to the leading edge of 
the cell (Hannigan, Zhan et al. 2002).   PI3K is also believed to be an integral regulator 
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of pseudopod generation (Andrew and Insall 2007) and has been found to accelerate 
neutrophil movement towards chemoattractants (Heit, Liu et al. 2008). 
 
Class I PI3Ks are heterodimeric enzymes consisting of a 110kDa catalytic subunit in 
complex with a regulatory subunit (Vanhaesebroeck, Leevers et al. 2001).  Tissue 
distribution and the regulation of PI3K expression has recently been reviewed (Kok, 
Geering et al. 2009). Whereas p110α and p110β appear to have a broad tissue 
distribution, p110γ is highly expressed in leukocytes but also found at lower levels in 
other cell types.  Class 1 PI3 kinases have genes for 8 catalytic and 6 regulatory 
subunits.   
 
IL-8 has its’ inflammatory actions via G protein receptors which activate p110γ.   The 
gene for this subunit is PIK3CG found on chromosome 7q22.3.  Its’ regulatory subunits 
are p101 and p84, the genes for which are PIK3R5 and PIK3R6, both placed upon 
chromosome 17p13.1.  A promoter region for murine p110γ has been identified (Zhao, 
Cheng et al. 2006). Multiple transcriptional start sites exist for p110γ, resulting in 
transcripts with varying 5′ untranslated regions (5′UTRs), up to 874 bp in length. 
Analysis of the genomic p110γ DNA up to 1.2 kb upstream from the transcription start 
site revealed that the putative promoter region contains consensus sites for housekeeping 
transcription factors such as AP1 and SP1, as well as several putative binding sites for 
leukocyte-specific transcription factors.  There have been no studies of gene regulation 
of p101 or p84.  
 
The data included in this chapter identify a potential mechanistic action for aberrant 
migration: one of altered PtdIns(3,4,5)P3  signaling by potentially increased PI3 Kinase 
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expression (or potentially reduced PTEN/ SHIP1 activity, preventing PtdIns(3,4,5)P3 
degradation, lading to an effectual increase in PI3K activity).    
 
It is known that inflammatory stimuli, including TNFα and fMLP, cause an increase in 
p110γ expression and activity (Cadwallader, Condliffe et al. 2002). In p110γ-deficient 
mice, LPS (lipopolysaccharide)-induced lung oedema, neutrophil recruitment and pro-
inflammatory cytokine production are all reduced in vivo when compared with wild-type 
mice  (Yum, Arcaroli et al. 2001).  p110γ has also been associated with some 
inflammatory conditions such as atheroma formation (Chang, Sukhova et al. 2007) and 
ulcerative colitis, both of which involve neutrophil recruitment (Gonzalez-Garcia, 
Sanchez-Ruiz et al. 2010).   
 
It is unclear if inflammation alone drives PI3 kinase expression, or whether PI3 kinase 
over-activity is a recognized phenomenon on its own.  However, it is interesting that the 
inhibitor did not improve migratory dynamics in neutrophils from patients with A1ATD, 
suggesting that inflammation alone cannot account for migratory differences seen.  
There are no studies that report polymorphisms of p110γ, or p101 and p84, however, 
potentially, genetic variations could lead to alterations in expression.  
 
If excessive PI3 kinase activity causes aberrant neutrophil migration, potentially, the PI3 
kinase inhibitor would correct it.    It is known that the inhibitor can slow migration and 
alter pseudopod extension,   (as seen with Dictyostelium strains (Andrew and Insall 
2007)).   However, PI3 kinase is thought to have more widespread effects in migratory 
cells.  Of note, it can diminish cell polarisation (Eddy, Plerinl et al. 2000; Fais and 
Malorni 2003), and may alter pseudopod placement (Andrew and Insall 2007; Wessels, 
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Lusche et al. 2007) which would enhance the efficiency of directional locomotion, 
potentially focusing  signalling capacity at the leading edge of the cell (Wessels, Lusche 
et al. 2007).     
 
It is also very interesting that COPD neutrophils responded differentially to very low 
concentrations of LY294002 (nM).  Previous studies of this inhibitor have used much 
higher concentrations (µM) (for example Andew and Insall, 2007) however, these 
studies sought to determine the maximal affect of the inhibitor, whereas the studies 
included in this chapter aimed for modulation of migration (a partial inhibition).    
Furthermore, the reduction of cell adhesion to the albumn-coated coverslip prevented 
higher concentrations being used in this assay.  This is in-keeping with previous studies 
suggesting that PI3K is important in regulating integrin-based adhesion (Ferguson et al, 
2007).  It could be that COPD neutrophils are sensitive to lower concentrations of the 
antagonist, however, this should be confirmed in separate studies including a range of 
COPD severity to determine if this is a progressive phenomenon.   Furthermore, it is 
known that chemotaxis involves pathways that are parallel to PtdIns(3,4,5)P3 signalling, 
and it would be important to determine (using other antagonists, such as those acting on 
MAP kinases) whether PI3K inhibition was both necessary and sufficient to alter 
cellular migration.  
 
Certainly, the findings reported here warrant further investigation, including studies of 
PI3 kinase, PTEN and SHIP1 activity and expression in neutrophils from COPD patients 
and other related neutrophilic inflammatory conditions.  It would also be of interest to 
repeat these studies using neutrophils from healthy controls that had been activated 
using inflammatory mediators (such as TNFα) or plasma from COPD patients, to 
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explore if behavioural differences were due to an intrinsic flaw in COPD neutrophils or 
whether they could be induced by an inflammatory stimulus or environment.  If these 
studies suggest that PI3 Kinase activity is excessive in COPD it would provide a novel 
target for therapeutic intervention. 
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9 General Discussion 
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Current estimations suggest that 10% of the worlds population aged over 40 have COPD 
(Zhong, Ran et al. 2004) and by the year 2020, it is predicted that COPD will be the fifth 
leading cause of morbidity and mortality worldwide (World Health Organization 2007).  
Despite this immense burden of current and future disease, there is still no 
pharmacological therapy available that alters disease progression.   It is clear that COPD 
is associated with an inflammatory process in both the small and large airways and in 
the lung parenchyma (Saetta, Turato et al. 2001), which is known to continue even 
following smoking cessation (Retamales, Elliot et al. 2001).   
 
Although many cells and mediators have been implicated in the pathogenesis of COPD, 
it is clear that the neutrophil is central to its development and progression (Sapey and 
Stockley 2008) .  There is an increased presence of neutrophils in the lungs of patients 
with COPD (Stansecu, Sanna et al. 1996), and the degree of neutrophilia correlates with 
airflow obstruction (Sparrow, Glynn et al. 1984) and emphysema (Parr, White et al. 
2006).  Furthermore, neutrophils have been shown to cause all of the pathological 
features of COPD, including emphysema (Janoff, Sloan et al. 1977), mucous gland 
hyperplasia (Lucey, Stone et al. 1985) and mucus hypersecretion (Shimura and 
Takishima 1994).  These features suggest that neutrophil products and neutrophil 
chemoattractants are potential targets for novel therapeutic strategies.  However, many 
mediators are raised in COPD, and there is likely to be an element of redundancy 
(Barnes, Chowdhury et al. 2006). It is important to assess which mediators are more 
closely associated with disease (which could qualify as biomarkers), and to understand 
the variability in day to day expression, in order to target the most promising candidates 
and to power studies adequately.  
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Neutrophils migration is of fundamental importance in the inflammatory response, and 
the leukocyte’s ability to sense and move towards a chemoattractant gradient is finely 
controlled.  The detection of a chemotactic stimulus leads to the activation of signalling 
pathways, cytoskeletal rearrangement and changes in cell surface molecules that 
facilitate neutrophil migration.  In the bronchial circulation, it is believed that 
neutrophils are recruited by the “rolling-tethering” paradigm (explained extensively in 
the introduction and in (Wagner and Roth 2000)).  In the pulmonary circulation, where 
the majority of neutrophil migration occurs at the capillary level, cell rheology and not 
surface receptors may be of greater importance (Yoshida, Kondo et al. 2006).  In a 
recent study, 70% of neutrophil transmigration was achieved by direct engulfment of 
neutrophils by endothelial cells, by a process dependent on RhoG (van Buul, Allingham 
et al. 2007).    Migration through the basement membrane is less well understood, but 
may require proteinase release (Cepinskas, Sandig et al. 1999) with cells targeting areas 
of reduced matrix protein density (Wang, Voisin et al. 2006). 
 
Directional neutrophil recruitment appears to be reliant on the temporal and spacial 
occupancy of chemoattractant mediator receptors expressed preferentially in pseudopods 
at the front of a polarised cell (Weber 2006).  G-protein receptors act via PI3 Kinase 
(p110 gammaγ), which is known to modulate both cell polarity and pseudopod 
extension, facilitating neutrophil migration (Andrew and Insall 2007).   
 
Studies of neutrophil migration in COPD have shown variable results.  An initial study 
by Burnett et al  demonstrated increased neutrophil migration and enhanced extracellular 
proteolysis compared to healthy controls (Burnett, Chamba et al. 1987).  In keeping with 
this, increased expression of  adhesion proteins including CD11b and L-selectin have 
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been found in some studies of patients with COPD (Noguera, Batle et al. 2001; 
Woolhouse, Bayley et al. 2005).  However, Yoshikawa et al (Yoshikawa, Dent et al. 
2007) found higher numbers of neutrophils in induced sputum from patients with COPD 
compared with healthy controls but described a reduced neutrophilic chemotactic 
response to interleukin 8 and fMLP in the COPD patients which worsened with 
increasing disease severity.   Furthermore, Gonzalez (Gonalez, Hards et al. 1996) found 
no differences between levels of adhesion molecules in smokers with and without 
airflow obstruction.    
 
Increased or aberrant neutrophil migration could be of fundamental importance in the 
pathogenesis of COPD.  Neutrophils express membrane bound proteinases during 
migration, a proportion of which is released as free elastase (Cepinskas, Sandig et al. 
1999).  This causes an area of obligate tissue damage due to quantum proteolysis (Liou 
and Campbell 1996).  If COPD is associated with increased numbers of migrating 
neutrophils due to enhanced inflammatory signal (Barnes, Chowdhury et al. 2006), or 
aberrant migration due to faulty cell signalling, (or both), the potential for tissue damage 
maybe amplified.    
 
However, studies published to date have been unable to dissect differences in neutrophil 
migration in COPD because of many important factors.  Firstly, COPD is a 
heterogenous disease, and a general lack of in-depth characterization of the small 
number of the patients included in each study will increase the variability of the data.  
Secondly, the methodologies utilised (such as under agarose studies and the Boyden 
chamber) have been unable to describe individual cell behaviour, and instead comment 
on an overall pattern of cell behaviour, quoting the numbers of cells able to migrate 
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(Boyden Chamber) or the distance of overall migration (Under Agarose).  Newer 
modalities exist (such as the zebra fish model (Renshaw, Loynes et al. 2006)) provide 
exciting opportunities to monitor in vivo neutrophil migration.  However, these cannot 
be applicable to  COPD until any molecular mechanism of aberrant migration is known 
and transferable to the appropriate model.  The same is true of murine models of COPD.  
These can provide insight into the physiological importance of over or under expression 
of a mediator or a  receptor, however their use remains limited until a defining 
mechanism of COPD is identified.  Therefore, in the initial phases of understanding 
neutrophil migration in COPD, a simple assay, where individual cell migratory 
dynamics can be filmed and analysed, is essential.  Finally, although there is some 
evidence that ageing affects neutrophil migration (Fulop, Larbi et al. 2004), studies of 
migration in COPD to date have not always applied rigorous age matching with control 
groups.  The impact of healthy ageing on neutrophil function is poorly understood, but 
any differences in migration between age groups needs to be established to determine 
the validity of previous studies in COPD.    The studies included in this thesis were 
specifically designed to address some of these issues. 
 
9.1 The quantification and variability of inflammatory mediators and 
cells in COPD 
In order to characterise inflammation in COPD, there must be an understanding of the 
mediators that are raised in the condition, the variability of their expression and the 
relationships that exist between the mediators and parameters of disease.   While there is 
interest in the systemic components of COPD, it is primarily understood to be a disease 
of the lung, and so sampling of the respiratory system remains critical.  In the 
experiments described in this thesis, the variability of mediator and cell concentrations 
were studied by collecting daily spontaneous sputum samples for five sequential days, 
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and then twice weekly for three weeks in patients with stable COPD and a chronic 
bronchitis phenotype.  
 
There are many techniques that have been employed in sampling lung secretions, 
including bronchial biopsies, bronchoalveolar lavage, spontaneous and induced sputum 
and exhaled gas analysis (Barnes, Chowdhury et al. 2006).  Bronchial biopsies have been 
used to document the structural changes, cellular patterns and mediator profiles seen in 
the tissues in COPD (O'Shaughnessy, Ansari et al. 1997) (Saetta, Turato et al. 2001). 
This technique has the advantage of directly sampling airway tissue providing spatially 
intact components of the airway wall.  However, the procedure is invasive, can only 
sample proximal airways and is not well tolerated by those with severe disease or those 
with significant cardiac co-morbidity (Hattotuwa, Gizycki et al. 2002) and biopsy only 
documents those cells retained in the tissues and not migratory cells.  Variability in 
sampling is high.  A recent study demonstrated that 132 patients would be required in 
order to have an 80% chance of detecting a 50% reduction in cells which were mRNA 
positive for IL-8, using a parallel study design. (Gamble, Qiu et al. 2006).   Therefore 
obtaining meaningful results requires large numbers and repeated sampling. 
 
Bronchoalveolar lavage (BAL) has the advantage of sampling the distal airways and the 
resultant cell counts have been used in interventional studies of corticosteroids (Verhoeven, 
Hegmans et al. 2002) (Balbi, Majori et al. 2000). However, BAL is also an invasive 
procedure, and causes transient fever in some patients (Hattotuwa, Gamble et al. 2002). 
Furthermore, quantification of biomarkers is complicated by dilution from the saline lavage 
which is operator dependent and variable (Barnes, Chowdhury et al. 2006).   In addition, the 
variability of biomarkers using this sampling technique is currently unknown, as this 
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requires repeated sampling, and the lavage itself induces an inflammatory response, which 
may impact on biomarker concentrations (Hattotuwa, Gamble et al. 2002). 
 
Sputum induction using hypertonic saline provides samples which are essentially derived 
from the more proximal airways (Holz, Richter et al. 1998).  There have been many 
studies reporting on the cellular and inflammatory mediator concentrations in COPD 
using induced sputum, including a number of interventional studies assessing the affect 
of inhaled corticosteroids (for example (Keatings, Jatakanon et al. 1997)).  To date, only 
one study has provided data regarding reproducibility (Beeh, Kornmann et al. 2003).  
However, sputum induction is poorly tolerated by patients (especially those with an 
FEV1 < 30% predicted), causes transient airflow obstruction in some patients (Rytila, 
Lindqvist et al. 2000) (Taube, Holz et al. 2001) and induces a neutrophilic inflammation 
for at least twenty four hours, making repeat sampling within this time impractical (Holz, 
Richter et al. 1998) (Nightingale, Rogers et al. 1998).  This technique will not necessarily 
provide information of the processes underway in the broncho-alveolar region. 
 
Exhaled breath condensate (EBC) is a non-invasive technique (and hence can be 
repeated). The main problem with this technique remains that the concentrations of 
mediators in samples are low, (often at levels close to the lower level of detection and 
usually below the lower limit of quantification for assays that are currently available).  
This makes accurate measurements of mediators extremely difficult  and makes 
comparisons between groups almost impossible (Bayley, Abusriwil et al. 2008; Sapey, 
Bayley D et al. 2008). There is also a relatively high variability in repeated 
measurements of EBC inflammatory indices (Borrill, Starkey et al. 2005), which may be 
dependent  (at least in part) upon the difficulty in quantification of biomarkers or the 
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dilution caused by exhaled water vapour, and these problems need to be overcome 
before this technique can be routinely used in research and clinical trials. 
 
Spontaneous sputum samples have been extensively used in the study of COPD (Hill, 
Bayley et al. 2000; Hill, Campbell et al. 2000). Unlike other techniques, this is non-invasive, 
is acceptable to most patients who expectorate, and has no inflammatory sequelae to limit 
sequential sampling.   It is diluted by oropharyngeal secretions, but mouth washing 
procedures reduce this and squamous cell quantification provides some measure of this.  
The largest limitation of spontaneous sputum is that it only allows study of patients with 
chronic bronchitis, and is more frequent in moderate to severe disease. However,  this group 
of patients have increased levels of inflammation in induced samples whereas inflammation 
is not raised in those who do not (Gompertz, Hill et al. 2006) and expectoration is a 
predictor of disease progression and a tendancey to recurrent exacerbation This suggests that 
chronic expectoration should be documented to clarify the interpretation of all studies 
(Gompertz, Hill et al. 2006).   Finally, studies have shown that the inflammatory profile in 
sputum is similar in bronchial and bronchoalveolar lavage in the same patient indicating that 
it reflects processes throughout the bronchial tree (Wiggins, Hill et al. 1983) 
 
The studies presented in this thesis demonstrate the wide variability in mediators and cells in 
spontaneous sputum both between patients and within each patient, in the stable clinical 
state.  This finding could explain the wide range of cell counts and mediator concentrations 
described in individual studies of COPD with similar patient cohorts (Rutgers, Timens et al. 
2000; Gompertz and Stockley 2002; Woolhouse, Bayley et al. 2002), by suggesting that the 
“normal range” of inflammatory load in the lungs of patients, even with very similar disease 
burdens, may be vast.  The variability of raw data did not relate to any fluctuations in 
symptoms scores, clinical examination findings or lung function, and, therefore, did not 
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impact upon any clinical parameter that would be studied in clinical trials.  Changes most 
likely relate to contamination with oropharyngeal secretions or sputum humidification, 
although it remains possible this reflects real fluctuations in inflammatory load.  However, 
patients were followed for a month, with no clinical deterioration suggesting that the later 
possibility is less likley.  It may be that inflammatory changes need to be more sustained or 
of a greater magnitude before there is a change in clinical status (Pizzichini, Pizzichini et al. 
1999).  The studies confirm that sequential sampling and averaging three days data 
significantly reduces the impact of the fluctuations of mediators and cells, providing more 
individual data stability and thereby reducing the numbers needed to power putative studies 
where a primary endpoint is a reduction in an inflammatory protein or cell (in the case of 
IL-8, 61 patients would be required in a cross-over study aiming to detect a 50% change in 
IL-8 expression in single sputum samples, whereas only 7 would   be required if the mean of 
3 days data were used).  Sequential sampling also improved the strength of correlations 
between inflammatory mediators, cells and clinical parameters.   
 
Three neutrophil chemoattractants were studied, IL-8, LTB4 and GROα.  Consistently, IL-8 
correlated with other mediators, inflammatory cells and some markers of clinical severity 
(for example, airflow obstruction).  These findings complement those of other researchers 
(Woolhouse, Bayley et al. 2002; Hacievliyagil, Gunen et al. 2006; Parr, White et al. 2006) 
making it a clear candidate for future studies of neutrophil recruitment and neutrophil 
mediated pathology.     
9.2 Neutrophil migration in the healthy elderly 
 
The vast majority of studies in COPD include patients with a mean age of greater than 
60 (e.g., (Hill, Bayley et al. 1999; Sapey, Bayley et al. 2008; Borrill, Roy et al. 2009).   
In the majority of cases, great pains are taken to adequately match control subjects for 
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many parameters, including age which is an important consideration in any study of 
COPD.  Age is associated with changes in the structure and the function of the lung, 
which give rise to spirometric changes consistent with airflow obstruction (Turner, 
Mead et al. 1968; Knudson, Clark et al. 1977).  Age appears to make the lung more 
susceptible to inflammatory insults, with a reduction in cell proliferation following 
injury (Calabrese, Giacometti et al. 2005; Aoshiba. K. and Nagai 2009) causing alveolar 
enlargement which shares some, but not all of the features of emphysema (Verbeken, 
Cauberghs et al. 1992; Tsuji, Aoshiba et al. 2006).  Age affects nearly all of the immune 
system functions that have been studied to date (Panda, Arjona et al. 2009). With 
increasing age, there is an increase in cytokine expression in plasma (Mariotti, 
Bernardini et al. 2006), and alterations in both the initiation and sustainment of 
neutrophilic inflammation (Fulop, Larbi et al. 2004).  Finally, it is well recognised that 
ageing alters drug metabolism, therapeutic responses to drugs and the susceptibility to 
adverse effects, including drugs used in the treatment of COPD (Hall, Reed et al. 1974; 
Ray, Griffin et al. 1990; Feinberg 1993; Garbe, Suissa et al. 1998). 
 
Despite these important considerations, some studies of neutrophil migration in COPD 
have not provided closely age matched controls (for example (Woolhouse, Bayley et al. 
2002; Strassburg, Droemann et al. 2004; Yoshikawa, Dent et al. 2007)).  Often the 
differences in the mean age of the cohorts studied have been no more than 10 or 15 
years, but it is unclear how much impact this might have on neutrophil migration.  
Furthermore, there is an emerging theory of COPD as a form of advanced pulmonary 
ageing (Buist, McBurnie et al. 2007; Fukuchi 2009), despite there being differences in 
the pathological features of the so called “senile lung” and COPD (see above).    Given 
these factors, it was felt important to evaluate the affect of ageing on neutrophil 
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migration using both a traditional assay from which comparisons could be made to 
previous work, and an assay that allowed direct visualisation of single cells and the 
measurement of individual migratory parameters.  These studies were conducted firstly 
to determine the affect of ageing on neutrophil migration towards physiologically 
relevant chemoattractants in healthy subjects.  Secondly, to determine if there were 
similarities between the patterns of ageing neutrophil migration and COPD neutrophil 
migration, in order to assess whether neutrophil behaviour in COPD could represent an 
advanced ageing phenotype. 
 
The under agarose assays determined that there were significant differences in the 
migratory patterns of neutrophils from older subjects, in that there was a reduction in 
chemotaxis (directed migration towards the chemoattractant) with preserved 
chemokinesis (random movement away from the chemoattractant).  The Modified Dunn 
Chamber was able to characterise this further, demonstrating that the speed of cellular 
movement was preserved with ageing, but there was a reduction in velocity 
(chemotaxis).  This coupled with an increase in the number of directional changes each 
cell made during migration (a reduced persistence), resulted in an overall reduction in 
chemotactic accuracy.  This was consistently found using both IL-8 and GROα as 
chemoattractants.  The net result of the more circuitous migratory pathways of 
neutrophils from ageing subjects is of potential importance. Firstly, there might be an 
important delay in reaching the site of infection, as previous studies have suggested that 
reduced chemotaxis may be associated with worsening outcomes in bacterial infections 
(Niwa, Kasama et al. 1989; Egger, Aigner et al. 2004).  Secondly, these more circuitous 
migratory pathways may lead to an increase in by-stander tissue damage because of the 
expression and release of proteinases on the surface of neutrophils during migration 
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(Liou and Campbell 1996; Cepinskas, Sandig et al. 1999).  It is therefore also possible 
likely that neutrophil activation and migration in the elderly begets further inflammation 
by the release of further chemoattractants such as IL-8 and LTB4 (Hubbard, Fells et al. 
1991).  This could establish a low grade, self perpetuating cycle of damaging 
inflammation which may (in part) account for the age dependent development of mild 
emphysematous-like changes referred to as  “senile lung”.  
 
IL-8 signals via CXCR1 and CXCR2, while GROα signals preferentially via CXCR2. 
Interestingly, a CXCR2 small molecule antagonist changed migratory dynamics of 
neutrophils from young controls, giving them an ageing phenotype.  This suggested that 
reduced CXCR2 expression or function could account for the changes seen in migration 
of cells from the elderly. However, there were no differences in surface expression of 
CXCR1 or CXCR2 on quiescent cells indicating that the defect was more likely to be 
downstream from the CXCR2 receptor.  However, given the complex nature of receptor 
endocytosis and recycling, it is overly simplistic to state that there are not changes in 
CXCR1 or 2 function with advancing age.  The studies do not, at this stage, enable the 
identification of a potential mechanism for the migratory changes seen.  However, the 
migratory phenotype of neutrophils from ageing subjects has now been described and 
can be used in studies assessing migrating neutrophils from subjects with COPD.  The 
experiments contained within this thesis suggest that previous studies of neutrophil 
function in COPD where controls are not age matched should therefore be interpreted 
with a degree of caution.  
 
9.3 Neutrophil migration in COPD 
There is no doubt that there are increased numbers of neutrophils in the lungs of patients 
with COPD (Hill, Bayley et al. 1999; Sapey and Stockley 2008).  Their presence appears 
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to correlate with an increased pro-inflammatory signal from the lungs (Crooks and 
Stockley 1998; Hill, Bayley et al. 1999), without clear evidence of delayed apoptosis 
(Rytila, Plataki et al. 2006; Uller, Persson et al. 2006).  There has also been some 
suggestion that neutrophil function in COPD, including migration, may be altered 
(Burnett, Chamba et al. 1987; Strassburg, Droemann et al. 2004; Yoshikawa, Dent et al. 
2007).  It is known that an inflammatory signal remains in the lungs of patients with 
COPD, even after the cessation of smoking (Retamales, Elliot et al. 2001) and this may 
represent the presence of genetic predispositions towards disease or continuing 
environmental triggers.  Aberrant neutrophil migration could potentially lead to a 
continuation of inflammation even after the initial stimulus for disease is gone, by 
perpetuating an inflammatory response to neutrophil proteinases released during 
inaccurate migration (as outlined in the previous section).   
 
Neutrophil migration could be affected by a number of parameters, including smoking 
status, the presence of lung disease, lung inflammation and the therapies used to treat 
inflammation and airflow obstruction.  In order to account for these factors, a second 
control group was included in this section of work, namely patients with A1ATD.   
These patients were selected as they have a similar pattern of lung disease, but a known 
genetic predisposition with a recognised pathophysiological process, and hence can be 
chosen to match with age, gender, lung function, and treatments.   
 
Neutrophil migration was assessed firstly by the under agarose assay.  Here neutrophils 
from patients with COPD demonstrated a preserved chemotactic differential, with both 
enhanced chemotaxis (movement towards the chemoattractant) and enhanced 
chemokinesis (movement away from the chemoattractant) resulting in the neutrophils 
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spreading further.  This already demonstrated that the migratory dynamics of neutrophils 
from patients with COPD was different from the patterns noted in healthy ageing.   The 
same spreading pattern was not seen in patients with A1ATD, where migrational 
patterns resembled those from healthy controls.  Furthermore, detailed studies confirmed 
that there were no differences in the migratory pathways of neutrophils from healthy 
smokers and never smokers, suggesting that active smoking status does not affect this 
facet of neutrophil function.   These comparitive studies confirmed that the neutrophil 
dynamics were a feature of COPD and not recognised potential confounding factors. 
 
Throughout the studies included in this thesis, COPD neutrophils migrated with 
increased speed (chemokinesis), but with reduced velocity (chemotaxis) and a reduced 
chemotactic index (overall accuracy) towards IL-8 and GROα (and in later chapters, 
towards sputum).  This was not seen when the studies were replicated in A1ATD, where 
migratory patterns again resembled those from healthy controls.  Based on the work of 
Liou and Campbell (Liou and Campbell 1996; Campbell, Campbell et al. 1999), 
measurements of the dimensions of migrating neutrophils and maps of their migratory 
pathways, it is possible to estimate the potential volume of tissue damage that could 
occur during migration.  Using a simple mathematical model, it was estimated that 
neutrophils from patients with COPD have the potential to cause 30% extra tissue 
damage, purely because of the theoretical release of proteinase during inaccurate 
migration.     Neutrophils from patients with A1ATD also had an increased potential for 
tissue damage (90% more than healthy controls), but this is due to low prevailing 
concentrations of circulating A1AT  rather than aberrant migration.  Interestingly, these 
differences are comparable to the relative increase in decline of FEV1  seen in COPD and 
A1ATD (Burge, Calverley et al. 2000; Simmons, Connett et al. 2005; Dawkins, 
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Dawkins et al. 2009), suggesting a common paradigm of neutrophil mediated damage in 
both groups. 
9.4 Pseudopod formation in COPD 
Differences in migratory behaviour in neutrophils isolated from patients with COPD 
were accompanied by structural differences in migration, with a reduction in pseudopod 
formation following neutrophil activation with IL-8.  This was not seen in matched 
patients with A1ATD, and there were no differences in pseudopod formation between 
healthy smokers and never smokers.  This is the first evaluation of pseudopod formation 
in a disease state, but as formation was not altered by smoking or the presence of 
pulmonary inflammation (as seen in the healthy smokers and A1ATD groups) or therapy 
(as A1ATD patients were matched for this), it appears to be a feature of usual COPD.   
Further studies of other chronic inflammatory disease states would be of great interest to 
determine whether this observation is unique to COPD.  
 
Studies contained within the current body of work cannot prove that a decrease in 
pseudopod formation is causally associated with an increase in migratory speed or a 
reduced migratory accuracy.  However, this association fits well with current 
understanding of the function of pseudopodia (Wang, Herzmark et al. 2002; Weber 
2006; Wessels, Lusche et al. 2007).  In particular that the rate of pseudopod formation is 
central to both the speed and accuracy of migration (Zhelev, Alteraifi et al. 2004; Weber 
2006) and pseudopod generation is altered in the presence of chemoattractants and by  
components of the migratory pathway (Zhelev, Alteraifi et al. 2004; Andrew and Insall 
2007).   
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It may be that pseudopod formation is altered by differential activation of signalling 
pathways in COPD or that altered pseudopod formation is the primary event, due to 
changes in microtubule formation or actin and myosin function and that this leads to 
changes in signalling.  Certainly, it is less likely that alterations in pseudopod formation 
are a product of exposure to inflammation, as patients with A1ATD are known to have 
in general a higher burden of inflammation (Woolhouse, Bayley et al. 2002), and there 
were no differences in pseudopod formation between the A1ATD patients and healthy 
controls.      
9.5 CXCR1 and CXCR2 function in COPD 
Studying cell signalling pathways suggested further differences in circulating 
neutrophils isolated from patients with COPD.  There was a significant reduction in 
surface expression of CXCR1 and CXCR2 when receptor levels were semi quantified in 
COPD neutrophils.   This is not a universal phenomenon in inflammatory disease, as 
most reports in chronic inflammation suggest increased expression, especially of 
CXCR2 (Banks, Bateman et al. 2003; Qiao, Sonoda et al. 2005).  Studies of CXCR1 and 
CXCR2 expression in COPD have been inconsistent,  although most have found either a 
decrease or a trend towards a decrease in CXCR2 expression (Traves, Smith et al. 2004; 
Pignatti, Moscato et al. 2005). 
 
Interestingly, the reduction in pseudopod formation seen in activated neutrophils (with 
IL-8 10nM) in COPD compared with healthy controls was approximately 45%.  The 
reduction in surface expression of CXCR1 or CXCR2 in activated cells (again, using 
10nM IL-8) in COPD compared with healthy controls was approximately 56% and 45% 
respectively.  These reductions are comparable and it is interesting to speculate that a 
reduction in pseudopod formation may limit chemoattractant receptor surface expression 
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due to constraints of space.  Work in this series of experiments does not allow for a 
comment on the whole cellular content of CXCR1 or CXCR2, nor potential differences 
in receptor recycling or endocytosis, but these mechanisms warrant further study. 
 
Studies using antagonists and antibodies to CXCR1 and CXCR2 demonstrated that both 
have a role in neutrophil migration.  Inhibiting both CXCR1 and CXCR2 reduced 
chemokinesis to levels comparable to controls, whereas CXCR2 inhibition had the most 
profound reduction on chemotaxis, directional persistence and overall accuracy.    There 
have been few comparative studies of the roles of CXCR1 and CXCR2 receptors in 
neutrophils (Hartl, Latzin et al. 2007), and there remain concerns about the design of 
some of the studies which limit interpretation (for example, (Godaly, Hang et al. 2000).  
However, it seems clear that CXCR2 is important in neutrophil recruitment (Del Rio, 
Bennouna et al. 2001; Farooq, Stillie et al. 2009). 
 
CXCR1 or CXCR2 blocking strategies did not have large differential affects on 
neutrophil migration between COPD and healthy controls, and neutrophils from healthy 
subjects did not display a COPD phenotype when CXCR1 or CXCR2 function was 
down-regulated.  Furthermore, COPD neutrophils retained their phenotypic migratory 
characteristics towards sputum, even when IL-8, GROα or CXCR1 and CXCR2 were 
inhibited.  Together, these data suggest that expression or function of these receptors is 
not  the underlying cause of  migratory differences in COPD and instead suggest that 
these migrational patterns may be part of a generalised phenomenon to many 
chemoattractants.  To clarify this possibility, similar migrational studies would need to 
be carried out using other chemoattractants, acting via other surface receptors. One such 
study reported that fMLP receptor expression (measured indirectly in  subjects who were 
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not age matched) was dependent upon smoking status rather than COPD (Matheson, 
Rynell et al. 2003), while another found an increase in LTB4 receptors in tissue from 
patients with COPD, but did not measure receptors on neutrophils (Marian, Baraldo et 
al. 2006).    
 
Presently, it is unclear whether neutrophil migration in COPD is unusually fast but 
inaccurate  in the presence of a wider range of stimuli.  However, given that receptor 
expression and function (as studied in this body of work) did not account for changes in 
migratory pathways, a more generic component of the migratory pathway was studied. 
 
9.6 PI3 Kinase activity in COPD 
PI3 kinase is central to many cellular functions, including neutrophil migration (Knall, 
Worthen et al. 1997; Sasaki, Irie-Sasaki et al. 2000), and especially directed migration 
through cell polarisation (Sadhu, Masinovsky et al. 2003).  Incubation of COPD 
neutrophils with a Type 1 PI3 Kinase inhibitor altered migratory dynamics, so that they 
resembled those from healthy controls.  Migratory speed was reduced, but accuracy was 
increased, both in terms of migratory velocity and chemotactic index (a vector analysis 
of migration).  
 
There are no comparable studies in the literature to facilitate interpretation of these 
findings.  However, studies of PI3 kinase function suggest that it is an integral regulator 
of the rate of pseudopod generation (Andrew and Insall 2007) and accelerates neutrophil 
movement towards chemoattractants (Heit, Liu et al. 2008).  IL-8 and GROα are ligands 
G protein receptors that activate p100γ. It is known that inflammatory stimuli cause an 
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increase in p110 gammaγ expression and activity (Cadwallader, Condliffe et al. 2002) 
and that some chronic inflammatory conditions  have been associated with increased 
expression of this subunit (Chang, Sukhova et al. 2007; Gonzalez-Garcia, Sanchez-Ruiz 
et al. 2010).   
 
The studies contained within the current thesis suggest that inflammation alone does not 
drive the differences in responses to a PI3 kinase inhibitor, as cells from patients with 
A1ATD resembled those from healthy controls, rather than patients with COPD.   This 
suggests that there is something unique or unusual about the behaviour of COPD 
neutrophils.  There are no studies that report polymorphisms of p110 gammaγ, or p101 
and p84, however, potentially, genetic variations could lead to alterations in expression 
or activity, as with other genetic polymorphisms in COPD (Sapey, Wood et al. 2010). 
 
If excessive PI3 kinase activity causes aberrant neutrophil migration, it is expected that 
the PI3 kinase inhibitor would correct it. The inhibitor is known to slow migration and 
alter pseudopod extension (Andrew and Insall 2007), diminish cell polarisation (Eddy, 
Plerinl et al. 2000; Fais and Malorni 2003), and may alter pseudopod placement 
(Andrew and Insall 2007; Wessels, Lusche et al. 2007).   All of these factors would 
theoretically improve migratory dynamics and explain the results of the current 
experiments. 
 
Although the studies contained in this thesis have not identified an exact mechanism for 
aberrant neutrophil migration in COPD, a pathway has been identified, with a means to 
alter migration so that it resembles that seen in health.  This is potentially an important 
starting point in understanding neutrophil function and the role of the neutrophil in the 
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development and progression of COPD, and may, in time, offer a new therapeutic 
paradigm in this important disease. 
 
9.7 Future work 
This thesis has identified many features of the inflammation and neutrophil function in 
COPD.  It provides a series of important pathophysiologically relevant results that 
provide potential mechanisms to explain disease susceptibility.  However many further 
studies are needed to clarify the exact mechanisms involved and their specificity both in 
the field of ageing and immunosenescence and in COPD. 
 
The work on migrational studies in neutrophils from ageing subjects was instigated to 
help interpret studies of migration in COPD.  However, it is also important to 
characterise the affects and mechanisms of neutrophil migration in the elderly further.   
 
1. Initially, migrational studies should be repeated using physiologically important 
chemoattractants such as LTB4, fMLP and C5a, to determine if the less accurate 
migration is a general feature to all stimuli, acting via different receptors. The 
interpretation should also  include an assessment of pseudopod formation and placement 
to determine whether there are structural differences in cell migration with advancing 
age.    
2. Receptor function and expression should be a characterised more fully, including 
studies of receptor placement in the lipid raft, surface Vs cellular content of receptors 
and studies of receptor recycling. This data would identify if receptor placement, 
endocytosis and /or recycling was involved in migrational defects.   
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3. All of the studied receptors act via calcium signalling, and this can be quantified 
and compared between groups as a study of the initial components of cell signalling.    
4. The migratory pathway has many generic components, and it is possible to study 
each one in a step-wise, progressive manner, including PI3 kinase expression and 
activity, Phospho-ERK expression and activity and the role of PTEN.   This would 
determine if there was a single step responsible for the observations found.  
5. Further studies could also include the activation of small GTPases, such as Rho 
and Rac, and interactions between actin and myosin, as this is the final step in migration.   
6. In vitro and in vivo studies are needed to assess the clinical importance of 
aberrant migration in the elderly, including studies of the migration in gel matrices and 
the inflammatory sequelae of an inflammatory challenge to the lungs (such as inhaled 
LPS).     
7. In addition real time observations of bacterial phagocytosis by neutrophils from 
the elderly will determine whether these differences impact upon he final step of 
bacterial clearance and hence relate to the increased susceptibility to infection.  
8. It would also be of importance to repeat key studies following incubation of 
neutrophils from young or older subjects with serum or plasma from young or old 
donors.  This would help to determine if differences were caused by the neutrophils 
alone or by the pro-inflammatory environment of the cells in older subjects. 
 
The same series of experiments should be pursued in COPD, but here an additional 
control group is needed to account for the presence of inflammation.   A1ATD patients 
have proven to be suitable for this, as they have a similar lung insult as usual COPD, a 
similar pattern of inflammation (although inflammatory markers are often higher in 
pulmonary secretions from A1ATD (Woolhouse, Bayley et al. 2002)) and can be 
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matched for smoking status, disease phenotype (such as chronic bronchitis) and 
therapies. 
 
 In conclusion, the studies contained within this body of work have demonstrated unique 
differences in migrating neutrophils isolated from healthy ageing subjects and patients 
with COPD.  In healthy ageing, cells become less accurate during migration, but 
maintain their overall speed.  In COPD, inaccuracy is coupled with enhanced speed of 
migration. Theoretically, both migratory flaws would lead to worsening clinical 
outcomes.  Firstly, inaccurate migration may delay the cell’s response to infection (by 
potentially delaying bacterial clearance).  Secondly, inaccurate migration may lead to an 
increase in by-stander tissue damage mediated by the release of free proteinases, as 
neutrophils migrated along more meandering pathways.  Both may explain the poorer 
response too infections and the decline in end organ function seen in these groups.  The 
studies provide some insight into potential mechanism, but no definitive mechanism is 
identified.  There is a clear need for further study, both in the healthy ageing and in 
COPD.
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11.1 Abbreviations in alphabetical order 
 
A1AT  Alpha one anti-trypsin 
A1ATD Alpha one anti-trypsin deficiency 
Akt  Protein kinases B 
Cdc42  Cell division control protein 42 
CI   95% confidence intervals 
COPD  Chronic Obstructive Pulmonary Disease 
DDT  Dithiothreitol 
FEV1  Forced expiratory volume in one second 
FVC  Forced vital capacity 
fMLP  N-formyl-methionyl leucylphenylalanine 
GEF  Guanine nucleotide exchange factor 
GROα  Growth related oncogene alpha 
GTP  Guanosine trisphosphate 
HC  Healthy control 
ICAM-1 Intracellular adhesion molecule 1 
Ig  Immunoglobulin 
IκB  I kappa B 
IL-1β  Interleukin-1 beta 
IL-8  Interleukin 8 
LTB4  Leukotriene B4 
Mac-1  Macrophage antigen 1 
MD  Mean Difference 
MPO  Myeloperoxidas 
NE  Neutrophil elastase 
Pak 1  P21-activated kinase (Serine/threonine-protein kinase PAK1) 
PI  Phosphatidylinositol 
PIP  Phosphatidylinositol-4-phosphate 
PIP2  Phosphatidlyinositol – 4,5 bisphosphate 
PIP3  Phosphatidlyinositol – 3,4,5 trisphosphate 
PI3K  Phosphoinositide 3-kinase 
PIXα  PAK-associated guanine nucleotide exchange factor 
PLC  Phospholipase C 
PMN  Polymorphonuclear cell (neutrophil) 
P-Rex – 1 Phosphatidlyinositol – 3,4,5 trisphosphate dependent Rac exchanger 1 
protein 
PTEN  Protein Tyrosine Phosphatase 
SD  Standard deviation 
SEM  Standard error of the mean 
SLPI  Secretory leukoprotease inhibitor 
TNFα  Tumour necrosis factor alpha 
VCAM-1 Vascular cell adhesion molecule-1 
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